FN Thomson Reuters Web of Science™ VR 1.0 PT J AU DAHLBERG, CGW SPENCE, CR QUINN, DA BONVENTRE, JV JOSEPH, PM THOMPSON, BT HALES, CA AF DAHLBERG, CGW SPENCE, CR QUINN, DA BONVENTRE, JV JOSEPH, PM THOMPSON, BT HALES, CA TI HEPARIN INTERFERES WITH PDGF-STIMULATED INTRACELLULAR ALKALINIZATION OF BOVINE PULMONARY-ARTERY SMOOTH-MUSCLE CELLS VIA INHIBITION OF NA+/H+ EXCHANGE SO AMERICAN REVIEW OF RESPIRATORY DISEASE LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,PULM CRIT CARE UNIT,BOSTON,MA 02114. MASSACHUSETTS GEN HOSP,RENAL UNIT,BOSTON,MA 02114. HARVARD UNIV,SCH MED,BOSTON,MA 02115. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER LUNG ASSOC PI NEW YORK PA 1740 BROADWAY, NEW YORK, NY 10019 SN 0003-0805 J9 AM REV RESPIR DIS JI Am. Rev. Respir. Dis. PD APR PY 1993 VL 147 IS 4 SU S BP A495 EP A495 PG 1 WC Respiratory System SC Respiratory System GA LB149 UT WOS:A1993LB14901881 ER PT J AU DAHLBERG, CGW QUINN, DA BONVENTRE, JV JOSEPH, PM THOMPSON, BT HALES, CA AF DAHLBERG, CGW QUINN, DA BONVENTRE, JV JOSEPH, PM THOMPSON, BT HALES, CA TI HEPARIN ATTENUATES PDGF-INDUCED INTRACELLULAR ALKALINIZATION OF RAT LUNG FIBROBLASTS VIA ATTENUATION OF NA+/H+ EXCHANGE SO AMERICAN REVIEW OF RESPIRATORY DISEASE LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,PULM UNIT,BOSTON,MA 02114. MASSACHUSETTS GEN HOSP,CRIT CARE UNIT,BOSTON,MA 02114. MASSACHUSETTS GEN HOSP,RENAL UNIT,BOSTON,MA 02114. HARVARD UNIV,SCH MED,BOSTON,MA 02115. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER LUNG ASSOC PI NEW YORK PA 1740 BROADWAY, NEW YORK, NY 10019 SN 0003-0805 J9 AM REV RESPIR DIS JI Am. Rev. Respir. Dis. PD APR PY 1993 VL 147 IS 4 SU S BP A357 EP A357 PG 1 WC Respiratory System SC Respiratory System GA LB149 UT WOS:A1993LB14901344 ER PT J AU DHANANI, S HUANG, M DUBINETT, SM AF DHANANI, S HUANG, M DUBINETT, SM TI INTERFERON-ALPHA INHIBITS MURINE MACROPHAGE TRANSFORMING GROWTH-FACTOR-BETA PRODUCTION SO AMERICAN REVIEW OF RESPIRATORY DISEASE LA English DT Meeting Abstract C1 UNIV CALIF LOS ANGELES, SCH MED, LOS ANGELES, CA 90024 USA. W LOS ANGELES VAMC, DIV PULM & CRIT CARE MED, LOS ANGELES, CA USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA SN 0003-0805 J9 AM REV RESPIR DIS JI Am. Rev. Respir. Dis. PD APR PY 1993 VL 147 IS 4 SU S BP A758 EP A758 PG 1 WC Respiratory System SC Respiratory System GA LB149 UT WOS:A1993LB14902907 ER PT J AU DOSANJH, A STOW, J BROWN, D AUSIELLO, DA AF DOSANJH, A STOW, J BROWN, D AUSIELLO, DA TI AN ALTERATION OF SIALYLATION IN C127 CELLS TRANSFECTED WITH DELTA-F-508 CFTR SO AMERICAN REVIEW OF RESPIRATORY DISEASE LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,CTR CYST FIBROSIS,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER LUNG ASSOC PI NEW YORK PA 1740 BROADWAY, NEW YORK, NY 10019 SN 0003-0805 J9 AM REV RESPIR DIS JI Am. Rev. Respir. Dis. PD APR PY 1993 VL 147 IS 4 SU S BP A32 EP A32 PG 1 WC Respiratory System SC Respiratory System GA LB149 UT WOS:A1993LB14900083 ER PT J AU DUPUY, PM WINKLER, M STANEK, K ZAPOL, WM AF DUPUY, PM WINKLER, M STANEK, K ZAPOL, WM TI EFFECT OF METHYLENE-BLUE ON AIRWAY MECHANICS DURING CHOLINERGIC STIMULATION SO AMERICAN REVIEW OF RESPIRATORY DISEASE LA English DT Meeting Abstract C1 HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,BOSTON,MA 02114. UNIV DIJON,HOP BOCAGE,F-21004 DIJON,FRANCE. NR 0 TC 2 Z9 2 U1 0 U2 0 PU AMER LUNG ASSOC PI NEW YORK PA 1740 BROADWAY, NEW YORK, NY 10019 SN 0003-0805 J9 AM REV RESPIR DIS JI Am. Rev. Respir. Dis. PD APR PY 1993 VL 147 IS 4 SU S BP A286 EP A286 PG 1 WC Respiratory System SC Respiratory System GA LB149 UT WOS:A1993LB14901062 ER PT J AU DUPUY, PM SHORE, SA KIM, K DRAZEN, JM ZAPOL, WM AF DUPUY, PM SHORE, SA KIM, K DRAZEN, JM ZAPOL, WM TI BRONCHODILATOR ACTION OF INHALED NITRIC-OXIDE IN HISTAMINE, LEUKOTRIENE-D(4), AND NEUROKININ-A CONSTRICTED GUINEA-PIGS SO AMERICAN REVIEW OF RESPIRATORY DISEASE LA English DT Meeting Abstract C1 HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,BOSTON,MA 02114. HARVARD UNIV,SCH PUBL HLTH,RESP BIOL PROGRAM,BOSTON,MA 02115. BETH ISRAEL HOSP,BOSTON,MA 02215. BRIGHAM & WOMENS HOSP,BOSTON,MA 02115. UNIV DIJON,HOP BOCAGE,F-21004 DIJON,FRANCE. NR 0 TC 2 Z9 2 U1 0 U2 0 PU AMER LUNG ASSOC PI NEW YORK PA 1740 BROADWAY, NEW YORK, NY 10019 SN 0003-0805 J9 AM REV RESPIR DIS JI Am. Rev. Respir. Dis. PD APR PY 1993 VL 147 IS 4 SU S BP A288 EP A288 PG 1 WC Respiratory System SC Respiratory System GA LB149 UT WOS:A1993LB14901070 ER PT J AU GREENE, KE SMITH, DB KING, RJ AF GREENE, KE SMITH, DB KING, RJ TI THE EFFECTS OF TUMOR-NECROSIS-FACTOR-ALPHA ON SURFACTANT PROTEIN-A SYNTHESIS AND SECRETION IN ADULT-RAT TYPE-II CELLS SO AMERICAN REVIEW OF RESPIRATORY DISEASE LA English DT Meeting Abstract C1 UNIV TEXAS,HLTH SCI CTR,DEPT PHYSIOL,SAN ANTONIO,TX 78284. UNIV TEXAS,HLTH SCI CTR,DEPT MED,SAN ANTONIO,TX 78284. AUDIE L MURPHY MEM VET ADM MED CTR,SAN ANTONIO,TX 78284. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER LUNG ASSOC PI NEW YORK PA 1740 BROADWAY, NEW YORK, NY 10019 SN 0003-0805 J9 AM REV RESPIR DIS JI Am. Rev. Respir. Dis. PD APR PY 1993 VL 147 IS 4 SU S BP A250 EP A250 PG 1 WC Respiratory System SC Respiratory System GA LB149 UT WOS:A1993LB14900924 ER PT J AU HAYES, GB CHRISTIANI, DC AF HAYES, GB CHRISTIANI, DC TI DOES COTTON DUST EXPOSURE CAUSE SMALL AIRWAYS DISEASE SO AMERICAN REVIEW OF RESPIRATORY DISEASE LA English DT Meeting Abstract C1 HARVARD UNIV,SCH PUBL HLTH,BOSTON,MA 02115. MASSACHUSETTS GEN HOSP,BOSTON,MA 02114. HARVARD UNIV,SCH MED,BOSTON,MA 02115. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER LUNG ASSOC PI NEW YORK PA 1740 BROADWAY, NEW YORK, NY 10019 SN 0003-0805 J9 AM REV RESPIR DIS JI Am. Rev. Respir. Dis. PD APR PY 1993 VL 147 IS 4 SU S BP A527 EP A527 PG 1 WC Respiratory System SC Respiratory System GA LB149 UT WOS:A1993LB14901999 ER PT J AU HERLIHY, JP VENEGAS, JG GREENE, RE MCKUSICK, KA WAIN, JC GINNS, LC AF HERLIHY, JP VENEGAS, JG GREENE, RE MCKUSICK, KA WAIN, JC GINNS, LC TI EXPIRATORY FLOW PATTERN FOLLOWING SINGLE-LUNG TRANSPLANTATION IN COPD SO AMERICAN REVIEW OF RESPIRATORY DISEASE LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,PULM & CRIT CARE UNIT,BOSTON,MA 02114. MASSACHUSETTS GEN HOSP,THORAC SURG UNIT,BOSTON,MA 02114. MASSACHUSETTS GEN HOSP,RADIOL UNIT,BOSTON,MA 02114. MASSACHUSETTS GEN HOSP,NUCL MED UNIT,BOSTON,MA 02114. MASSACHUSETTS GEN HOSP,BIOMED ENGN UNIT,BOSTON,MA 02114. HARVARD UNIV,SCH MED,BOSTON,MA 02115. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER LUNG ASSOC PI NEW YORK PA 1740 BROADWAY, NEW YORK, NY 10019 SN 0003-0805 J9 AM REV RESPIR DIS JI Am. Rev. Respir. Dis. PD APR PY 1993 VL 147 IS 4 SU S BP A335 EP A335 PG 1 WC Respiratory System SC Respiratory System GA LB149 UT WOS:A1993LB14901255 ER PT J AU HOO, GWS ELLISON, MJ ZHANG, C WILLIAMS, AJ AF HOO, GWS ELLISON, MJ ZHANG, C WILLIAMS, AJ TI COMPARISON OF 4 MODES OF NASAL MECHANICAL VENTILATION IN PATIENTS WITH COPD SO AMERICAN REVIEW OF RESPIRATORY DISEASE LA English DT Meeting Abstract C1 W LOS ANGELES VAMC, LOS ANGELES, CA USA. UNIV CALIF LOS ANGELES, SCH MED, LOS ANGELES, CA USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA SN 0003-0805 J9 AM REV RESPIR DIS JI Am. Rev. Respir. Dis. PD APR PY 1993 VL 147 IS 4 SU S BP A322 EP A322 PG 1 WC Respiratory System SC Respiratory System GA LB149 UT WOS:A1993LB14901204 ER PT J AU HUANG, M DHANANI, S MINTZ, LE DUBINETT, SM AF HUANG, M DHANANI, S MINTZ, LE DUBINETT, SM TI DOWN-REGULATION OF INTERLEUKIN-2-INDUCED TRANSFORMING GROWTH-FACTOR-BETA BY INTERLEUKIN-7 SO AMERICAN REVIEW OF RESPIRATORY DISEASE LA English DT Meeting Abstract C1 UNIV CALIF LOS ANGELES, JONSSON COMPREHENS CANC CTR,SCH MED, DIV PULM & CRIT CARE MED,PULM IMMUNOL LAB, LOS ANGELES, CA USA. W LOS ANGELES VA MED CTR, LOS ANGELES, CA 90073 USA. NR 0 TC 2 Z9 2 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA SN 0003-0805 J9 AM REV RESPIR DIS JI Am. Rev. Respir. Dis. PD APR PY 1993 VL 147 IS 4 SU S BP A757 EP A757 PG 1 WC Respiratory System SC Respiratory System GA LB149 UT WOS:A1993LB14902904 ER PT J AU JONES, R WANG, CC POWELL, PP AF JONES, R WANG, CC POWELL, PP TI DEVELOPMENTAL EXPRESSION OF MESSENGER-RNAS ENCODING ACIDIC AND BASIC FIBROBLAST GROWTH-FACTORS AND FIBROBLAST GROWTH-FACTOR RECEPTOR-1,RECEPTOR-2 AND RECEPTOR-3 IN RAT LUNG SO AMERICAN REVIEW OF RESPIRATORY DISEASE LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,DEPT ANESTHESIA,BOSTON,MA 02114. MASSACHUSETTS GEN HOSP,DEPT PATHOL,BOSTON,MA 02114. HARVARD UNIV,SCH MED,BOSTON,MA 02115. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER LUNG ASSOC PI NEW YORK PA 1740 BROADWAY, NEW YORK, NY 10019 SN 0003-0805 J9 AM REV RESPIR DIS JI Am. Rev. Respir. Dis. PD APR PY 1993 VL 147 IS 4 SU S BP A942 EP A942 PG 1 WC Respiratory System SC Respiratory System GA LB149 UT WOS:A1993LB14903615 ER PT J AU JOSEPH, PM CALLAHAN, TA HALES, CA AF JOSEPH, PM CALLAHAN, TA HALES, CA TI BOVINE PULMONARY-ARTERY ENDOTHELIAL-CELLS ARE THE TARGET OF ENDOTOXIN-INDUCED NEUTROPHIL ADHESION SO AMERICAN REVIEW OF RESPIRATORY DISEASE LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,BOSTON,MA 02114. HARVARD UNIV,SCH MED,BOSTON,MA 02115. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER LUNG ASSOC PI NEW YORK PA 1740 BROADWAY, NEW YORK, NY 10019 SN 0003-0805 J9 AM REV RESPIR DIS JI Am. Rev. Respir. Dis. PD APR PY 1993 VL 147 IS 4 SU S BP A248 EP A248 PG 1 WC Respiratory System SC Respiratory System GA LB149 UT WOS:A1993LB14900917 ER PT J AU JOSEPH, PM CALLAHAN, TA HALES, CA AF JOSEPH, PM CALLAHAN, TA HALES, CA TI ACROLEIN INDUCED-INHIBITION OF ENDOTOXIN MEDIATED NEUTROPHIL ADHESION DOES NOT OCCUR VIA A CYCLOOXYGENASE PRODUCT SO AMERICAN REVIEW OF RESPIRATORY DISEASE LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,BOSTON,MA 02114. HARVARD UNIV,SCH MED,BOSTON,MA 02115. NR 1 TC 0 Z9 0 U1 0 U2 0 PU AMER LUNG ASSOC PI NEW YORK PA 1740 BROADWAY, NEW YORK, NY 10019 SN 0003-0805 J9 AM REV RESPIR DIS JI Am. Rev. Respir. Dis. PD APR PY 1993 VL 147 IS 4 SU S BP A247 EP A247 PG 1 WC Respiratory System SC Respiratory System GA LB149 UT WOS:A1993LB14900910 ER PT J AU KACMAREK, RM COCKRILL, BA RIPPLE, RE DONOHOE, M ZAPOL, WM JOHNSON, D AF KACMAREK, RM COCKRILL, BA RIPPLE, RE DONOHOE, M ZAPOL, WM JOHNSON, D TI NITRIC-OXIDE AS A BRONCHODILATOR IN METHACHOLINE-INDUCED BRONCHOSPASM IN MILD ASTHMATICS SO AMERICAN REVIEW OF RESPIRATORY DISEASE LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,BOSTON,MA 02114. HARVARD UNIV,SCH MED,DEPT RESP CARE,BOSTON,MA 02115. HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115. HARVARD UNIV,SCH MED,DEPT ANESTHESIOL,BOSTON,MA 02115. NR 0 TC 2 Z9 2 U1 0 U2 0 PU AMER LUNG ASSOC PI NEW YORK PA 1740 BROADWAY, NEW YORK, NY 10019 SN 0003-0805 J9 AM REV RESPIR DIS JI Am. Rev. Respir. Dis. PD APR PY 1993 VL 147 IS 4 SU S BP A835 EP A835 PG 1 WC Respiratory System SC Respiratory System GA LB149 UT WOS:A1993LB14903191 ER PT J AU KHARASCH, VS SANTIS, WF HALLOWELL, J LIPSITZ, S GOORIN, AM AF KHARASCH, VS SANTIS, WF HALLOWELL, J LIPSITZ, S GOORIN, AM TI LONG-TERM PULMONARY TOXICITY OF MULTIAGENT CHEMOTHERAPY INCLUDING BLEOMYCIN AND CYCLOPHOSPHAMIDE IN OSTEOSARCOMA SURVIVORS SO AMERICAN REVIEW OF RESPIRATORY DISEASE LA English DT Meeting Abstract C1 HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115. CHILDRENS HOSP MED CTR,BOSTON,MA 02115. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER LUNG ASSOC PI NEW YORK PA 1740 BROADWAY, NEW YORK, NY 10019 SN 0003-0805 J9 AM REV RESPIR DIS JI Am. Rev. Respir. Dis. PD APR PY 1993 VL 147 IS 4 SU S BP A87 EP A87 PG 1 WC Respiratory System SC Respiratory System GA LB149 UT WOS:A1993LB14900300 ER PT J AU KINANE, TB FINDER, J SHANG, C SUKHATME, V ERCOLANI, L AF KINANE, TB FINDER, J SHANG, C SUKHATME, V ERCOLANI, L TI CELL-GROWTH IS MEDIATED BY EGR-1 ACTIVATION OF THE G-ALPHA-2 PROTOONCOGENE IN EPITHELIAL-CELLS SO AMERICAN REVIEW OF RESPIRATORY DISEASE LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,PEDIAT PULM UNIT,BOSTON,MA 02114. MASSACHUSETTS GEN HOSP,RENAL UNIT,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER LUNG ASSOC PI NEW YORK PA 1740 BROADWAY, NEW YORK, NY 10019 SN 0003-0805 J9 AM REV RESPIR DIS JI Am. Rev. Respir. Dis. PD APR PY 1993 VL 147 IS 4 SU S BP A943 EP A943 PG 1 WC Respiratory System SC Respiratory System GA LB149 UT WOS:A1993LB14903618 ER PT J AU KRADIN, R XIA, W PIKE, M AF KRADIN, R XIA, W PIKE, M TI PULMONARY DENDRITIC CELLS SHOW ENHANCED MOTILITY AND PULMONARY MIGRATION IN RESPONSE TO TH1 LYMPHOKINES INVIVO SO AMERICAN REVIEW OF RESPIRATORY DISEASE LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,BOSTON,MA 02114. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER LUNG ASSOC PI NEW YORK PA 1740 BROADWAY, NEW YORK, NY 10019 SN 0003-0805 J9 AM REV RESPIR DIS JI Am. Rev. Respir. Dis. PD APR PY 1993 VL 147 IS 4 SU S BP A473 EP A473 PG 1 WC Respiratory System SC Respiratory System GA LB149 UT WOS:A1993LB14901797 ER PT J AU KRADIN, R PINTO, C RODBERG, G PREFFER, F DOMKOWSKI, D AF KRADIN, R PINTO, C RODBERG, G PREFFER, F DOMKOWSKI, D TI CD4+ LYMPHOCYTES IN LUNG ARE TYPE-2 MEMORY CELLS THAT COEXPRESS THE CD45RB EPITOPE AT DIMINISHED LEVELS SO AMERICAN REVIEW OF RESPIRATORY DISEASE LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER LUNG ASSOC PI NEW YORK PA 1740 BROADWAY, NEW YORK, NY 10019 SN 0003-0805 J9 AM REV RESPIR DIS JI Am. Rev. Respir. Dis. PD APR PY 1993 VL 147 IS 4 SU S BP A11 EP A11 PG 1 WC Respiratory System SC Respiratory System GA LB149 UT WOS:A1993LB14900004 ER PT J AU LADERBERG, RK SYSTROM, DM FISHMAN, RS BOUCHER, CA WAIN, JC GINNS, LC AF LADERBERG, RK SYSTROM, DM FISHMAN, RS BOUCHER, CA WAIN, JC GINNS, LC TI CARDIAC-FUNCTION DURING EXERCISE BEFORE AND AFTER SINGLE-LUNG TRANSPLANTATION FOR CHRONIC OBSTRUCTIVE PULMONARY-DISEASE SO AMERICAN REVIEW OF RESPIRATORY DISEASE LA English DT Meeting Abstract C1 HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,PULM & CRIT CARE UNIT,BOSTON,MA 02114. HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,GEN THORAC SURG UNIT,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER LUNG ASSOC PI NEW YORK PA 1740 BROADWAY, NEW YORK, NY 10019 SN 0003-0805 J9 AM REV RESPIR DIS JI Am. Rev. Respir. Dis. PD APR PY 1993 VL 147 IS 4 SU S BP A336 EP A336 PG 1 WC Respiratory System SC Respiratory System GA LB149 UT WOS:A1993LB14901259 ER PT J AU LADERBERG, RK ROSE, J SYSTROM, DM AF LADERBERG, RK ROSE, J SYSTROM, DM TI DICHLOROACETATE AND SKELETAL-MUSCLE PHI REGULATION DURING EXERCISE SO AMERICAN REVIEW OF RESPIRATORY DISEASE LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,PULM & CRIT CARE,BOSTON,MA 02114. HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,NMR LAB PHYSIOL CHEM,BOSTON,MA 02115. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER LUNG ASSOC PI NEW YORK PA 1740 BROADWAY, NEW YORK, NY 10019 SN 0003-0805 J9 AM REV RESPIR DIS JI Am. Rev. Respir. Dis. PD APR PY 1993 VL 147 IS 4 SU S BP A192 EP A192 PG 1 WC Respiratory System SC Respiratory System GA LB149 UT WOS:A1993LB14900712 ER PT J AU LEEVERS, AM SIMON, PM MURTY, JL LANDRY, DM DEMPSEY, JA AF LEEVERS, AM SIMON, PM MURTY, JL LANDRY, DM DEMPSEY, JA TI EFFECTS OF INSPIRATORY FLOW-RATE DURING MECHANICAL VENTILATION ON NEUROMECHANICAL INHIBITION OF INSPIRATORY MUSCLE-ACTIVITY SO AMERICAN REVIEW OF RESPIRATORY DISEASE LA English DT Meeting Abstract C1 UNIV WISCONSIN,MADISON,WI 53705. MIDDLETON VET ADM HOSP,MADISON,WI 53705. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER LUNG ASSOC PI NEW YORK PA 1740 BROADWAY, NEW YORK, NY 10019 SN 0003-0805 J9 AM REV RESPIR DIS JI Am. Rev. Respir. Dis. PD APR PY 1993 VL 147 IS 4 SU S BP A163 EP A163 PG 1 WC Respiratory System SC Respiratory System GA LB149 UT WOS:A1993LB14900595 ER PT J AU LEVINE, SM PETERS, JI ANZUETO, A TILLIS, WP CALHOON, J TRINKLE, JK JENKINSON, SG BRYAN, CL AF LEVINE, SM PETERS, JI ANZUETO, A TILLIS, WP CALHOON, J TRINKLE, JK JENKINSON, SG BRYAN, CL TI ASPERGILLUS INFECTION IN SINGLE-LUNG TRANSPLANT RECIPIENTS SO AMERICAN REVIEW OF RESPIRATORY DISEASE LA English DT Meeting Abstract C1 UNIV TEXAS,HLTH SCI CTR,SAN ANTONIO,TX 78284. AUDIE L MURPHY MEM VET ADM MED CTR,SAN ANTONIO,TX 78284. NR 0 TC 4 Z9 4 U1 0 U2 0 PU AMER LUNG ASSOC PI NEW YORK PA 1740 BROADWAY, NEW YORK, NY 10019 SN 0003-0805 J9 AM REV RESPIR DIS JI Am. Rev. Respir. Dis. PD APR PY 1993 VL 147 IS 4 SU S BP A599 EP A599 PG 1 WC Respiratory System SC Respiratory System GA LB149 UT WOS:A1993LB14902284 ER PT J AU LEVINE, SM PETERS, JI BRYAN, CL ANZUETO, A TRINKLE, K JENKINSON, SG AF LEVINE, SM PETERS, JI BRYAN, CL ANZUETO, A TRINKLE, K JENKINSON, SG TI MEDICAL COMPLICATIONS IN LUNG-TRANSPLANT RECIPIENTS SO AMERICAN REVIEW OF RESPIRATORY DISEASE LA English DT Meeting Abstract C1 UNIV TEXAS,HLTH SCI CTR,SAN ANTONIO,TX 78284. AUDIE L MURPHY MEM VET ADM MED CTR,SAN ANTONIO,TX 78284. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER LUNG ASSOC PI NEW YORK PA 1740 BROADWAY, NEW YORK, NY 10019 SN 0003-0805 J9 AM REV RESPIR DIS JI Am. Rev. Respir. Dis. PD APR PY 1993 VL 147 IS 4 SU S BP A602 EP A602 PG 1 WC Respiratory System SC Respiratory System GA LB149 UT WOS:A1993LB14902297 ER PT J AU MEYERS, BF FISCHBEIN, MP DONAHUE, DM WAIN, JC AF MEYERS, BF FISCHBEIN, MP DONAHUE, DM WAIN, JC TI CHARACTERIZATION OF DECREASED DNA METHYLATION IN NONSMALL CELL LUNG CANCERS (NSCLC) WITH A REPEATED SEQUENCE OLIGONUCLEOTIDE SO AMERICAN REVIEW OF RESPIRATORY DISEASE LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,THORAC SURG UNIT,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER LUNG ASSOC PI NEW YORK PA 1740 BROADWAY, NEW YORK, NY 10019 SN 0003-0805 J9 AM REV RESPIR DIS JI Am. Rev. Respir. Dis. PD APR PY 1993 VL 147 IS 4 SU S BP A154 EP A154 PG 1 WC Respiratory System SC Respiratory System GA LB149 UT WOS:A1993LB14900559 ER PT J AU NISHIMURA, M KACMAREK, RM BARKER, S KIMBALL, W AF NISHIMURA, M KACMAREK, RM BARKER, S KIMBALL, W TI EFFECT OF INSPIRATORY GAS-FLOW PATTERN ON LUNG COMPARTMENT DISTRIBUTION - A LUNG MODEL STUDY SO AMERICAN REVIEW OF RESPIRATORY DISEASE LA English DT Meeting Abstract C1 HARVARD UNIV,SCH MED,DEPT ANESTHESIA,BOSTON,MA 02115. HARVARD UNIV,SCH MED,DEPT RESP CARE,BOSTON,MA 02115. MASSACHUSETTS GEN HOSP,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER LUNG ASSOC PI NEW YORK PA 1740 BROADWAY, NEW YORK, NY 10019 SN 0003-0805 J9 AM REV RESPIR DIS JI Am. Rev. Respir. Dis. PD APR PY 1993 VL 147 IS 4 SU S BP A880 EP A880 PG 1 WC Respiratory System SC Respiratory System GA LB149 UT WOS:A1993LB14903368 ER PT J AU NISHIMURA, M KIRMSE, M KIMBALL, W TOBIN, MJ KACMAREK, RM AF NISHIMURA, M KIRMSE, M KIMBALL, W TOBIN, MJ KACMAREK, RM TI MEASUREMENT OF AUTO-PEEP - EFFECT OF METHODOLOGY SO AMERICAN REVIEW OF RESPIRATORY DISEASE LA English DT Meeting Abstract C1 HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEPT ANESTHESIA,BOSTON,MA 02114. HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEPT RESP CARE,BOSTON,MA 02114. LOYOLA UNIV,DEPT MED,HINES,IL. VET ADM MED CTR,HINES,IL 60141. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER LUNG ASSOC PI NEW YORK PA 1740 BROADWAY, NEW YORK, NY 10019 SN 0003-0805 J9 AM REV RESPIR DIS JI Am. Rev. Respir. Dis. PD APR PY 1993 VL 147 IS 4 SU S BP A878 EP A878 PG 1 WC Respiratory System SC Respiratory System GA LB149 UT WOS:A1993LB14903360 ER PT J AU PETERS, JI LEVINE, SM ANZUETO, A BRYAN, CL CALHOON, JH TRINKLE, JK JENKINSON, SG AF PETERS, JI LEVINE, SM ANZUETO, A BRYAN, CL CALHOON, JH TRINKLE, JK JENKINSON, SG TI INFECTIOUS COMPLICATIONS IN SINGLE-LUNG TRANSPLANT RECIPIENTS - A 5-YEAR EXPERIENCE SO AMERICAN REVIEW OF RESPIRATORY DISEASE LA English DT Meeting Abstract C1 UNIV TEXAS,HLTH SCI CTR,DEPT MED,SAN ANTONIO,TX 78284. UNIV TEXAS,HLTH SCI CTR,DEPT SURG,SAN ANTONIO,TX 78284. AUDIE L MURPHY MEM VET ADM MED CTR,SAN ANTONIO,TX 78284. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER LUNG ASSOC PI NEW YORK PA 1740 BROADWAY, NEW YORK, NY 10019 SN 0003-0805 J9 AM REV RESPIR DIS JI Am. Rev. Respir. Dis. PD APR PY 1993 VL 147 IS 4 SU S BP A601 EP A601 PG 1 WC Respiratory System SC Respiratory System GA LB149 UT WOS:A1993LB14902292 ER PT J AU ROVIRA, I CHEN, TY WINKLER, M KAWAI, N BLOCH, K ZAPOL, WM AF ROVIRA, I CHEN, TY WINKLER, M KAWAI, N BLOCH, K ZAPOL, WM TI INCREASED PLASMA CGMP AND PULMONARY VASODILATION WITH INHALED NITRIC-OXIDE IN AN OVINE ARDS MODEL SO AMERICAN REVIEW OF RESPIRATORY DISEASE LA English DT Meeting Abstract C1 HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEPT MED,BOSTON,MA 02114. HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEPT ANESTHESIA,BOSTON,MA 02114. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER LUNG ASSOC PI NEW YORK PA 1740 BROADWAY, NEW YORK, NY 10019 SN 0003-0805 J9 AM REV RESPIR DIS JI Am. Rev. Respir. Dis. PD APR PY 1993 VL 147 IS 4 SU S BP A720 EP A720 PG 1 WC Respiratory System SC Respiratory System GA LB149 UT WOS:A1993LB14902760 ER PT J AU SILMAN, JB BRYAN, CL CALHOON, JH AF SILMAN, JB BRYAN, CL CALHOON, JH TI CRYOPRESERVATION WITH LAZAROID U74006F IN DOG LUNG AUTOTRANSPLANTATION SO AMERICAN REVIEW OF RESPIRATORY DISEASE LA English DT Meeting Abstract C1 UNIV TEXAS,HLTH SCI CTR,DEPT MED,SAN ANTONIO,TX 78284. UNIV TEXAS,HLTH SCI CTR,DEPT SURG,SAN ANTONIO,TX 78284. AUDIE L MURPHY MEM VET ADM MED CTR,SAN ANTONIO,TX 78284. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER LUNG ASSOC PI NEW YORK PA 1740 BROADWAY, NEW YORK, NY 10019 SN 0003-0805 J9 AM REV RESPIR DIS JI Am. Rev. Respir. Dis. PD APR PY 1993 VL 147 IS 4 SU S BP A263 EP A263 PG 1 WC Respiratory System SC Respiratory System GA LB149 UT WOS:A1993LB14900975 ER PT J AU SILMAN, JB ANDRADE, F ANZUETO, A LEVINE, SM MAXWELL, LC JENKINSON, SG AF SILMAN, JB ANDRADE, F ANZUETO, A LEVINE, SM MAXWELL, LC JENKINSON, SG TI DIAPHRAGM MUSCLE FUNCTION AFTER LAZAROIDS (U74006F) EXPOSURE SO AMERICAN REVIEW OF RESPIRATORY DISEASE LA English DT Meeting Abstract C1 UNIV TEXAS,HLTH SCI CTR,DEPT MED,SAN ANTONIO,TX 78284. UNIV TEXAS,HLTH SCI CTR,DEPT PHYSIOL,SAN ANTONIO,TX 78284. AUDIE L MURPHY MEM VET ADM MED CTR,SAN ANTONIO,TX 78284. RI Andrade, Francisco/F-1258-2011 OI Andrade, Francisco/0000-0002-2460-5798 NR 2 TC 0 Z9 0 U1 0 U2 0 PU AMER LUNG ASSOC PI NEW YORK PA 1740 BROADWAY, NEW YORK, NY 10019 SN 0003-0805 J9 AM REV RESPIR DIS JI Am. Rev. Respir. Dis. PD APR PY 1993 VL 147 IS 4 SU S BP A237 EP A237 PG 1 WC Respiratory System SC Respiratory System GA LB149 UT WOS:A1993LB14900883 ER PT J AU SIMON, PM LEEVERS, AM MURTY, JL LANDRY, DM AF SIMON, PM LEEVERS, AM MURTY, JL LANDRY, DM TI VOLUME AND FREQUENCY THRESHOLDS FOR INHIBITION OF INSPIRATORY MOTOR OUTPUT DURING MECHANICAL VENTILATION SO AMERICAN REVIEW OF RESPIRATORY DISEASE LA English DT Meeting Abstract C1 UNIV WISCONSIN,MADISON,WI 53705. MIDDLETON VET ADM HOSP,MADISON,WI 53705. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER LUNG ASSOC PI NEW YORK PA 1740 BROADWAY, NEW YORK, NY 10019 SN 0003-0805 J9 AM REV RESPIR DIS JI Am. Rev. Respir. Dis. PD APR PY 1993 VL 147 IS 4 SU S BP A166 EP A166 PG 1 WC Respiratory System SC Respiratory System GA LB149 UT WOS:A1993LB14900608 ER PT J AU SUSANTO, I LAWRENCE, RA DENEKE, SM BUKOWSKI, DM JENKINSON, SG AF SUSANTO, I LAWRENCE, RA DENEKE, SM BUKOWSKI, DM JENKINSON, SG TI GLUTATHIONE REDOX CYCLE IS IMPORTANT IN PROTECTION AGAINST TYPE-II ALVEOLAR EPITHELIAL-CELL INJURY CAUSED BY H2O2 SO AMERICAN REVIEW OF RESPIRATORY DISEASE LA English DT Meeting Abstract C1 UNIV TEXAS,HLTH SCI CTR,SAN ANTONIO,TX 78284. AUDIE L MURPHY MEM VET ADM MED CTR,SAN ANTONIO,TX 78284. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER LUNG ASSOC PI NEW YORK PA 1740 BROADWAY, NEW YORK, NY 10019 SN 0003-0805 J9 AM REV RESPIR DIS JI Am. Rev. Respir. Dis. PD APR PY 1993 VL 147 IS 4 SU S BP A152 EP A152 PG 1 WC Respiratory System SC Respiratory System GA LB149 UT WOS:A1993LB14900552 ER PT J AU TILLIS, WP ANZUETO, A LEVINE, SM PETERS, JI CALHOON, JH TRINKLE, JK JENKINSON, SG BRYAN, CL AF TILLIS, WP ANZUETO, A LEVINE, SM PETERS, JI CALHOON, JH TRINKLE, JK JENKINSON, SG BRYAN, CL TI OUTCOME OF OBLITERATIVE BRONCHIOLITIS IN SINGLE-LUNG TRANSPLANT RECIPIENTS SO AMERICAN REVIEW OF RESPIRATORY DISEASE LA English DT Meeting Abstract C1 UNIV TEXAS,HLTH SCI CTR,DEPT MED,SAN ANTONIO,TX 78284. UNIV TEXAS,HLTH SCI CTR,DEPT SURG,SAN ANTONIO,TX 78284. AUDIE L MURPHY MEM VET ADM MED CTR,SAN ANTONIO,TX 78284. NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER LUNG ASSOC PI NEW YORK PA 1740 BROADWAY, NEW YORK, NY 10019 SN 0003-0805 J9 AM REV RESPIR DIS JI Am. Rev. Respir. Dis. PD APR PY 1993 VL 147 IS 4 SU S BP A198 EP A198 PG 1 WC Respiratory System SC Respiratory System GA LB149 UT WOS:A1993LB14900734 ER PT J AU VENEGAS, JG AF VENEGAS, JG TI PULMONARY IMAGING OF LOCAL VENTILATION-PERFUSION RATIOS, PERFUSION, ARTERIAL TRANSIT-TIME AND ARTERIAL PATH VOLUME USING PET SO AMERICAN REVIEW OF RESPIRATORY DISEASE LA English DT Meeting Abstract C1 HARVARD UNIV,SCH MED,BOSTON,MA 02115. MASSACHUSETTS GEN HOSP,DEPT ANESTHESIA & BIOMED ENGN,BOSTON,MA 02114. NR 1 TC 0 Z9 0 U1 0 U2 0 PU AMER LUNG ASSOC PI NEW YORK PA 1740 BROADWAY, NEW YORK, NY 10019 SN 0003-0805 J9 AM REV RESPIR DIS JI Am. Rev. Respir. Dis. PD APR PY 1993 VL 147 IS 4 SU S BP A779 EP A779 PG 1 WC Respiratory System SC Respiratory System GA LB149 UT WOS:A1993LB14902975 ER PT J AU WILSON, DJ AF WILSON, DJ TI THE RELIABILITY AND VALIDITY OF THE METHYLENE-BLUE TEST TO DETECT ASPIRATION IN PATIENTS WITH A TRACHEOSTOMY TUBE SO AMERICAN REVIEW OF RESPIRATORY DISEASE LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,INST HLTH PROFESS,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER LUNG ASSOC PI NEW YORK PA 1740 BROADWAY, NEW YORK, NY 10019 SN 0003-0805 J9 AM REV RESPIR DIS JI Am. Rev. Respir. Dis. PD APR PY 1993 VL 147 IS 4 SU S BP A409 EP A409 PG 1 WC Respiratory System SC Respiratory System GA LB149 UT WOS:A1993LB14901551 ER PT J AU XIA, W PINTO, C KRADIN, R AF XIA, W PINTO, C KRADIN, R TI LUNG PHAGOCYTES SEQUESTER PARTICULATE ANTIGENS AND LIMIT THEIR ACCESS TO IA+ INTERSTITIAL DENDRITIC CELLS INVIVO SO AMERICAN REVIEW OF RESPIRATORY DISEASE LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER LUNG ASSOC PI NEW YORK PA 1740 BROADWAY, NEW YORK, NY 10019 SN 0003-0805 J9 AM REV RESPIR DIS JI Am. Rev. Respir. Dis. PD APR PY 1993 VL 147 IS 4 SU S BP A209 EP A209 PG 1 WC Respiratory System SC Respiratory System GA LB149 UT WOS:A1993LB14900775 ER PT J AU BREWER, TF WILSON, ME FINEBERG, HV AF BREWER, TF WILSON, ME FINEBERG, HV TI MAKING THE BLOOD-SUPPLY SAFER - RESPONSE SO ANNALS OF INTERNAL MEDICINE LA English DT Letter ID TRANSFUSION C1 MT AUBURN HOSP,CAMBRIDGE,MA 02138. HARVARD UNIV,SCH PUBL HLTH,BOSTON,MA 02115. RP BREWER, TF (reprint author), MASSACHUSETTS GEN HOSP,BOSTON,MA 02114, USA. NR 5 TC 0 Z9 0 U1 0 U2 0 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 SN 0003-4819 J9 ANN INTERN MED JI Ann. Intern. Med. PD APR 1 PY 1993 VL 118 IS 7 BP 574 EP 575 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA KU079 UT WOS:A1993KU07900034 ER PT J AU SIDTIS, JJ GATSONIS, C PRICE, RW SINGER, EJ COLLIER, AC RICHMAN, DD HIRSCH, MS SCHAERF, FW FISCHL, MA KIEBURTZ, K SIMPSON, D KOCH, MA FEINBERG, J DAFNI, U AF SIDTIS, JJ GATSONIS, C PRICE, RW SINGER, EJ COLLIER, AC RICHMAN, DD HIRSCH, MS SCHAERF, FW FISCHL, MA KIEBURTZ, K SIMPSON, D KOCH, MA FEINBERG, J DAFNI, U TI ZIDOVUDINE TREATMENT OF THE AIDS DEMENTIA COMPLEX - RESULTS OF A PLACEBO-CONTROLLED TRIAL SO ANNALS OF NEUROLOGY LA English DT Article ID ACQUIRED-IMMUNODEFICIENCY-SYNDROME; VACUOLAR MYELOPATHY; HIV-1 INFECTION; AZT AB The efficacy of two doses of zidovudine was examined for the treatment of the acquired immunodeficiency syndrome (AIDS) dementia complex in a randomized, double-blinded, placebo-controlled trial conducted at nine study centers. For the initial 16 weeks, 40 subjects with mild to moderate AIDS dementia complex were randomized to one of three treatment arms: 400 mg of zidovudine five times daily, 200 mg of zidovudine five times daily, or placebo five times daily. After week 16, patients initially randomized to the placebo group were rerandomized to one of the two zidovudine treatment arms. The primary efficacy end point was improvement in performance on a battery of seven neuropsychological tests; the secondary end point was improvement on a protocol neurological evaluation directed at the cardinal features of the AIDS dementia complex. For the initial 16-week period, average z scores based on the neuropsychological test battery revealed a significant improvement in the combined treatment groups compared to the placebo group; however, when the two treatment groups were compared separately to the placebo group, only the group receiving the higher zidovudine dose exhibited significant improvement. After rerandomization of the placebo patients to one of the two treatment arms at week 16, this group also showed significant improvement in the average neuropsychological z score by week 32. These results extend previous observations that indicate a therapeutic benefit of zidovudine for the treatment of AIDS dementia complex. C1 HARVARD UNIV,SCH PUBL HLTH,AIDS CLIN TRIALS GRP STAT & DATA ANAL CTR,BOSTON,MA 02115. UNIV ROCHESTER,SCH MED,DEPT NEUROL,ROCHESTER,NY 14627. MASSACHUSETTS GEN HOSP,INFECT DIS UNIT,BOSTON,MA 02114. JOHNS HOPKINS UNIV HOSP,DIV INFECT DIS,BALTIMORE,MD 21205. UNIV MIAMI,SCH MED,DEPT MED,MIAMI,FL 33152. CUNY MT SINAI SCH MED,DEPT MED,NEW YORK,NY 10029. RES TRIANGLE INST,RES TRIANGLE PK,NC 27709. NIAID,BETHESDA,MD 20892. MEM SLOAN KETTERING CANC CTR,DEPT NEUROL,NEW YORK,NY 10021. UNIV CALIF LOS ANGELES,DEPT NEUROL,LOS ANGELES,CA 90024. UNIV WASHINGTON,DEPT MED,SEATTLE,WA 98195. UNIV CALIF SAN DIEGO,DEPT PATHOL,SAN DIEGO,CA 92103. UNIV CALIF SAN DIEGO,DEPT MED,SAN DIEGO,CA 92103. RP SIDTIS, JJ (reprint author), UNIV MINNESOTA HOSP & CLIN,DEPT NEUROL,BOX 295,420 DELAWARE ST SE,MINNEAPOLIS,MN 55455, USA. FU NIAID NIH HHS [AI-27670]; NINDS NIH HHS [NS25701, NS26643] NR 21 TC 226 Z9 229 U1 1 U2 1 PU LITTLE BROWN CO PI BOSTON PA 34 BEACON STREET, BOSTON, MA 02108-1493 SN 0364-5134 J9 ANN NEUROL JI Ann. Neurol. PD APR PY 1993 VL 33 IS 4 BP 343 EP 349 DI 10.1002/ana.410330403 PG 7 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA KW781 UT WOS:A1993KW78100002 PM 8489204 ER PT J AU PELLEGRINI, JW LIPTON, SA AF PELLEGRINI, JW LIPTON, SA TI DELAYED ADMINISTRATION OF MEMANTINE PREVENTS N-METHYL-D-ASPARTATE RECEPTOR-MEDIATED NEUROTOXICITY SO ANNALS OF NEUROLOGY LA English DT Note ID RETINAL GANGLION-CELLS; AMINO-ACID RECEPTORS; RAT; ANTAGONISTS; INVITRO; DISEASE AB Increasing evidence supports the hypothesis that escalating levels of excitatory amino acids (EAAs) are responsible for neuronal cell death in a variety of acute neurological conditions including hypoxia/ischemia, trauma, seizures, and hypoglycemia. EAAs may also contribute to several chronic neurodegenerative diseases including Huntington's disease, parkinsonism, and acquired immunodeficiency syndrome dementia. A predominant form of neurotoxicity appears to be mediated by excessive activation of the N-methyl-D-aspartate subtype of glutamate receptor. This laboratory recently reported that memantine, an antiparkinsonian drug, is a potent N-methyl-D-aspartate antagonist capable of preventing the death of central neurons both in vitro and in vivo when given coincident to an EAA insult. In the present study, we found that 12 muM memantine prevented the death of neonatal rat retinal ganglion cells in primary culture when administered up to 4 hours after the initiation of N-methyl-D-aspartate receptor-mediated neurotoxicity. C1 CHILDRENS HOSP MED CTR,DEPT NEUROL,CELLULAR & MOLEC NEUROSCI LAB,BOSTON,MA 02115. CHILDRENS HOSP MED CTR,JOINT PROGRAM NEONATOL,BOSTON,MA 02115. HARVARD UNIV,SCH MED,PROGRAM NEUROSCI,BOSTON,MA 02115. MASSACHUSETTS GEN HOSP,DEPT NEUROL,BOSTON,MA 02114. BRIGHAM & WOMENS HOSP,DEPT NEUROL,BOSTON,MA 02115. FU NEI NIH HHS [EY05477, EY09024]; NICHD NIH HHS [HD29587] NR 16 TC 62 Z9 64 U1 1 U2 1 PU LITTLE BROWN CO PI BOSTON PA 34 BEACON STREET, BOSTON, MA 02108-1493 SN 0364-5134 J9 ANN NEUROL JI Ann. Neurol. PD APR PY 1993 VL 33 IS 4 BP 403 EP 407 DI 10.1002/ana.410330414 PG 5 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA KW781 UT WOS:A1993KW78100013 PM 8098195 ER PT J AU CHENEY, ML BHATT, S GOOGE, P HIBBERD, PL AF CHENEY, ML BHATT, S GOOGE, P HIBBERD, PL TI ANGIOLYMPHOID HYPERPLASIA WITH EOSINOPHILIA (HISTIOCYTOID HEMANGIOMA) - EVALUATION OF TREATMENT OPTIONS SO ANNALS OF OTOLOGY RHINOLOGY AND LARYNGOLOGY LA English DT Article DE ANGIOLYMPHOID HYPERPLASIA; HISTIOCYTOID HEMANGIOMA; TEMPOROPARIETAL FASCIAL FLAP ID KIMURAS DISEASE; SKIN AB Angiolymphoid hyperplasia with eosinophilia is an uncommon benign vascular proliferative lesion of unknown cause. In this report, a case is presented of a patient who was confirmed to be positive for human immunodeficiency virus and in whom the lesion had shown rapid accelerated growth. The case is used to illustrate a variety of therapeutic techniques and to evaluate the effectiveness of the various alternatives in the treatment of this unusual clinical problem. Long-term follow-up after radical excision of the tumor mass is presented. C1 MASSACHUSETTS EYE & EAR INFIRM,MED UNIT,BOSTON,MA 02114. HARVARD UNIV,SCH MED,DEPT OTOLARYNGOL,BOSTON,MA 02115. MASSACHUSETTS GEN HOSP,INFECT DIS UNIT,BOSTON,MA 02114. UNIV TENNESSEE,MED CTR,DEPT PATHOL,KNOXVILLE,TN 37996. RP CHENEY, ML (reprint author), MASSACHUSETTS EYE & EAR INFIRM,DEPT OTOLARYNGOL,BOSTON,MA 02114, USA. NR 17 TC 26 Z9 28 U1 0 U2 0 PU ANNALS PUBL CO PI ST LOUIS PA 4507 LACLEDE AVE, ST LOUIS, MO 63108 SN 0003-4894 J9 ANN OTO RHINOL LARYN JI Ann. Otol. Rhinol. Laryngol. PD APR PY 1993 VL 102 IS 4 BP 303 EP 308 PN 1 PG 6 WC Otorhinolaryngology SC Otorhinolaryngology GA KY072 UT WOS:A1993KY07200010 PM 8476172 ER PT J AU WEBER, AL LOEWENHEIM, H AF WEBER, AL LOEWENHEIM, H TI IMAGING CASE-STUDY OF THE MONTH - LYMPHOMA OF THE SPHENOID SINUS PRESENTING AS AN EXPANSILE MASS SO ANNALS OF OTOLOGY RHINOLOGY AND LARYNGOLOGY LA English DT Note ID PARA-NASAL SINUSES; DIFFERENTIATION; TUMORS; CAVITY; NOSE RP WEBER, AL (reprint author), MASSACHUSETTS EYE & EAR INFIRM,DEPT RADIOL,243 CHARLES ST,BOSTON,MA 02114, USA. NR 11 TC 10 Z9 10 U1 0 U2 0 PU ANNALS PUBL CO PI ST LOUIS PA 4507 LACLEDE AVE, ST LOUIS, MO 63108 SN 0003-4894 J9 ANN OTO RHINOL LARYN JI Ann. Otol. Rhinol. Laryngol. PD APR PY 1993 VL 102 IS 4 BP 318 EP 321 PN 1 PG 4 WC Otorhinolaryngology SC Otorhinolaryngology GA KY072 UT WOS:A1993KY07200013 PM 8476174 ER PT J AU ROGGO, A WOOD, WC OTTINGER, LW AF ROGGO, A WOOD, WC OTTINGER, LW TI CARCINOID-TUMORS OF THE APPENDIX SO ANNALS OF SURGERY LA English DT Article ID GASTROINTESTINAL-TRACT; HORMONE PRODUCTION; SMALL-INTESTINE; PROGNOSIS; CELLS AB Objective A retrospective study of 41 patients with histologically confirmed diagnosis of appendix carcinoid tumors was undertaken by reviewing the surgical records at Massachusetts General Hospital. Methods There were 8 male and 33 female patients (mean age 32 years). Twenty-two patients (54%) presented with signs and symptoms suggestive of acute appendicitis. In 19 patients (46%) the lesions were discovered incidentally. The tumors were located in 32 patients at the tip, in 6 patients in the middle third, and in 3 patients at the base of the appendix. The tumor was less than 1 cm in diameter in 32 patients, between 1 and 2 cm in 7 patients, and was bigger than 2 cm in 2 patients. In 29 patients, the depth of tumor penetration was confined to the submucosa or to the muscle layers of the appendix, and in 8 patients the serosa was involved. In 4 patients, evidence of tumor extension into the meso-appendicular fat was present, including one patient with a tumor bigger than 2 cm and local lymph-node metastases. Forty patients underwent appendectomy alone. One patient with a tumor size bigger than 2 cm in diameter with positive lymph nodes in the mesoappendix underwent secondary right hemicolectomy. Complete follow-up was achieved in 35 patients, and all patients remained free of tumor recurrence. Conclusions The authors conclude that appendiceal carcinoids are rare and most often are asymptomatic. Tumors of less than 1 cm are adequately managed by appendectomy alone. The appropriate treatment for tumors of 1 to 2 cm continues to be controversial. Right hemicolectomy is recommended for all tumors larger than 2 cm, whereas preference for an aggressive approach should be given in young patients. C1 HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,GEN SURG SERV,BOSTON,MA 02114. NR 55 TC 78 Z9 81 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0003-4932 J9 ANN SURG JI Ann. Surg. PD APR PY 1993 VL 217 IS 4 BP 385 EP 390 DI 10.1097/00000658-199304000-00010 PG 6 WC Surgery SC Surgery GA KY266 UT WOS:A1993KY26600010 PM 8466309 ER PT J AU RUBIN, RH TOLKOFFRUBIN, NE AF RUBIN, RH TOLKOFFRUBIN, NE TI ANTIMICROBIAL STRATEGIES IN THE CARE OF ORGAN TRANSPLANT RECIPIENTS SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY LA English DT Review ID GANCICLOVIR-RESISTANT CYTOMEGALOVIRUS; BONE-MARROW TRANSPLANTS; RENAL-TRANSPLANTATION; TRIMETHOPRIM-SULFAMETHOXAZOLE; FUNGAL-INFECTIONS; FOSCARNET THERAPY; CONTROLLED TRIAL; VIRUS INFECTION; IMMUNE GLOBULIN; ORAL ACYCLOVIR C1 MASSACHUSETTS GEN HOSP,INFECT DIS UNIT,BOSTON,MA 02114. MASSACHUSETTS GEN HOSP,MED SERV,BOSTON,MA 02114. HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115. RP RUBIN, RH (reprint author), MASSACHUSETTS GEN HOSP,TRANSPLANTAT DIALYSIS UNIT,BOSTON,MA 02114, USA. NR 62 TC 66 Z9 69 U1 0 U2 0 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171 SN 0066-4804 J9 ANTIMICROB AGENTS CH JI Antimicrob. Agents Chemother. PD APR PY 1993 VL 37 IS 4 BP 619 EP 624 PG 6 WC Microbiology; Pharmacology & Pharmacy SC Microbiology; Pharmacology & Pharmacy GA KV991 UT WOS:A1993KV99100001 PM 8494357 ER PT J AU MOHIMEN, A AHMED, AR AF MOHIMEN, A AHMED, AR TI IMMUNOBLOT ASSAY TO STUDY THE PEMPHIGUS-VULGARIS ANTIGEN IN NORMAL HUMAN EPIDERMIS AND COLO-16 CELL-LINE SO ARCHIVES OF DERMATOLOGICAL RESEARCH LA English DT Note DE PEMPHIGUS-VULGARIS; ABSORPTION STUDIES; SENSITIVE MODIFIED IMMUNOBLOT ASSAY; COLO-16 CELL LINES ID FOLIACEUS; IDENTIFICATION; MEMBRANE; AUTOANTIBODIES; ANTIBODIES; SKIN C1 HARVARD UNIV,SCH DENT MED,DEPT ORAL PATHOL,CTR BLOOD RES,800 HUNTINGTON AVE,BOSTON,MA 02115. FU NEI NIH HHS [EYO8379]; NIDCR NIH HHS [DEO9978] NR 15 TC 7 Z9 7 U1 0 U2 0 PU SPRINGER VERLAG PI NEW YORK PA 175 FIFTH AVE, NEW YORK, NY 10010 SN 0340-3696 J9 ARCH DERMATOL RES JI Arch. Dermatol. Res. PD APR PY 1993 VL 285 IS 3 BP 165 EP 167 DI 10.1007/BF01112920 PG 3 WC Dermatology SC Dermatology GA KX441 UT WOS:A1993KX44100010 PM 8503697 ER PT J AU MOHIMEN, A NARULA, M RUOCCO, V PISANI, M AHMED, AR AF MOHIMEN, A NARULA, M RUOCCO, V PISANI, M AHMED, AR TI PRESENCE OF THE AUTOANTIBODY IN HEALTHY RELATIVES OF ITALIAN PATIENTS WITH PEMPHIGUS-VULGARIS SO ARCHIVES OF DERMATOLOGICAL RESEARCH LA English DT Note DE HEALTHY RELATIVES; PEMPHIGUS ANTIBODY; PEMPHIGUS-VULGARIS; INDIRECT IMMUNOFLUORESCENCE; IMMUNOBLOT ASSAY ID SYSTEMIC LUPUS-ERYTHEMATOSUS C1 HARVARD UNIV,SCH DENT MED,DEPT ORAL PATHOL,CTR BLOOD RES,800 HUNTINGTON AVE,BOSTON,MA 02115. UNIV NAPLES,FAC MED & CHIRURG 1,DERMOSIFILOPAT CLIN,I-80138 NAPLES,ITALY. FU NEI NIH HHS [EY08379]; NIDCR NIH HHS [DE09978] NR 18 TC 22 Z9 22 U1 0 U2 0 PU SPRINGER VERLAG PI NEW YORK PA 175 FIFTH AVE, NEW YORK, NY 10010 SN 0340-3696 J9 ARCH DERMATOL RES JI Arch. Dermatol. Res. PD APR PY 1993 VL 285 IS 3 BP 176 EP 177 DI 10.1007/BF01112924 PG 2 WC Dermatology SC Dermatology GA KX441 UT WOS:A1993KX44100014 PM 8503701 ER PT J AU ROOK, AH VOWELS, BR JAWORSKY, C SINGH, A LESSIN, SR AF ROOK, AH VOWELS, BR JAWORSKY, C SINGH, A LESSIN, SR TI THE IMMUNOPATHOGENESIS OF CUTANEOUS T-CELL LYMPHOMA - ABNORMAL CYTOKINE PRODUCTION BY SEZARY T-CELLS SO ARCHIVES OF DERMATOLOGY LA English DT Editorial Material ID INTERCELLULAR-ADHESION MOLECULE-1; TUMOR NECROSIS FACTOR; MYCOSIS-FUNGOIDES; EXTRACORPOREAL PHOTOCHEMOTHERAPY; GAMMA-INTERFERON; PROLIFERATION; EXPRESSION; SUBSETS; CLONES C1 PHILADELPHIA VET AFFAIRS MED CTR,PHILADELPHIA,PA 19104. RP ROOK, AH (reprint author), UNIV PENN,DEPT DERMATOL,CUTANEOUS LYMPHONA GRP,PHILADELPHIA,PA 19104, USA. FU NCI NIH HHS [R29-CA 55017] NR 30 TC 75 Z9 75 U1 0 U2 4 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610 SN 0003-987X J9 ARCH DERMATOL JI Arch. Dermatol. PD APR PY 1993 VL 129 IS 4 BP 486 EP 489 DI 10.1001/archderm.129.4.486 PG 4 WC Dermatology SC Dermatology GA KW765 UT WOS:A1993KW76500014 PM 8466223 ER PT J AU ADAMIS, AP SCHEIN, OD KENYON, KR AF ADAMIS, AP SCHEIN, OD KENYON, KR TI ANTERIOR CORNEAL DISEASE OF EPIDERMOLYSIS-BULLOSA SIMPLEX SO ARCHIVES OF OPHTHALMOLOGY LA English DT Article ID INVOLVEMENT; ABNORMALITIES AB We report the histopathological findings of the anterior cornea from a patient with skin biopsy-proven epidermolysis bullosa simplex. As seen with light microscopy, the cornea had a fibrocellular pannus deep to a thickened epithelial basement membrane. Transmission electron microscopy of the anterior cornea demonstrated a nonhomogeneous basal epithelial layer with abnormal attachment complexes to an irregular, multilaminar basement membrane. The findings of transmission electron microscopy of the bulbar conjunctiva were normal. C1 JOHNS HOPKINS UNIV,SCH MED,WILMER OPHTHALMOL INST,BALTIMORE,MD 21205. HARVARD UNIV,SCH MED,DEPT OPHTHALMOL,BOSTON,MA 02115. SCHEPENS EYE RES INST,IMMUNOL UNIT,BOSTON,MA. RP ADAMIS, AP (reprint author), MASSACHUSETTS EYE & EAR INFIRM,CORNEA SERV,243 CHARLES ST,BOSTON,MA 02114, USA. FU NEI NIH HHS [R01 EY 35799] NR 11 TC 10 Z9 10 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610 SN 0003-9950 J9 ARCH OPHTHALMOL-CHIC JI Arch. Ophthalmol. PD APR PY 1993 VL 111 IS 4 BP 499 EP 502 PG 4 WC Ophthalmology SC Ophthalmology GA KW767 UT WOS:A1993KW76700033 PM 8470983 ER PT J AU HANKINSON, SE SEDDON, JM COLDITZ, GA STAMPFER, MJ ROSNER, B SPEIZER, FE WILLETT, WC AF HANKINSON, SE SEDDON, JM COLDITZ, GA STAMPFER, MJ ROSNER, B SPEIZER, FE WILLETT, WC TI A PROSPECTIVE-STUDY OF ASPIRIN USE AND CATARACT-EXTRACTION IN WOMEN SO ARCHIVES OF OPHTHALMOLOGY LA English DT Article ID RISK-FACTORS; SENILE CATARACTS; RANDOMIZED TRIAL; LENS; PROTECTION; FRAMINGHAM AB We examined the association between aspirin use and the rates of cataract extraction during 8 years of follow-up in a large prospective study of women, the Nurses' Health Study. From 1980 to 1988, we documented 448 senile cataracts diagnosed and extracted during 434680 person-years of follow-up. While we observed a modest positive association at the higher doses of aspirin use in the age-adjusted analyses, no association was found after accounting for other cataract risk factors (relative risk for greater-than-or-equal-to 20 years of use, 1.08; 95% confidence interval, 0.84 to 1.39). Among women who consumed seven or more tablets per week for 20 or more years, there was no suggestion of protection; if anything, a non-significantly elevated risk was observed (relative risk, 1.31; 95% confidence interval, 0.94 to 1.80). We observed no consistent difference in the relationship between aspirin use and cataract when assessed by age. Overall, we found no evidence to support the substantial reduction in risk of cataract among aspirin users as reported in several previous studies. C1 HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02115. HARVARD UNIV,MASSACHUSETTS EYE & EAR INFIRM,SCH MED,DEPT OPHTHALMOL,BOSTON,MA 02114. RP HANKINSON, SE (reprint author), HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,CHANNING LAB,DEPT MED,180 LONGWOOD AVE,BOSTON,MA 02115, USA. RI Colditz, Graham/A-3963-2009 OI Colditz, Graham/0000-0002-7307-0291 FU NCI NIH HHS [CA 40356]; NIEHS NIH HHS [5T32 ES07069] NR 36 TC 24 Z9 25 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610 SN 0003-9950 J9 ARCH OPHTHALMOL-CHIC JI Arch. Ophthalmol. PD APR PY 1993 VL 111 IS 4 BP 503 EP 508 PG 6 WC Ophthalmology SC Ophthalmology GA KW767 UT WOS:A1993KW76700034 PM 8470984 ER PT J AU BROWN, MT CUNNINGHAM, MJ INGELFINGER, JR BECKER, AN AF BROWN, MT CUNNINGHAM, MJ INGELFINGER, JR BECKER, AN TI PROGRESSIVE SENSORINEURAL HEARING-LOSS IN ASSOCIATION WITH DISTAL RENAL TUBULAR-ACIDOSIS SO ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY LA English DT Article ID NERVE DEAFNESS; FAMILY AB The autosomal recessive inherited syndrome of distal renal tubular acidosis and sensorineural hearing loss may present in one of two distinct fashions. The rare adolescent form is characterized by mild renal tubular acidosis, mild to moderate sensorineural hearing loss, and otherwise normal growth and development. The more common infantile type typically presents in the first year of life with failure to thrive, acidosis, and a more severe sensorineural hearing loss. In this report, progression of sensorineural hearing loss is documented for the first time in two siblings with the infantile variant. This association suggests that all children with distal renal tubular acidosis should undergo sequential audiologic evaluations with the institution of appropriate amplification and educational intervention as needed. C1 MASSACHUSETTS EYE & EAR INFIRM,DEPT OTOLARYNGOL,243 CHARLES ST,BOSTON,MA 02114. MASSACHUSETTS GEN HOSP,DEPT PEDIAT,BOSTON,MA 02114. NR 18 TC 23 Z9 24 U1 0 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610 SN 0886-4470 J9 ARCH OTOLARYNGOL JI Arch. Otolaryngol. Head Neck Surg. PD APR PY 1993 VL 119 IS 4 BP 458 EP 460 PG 3 WC Otorhinolaryngology; Surgery SC Otorhinolaryngology; Surgery GA KW469 UT WOS:A1993KW46900018 PM 8457310 ER PT J AU NAITO, HK KWAK, YS HARTFIEL, JL PARK, JK TRAVERS, EM MYERS, GL ROSS, JW ECKFELDT, JH HARTMANN, AE AF NAITO, HK KWAK, YS HARTFIEL, JL PARK, JK TRAVERS, EM MYERS, GL ROSS, JW ECKFELDT, JH HARTMANN, AE TI MATRIX EFFECTS ON PROFICIENCY TESTING MATERIALS - IMPACT ON ACCURACY OF CHOLESTEROL MEASUREMENT IN LABORATORIES IN THE NATIONS LARGEST HOSPITAL SYSTEM SO ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE LA English DT Article ID HYDROLYSIS AB The objective of this collaborative study with the Department of Veterans Affairs (VA), College of American Pathologists (CAP), and the Centers for Disease Control and Prevention (CDC) was to quantitate the matrix-induced biases of cholesterol measurements on the CAP Comprehensive Chemistry Surveys materials used in proficiency testing (PT). A total of 174 VA Medical Centers outpatient clinics and clinical laboratories participate in the VA-CDC National Cholesterol Standardization and Certification Program. This study was conducted in 112 VA laboratories that have been standardized for measuring cholesterol accurately (within +/- 3.0% of the CDC reference-method values) using fresh, unfrozen, unadulterated human serum samples. Fresh serum samples and 1990 CAP Surveys materials were sent by overnight mail, and the laboratories were asked to analyze them simultaneously in triplicate in a single analytic batch run. The results showed significant matrix-effect biases with the CAP Surveys materials with six of the eight major peer groups, despite the fact that accuracy of cholesterol measurements was maintained with fresh serum samples. The magnitude and direction (positive or negative) of the matrix-effect biases were instrument, reagent, and method specific using the following peer groups: du Pont Dimension (-8.9%); Beckman CX4, CX5, and CX7 (-5.5%); Kodak Ektachem 400, 500, and 700 (+4.4%); Instrumentation Laboratory Monarch (-3.1%); Baxter Paramax (-2.4%); Technicon SMAC and RA (+1.3%); Hitachi/BMD 704 through 747 (+0.4%); and Abbott Spectrum (-0.3%). The CAP PT materials used currently do not behave in a manner identical to fresh human serum when measuring cholesterol on many, but not all, analytic systems. The observed biases due to ''matrix effects' with PT materials will cause incorrect conclusions about the accuracy of many laboratory procedures performed on fresh patient specimens. This matrix-effect phenomenon will severely hamper interlaboratory accuracy transfer, standardization efforts, and monitoring performance of a laboratory's testing accuracy with the use of the current survey materials used in PT programs. Collaborative efforts are needed to (1) improve PT fluids to analytically behave more like fresh, human serum; (2) improve instrument design and reagent formulation; and (3) select methods and methodologic parameters that are more ''robust'' and less sensitive to the exact character of processed calibrators, quality control, and PT materials. C1 CASE WESTERN RESERVE UNIV,SCH MED,DEPT PATHOL,CLEVELAND,OH 44106. US DEPT VET AFFAIRS,CENT OFF,PATHOL & LAB MED SERV,WASHINGTON,DC. CTR DIS CONTROL,NATL CTR ENVIRONM HLTH,DIV ENVIRONM HLTH LAB SCI,ATLANTA,GA 30333. KENNESTONE HOSP,DEPT PATHOL,MARIETTA,GA. UNIV MINNESOTA HOSP & CLIN,DEPT LAB MED & PATHOL,MINNEAPOLIS,MN 55455. PHYSICIANS LAB,SIOUX FALLS,SD. COLL AMER PATHOLOGISTS,COMM CHEM RESOURCE,NORTHFIELD,IL. RP NAITO, HK (reprint author), VET AFFAIRS MED CTR,NATL CTR LAB ACCURACY & STANDARDIZAT,PATHOL & LAB MED SERV,10701 EAST BLVD,CLEVELAND,OH 44106, USA. NR 29 TC 26 Z9 26 U1 0 U2 0 PU COLLEGE AMER PATHOLOGISTS PI NORTHFIELD PA C/O KIMBERLY GACKI, 325 WAUKEGAN RD, NORTHFIELD, IL 60093-2750 SN 0003-9985 J9 ARCH PATHOL LAB MED JI Arch. Pathol. Lab. Med. PD APR PY 1993 VL 117 IS 4 BP 345 EP 351 PG 7 WC Medical Laboratory Technology; Medicine, Research & Experimental; Pathology SC Medical Laboratory Technology; Research & Experimental Medicine; Pathology GA KV587 UT WOS:A1993KV58700002 PM 8466396 ER PT J AU HOWANITZ, JH AF HOWANITZ, JH TI REVIEW OF THE INFLUENCE OF POLYPEPTIDE HORMONE FORMS ON IMMUNOASSAY RESULTS SO ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE LA English DT Article ID HUMAN GROWTH-HORMONE; BETA-SUBUNIT; CHORIO-GONADOTROPIN; HUMAN-PROLACTIN; SERUM; HCG; REEVALUATION; THYROTROPIN; SECRETION; AFFINITY AB Various forms of the polypeptide hormones that occur in blood, fluids, or tissues can differ according to physiologic and pathologic states. Forms include subunits of luteinizing hormone, follicle-stimulating hormone, human chorionic gonadotropin, and thyroid-stimulating hormone. Hormonal isoforms occur for these hormones as well as for prolactin and growth hormone. Variation in hormonal forms appears to contribute significantly to the wide variation in immunoassay results for these polypeptide hormones. Subunits and isoforms of the polypeptide hormones can overreact or underreact in monoclonal antibody assays. The underreaction or overreaction can occur with standards, controls, and patient specimens as well as with the assay label. C1 UNIV CALIF LOS ANGELES, DEPT PATHOL & LAB MED, LOS ANGELES, CA 90024 USA. RP HOWANITZ, JH (reprint author), W LOS ANGELES DEPT VET AFFAIRS MED CTR, LAB SERV, LOS ANGELES, CA USA. NR 22 TC 11 Z9 12 U1 0 U2 1 PU COLL AMER PATHOLOGISTS PI NORTHFIELD PA C/O KIMBERLY GACKI, 325 WAUKEGAN RD, NORTHFIELD, IL 60093-2750 USA SN 0003-9985 EI 1543-2165 J9 ARCH PATHOL LAB MED JI Arch. Pathol. Lab. Med. PD APR PY 1993 VL 117 IS 4 BP 369 EP 372 PG 4 WC Medical Laboratory Technology; Medicine, Research & Experimental; Pathology SC Medical Laboratory Technology; Research & Experimental Medicine; Pathology GA KV587 UT WOS:A1993KV58700005 PM 8466399 ER PT J AU WONG, ML EDELSTEIN, J WOLLMAN, J BOND, MG AF WONG, ML EDELSTEIN, J WOLLMAN, J BOND, MG TI ULTRASONIC PATHOLOGICAL COMPARISON OF THE HUMAN ARTERIAL-WALL - VERIFICATION OF INTIMA MEDIA THICKNESS SO ARTERIOSCLEROSIS AND THROMBOSIS LA English DT Article DE ULTRASONOGRAPHY; ARTERIAL WALL; TUNICA THICKNESS AB Recent intravascular ultrasound experience challenges the accuracy of ultrasonic measurement of arterial wall thickness. We reevaluated the correlation between histological and sonographic measurements of intima-media thickness using standard transcutaneous vascular technology. Carotid and femoral arterial segments were imaged before and after fixation using a 7-MHz linear-array vascular transducer. Log compression and beam orientation were varied. Mean intima, media, and adventitia thicknesses were measured and compared with corresponding histological tunica. Tissue processing caused 2.5% shrinkage. Intraobserver reading error was 0.7% for histology and 5.4% for sonography. Ultrasound overestimated the thickness of the intima and adventitia and underestimated the thickness of the media. For combined intima-media thickness, the differences between histology and imaging were insignificant, averaging 4% for the carotid artery and 9% for the femoral artery in the far-wall projection. In the near-wall projection, sonographic intima-media thickness was 20% less than that determined histologically. We conclude that ultrasonography is limited mainly by axial resolution in quantifying the dimensions of individual arterial tunica but is capable of accurately measuring far-wall intima-media thickness. C1 W LOS ANGELES DEPT VET AFFAIRS MED CTR,ANAT PATHOL SECT,LOS ANGELES,CA 90073. UNIV CALIF LOS ANGELES,DEPT MED,LOS ANGELES,CA 90024. WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DIV VASC ULTRASOUND RES,WINSTON SALEM,NC 27103. RP WONG, ML (reprint author), W LOS ANGELES DEPT VET AFFAIRS MED CTR,CARDIOL SECT WIIIE,LOS ANGELES,CA 90073, USA. NR 12 TC 207 Z9 230 U1 0 U2 1 PU AMER HEART ASSOC PI DALLAS PA 7272 GREENVILLE AVENUE, DALLAS, TX 75231-4596 SN 1049-8834 J9 ARTERIOSCLER THROMB JI Arterioscler. Thromb. PD APR PY 1993 VL 13 IS 4 BP 482 EP 486 PG 5 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA KW817 UT WOS:A1993KW81700003 PM 8466883 ER PT J AU CUMMINGS, JL GORMAN, DG SHAPIRA, J AF CUMMINGS, JL GORMAN, DG SHAPIRA, J TI PHYSOSTIGMINE AMELIORATES THE DELUSIONS OF ALZHEIMERS-DISEASE SO BIOLOGICAL PSYCHIATRY LA English DT Article DE ALZHEIMERS DISEASE; DELUSIONS; PHYSOSTIGMINE; HALOPERIDOL; ACETYLCHOLINE; ACETYLCHOLINESTERASE; ACETYLCHOLINESTERASE INHIBITOR ID ORAL PHYSOSTIGMINE; DEMENTIA; DEPRESSION; PSYCHOSIS AB Alzheimer's disease (AD) patients frequently manifest delusions, and the cholinergic deficiency of AD may contribute to this aspect of the psychopathology of the disorder. In a double-blind, crossover study involving two patients, we compared the antidelusional efficacy of physostigmine, an acetylcholinesterase inhibitor, with haloperidol, a widely used neuroleptic agent. Physostigmine ameliorated the delusions and produced fewer side effects. These preliminary observations suggest that the cholinergic deficiency contributes to the occurrence of delusions in AD and cholinergic therapy may have a role in the treatment of the delusional symptoms. C1 W LOS ANGELES VET AFFAIRS MED CTR, NURSING SERV, LOS ANGELES, CA USA. UNIV CALIF LOS ANGELES, SCH MED, CTR ALZHEIMERS DIS, LOS ANGELES, CA USA. UNIV CALIF LOS ANGELES, SCH MED, DEPT NEUROL, LOS ANGELES, CA USA. UNIV CALIF LOS ANGELES, SCH MED, DEPT PSYCHIAT & BIOBEHAV SCI, LOS ANGELES, CA USA. UNIV CALIF LOS ANGELES, SCH NURSING, LOS ANGELES, CA USA. RP CUMMINGS, JL (reprint author), W LOS ANGELES VET AFFAIRS MED CTR, PSYCHIAT SERV, NEUROBEHAV UNIT, BEHAV NEUROSCI SECT, BLDG 256B, LOS ANGELES, CA 90073 USA. FU NIA NIH HHS [AG 10123] NR 29 TC 98 Z9 98 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 1 PY 1993 VL 33 IS 7 BP 536 EP 541 DI 10.1016/0006-3223(93)90009-3 PG 6 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA LD103 UT WOS:A1993LD10300009 PM 8513039 ER PT J AU GUINAN, EC LEE, YS LOPEZ, KD KOHLER, S OETTE, DH BRUNO, E KOZAKEWICH, H NATHAN, DG HOFFMAN, R AF GUINAN, EC LEE, YS LOPEZ, KD KOHLER, S OETTE, DH BRUNO, E KOZAKEWICH, H NATHAN, DG HOFFMAN, R TI EFFECTS OF INTERLEUKIN-3 AND GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR ON THROMBOPOIESIS IN CONGENITAL AMEGAKARYOCYTIC THROMBOCYTOPENIA SO BLOOD LA English DT Article ID BONE-MARROW FAILURE; RECOMBINANT HUMAN INTERLEUKIN-3; FORMING UNIT-MEGAKARYOCYTE; APLASTIC-ANEMIA; CYTOKINE REGULATION; PHASE-I/II; HUMAN IL-3; HEMATOPOIESIS; RECEPTOR; INVITRO C1 HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DIV HEMATOL,BOSTON,MA 02115. INDIANA UNIV,DEPT MED,INDIANAPOLIS,IN 46204. CHILDRENS HOSP MED CTR,DIV HEMATOL ONCOL,BOSTON,MA 02115. CHILDRENS HOSP MED CTR,DEPT PATHOL,BOSTON,MA 02115. HOECHST ROUSSEL PHARMACEUT PROPRIETARY LTD,SOMERVILLE,NJ 08876. RP GUINAN, EC (reprint author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DEPT PEDIAT ONCOL,44 BINNEY ST,BOSTON,MA 02115, USA. NR 25 TC 44 Z9 44 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 SN 0006-4971 J9 BLOOD JI Blood PD APR 1 PY 1993 VL 81 IS 7 BP 1691 EP 1698 PG 8 WC Hematology SC Hematology GA KV696 UT WOS:A1993KV69600004 PM 8461459 ER PT J AU RABINOWE, SN NEUBERG, D BIERMAN, PJ VOSE, JM NEMUNAITIS, J SINGER, JW FREEDMAN, AS MAUCH, P DEMETRI, G ONETTO, N GILLIS, S OETTE, D BUCKNER, D HANSEN, JA RITZ, J ARMITAGE, JO NADLER, LM APPELBAUM, FR AF RABINOWE, SN NEUBERG, D BIERMAN, PJ VOSE, JM NEMUNAITIS, J SINGER, JW FREEDMAN, AS MAUCH, P DEMETRI, G ONETTO, N GILLIS, S OETTE, D BUCKNER, D HANSEN, JA RITZ, J ARMITAGE, JO NADLER, LM APPELBAUM, FR TI LONG-TERM FOLLOW-UP OF A PHASE-III STUDY OF RECOMBINANT HUMAN GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR AFTER AUTOLOGOUS BONE-MARROW TRANSPLANTATION FOR LYMPHOID MALIGNANCIES SO BLOOD LA English DT Article ID HIGH-DOSE CHEMOTHERAPY; HEMATOPOIETIC PROGENITOR CELLS; NON-HODGKINS-LYMPHOMA; CYTO-TOXIC AGENTS; GM-CSF; MYELODYSPLASTIC SYNDROMES; NEUTROPHIL RECOVERY; CYTOTOXIC DRUGS; STEM-CELLS; DISEASE C1 HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV CLIN ONCOL,BOSTON,MA 02115. HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV BIOSTAT,BOSTON,MA 02115. FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98104. UNIV WASHINGTON,SEATTLE,WA 98195. VET AFFAIRS MED CTR,SEATTLE,WA. IMMUNEX CORP,SEATTLE,WA. UNIV NEBRASKA,MED CTR,OMAHA,NE 68105. HOECHST ROUSSEL PHARMACEUT PROPRIETARY LTD,SOMERVILLE,NJ 08876. RP RABINOWE, SN (reprint author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV TUMOR IMMUNOL,44 BINNEY ST,BOSTON,MA 02115, USA. OI Singer, Jack/0000-0003-4001-4549 FU NCI NIH HHS [CA 34183, CA 47748] NR 41 TC 54 Z9 54 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 SN 0006-4971 J9 BLOOD JI Blood PD APR 1 PY 1993 VL 81 IS 7 BP 1903 EP 1908 PG 6 WC Hematology SC Hematology GA KV696 UT WOS:A1993KV69600031 PM 8461475 ER PT J AU STRONCEK, DF HOLLAND, PV BARTCH, G BIXBY, T SIMMONS, RG ANTIN, JH ANDERSON, KC ASH, RC BOLWELL, BJ HANSEN, JA HEAL, JM HENSLEEDOWNEY, PJ JAFFE, ER KLEIN, HG LAU, PM PERKINS, HA POPOVSKY, MA PRICE, TH ROWLEY, SD STEHLING, LC WEIDEN, PL WISSEL, ME MCCULLOUGH, J AF STRONCEK, DF HOLLAND, PV BARTCH, G BIXBY, T SIMMONS, RG ANTIN, JH ANDERSON, KC ASH, RC BOLWELL, BJ HANSEN, JA HEAL, JM HENSLEEDOWNEY, PJ JAFFE, ER KLEIN, HG LAU, PM PERKINS, HA POPOVSKY, MA PRICE, TH ROWLEY, SD STEHLING, LC WEIDEN, PL WISSEL, ME MCCULLOUGH, J TI EXPERIENCES OF THE 1ST 493 UNRELATED MARROW DONORS IN THE NATIONAL-MARROW-DONOR-PROGRAM SO BLOOD LA English DT Article ID SEVERE COMBINED IMMUNODEFICIENCY; BONE-MARROW; APLASTIC-ANEMIA; TRANSPLANTATION; PATIENT C1 UNIV MINNESOTA,MINNEAPOLIS,MN 55455. SACRAMENTO MED FDN,CTR BLOOD,SACRAMENTO,CA. UNIV PITTSBURGH,PITTSBURGH,PA 15260. BRIGHAM & WOMENS HOSP,BOSTON,MA 02115. HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115. MED COLL WISCONSIN,MILWAUKEE,WI 53226. CLEVELAND CLIN EDUC FDN,CLEVELAND,OH 44106. FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98104. AMER RED CROSS,REG BLOOD SERV,ROCHESTER,NY. AMER RED CROSS,REG BLOOD SERV,ST PAUL,MN. UNIV KENTUCKY,LEXINGTON,KY 40506. YESHIVA UNIV ALBERT EINSTEIN COLL MED,BRONX,NY 10461. NIH,CTR CLIN,BETHESDA,MD 20892. IRWIN MEM BLOOD BANK,SAN FRANCISCO,CA. VIRGINIA MASON CLIN,SEATTLE,WA. FU NHLBI NIH HHS [N01-HB-97075] NR 17 TC 76 Z9 78 U1 2 U2 2 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 SN 0006-4971 J9 BLOOD JI Blood PD APR 1 PY 1993 VL 81 IS 7 BP 1940 EP 1946 PG 7 WC Hematology SC Hematology GA KV696 UT WOS:A1993KV69600036 PM 8461478 ER PT J AU PAIETTA, E WIERNIK, PH ANDERSEN, J AF PAIETTA, E WIERNIK, PH ANDERSEN, J TI IMMUNOPHENOTYPIC FEATURES OF T(8-21) (Q22-Q22) ACUTE MYELOID-LEUKEMIA IN ADULTS SO BLOOD LA English DT Letter C1 HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV BIOSTAT,BOSTON,MA 02115. RP PAIETTA, E (reprint author), MONTEFIORE & ALBERT EINSTEIN CANC CTR,BRONX,NY, USA. NR 3 TC 3 Z9 4 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 SN 0006-4971 J9 BLOOD JI Blood PD APR 1 PY 1993 VL 81 IS 7 BP 1975 EP 1975 PG 1 WC Hematology SC Hematology GA KV696 UT WOS:A1993KV69600047 PM 8461484 ER PT J AU TONNER, PH MILLER, KW AF TONNER, PH MILLER, KW TI ETHANOL ENHANCES SUBERYLDICHOLINES INTRINSIC EFFICACY AT THE NICOTINIC RECEPTOR OF TORPEDO ELECTROPLAQUES SO BRITISH JOURNAL OF PHARMACOLOGY LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,DEPT ANESTHESIA,BOSTON,MA 02114. HARVARD UNIV,SCH MED,DEPT BIOL CHEM,BOSTON,MA 02115. HARVARD UNIV,SCH MED,DEPT MOLEC PHARMACOL,BOSTON,MA 02115. NR 2 TC 1 Z9 1 U1 0 U2 0 PU STOCKTON PRESS PI BASINGSTOKE PA HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS SN 0007-1188 J9 BRIT J PHARMACOL JI Br. J. Pharmacol. PD APR PY 1993 VL 108 SU S BP P235 EP P235 PG 1 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA KX107 UT WOS:A1993KX10700235 ER PT J AU MALT, RA AF MALT, RA TI PERFORATION OF THE BOWEL BY SUCTION DRAINS SO BRITISH JOURNAL OF SURGERY LA English DT Letter RP MALT, RA (reprint author), MASSACHUSETTS GEN HOSP,BOSTON,MA 02114, USA. NR 1 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL SCIENCE LTD PI OXFORD PA OSNEY MEAD, OXFORD, OXON, ENGLAND OX2 0EL SN 0007-1323 J9 BRIT J SURG JI Br. J. Surg. PD APR PY 1993 VL 80 IS 4 BP 536 EP 536 DI 10.1002/bjs.1800800443 PG 1 WC Surgery SC Surgery GA KX723 UT WOS:A1993KX72300037 ER PT J AU URBA, SG FORASTIERE, AA WOLF, GT AMREIN, PC AF URBA, SG FORASTIERE, AA WOLF, GT AMREIN, PC TI INTENSIVE RECOMBINANT INTERLEUKIN-2 AND ALPHA-INTERFERON THERAPY IN PATIENTS WITH ADVANCED HEAD AND NECK SQUAMOUS CARCINOMA SO CANCER LA English DT Article DE HEAD AND NECK CANCER; INTERLEUKIN-2; ALPHA-INTERFERON; IMMUNOTHERAPY ID LYMPHOKINE-ACTIVATED KILLER; CELL CARCINOMA; COMBINATION THERAPY; ADVANCED CANCER; LYMPHOCYTES; METASTASES; INDUCTION; PROGNOSIS; IMMUNITY; LYSIS AB Background. Cellular immune deficiency is a consistent finding in patients with advanced head and neck cancer. Interleukin-2 and alpha-interferon are modulators of the immune system. Methods. Eleven patients with recurrent head and neck cancer were treated in a Phase II study of recombinant human interleukin-2 (rlL-2) and alpha-2a-interferon (Roferon-A, Hoffmann-La Roche, Inc., Nutley, NJ). Each course consisted of rIL-2, 3 X 10(6) U/m2/day, as a continuous intravenous infusion over 24 hours for 4 days, and recombinant alpha-2a-interferon, 5 X 10(6) U/m2/day intramuscularly or subcutaneously daily for 4 days. This treatment was repeated weekly for 4 weeks, and then a second cycle was given after a 2-week break. Results. Two patients (18%) achieved a partial response. Toxic effects were substantial. Three of 11 patients experienced Grade 3 hypotension, 3 patients had Grade 3 oliguria, and Grade 3 fatigue was one of the most common reasons for withdrawal from the study. There were no deaths or need for intensive care monitoring. Conclusions. In view of the 18% response rate, additional investigation of biologic therapy in advanced head and neck cancer is warranted. C1 UNIV MICHIGAN,MED CTR,DEPT OTOLARYNGOL HEAD & NECK SURG,ANN ARBOR,MI 48109. JOHNS HOPKINS UNIV,CTR ONCOL,DEPT ONCOL,BALTIMORE,MD 21218. MASSACHUSETTS GEN HOSP,DEPT HEMATOL & ONCOL,BOSTON,MA 02114. RP URBA, SG (reprint author), UNIV MICHIGAN,MED CTR,DIV ONCOL,1500 E MED CTR DR,3118 TAUBMAN CTR,ANN ARBOR,MI 48109, USA. NR 33 TC 27 Z9 27 U1 0 U2 0 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012 SN 0008-543X J9 CANCER JI Cancer PD APR 1 PY 1993 VL 71 IS 7 BP 2326 EP 2331 DI 10.1002/1097-0142(19930401)71:7<2326::AID-CNCR2820710725>3.0.CO;2-H PG 6 WC Oncology SC Oncology GA KU002 UT WOS:A1993KU00200024 PM 8453554 ER PT J AU NAEEM, R DONOVAN, K CORSON, JM FLETCHER, JA AF NAEEM, R DONOVAN, K CORSON, JM FLETCHER, JA TI FLUORESCENT INSITU HYBRIDIZATION ASSESSMENT OF CHROMOSOME-7 COPY NUMBER IN UNCULTURED LUNG AND KIDNEY-CELLS SO CANCER GENETICS AND CYTOGENETICS LA English DT Article ID TRISOMY-7; TISSUE; TUMOR AB Trisomy 7 is common in cells cultured from nonneoplastic lung and kidney tissues, but the frequency of trisomy 7 in uncultured lung and kidney has not been determined. In this study, we used fluorescent in situ hybridization (FISH) to assess chromosome 7 copy number in uncultured interphase nuclei from lung and kidney specimens. All specimens had low level mosaicism for trisomy 7 (1.5-5.25%), but control experiments indicated a potential wide margin of error in quantifying these events. C1 BRIGHAM & WOMENS HOSP,DEPT PATHOL,75 FRANCIS ST,BOSTON,MA 02115. HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DEPT PEDIAT ONCOL,BOSTON,MA 02115. HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115. HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02115. FU NCI NIH HHS [1K11CA01498-02] NR 7 TC 12 Z9 12 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 SN 0165-4608 J9 CANCER GENET CYTOGEN JI Cancer Genet. Cytogenet. PD APR PY 1993 VL 66 IS 2 BP 100 EP 102 DI 10.1016/0165-4608(93)90235-E PG 3 WC Oncology; Genetics & Heredity SC Oncology; Genetics & Heredity GA LE601 UT WOS:A1993LE60100003 PM 8500094 ER PT J AU MOK, SCH BELL, DA KNAPP, RC FISHBAUGH, PM WELCH, WR MUTO, MG BERKOWITZ, RS TSAO, SW AF MOK, SCH BELL, DA KNAPP, RC FISHBAUGH, PM WELCH, WR MUTO, MG BERKOWITZ, RS TSAO, SW TI MUTATION OF K-RAS PROTOONCOGENE IN HUMAN OVARIAN EPITHELIAL TUMORS OF BORDERLINE MALIGNANCY SO CANCER RESEARCH LA English DT Note ID CARCINOMA-CELLS; DIFFERENTIATION; ONCOGENE; ASSOCIATION; TRISOMY-12; ACTIVATION AB The mutation of K-ras protooncogene was examined in 44 cases of borderline ovarian epithelial tumors and 18 cases of invasive ovarian carcinomas. In borderline tumors, K-ras mutations are a common feature, having been found in 21 of 44 cases (48%). Twenty of the 21 mutations were identified at codon 12, and one was identified at codon 13. A detailed analysis of the mutation pattern of K-ras revealed a close association with the histological cell types of the tumor. Mutation of K-ras was detected at a higher frequency in mucinous borderline tumor (identified in 12 of 19 cases) compared to serous borderline tumor (identified in 9 of 25 cases). K-ras mutation was also detected in invasive mucinous and serous ovarian carcinomas, hence supporting the notion that borderline ovarian tumors may represent a pathological continuum between benign and frankly invasive diseases. C1 BRIGHAM & WOMENS HOSP,DEPT OBSTET GYNECOL & REPROD SCI,GYNECOL ONCOL LAB,ROOM 210,BOSTON,MA 02115. HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV GYNECOL ONCOL,BOSTON,MA 02115. BRIGHAM & WOMENS HOSP,DIV WOMENS & PERINATAL PATHOL,BOSTON,MA 02115. HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEPT PATHOL,BOSTON,MA 02114. NR 20 TC 206 Z9 211 U1 0 U2 2 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA PUBLIC LEDGER BLDG, SUITE 816, 150 S. INDEPENDENCE MALL W., PHILADELPHIA, PA 19106 SN 0008-5472 J9 CANCER RES JI Cancer Res. PD APR 1 PY 1993 VL 53 IS 7 BP 1489 EP 1492 PG 4 WC Oncology SC Oncology GA KV615 UT WOS:A1993KV61500004 PM 8384077 ER PT J AU DOU, QP LEVIN, AH ZHAO, SC PARDEE, AB AF DOU, QP LEVIN, AH ZHAO, SC PARDEE, AB TI CYCLIN-E AND CYCLIN-A AS CANDIDATES FOR THE RESTRICTION POINT PROTEIN SO CANCER RESEARCH LA English DT Note ID CELL-PROLIFERATION; PROMOTING FACTOR; LABILE; GROWTH; CDC2 AB Progression of cells into S phase is proposed to be determined by accumulation of a labile protein (the restriction point protein R; A. B. Pardee, Proc. Natl. Acad. Sci. USA, 71: 1286-1290, 1974). We report here that cyclin E and cyclin A proteins as well as their dependent histone H1 kinases satisfy all of the criteria for the R protein, which includes late G1 phase increase, an excess delay of appearance after inhibition of protein synthesis in nontransformed cells, and a faster recovery in transformed cells. We suggest that the molecular basis of the R protein could be cyclin production and inactivation. C1 HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115. RP DOU, QP (reprint author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV CELL GROWTH & REGULAT,ROOM D814,44 BINNEY ST,BOSTON,MA 02115, USA. FU NCI NIH HHS [CA22427]; NCRR NIH HHS [2 S07RR05526-28]; NIGMS NIH HHS [GM24571] NR 20 TC 125 Z9 128 U1 0 U2 2 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA PUBLIC LEDGER BLDG, SUITE 816, 150 S. INDEPENDENCE MALL W., PHILADELPHIA, PA 19106 SN 0008-5472 J9 CANCER RES JI Cancer Res. PD APR 1 PY 1993 VL 53 IS 7 BP 1493 EP 1497 PG 5 WC Oncology SC Oncology GA KV615 UT WOS:A1993KV61500005 PM 8384078 ER PT J AU MARKS, DR RAPOPORT, A PADLA, D WEEKS, R ROSUM, R SHEFTELL, F ARROWSMITH, F AF MARKS, DR RAPOPORT, A PADLA, D WEEKS, R ROSUM, R SHEFTELL, F ARROWSMITH, F TI A DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL OF INTRANASAL CAPSAICIN FOR CLUSTER HEADACHE SO CEPHALALGIA LA English DT Article DE CAPSAICIN; CLUSTER HEADACHE; SUBSTANCE-P ID TOPICAL CAPSAICIN AB It has been suggested that treatment of cluster headache (CH) patients with topical capsaicin may desensitize sensory neurons by depleting the nerve terminals of substance P. We attempted to determine whether capsaicin is effective in aborting CH attacks. Patients in acute cluster were randomized to receive either capsaicin or placebo in the ipsilateral nostril for 7 days. Patients recorded the severity of each headache for 15 days. Headaches on days 8-15 of the study were significantly less severe in the capsaicin group vs the placebo group. There was also a significant decrease in headache severity in the capsaicin group on days 8-15 compared to days 1-7, but not in the placebo group. Episodic CH patients appeared to benefit more than chronic CH patients. These results indicate that intranasal capsaicin may provide a new therapeutic option for the treatment of this disease. C1 MASSACHUSETTS GEN HOSP,ALLERGY UNIT,BOSTON,MA 02114. NEW ENGLAND CTR HEADACHE,STAMFORD,CT. RP MARKS, DR (reprint author), MASSACHUSETTS GEN HOSP,CLIN IMMUNOL UNIT,BULFINCH 422,BOSTON,MA 02114, USA. NR 7 TC 60 Z9 63 U1 0 U2 1 PU SCANDINAVIAN UNIVERSITY PRESS PI OSLO PA PO BOX 2959 TOYEN, JOURNAL DIVISION CUSTOMER SERVICE, N-0608 OSLO, NORWAY SN 0333-1024 J9 CEPHALALGIA JI Cephalalgia PD APR PY 1993 VL 13 IS 2 BP 114 EP 116 DI 10.1046/j.1468-2982.1993.1302114.x PG 3 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA KY682 UT WOS:A1993KY68200011 PM 8495452 ER PT J AU ANTMAN, KH AF ANTMAN, KH TI NATURAL-HISTORY AND EPIDEMIOLOGY OF MALIGNANT MESOTHELIOMA SO CHEST LA English DT Article; Proceedings Paper CT HARVARD MEDICAL SCHOOL SYMP ON MULTIMODALITY THERAPY OF CHEST MALIGNANCIES CY APR 09-11, 1992 CL BOSTON, MA SP DANA FARBER CANC INST, DEPT ONCOL, BRIGHAM & WOMENS HOSP, DIV THORAC SURG ID ASBESTOS-ASSOCIATED DISEASES; FIBER TYPE; EXPOSURE AB Asbestos exposure constitutes the primary cause of pleural and peritoneal mesothelioma in humans. Risk relates to the duration and intensity of exposure. Thus, those exposed at younger ages are at higher lifetime risk. Families of asbestos workers exposed to asbestos on hair and clothing as well as to asbestos items brought home from the workplace are also at risk, as are employees working in the same vicinity as asbestos workers. The public health significance of exposure from asbestos in public and private buildings remains controversial. Malignant mesothelioma is difficult to diagnose and carries a poor prognosis. Chemotherapy with single or multiple agents has thus far been disappointing, but doxorubicin and cisplatin or mitomycin and cisplatin are probably most active with response rates in measurable disease of 25%. Palliative radiotherapy is also problematic since differences between tumor cytotoxicity and pulmonary tolerance are small and radiation pneumonitis may significantly impair quality of life. RP ANTMAN, KH (reprint author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DEPT MED,BOSTON,MA 02115, USA. NR 22 TC 47 Z9 47 U1 0 U2 0 PU AMER COLL CHEST PHYSICIANS PI NORTHBROOK PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 SN 0012-3692 J9 CHEST JI Chest PD APR PY 1993 VL 103 IS 4 SU S BP S373 EP S376 DI 10.1378/chest.103.4_Supplement.373S PG 4 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA KW660 UT WOS:A1993KW66000015 PM 8462328 ER PT J AU DEMETRI, GD AF DEMETRI, GD TI IMPACT OF HEMATOPOIETIC GROWTH-FACTORS ON THE MANAGEMENT OF SMALL-CELL LUNG-CANCER SO CHEST LA English DT Article; Proceedings Paper CT HARVARD MEDICAL SCHOOL SYMP ON MULTIMODALITY THERAPY OF CHEST MALIGNANCIES CY APR 09-11, 1992 CL BOSTON, MA SP DANA FARBER CANC INST, DEPT ONCOL, BRIGHAM & WOMENS HOSP, DIV THORAC SURG ID COLONY-STIMULATING FACTOR; NONHEMATOPOIETIC TUMOR-CELLS; GRANULOCYTE-COLONY; ENDOTHELIAL-CELLS; GM-CSF; CHEMOTHERAPY; NEUTROPENIA; INVIVO; KINETICS AB Hematopoietic growth factors regulate the production and differentiation of immature progenitor cells and activate mature effector cells. With recombinant DNA technology, these human proteins have been biosynthesized, and their clinical applications hold promise for beneficial therapeutic effects. The hematopoietic growth factors are generally classified in 2 groups, the colony-stimulating factors (CSFs) and the interleukins. In oncology, it has been shown that the administration of CSFs will attenuate chemotherapy-induced myelosuppression and permit administration of the planned chemotherapy doses, especially in chemosensitive tumors like small-cell lung cancer. Widespread clinical administration of the CSFs at this time without regard to the predicted risk of a given therapeutic regimen would seem to be inappropriate both therapeutically and economically. Continuing investigations should focus on important clinical end points. Until then, our ability to use the CSFs optimally, rationally, and in a cost-effective manner will remain limited. C1 HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115. RP DEMETRI, GD (reprint author), HARVARD UNIV,SCH MED,BOSTON,MA 02115, USA. NR 23 TC 1 Z9 1 U1 0 U2 0 PU AMER COLL CHEST PHYSICIANS PI NORTHBROOK PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 SN 0012-3692 J9 CHEST JI Chest PD APR PY 1993 VL 103 IS 4 SU S BP S427 EP S432 DI 10.1378/chest.103.4_Supplement.427S PG 6 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA KW660 UT WOS:A1993KW66000029 PM 8384974 ER PT J AU ELIAS, A AF ELIAS, A TI CHEMOTHERAPY AND RADIOTHERAPY FOR REGIONALLY ADVANCED NON-SMALL-CELL LUNG-CANCER SO CHEST LA English DT Article; Proceedings Paper CT HARVARD MEDICAL SCHOOL SYMP ON MULTIMODALITY THERAPY OF CHEST MALIGNANCIES CY APR 09-11, 1992 CL BOSTON, MA SP DANA FARBER CANC INST, DEPT ONCOL, BRIGHAM & WOMENS HOSP, DIV THORAC SURG ID THERAPY-ONCOLOGY-GROUP; RADIATION-THERAPY; RANDOMIZED TRIAL; TUMOR-CONTROL; CARCINOMA; SURVIVAL; IRRADIATION; BENEFIT; IMPACT; GY AB Treatment of inoperable, regionally advanced non-small-cell lung cancer has been problematic, given the poor long-term results and toxicity of current treatment measures and the extensive comorbid disease commonly found in these predominantly elderly patients. The generally acknowledged standard of care has been administration of radio-therapy to the involved sites and nodal drainage sites. This may improve survival in patients with good prognostic factors. No modality, however, has demonstrated a clear benefit over the others in this setting. Of 13 randomized trials comparing radiotherapy with or without chemotherapy, 5 using non-cisplatin-containing regimens showed no benefit. However, 4 of 6 trials with cisplatin-containing regimens have shown modest benefit. Cisplatin given concurrently with radiotherapy on a daily basis was significantly better than radiotherapy alone and was associated with improved locoregional control, suggesting that the radiation sensitization properties of the drug and consequent local control may be important for enhanced survival. Determining relapse patterns of patients according to these and other treatment approaches may help guide future development of therapeutic options. Improvements in both local and systemic control will be required before a curative approach to treatment can be considered. In this regard, hyperfractionated radiotherapy or radiation sensitizers to enhance locoregional control may complement enhancement of systemic control with chemotherapy, especially if a balance can be struck between the efficacy and toxicity of these modalities. RP ELIAS, A (reprint author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DEPT MED,BOSTON,MA 02115, USA. NR 28 TC 11 Z9 11 U1 0 U2 0 PU AMER COLL CHEST PHYSICIANS PI NORTHBROOK PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 SN 0012-3692 J9 CHEST JI Chest PD APR PY 1993 VL 103 IS 4 SU S BP S362 EP S366 DI 10.1378/chest.103.4_Supplement.362S PG 5 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA KW660 UT WOS:A1993KW66000012 PM 8384971 ER PT J AU ELIAS, AD AYASH, L SKARIN, AT WHEELER, C SCHWARTZ, G MAZANET, R TEPLER, I SCHNIPPER, L FREI, E ANTMAN, KH AF ELIAS, AD AYASH, L SKARIN, AT WHEELER, C SCHWARTZ, G MAZANET, R TEPLER, I SCHNIPPER, L FREI, E ANTMAN, KH TI HIGH-DOSE COMBINED ALKYLATING AGENT THERAPY WITH AUTOLOGOUS STEM-CELL SUPPORT AND CHEST RADIOTHERAPY FOR LIMITED SMALL-CELL LUNG-CANCER SO CHEST LA English DT Article; Proceedings Paper CT HARVARD MEDICAL SCHOOL SYMP ON MULTIMODALITY THERAPY OF CHEST MALIGNANCIES CY APR 09-11, 1992 CL BOSTON, MA SP DANA FARBER CANC INST, DEPT ONCOL, BRIGHAM & WOMENS HOSP, DIV THORAC SURG ID BONE-MARROW TRANSPLANTATION; BRONCHOGENIC-CARCINOMA; INTENSIFICATION THERAPY; INTENSIVE CHEMOTHERAPY; CYCLOPHOSPHAMIDE; ETOPOSIDE; VP-16; INDUCTION; RESCUE AB Although initially responsive to chemotherapy, patients with small-cell lung cancer (SCLC) almost invariably suffer relapse. Recurrent SCLC responds poorly to treatment. Previous trials using high-dose chemotherapy with bone marrow support have commonly used single agents or combined alkylating agents without chest radiotherapy. Among patients with limited disease receiving dose-intensive chemotherapy, locoregional relapse remained the predominant site of first failure. Recent phase II trials using intensive locoregional therapy (aggressive concurrent chemoradiotherapy) have resulted in promising survival. Our trial used combined alkylating agents with autologous marrow support and chest radiotherapy in patients with limited disease in response to conventional-dose induction chemotherapy. Of 19 patients treated, the actuarial survival was 56% with a median follow-up of 18 months following high-dose therapy. Patients who achieved complete or near-complete response prior to high-dose therapy enjoyed the best prognosis. Continued evaluation of intensive systemic and local therapy for SCLC is indicated. C1 HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DEPT MED,DIV RADIAT THERAPY,BOSTON,MA 02115. HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,DEPT MED,BOSTON,MA 02215. RP ELIAS, AD (reprint author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DEPT MED,DIV BIOSTAT,BOSTON,MA 02115, USA. NR 37 TC 5 Z9 5 U1 0 U2 0 PU AMER COLL CHEST PHYSICIANS PI NORTHBROOK PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 SN 0012-3692 J9 CHEST JI Chest PD APR PY 1993 VL 103 IS 4 SU S BP S433 EP S435 DI 10.1378/chest.103.4_Supplement.433S PG 3 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA KW660 UT WOS:A1993KW66000030 PM 8096454 ER PT J AU KANTOFF, P AF KANTOFF, P TI SURGICAL AND MEDICAL-MANAGEMENT OF GERM-CELL TUMORS OF THE CHEST SO CHEST LA English DT Article; Proceedings Paper CT HARVARD MEDICAL SCHOOL SYMP ON MULTIMODALITY THERAPY OF CHEST MALIGNANCIES CY APR 09-11, 1992 CL BOSTON, MA SP DANA FARBER CANC INST, DEPT ONCOL, BRIGHAM & WOMENS HOSP, DIV THORAC SURG ID TESTICULAR CANCER; CHEMOTHERAPY; ETOPOSIDE AB Germ cell tumors are highly curable when treated appropriately. The majority of germ cell tumors arise in the testes, with a proportion having pulmonary parenchymal or mediastinal metastases. For patients who have such tumors, prompt diagnosis and treatment with chemotherapy are essential. A subset of these patients will have persistent radiographic abnormalities after chemotherapy and will benefit from postchemotherapy resection of residual masses. These patients need to be distinguished from those who should be observed and those who require further chemotherapy. A small proportion of patients with germ cell tumors will present with tumors arising in the mediastinum. Prompt diagnosis, with adequate tissue for histopathologic and immunohistochemical staining, is essential. Primary therapy for such patients should be chemotherapy, except for some patients with mediastinal seminomas in whom radiotherapy is preferable. Mediastinal nonseminomatous germ cell tumors have a poor prognosis due, in part, to their bulk and relative cheminsensitivity, but also due in part to their association with non-germ cell elements and acute leukemia. Proper coordination of the different modalities is essential in optimizing the cure rate of patients with these tumors. C1 HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DEPT MED,BOSTON,MA 02115. RP KANTOFF, P (reprint author), HARVARD UNIV,SCH MED,BOSTON,MA 02115, USA. NR 12 TC 3 Z9 3 U1 0 U2 0 PU AMER COLL CHEST PHYSICIANS PI NORTHBROOK PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 SN 0012-3692 J9 CHEST JI Chest PD APR PY 1993 VL 103 IS 4 SU S BP S331 EP S333 DI 10.1378/chest.103.4_Supplement.331S PG 3 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA KW660 UT WOS:A1993KW66000003 PM 8384966 ER PT J AU LYNCH, TJ AF LYNCH, TJ TI MANAGEMENT OF MALIGNANT PLEURAL EFFUSIONS SO CHEST LA English DT Article; Proceedings Paper CT HARVARD MEDICAL SCHOOL SYMP ON MULTIMODALITY THERAPY OF CHEST MALIGNANCIES CY APR 09-11, 1992 CL BOSTON, MA SP DANA FARBER CANC INST, DEPT ONCOL, BRIGHAM & WOMENS HOSP, DIV THORAC SURG ID LUNG-CANCER; INTRACAVITARY BLEOMYCIN; CORYNEBACTERIUM-PARVUM; TETRACYCLINE; DISEASE; PLEURODESIS; DIAGNOSIS; TALC; THORACOSCOPY; INSTILLATION AB Malignant pleural effusions (MPEs) are a common complication of advanced malignancies, particularly lung and breast cancer. They are caused by a variety of mechanisms including tumor obstruction of lymphatic flow, spread of malignant cells via the systemic circulation, and tumor invasion of the pulmonary arterioles. Therapy is determined by tumor histology, stage of malignancy, and a careful assessment of a patient's performance status and comorbid diseases. A number of approaches have been used to treat patients with MPE ranging from thoracentesis to pleurectomy. Tube thoracostomy drainage followed by application of a sclerosing agent is the most common strategy. Effective sclerosing agents include quinacrine, talc, bleomycin, tetracycline and Corynebacterium parvum. Results from a recent multicenter randomized trial suggest that bleomycin may be superior in terms of control of effusion at 30 days. Further randomized studies are ongoing to determine the optimal method of draining the pleural space and the most effective sclerosing agent. Thoracoscopy using video-assisted techniques is a promising new approach to MPEs both for diagnosis and treatment. The application of biological agents such as interleukin-2, the interferons, and novel chemotherapeutic agents are experimental approaches that are under investigation. RP LYNCH, TJ (reprint author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV CLIN ONCOL,BOSTON,MA 02115, USA. NR 43 TC 45 Z9 45 U1 0 U2 0 PU AMER COLL CHEST PHYSICIANS PI NORTHBROOK PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 SN 0012-3692 J9 CHEST JI Chest PD APR PY 1993 VL 103 IS 4 SU S BP S385 EP S389 PG 5 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA KW660 UT WOS:A1993KW66000018 PM 7681744 ER PT J AU LYNCH, TJ AF LYNCH, TJ TI IMMUNOTOXIN THERAPY OF SMALL-CELL LUNG-CANCER - N901-BLOCKED RICIN FOR RELAPSED SMALL-CELL LUNG-CANCER SO CHEST LA English DT Article; Proceedings Paper CT HARVARD MEDICAL SCHOOL SYMP ON MULTIMODALITY THERAPY OF CHEST MALIGNANCIES CY APR 09-11, 1992 CL BOSTON, MA SP DANA FARBER CANC INST, DEPT ONCOL, BRIGHAM & WOMENS HOSP, DIV THORAC SURG ID NATURAL-KILLER CELLS; BONE-MARROW; MONOCLONAL-ANTIBODIES; RADIATION-THERAPY; NONHUMAN-PRIMATES; CLINICAL-TRIAL; CHEMOTHERAPY; CARCINOMA; ANTIGENS AB Despite its initial chemosensitivity, small-cell lung cancer (SCLC) is rarely cured with chemotherapy alone, and fewer than 5% of patients are alive at 5 years. Immunotoxin therapy appears to offer promise in treating the minimal residual disease that remains after induction chemotherapy. We have studied N901-bB in patients with relapsed SCLS. N901-bR consists of the N901 monoclonal antibody (MoAb) and blocked ricin, an altered ricin molecule in which the galactose binding sites of the ricin B-chain which mediate nonspecific binding of the toxin are blocked through the covalent binding of ligands. N901 is an anti-NCAM (CD56) MoAb which binds to SCLC tumors and cell lines, cardiac muscle, natural killer (NK) cells, and peripheral nerve. N901-bR showed a 2.7 log greater in vitro cytotoxicity to the CD56-positive cell line SE-2 than to the antigen-negative Namalwa cell line. Nineteen patients with relapsed antigen-negative Namalwa cell line. Nineteen patients with relapsed and/or refractory SCLC have been entered into a phase I study at doses ranging from 5 to 40 mug/kg/day given as a 7-day continuous infusion. The dose-limiting toxicity is capillary leak syndrome observed in two thirds of the patients treated at 40 mug/kg/day. One patient at the maximum tolerated dose, 30 mug/kg/day x 7 days, has achieved a partial response to N901-bR. No patient has developed clinically significant peripheral or central neuropathy. We plan to begin a phase II study of N901-bR following induction chemotherapy in patients with SCLC. RP LYNCH, TJ (reprint author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV CLIN ONCOL,BOSTON,MA 02115, USA. NR 26 TC 21 Z9 21 U1 0 U2 0 PU AMER COLL CHEST PHYSICIANS PI NORTHBROOK PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 SN 0012-3692 J9 CHEST JI Chest PD APR PY 1993 VL 103 IS 4 SU S BP S436 EP S439 DI 10.1378/chest.103.4_Supplement.436S PG 4 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA KW660 UT WOS:A1993KW66000031 PM 8384975 ER PT J AU MAYER, RJ AF MAYER, RJ TI OVERVIEW - THE CHANGING NATURE OF ESOPHAGEAL CANCER SO CHEST LA English DT Article; Proceedings Paper CT HARVARD MEDICAL SCHOOL SYMP ON MULTIMODALITY THERAPY OF CHEST MALIGNANCIES CY APR 09-11, 1992 CL BOSTON, MA SP DANA FARBER CANC INST, DEPT ONCOL, BRIGHAM & WOMENS HOSP, DIV THORAC SURG ID BARRETTS ESOPHAGUS; GASTRIC ADENOCARCINOMA; CARDIA AB Squamous cell carcinomas of the esophagus, while still frequent in many locations throughout the world, now comprise a smaller percentage of esophageal cancers in the United States than was previously believed. Such tumors occur most often in black men and in association with tobacco and alcohol abuse. Adenocarcinomas of the distal esophagus represent an increasing proportion of esophageal tumors. These neoplasms arise in columnar epithelium (ie, Barrett's esophagus) or extend into the esophagus from their site of origin in the proximal stomach. Esophageal adenocarcinomas appear more often in white than black subjects and in men more than women. The clinical features and diagnostic approaches to squamous cell tumors and adenocarcinomas of the esophagus are similar. RP MAYER, RJ (reprint author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,44 BINNEY ST,BOSTON,MA 02115, USA. NR 22 TC 14 Z9 15 U1 0 U2 0 PU AMER COLL CHEST PHYSICIANS PI NORTHBROOK PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 SN 0012-3692 J9 CHEST JI Chest PD APR PY 1993 VL 103 IS 4 SU S BP S404 EP S405 DI 10.1378/chest.103.4_Supplement.404S PG 2 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA KW660 UT WOS:A1993KW66000023 PM 8462335 ER PT J AU SKARIN, AT AF SKARIN, AT TI ANALYSIS OF LONG-TERM SURVIVORS WITH SMALL-CELL LUNG-CANCER SO CHEST LA English DT Article; Proceedings Paper CT HARVARD MEDICAL SCHOOL SYMP ON MULTIMODALITY THERAPY OF CHEST MALIGNANCIES CY APR 09-11, 1992 CL BOSTON, MA SP DANA FARBER CANC INST, DEPT ONCOL, BRIGHAM & WOMENS HOSP, DIV THORAC SURG ID KINGDOM COORDINATING COMMITTEE; PROGNOSTIC FACTORS; COMBINATION CHEMOTHERAPY; LABORATORY PARAMETERS; STAGING PROCEDURES; CARCINOMA; IRRADIATION; DETERMINANTS; SUBCOMMITTEE; SYSTEM AB Survival among patients with small-cell lung cancer (SCLC) appears to have improved over the last 15 years. However, 2- to 3-year survival is still only 10% to 25% for patients with limited disease and 1% to 2% for those with extensive disease. Moreover, relapse of SCLC and the development of other cancers are common in patients surviving beyond 2 years. Clearly, new innovative therapy is needed, and continued research with recently developed agents is warranted. Modern multimodality therapy may have a role in patients with surgically resectable stage I or II disease, but development of better chemotherapy, bone marrow transplantation, hyperfractionation radiotherapy, and radiosensitizers will be necessary for most SCLC patients. Recently discovered prognostic indicators should help target individual SCLC patients for specific intensive treatments designed to prolong survival and achieve a cure. C1 HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115. RP SKARIN, AT (reprint author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,44 BINNEY ST,BOSTON,MA 02115, USA. NR 35 TC 22 Z9 22 U1 0 U2 0 PU AMER COLL CHEST PHYSICIANS PI NORTHBROOK PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 SN 0012-3692 J9 CHEST JI Chest PD APR PY 1993 VL 103 IS 4 SU S BP S440 EP S444 DI 10.1378/chest.103.4_Supplement.440S PG 5 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA KW660 UT WOS:A1993KW66000032 PM 8384976 ER PT J AU SCHUNKERT, H JACKSON, B TANG, SS SCHOEN, FJ SMITS, JFM APSTEIN, CS LORELL, BH AF SCHUNKERT, H JACKSON, B TANG, SS SCHOEN, FJ SMITS, JFM APSTEIN, CS LORELL, BH TI DISTRIBUTION AND FUNCTIONAL-SIGNIFICANCE OF CARDIAC ANGIOTENSIN-CONVERTING ENZYME IN HYPERTROPHIED RAT HEARTS SO CIRCULATION LA English DT Article DE ANGIOTENSIN-I; ANGIOTENSIN-II; DIASTOLE; ANGIOTENSIN CONVERTING ENZYME; ENDOTHELIUM; ENALAPRILAT ID LEFT-VENTRICULAR HYPERTROPHY; DIASTOLIC CHAMBER STIFFNESS; MYOCARDIAL-INFARCTION; HYPERTENSIVE PATIENTS; CALCIUM CURRENT; RABBIT HEARTS; INHIBITION; TISSUE; CAPTOPRIL; PRESSURE AB Background. The intracardiac conversion rate of angiotensin (Ang) I to Ang II and the expression of angiotensin converting enzyme (ACE) mRNA are amplified in rat hearts with left ventricular hypertrophy (LVH). To examine whether the accelerated intracardiac Ang II generation in LVH is related to an induction of cardiac ACE, we studied localization and function of cardiac ACE in hypertrophied rat hearts using specific ACE inhibitors. Methods and Results. Cardiac ACE was localized and quantified in hearts from male Wistar rats with LVH due to chronic experimental aortic stenosis and from control rats. With the ACE inhibitor I-125-351A, a derivative of lisinopril, as a radioligand on coronal sections of LVH and control hearts, in vitro autoradiography demonstrated ACE binding in aorta, coronary arteries, atria, and ventricles of both groups. Quantitative analyses revealed that ACE density (counts per minute per cross-sectional area of tissue) was twofold higher within the myocardium of hypertrophied left ventricles compared with controls (p<0.005). Quantitative morphometry demonstrated a modest increase in the fractional volume of myocytes as well as capillary volume without an increase in the fractional volume of endothelial cells in left ventricular tissue from aortic stenosis rats. These data suggest that an increase in endothelial cell volume per se cannot alone account for the observed doubling of ACE density and support an upregulation of ACE production in hypertrophied tissue. The role of cardiac ACE in intracardiac conversion of Ang I to Ang II and its specific inhibition was studied in isolated, isovolumic beating, buffer-perfused LVH and control hearts. Biochemical conversion rates as well as functional changes in response to 3 x 10(-7) M Ang I were examined in the absence or presence of the ACE inhibitor enalaprilat (4 x 10(-6) M). After a brief stabilization period, groups of LVH and control hearts were subjected to the following infusion protocols: 15 minutes of vehicle followed by 30 minutes of Ang I plus vehicle, 15 minutes of enalaprilat followed by 30 minutes of Ang I plus enalaprilat (enal/Ang I), or 45 minutes of vehicle only to allow comparison with a time control. Intracardiac Ang I-to-Ang II conversion rate was fourfold higher in LVH than in control hearts (p<0.05). Infusion of enalaprilat reduced the intracardiac Ang I-to-Ang II conversion rate in LVH hearts by 70% (p < 0.05 versus Ang I). At similar levels of constant coronary flow per gram, Ang I increased coronary perfusion pressure by 23+/-5 mm Hg (p<0.01 versus vehicle) in LVH hearts and by 36+/-10 mm Hg (p<0.005 versus vehicle) in control hearts. When enalaprilat was infused with Ang I, the increase in perfusion pressure was limited to 5+/-5 mm Hg (NS versus vehicle) in LVH hearts and 12+/-3 mm Hg (p<0.05 versus vehicle) in control hearts and was significantly lower than in hearts infused with Ang I only (p<0.05 in LVH and p<0.05 in control hearts, respectively). Systolic function was not affected by either infusion protocol. In contrast, Ang I infusion was associated with diastolic dysfunction. In LVH hearts, left ventricular end-diastolic pressure (LVEDP) increased from 10+/-1 mm Hg at baseline to 25+/-2 mm Hg at the end of the Ang I infusion (p<0.001 versus vehicle), which was inhibited by infusion of enalaprilat. In control hearts, there was a lesser increase in LVEDP from 10+/-I mm Hg to 15+/-l mm Hg in response to Ang I (p <0.05 versus LVH). Control hearts treated with enalaprilat with Ang I displayed no increase in LVEDP. Conclusions. These observations indicate that ACE protein is increased within the myocardium of LVH hearts, extending recent findings of increased cardiac ACE activity and mRNA levels in this model of pressure-overload LVH in the rat. Blockade of the enzyme by an ACE inhibitor decreases intracardiac Ang I-to-Ang II conversion rate and prevents the functional changes of Ang I-to-Ang II activation otherwise seen in LVH hearts. Taken together, these data suggest that ACE is a key enzyme involved in the enhanced conversion of Ang I to Ang II in the intact hypertrophied rat heart. C1 BETH ISRAEL HOSP,DEPT MED,DIV CARDIOVASC,330 BROOKLINE AVE,BOSTON,MA 02215. BOSTON CITY HOSP,THORNDIKE MEM LAB,CARDIOL SECT,BOSTON,MA 02118. BOSTON UNIV,SCH MED,INST CARDIOVASC,CARDIAC MUSCLE RES LAB,BOSTON,MA 02118. MASSACHUSETTS GEN HOSP,CHILDRENS SERV,PEDIAT RENAL RES LAB,BOSTON,MA 02114. BRIGHAM & WOMENS HOSP,DEPT PATHOL,BOSTON,MA 02115. UNIV LIMBURG,DEPT PHARMACOL,6200 MD MAASTRICHT,NETHERLANDS. BETH ISRAEL HOSP,THORNDIKE LAB,BOSTON,MA 02215. BETH ISRAEL HOSP,THORNDIKE LAB,CHARLES A DANA RES INST,BOSTON,MA 02215. HARVARD UNIV,SCH MED,BOSTON,MA 02115. UNIV MELBOURNE,DEPT MED,PARKVILLE,VIC 3052,AUSTRALIA. FU NHLBI NIH HHS [HL-38189, HL-43131] NR 72 TC 166 Z9 171 U1 0 U2 1 PU AMER HEART ASSOC PI DALLAS PA 7272 GREENVILLE AVENUE, DALLAS, TX 75231-4596 SN 0009-7322 J9 CIRCULATION JI Circulation PD APR PY 1993 VL 87 IS 4 BP 1328 EP 1339 PG 12 WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA KW422 UT WOS:A1993KW42200028 PM 8384939 ER PT J AU DEWOOD, MA KURNIK, PB JOLLY, MK JAIN, AC KHAJA, F GORFINKEL, HJ MORRIS, DL SATLER, L LITTLEJOHN, J AF DEWOOD, MA KURNIK, PB JOLLY, MK JAIN, AC KHAJA, F GORFINKEL, HJ MORRIS, DL SATLER, L LITTLEJOHN, J TI DOSE-RANGING STUDY WITH A NEW 2-CHAIN RT-PA IN PATIENTS WITH ACUTE MYOCARDIAL-INFARCTION - A MULTICENTER TRIAL SO CLINICAL CARDIOLOGY LA English DT Article DE THROMBOLYSIS; REPERFUSION; CORONARY THROMBOSIS; MYOCARDIAL INFARCTION; DUTEPLASE; RT-PA ID TISSUE PLASMINOGEN-ACTIVATOR; INTRACORONARY STREPTOKINASE; RANDOMIZED TRIAL; INTRAVENOUS STREPTOKINASE; CORONARY THROMBOLYSIS; MAINTENANCE INFUSION; REOCCLUSION; THERAPY; ANGIOPLASTY; PREVENTION AB Tissue-type plasminogen activator (t-PA) derived from a melanoma cell line was first used in patients with acute myocardial infarction in the early 1980s. Recombinant DNA technology then allowed production of large amounts of t-PA. The TIMI-I trial used a two-chain recombinant (rt-PA) product. A predominantly single-chain rt-PA (alteplase) was used in the majority of the TIMI II trial. The present study used a different form of two-chain rt-PA (duteplase) to determine the effective dose for thrombolysis at 60 min, and to evaluate time to reperfusion, reocclusion at 72-96 h, coagulation profiles, and bleeding events. Duteplase was given intravenously to 75 patients a mean of 3.8 +/- 1 h after the onset of myocardial infarction. Following angiography demonstrating coronary occlusion, 23 patients received a low dose of duteplase [0.16-0.29 million international units per kilogram (MIU/kg)] over 60 min followed by a 5-h infusion in conjunction with heparin, 25 patients received a middle dose (0.30-0.41 MIU/kg) and 23 patients received a high dose (0.43-0.74 MIU/kg). Angiography was then performed every 15 min x 4. Progressive recanalization occurred over 60 min (median 45 min) with an overall success rate of 59% (mean 60-min dose: 0.37 MIU/kg). No dose-response relationship was observed. The reocclusion rate was 9% at 72-96 h. Reductions in fibrinogen and plasminogen correlated with dose, but clinical events did not. These data are important because this form of rt-PA was employed in die recently reported ISIS-3 trial and the mean dose of duteplase in the present trial is the same as the 60-min dose employed in ISIS-3. C1 DEACONESS MED CTR,DIV CARDIOVASC RES,SPOKANE,WA. RP DEWOOD, MA (reprint author), SACRED HEART MED CTR,DIV CARDIOL,800 W 5TH AVE,SPOKANE,WA 99204, USA. NR 37 TC 2 Z9 2 U1 0 U2 0 PU CLINICAL CARDIOLOGY PUBL CO PI MAHWAH PA PO BOX 832, MAHWAH, NJ 07430-0832 SN 0160-9289 J9 CLIN CARDIOL JI Clin. Cardiol. PD APR PY 1993 VL 16 IS 4 BP 302 EP 310 PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA KU795 UT WOS:A1993KU79500004 PM 8458110 ER PT J AU LITWIN, CM CALDERWOOD, SB AF LITWIN, CM CALDERWOOD, SB TI ROLE OF IRON IN REGULATION OF VIRULENCE GENES SO CLINICAL MICROBIOLOGY REVIEWS LA English DT Review AB The abilities of bacterial pathogens to adapt to the environment within the host are essential to their virulence. Microorganisms have adapted to the iron limitation present in mammalian hosts by evolving diverse mechanisms for the assimilation of iron sufficient for growth. In addition, many bacterial pathogens have used the low concentration of iron present in the host as an important signal to enhance the expression of a wide variety of bacterial toxins and other virulence determinants. The molecular basis of coordinate regulation by iron has been most thoroughly studied in Escherichia coli. In this organism, coordinate regulation of gene expression by iron depends on the regulatory gene, fur. Regulation of gene expression by iron in a number of pathogenic organisms is coordinated by proteins homologous to the Fur protein of E. coli. Additional regulatory proteins may be superimposed on the Fur repressor to provide the fine-tuning necessary for the precise regulation of individual virulence genes in response to iron and other environmental signals. Studies of the mechanisms of regulation of iron acquisition systems and virulence determinants by iron should lead to a better understanding of the adaptive response of bacteria to the low-iron environment of the host and its importance in virulence. C1 MASSACHUSETTS GEN HOSP,INFECT DIS UNIT,BOSTON,MA 02114. OI Litwin, Christine/0000-0002-4311-7714 FU NIAID NIH HHS [AI27329] NR 0 TC 426 Z9 435 U1 3 U2 14 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171 SN 0893-8512 J9 CLIN MICROBIOL REV JI Clin. Microbiol. Rev. PD APR PY 1993 VL 6 IS 2 BP 137 EP 149 PG 13 WC Microbiology SC Microbiology GA KX255 UT WOS:A1993KX25500003 PM 8472246 ER PT J AU SPRINGFIELD, D AF SPRINGFIELD, D TI LIPOSARCOMA SO CLINICAL ORTHOPAEDICS AND RELATED RESEARCH LA English DT Article ID SOFT-TISSUE SARCOMAS; PATTERNS AB Liposarcoma is second in frequency only to malignant fibrous histiocytoma among the soft-tissue sarcomas. It occurs almost exclusively in adults and is found most often in the thigh or retroperitoneum. It rarely arises from a lipoma and does not occur in the subcutaneous tissues. Liposarcomas are divided into histologic subtypes with different microscopic appearances and slightly different behavior characteristics. Surgical resection with a wide surgical margin is the treatment of choice. When amputation is required to obtain an adequate surgical margin, local irradiation can be used as an adjuvant and a limb-sparing operation can be done. Currently, no evidence exists that adjuvant chemotherapy is indicated for patients with liposarcoma, although numerous studies are being done to investigate its use. As is the case for all sarcomas, the lung is the most common site of metastasis; however, liposarcoma has an unusual propensity to metastasize to the retroperitoneum, mediastinum, and bone. RP SPRINGFIELD, D (reprint author), MASSACHUSETTS GEN HOSP,DEPT ORTHOPAED MUSCULOSKELETAL ONCOL,BOSTON,MA 02114, USA. NR 18 TC 25 Z9 26 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0009-921X J9 CLIN ORTHOP RELAT R JI Clin. Orthop. Rel. Res. PD APR PY 1993 IS 289 BP 50 EP 57 PG 8 WC Orthopedics; Surgery SC Orthopedics; Surgery GA KY525 UT WOS:A1993KY52500007 PM 8472432 ER PT J AU ELIAS, AD AF ELIAS, AD TI CHEMOTHERAPY FOR SOFT-TISSUE SARCOMAS SO CLINICAL ORTHOPAEDICS AND RELATED RESEARCH LA English DT Article ID PHASE-II TRIAL; IFOSFAMIDE PLUS DOXORUBICIN; GYNECOLOGIC ONCOLOGY GROUP; ADJUVANT CHEMOTHERAPY; RANDOMIZED TRIAL; COMBINATION CHEMOTHERAPY; UNRESECTABLE SARCOMA; UTERINE SARCOMAS; ACTINOMYCIN-D; ADRIAMYCIN AB Single-agent and combination chemotherapy have greater than 20% single-agent activity: doxorubicin and ifosfamide. Certain other anthracycline analogues possess similar activity. It remains a question whether combination therapy is any better than single-agent doxorubicin. Randomized trials have demonstrated enhanced response rates and increased toxicity for the combinations, but survival, with limited follow-up data, is not improved. The role of adjuvant chemotherapy also is not yet established. Two of 12 trials demonstrate survival benefits; however, most show a delay in relapse with about a 10% risk of irreversible toxicity. New agents, targets, and methods to circumvent resistance mechanisms developed in the laboratory are necessary to advance the field. RP ELIAS, AD (reprint author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DEPT MED,44 BINNEY ST,BOSTON,MA 02115, USA. NR 82 TC 5 Z9 5 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0009-921X J9 CLIN ORTHOP RELAT R JI Clin. Orthop. Rel. Res. PD APR PY 1993 IS 289 BP 94 EP 105 PG 12 WC Orthopedics; Surgery SC Orthopedics; Surgery GA KY525 UT WOS:A1993KY52500012 PM 8472436 ER PT J AU AFTRING, RP FREEMAN, MW AF AFTRING, RP FREEMAN, MW TI CLONING AND CHARACTERIZATION OF THE MOUSE MACROPHAGE SCAVENGER RECEPTOR GENE - A 150 BASE PAIR PROMOTER FRAGMENT DRIVES CELL-SPECIFIC EXPRESSION SO CLINICAL RESEARCH LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,LIPID METAB UNIT,BOSTON,MA 02114. MASSACHUSETTS GEN HOSP,ENDOCRINE UNIT,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 SN 0009-9279 J9 CLIN RES JI Clin. Res. PD APR PY 1993 VL 41 IS 2 BP A143 EP A143 PG 1 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA KW761 UT WOS:A1993KW76100169 ER PT J AU AHMED, AR MOHIMAN, A NEUMAN, R FOSTER, CS AF AHMED, AR MOHIMAN, A NEUMAN, R FOSTER, CS TI THE AUTOANTIGEN CHARACTERIZING OCULAR CICATRICIAL PEMPHIGOID SO CLINICAL RESEARCH LA English DT Meeting Abstract C1 CTR BLOOD RES,BOSTON,MA. MASSACHUSETTS EYE & EAR INFIRM,BOSTON,MA 02114. HARVARD UNIV,SCH MED,BOSTON,MA 02115. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 SN 0009-9279 J9 CLIN RES JI Clin. Res. PD APR PY 1993 VL 41 IS 2 BP A407 EP A407 PG 1 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA KW761 UT WOS:A1993KW76101649 ER PT J AU AHMED, AR YUNIS, JJ SHERWANI, SI KATZ, AJ AWDEH, Z YUNIS, EJ ALPER, CA AF AHMED, AR YUNIS, JJ SHERWANI, SI KATZ, AJ AWDEH, Z YUNIS, EJ ALPER, CA TI MAJOR HISTOCOMPATIBILITY COMPLEX SUSCEPTIBILITY GENES FOR DERMATITIS-HERPETIFORMIS COMPARED WITH THOSE FOR GLUTEN-SENSITIVE ENTEROPATHY SO CLINICAL RESEARCH LA English DT Meeting Abstract C1 HARVARD UNIV,SCH MED,CTR BLOOD RES,BOSTON,MA 02115. HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115. HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DEPT PATHOL & PEDIAT,BOSTON,MA 02115. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 SN 0009-9279 J9 CLIN RES JI Clin. Res. PD APR PY 1993 VL 41 IS 2 BP A128 EP A128 PG 1 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA KW761 UT WOS:A1993KW76100080 ER PT J AU AIURA, K DINARELLO, CA MARGOLIS, N KAPLANSKI, G BURKE, JF GELFAND, JA AF AIURA, K DINARELLO, CA MARGOLIS, N KAPLANSKI, G BURKE, JF GELFAND, JA TI ACTIVATED PLATELETS DRAMATICALLY INCREASE INTERLEUKIN-1 AND TUMOR-NECROSIS-FACTOR PRODUCTION BY LEUKOCYTES STIMULATED WITH ENDOTOXIN SO CLINICAL RESEARCH LA English DT Meeting Abstract C1 TUFTS UNIV,NEW ENGLAND MED CTR,DEPT MED,BOSTON,MA 02111. MASSACHUSETTS GEN HOSP,DEPT SURG,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 1 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 SN 0009-9279 J9 CLIN RES JI Clin. Res. PD APR PY 1993 VL 41 IS 2 BP A213 EP A213 PG 1 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA KW761 UT WOS:A1993KW76100547 ER PT J AU ASAHINA, A HOSOI, J BRUVERS, S MURPHY, GF GRANSTEIN, RD AF ASAHINA, A HOSOI, J BRUVERS, S MURPHY, GF GRANSTEIN, RD TI REGULATION OF LANGERHANS CELL (LC) PROTEIN ANTIGEN PRESENTATION BY CALCITONIN GENE-RELATED PEPTIDE (CGRP), GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR (GM-CSF) AND TUMOR-NECROSIS-FACTOR-ALPHA (TNF-ALPHA) SO CLINICAL RESEARCH LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,MGH HARVARD CUTANEOUS BIOL RES CTR,BOSTON,MA 02114. UNIV PENN,DEPT DERMATOL,PHILADELPHIA,PA 19104. NR 1 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 SN 0009-9279 J9 CLIN RES JI Clin. Res. PD APR PY 1993 VL 41 IS 2 BP A461 EP A461 PG 1 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA KW761 UT WOS:A1993KW76101974 ER PT J AU ATLAS, SJ SINGER, DE KELLER, RB DEYO, RA AF ATLAS, SJ SINGER, DE KELLER, RB DEYO, RA TI PREDICTORS OF LUMBAR DISC SURGERY IN PATIENTS WITH SCIATICA SO CLINICAL RESEARCH LA English DT Meeting Abstract C1 BACK PAIN PATIENT OUTCOME ASSESSMENT TEAM,SEATTLE,WA. MASSACHUSETTS GEN HOSP,BOSTON,MA 02114. BACK PAIN PATIENT OUTCOME ASSESSMENT TEAM,BOSTON,MA. BACK PAIN PATIENT OUTCOME ASSESSMENT TEAM,AUGUSTA,ME. NR 0 TC 2 Z9 2 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 SN 0009-9279 J9 CLIN RES JI Clin. Res. PD APR PY 1993 VL 41 IS 2 BP A513 EP A513 PG 1 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA KW761 UT WOS:A1993KW76102281 ER PT J AU ATLAS, SJ WENNBERG, DE COLEY, CM DIENSTAG, JL SINGER, DE AF ATLAS, SJ WENNBERG, DE COLEY, CM DIENSTAG, JL SINGER, DE TI THE COST-EFFECTIVENESS OF AUTOLOGOUS BLOOD PREDEPOSIT IN TOTAL HIP-REPLACEMENT SURGERY SO CLINICAL RESEARCH LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,BOSTON,MA 02114. MAINE MED CTR,PORTLAND,ME 04102. NR 0 TC 1 Z9 1 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 SN 0009-9279 J9 CLIN RES JI Clin. Res. PD APR PY 1993 VL 41 IS 2 BP A525 EP A525 PG 1 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA KW761 UT WOS:A1993KW76102355 ER PT J AU ATLAS, SJ SINGER, DE KELLER, R CONVERY, K MOONEY, N DEYO, R AF ATLAS, SJ SINGER, DE KELLER, R CONVERY, K MOONEY, N DEYO, R TI THE EFFICACY OF LUMBAR DISC SURGERY IN PATIENTS WITH SCIATICA - PRELIMINARY-RESULTS FROM THE MAINE LUMBAR SPINE STUDY SO CLINICAL RESEARCH LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,BOSTON,MA 02114. BACK PAIN PATIENT OUTCOME ASSESSMENT TEAM,BOSTON,MA. BACK PAIN PATIENT OUTCOME ASSESSMENT TEAM,AUGUSTA,ME. BACK PAIN PATIENT OUTCOME ASSESSMENT TEAM,SEATTLE,WA. NR 0 TC 1 Z9 1 U1 1 U2 1 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 SN 0009-9279 J9 CLIN RES JI Clin. Res. PD APR PY 1993 VL 41 IS 2 BP A200 EP A200 PG 1 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA KW761 UT WOS:A1993KW76100484 ER PT J AU BARNHILL, RL FANDREY, K KANG, S HYMAN, B AF BARNHILL, RL FANDREY, K KANG, S HYMAN, B TI TUMOR VASCULARITY AS A PROGNOSTIC FACTOR IN CUTANEOUS MALIGNANT-MELANOMA SO CLINICAL RESEARCH LA English DT Meeting Abstract C1 HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT DERMATOL,BOSTON,MA 02115. HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT NEUROL,BOSTON,MA 02115. HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT PATHOL,BOSTON,MA 02115. HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEPT DERMATOL,BOSTON,MA 02114. HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEPT PATHOL,BOSTON,MA 02114. HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEPT NEUROL,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 SN 0009-9279 J9 CLIN RES JI Clin. Res. PD APR PY 1993 VL 41 IS 2 BP A426 EP A426 PG 1 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA KW761 UT WOS:A1993KW76101764 ER PT J AU BAUER, RL HAFFNER, SM AF BAUER, RL HAFFNER, SM TI AXIAL SKELETAL BONE DENSITIES IN DIABETICS IN A POPULATION-BASED SURVEY SO CLINICAL RESEARCH LA English DT Meeting Abstract C1 UNIV TEXAS,HLTH SCI CTR,SAN ANTONIO,TX 78284. AUDIE L MURPHY MEM VET ADM MED CTR,SAN ANTONIO,TX 78284. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 SN 0009-9279 J9 CLIN RES JI Clin. Res. PD APR PY 1993 VL 41 IS 2 BP A123 EP A123 PG 1 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA KW761 UT WOS:A1993KW76100055 ER PT J AU BOLDT, DH ALCANTARA, O ONER, T OBEID, L HANNUN, YA AF BOLDT, DH ALCANTARA, O ONER, T OBEID, L HANNUN, YA TI REGULATION OF LUCIFERASE EXPRESSION BY FERRIC TRANSFERRIN IN STABLE HREH9 TRANSFECTANTS CONTAINING PKC-BETA-LUCIFERASE GENE CONSTRUCTS SO CLINICAL RESEARCH LA English DT Meeting Abstract C1 AUDIE L MURPHY MEM VET ADM MED CTR,SAN ANTONIO,TX 78284. UNIV TEXAS,HLTH SCI CTR,SAN ANTONIO,TX 78284. DUKE UNIV,MED CTR,DURHAM,NC 27710. NR 1 TC 1 Z9 1 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 SN 0009-9279 J9 CLIN RES JI Clin. Res. PD APR PY 1993 VL 41 IS 2 BP A308 EP A308 PG 1 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA KW761 UT WOS:A1993KW76101074 ER PT J AU BOUFFARD, D DUNCAN, LM HOWARD, CA MIHM, MC BYERS, HR AF BOUFFARD, D DUNCAN, LM HOWARD, CA MIHM, MC BYERS, HR TI ACTIN-BINDING PROTEIN EXPRESSION IN BENIGN AND MALIGNANT MELANOCYTIC PROLIFERATIONS SO CLINICAL RESEARCH LA English DT Meeting Abstract C1 HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DIV DERMATOPATHOL,BOSTON,MA 02114. NR 1 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 SN 0009-9279 J9 CLIN RES JI Clin. Res. PD APR PY 1993 VL 41 IS 2 BP A489 EP A489 PG 1 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA KW761 UT WOS:A1993KW76102141 ER PT J AU CALLAHAN, T HALL, JE ETTNER, S GREENE, M CROWLEY, WF AF CALLAHAN, T HALL, JE ETTNER, S GREENE, M CROWLEY, WF TI THE ECONOMIC-IMPLICATIONS OF ASSISTED REPRODUCTIVE TECHNOLOGIES AND MULTIPLE GESTATION PREGNANCIES SO CLINICAL RESEARCH LA English DT Meeting Abstract C1 HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,REPROD ENDOCRINOL UNIT,BOSTON,MA 02114. HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,BOSTON,MA 02115. NR 0 TC 1 Z9 1 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 SN 0009-9279 J9 CLIN RES JI Clin. Res. PD APR PY 1993 VL 41 IS 2 BP A234 EP A234 PG 1 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA KW761 UT WOS:A1993KW76100661 ER PT J AU CARTER, ME GULICK, T RAISHER, BD CAIRA, T MOORE, DD KELLY, DP AF CARTER, ME GULICK, T RAISHER, BD CAIRA, T MOORE, DD KELLY, DP TI A PLEIOTROPIC RESPONSE ELEMENT IN THE MEDIUM-CHAIN ACYL-COA DEHYDROGENASE GENE (MCAD) PROMOTER MEDIATES TRANSCRIPTIONAL REGULATION BY MEMBERS OF THE NUCLEAR HORMONE RECEPTOR SUPERFAMILY AND DEFINES NOVEL RECEPTOR DNA-BINDING MOTIFS SO CLINICAL RESEARCH LA English DT Meeting Abstract C1 WASHINGTON UNIV,DEPT MED,ST LOUIS,MO 63130. MASSACHUSETTS GEN HOSP,DEPT MOLEC BIOL,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 SN 0009-9279 J9 CLIN RES JI Clin. Res. PD APR PY 1993 VL 41 IS 2 BP A265 EP A265 PG 1 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA KW761 UT WOS:A1993KW76100834 ER PT J AU DEKKER, SK VINK, J VERMEER, BJ BRUIJN, JA MIHM, MC BYERS, HR AF DEKKER, SK VINK, J VERMEER, BJ BRUIJN, JA MIHM, MC BYERS, HR TI TNF-ALPHA AND IL-1-ALPHA MODULATES MELANOMA INTEGRIN EXPRESSION AND CELL-MIGRATION SO CLINICAL RESEARCH LA English DT Meeting Abstract C1 HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEPT PATHOL,DIV DERMATOPATHOL,BOSTON,MA 02114. LEIDEN UNIV,DEPT DERMATOL & PATHOL,2300 RA LEIDEN,NETHERLANDS. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 SN 0009-9279 J9 CLIN RES JI Clin. Res. PD APR PY 1993 VL 41 IS 2 BP A490 EP A490 PG 1 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA KW761 UT WOS:A1993KW76102145 ER PT J AU DEULOFEUT, H YUNIS, EJ DEULOFEUT, R SALAZAR, M KRUSKALL, MS YUNIS, DE MARCUSBAGLEY, D AWDEH, Z ALPER, CA AF DEULOFEUT, H YUNIS, EJ DEULOFEUT, R SALAZAR, M KRUSKALL, MS YUNIS, DE MARCUSBAGLEY, D AWDEH, Z ALPER, CA TI NONRESPONSE TO HBSAG VACCINE IS DUE TO A DEFECT IN T-CELL PRECURSORS SO CLINICAL RESEARCH LA English DT Meeting Abstract C1 CTR BLOOD RES,BOSTON,MA. HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 SN 0009-9279 J9 CLIN RES JI Clin. Res. PD APR PY 1993 VL 41 IS 2 BP A369 EP A369 PG 1 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA KW761 UT WOS:A1993KW76101437 ER PT J AU DICPINIGAITIS, PV ALMENOFF, PL SPUNGEN, AM ABSGARTEN, A BAUMAN, WA AF DICPINIGAITIS, PV ALMENOFF, PL SPUNGEN, AM ABSGARTEN, A BAUMAN, WA TI EFFECT OF A GABA-AGONIST ON BRONCHIAL RESPONSIVENESS IN SUBJECTS WITH SPINAL-CORD INJURY SO CLINICAL RESEARCH LA English DT Meeting Abstract C1 CUNY MT SINAI SCH MED,DIV PULM & CRIT CARE MED,NEW YORK,NY 10029. BRONX VET ADM MED CTR,SPINAL CORD DAMAGE RES CTR,BRONX,NY. NR 1 TC 1 Z9 1 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 SN 0009-9279 J9 CLIN RES JI Clin. Res. PD APR PY 1993 VL 41 IS 2 BP A176 EP A176 PG 1 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA KW761 UT WOS:A1993KW76100361 ER PT J AU DUBEY, D YUNIS, EJ AWDEH, Z ALPER, CA AF DUBEY, D YUNIS, EJ AWDEH, Z ALPER, CA TI POLYMORPHIC HH GENES IN MAN CONTROL NATURAL-KILLER (NK) ACTIVITY AND CELL NUMBER SO CLINICAL RESEARCH LA English DT Meeting Abstract C1 CTR BLOOD RES,BOSTON,MA. HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 SN 0009-9279 J9 CLIN RES JI Clin. Res. PD APR PY 1993 VL 41 IS 2 BP A136 EP A136 PG 1 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA KW761 UT WOS:A1993KW76100131 ER PT J AU FALLON, J PRESS, W NADIRE, K COMPTON, C AF FALLON, J PRESS, W NADIRE, K COMPTON, C TI MORPHOMETRICAL STUDY OF ANCHORING FIBRIL REGENERATION DURING EPITHELIAL WOUND-HEALING SO CLINICAL RESEARCH LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,DEPT PATHOL,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 SN 0009-9279 J9 CLIN RES JI Clin. Res. PD APR PY 1993 VL 41 IS 2 BP A432 EP A432 PG 1 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA KW761 UT WOS:A1993KW76101796 ER PT J AU GOLENBOCK, D MILLHAM, F FREEMAN, M ZOELLER, R AF GOLENBOCK, D MILLHAM, F FREEMAN, M ZOELLER, R TI TRANSFECTION OF CD14 INTO CHO FIBROBLASTS TRANSFERS MACROPHAGE-LIKE RESPONSIVENESS TO LIPOPOLYSACCHARIDE SO CLINICAL RESEARCH LA English DT Meeting Abstract C1 BOSTON UNIV,BOSTON CITY HOSP,SCH MED,BOSTON,MA 02118. MASSACHUSETTS GEN HOSP,BOSTON,MA 02114. HARVARD UNIV,SCH MED,BOSTON,MA 02115. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 SN 0009-9279 J9 CLIN RES JI Clin. Res. PD APR PY 1993 VL 41 IS 2 BP A189 EP A189 PG 1 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA KW761 UT WOS:A1993KW76100429 ER PT J AU GRABBE, S GRANSTEIN, RD AF GRABBE, S GRANSTEIN, RD TI DIFFERENTIAL MODULATION OF PRIMARY AND SECONDARY EPIDERMAL-CELL ALLOANTIGEN PRESENTATION BY CYTOKINES SO CLINICAL RESEARCH LA English DT Meeting Abstract C1 UNIV MUNSTER,HAUTKLIN,W-4400 MUNSTER,GERMANY. HARVARD UNIV,MASSACHUSETTS GEN HOSP,CUTANEOUS BIOL RES CTR,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 SN 0009-9279 J9 CLIN RES JI Clin. Res. PD APR PY 1993 VL 41 IS 2 BP A469 EP A469 PG 1 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA KW761 UT WOS:A1993KW76102019 ER PT J AU GRANDALIANO, G BISWAS, P CHOUDHURY, GG BARNES, JL ABBOUD, HE AF GRANDALIANO, G BISWAS, P CHOUDHURY, GG BARNES, JL ABBOUD, HE TI PGE1 ANALOG MISOPROSTOL INHIBITS THROMBIN-INDUCED DNA-SYNTHESIS AND PDGF B-CHAIN GENE-EXPRESSION IN CULTURED HUMAN MESANGIAL CELLS SO CLINICAL RESEARCH LA English DT Meeting Abstract C1 UNIV TEXAS,HLTH SCI CTR,SAN ANTONIO,TX 78284. AUDIE L MURPHY MEM VET ADM MED CTR,SAN ANTONIO,TX. RI Grandaliano, Giuseppe/G-2963-2012 NR 0 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 SN 0009-9279 J9 CLIN RES JI Clin. Res. PD APR PY 1993 VL 41 IS 2 BP A141 EP A141 PG 1 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA KW761 UT WOS:A1993KW76100159 ER PT J AU GRANSTEIN, RD EGAN, C VIGLIONE, MJ HOSOI, I MURPHY, GF AF GRANSTEIN, RD EGAN, C VIGLIONE, MJ HOSOI, I MURPHY, GF TI LANGERHANS CELLS (LC) AND CALCITONIN GENE-RELATED PEPTIDE (CGRP)-CONTAINING EPIDERMAL AXONS ARE ANATOMICALLY ASSOCIATED SO CLINICAL RESEARCH LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,MGH HARVARD CUTANEOUS BIOL RES CTR,BOSTON,MA 02114. UNIV PENN,DEPT DERMATOL,PHILADELPHIA,PA 19104. NR 1 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 SN 0009-9279 J9 CLIN RES JI Clin. Res. PD APR PY 1993 VL 41 IS 2 BP A177 EP A177 PG 1 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA KW761 UT WOS:A1993KW76100367 ER PT J AU GULICK, T CRESCI, S CARTER, ME MOORE, DD KELLY, DP AF GULICK, T CRESCI, S CARTER, ME MOORE, DD KELLY, DP TI TRANSCRIPTIONAL REGULATION OF A MITOCHONDRIAL FATTY-ACID BETA-OXIDATION GENE IS MEDIATED BY PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) SO CLINICAL RESEARCH LA English DT Meeting Abstract C1 WASHINGTON UNIV,SCH MED,ST LOUIS,MO 63110. MASSACHUSETTS GEN HOSP,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 SN 0009-9279 J9 CLIN RES JI Clin. Res. PD APR PY 1993 VL 41 IS 2 BP A267 EP A267 PG 1 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA KW761 UT WOS:A1993KW76100844 ER PT J AU HATTORI, M YAMATO, E HIROKAWA, K AF HATTORI, M YAMATO, E HIROKAWA, K TI SUSCEPTIBILITY GENE(S) TO GLOMERULOSCLEROSIS TO RECESSIVE AND INDEPENDENT OF DIABETES AND INSULITIS IN THE NOD MOUSE SO CLINICAL RESEARCH LA English DT Meeting Abstract C1 JOSLIN DIABET CTR,BOSTON,MA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 SN 0009-9279 J9 CLIN RES JI Clin. Res. PD APR PY 1993 VL 41 IS 2 BP A131 EP A131 PG 1 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA KW761 UT WOS:A1993KW76100101 ER PT J AU HERBERT, V STOPLERKASDAN, T AF HERBERT, V STOPLERKASDAN, T TI CAN GENETIC NUTRITION BE USED TO PREDICT AND PREVENT HEART-ATTACKS - THE MOUNT-SINAI HEART-ATTACK PREDICTION AND PREVENTION PROFILE (THE PROFILE) SO CLINICAL RESEARCH LA English DT Meeting Abstract C1 MT SINAI MED CTR,NEW YORK,NY 10029. BRONX VET AFFAIRS MED CTR,NEW YORK,NY. NR 1 TC 1 Z9 1 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 SN 0009-9279 J9 CLIN RES JI Clin. Res. PD APR PY 1993 VL 41 IS 2 BP A397 EP A397 PG 1 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA KW761 UT WOS:A1993KW76101593 ER PT J AU HIBINO, T TAKAHASHI, T HORII, I GOETINCK, PF AF HIBINO, T TAKAHASHI, T HORII, I GOETINCK, PF TI EGF-LIKE DOMAIN OF UROKINASE PLASMINOGEN-ACTIVATOR (UPA) PLAYS AN ESSENTIAL ROLE IN KERATINOCYTE GROWTH-STIMULATION SO CLINICAL RESEARCH LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,CUTANEOUS BIOL RES CTR,BOSTON,MA 02114. SHISEIDO RES CTR,YOKOHAMA,JAPAN. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 SN 0009-9279 J9 CLIN RES JI Clin. Res. PD APR PY 1993 VL 41 IS 2 BP A478 EP A478 PG 1 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA KW761 UT WOS:A1993KW76102074 ER PT J AU HOLLENBERG, AN ALBANESE, C PESTELL, RG JAMESON, JL AF HOLLENBERG, AN ALBANESE, C PESTELL, RG JAMESON, JL TI PLACENTAL SPECIFIC EXPRESSION OF THE BETA-SUBUNIT OF CHORIONIC-GONADOTROPIN REQUIRES MULTIPLE PROMOTER ELEMENTS SO CLINICAL RESEARCH LA English DT Meeting Abstract C1 HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,THYROID UNIT,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 SN 0009-9279 J9 CLIN RES JI Clin. Res. PD APR PY 1993 VL 41 IS 2 BP A201 EP A201 PG 1 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA KW761 UT WOS:A1993KW76100489 ER PT J AU HOSOI, J GRABBE, S GRANSTEIN, RD AF HOSOI, J GRABBE, S GRANSTEIN, RD TI EFFECTS OF HYDROCORTISONE ON PRESENTATION OF TUMOR-ASSOCIATED ANTIGENS BY MURINE EPIDERMAL ANTIGEN PRESENTING CELLS SO CLINICAL RESEARCH LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,MGH HARVARD CUTANEOUS BIOL RES CTR,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 SN 0009-9279 J9 CLIN RES JI Clin. Res. PD APR PY 1993 VL 41 IS 2 BP A455 EP A455 PG 1 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA KW761 UT WOS:A1993KW76101936 ER PT J AU HRUZA, LL KOLLIAS, N LUI, H GULICK, R FLOTTE, TJ WIMBERLY, J CRUMPACKER, C ANDERSON, RR AF HRUZA, LL KOLLIAS, N LUI, H GULICK, R FLOTTE, TJ WIMBERLY, J CRUMPACKER, C ANDERSON, RR TI HYPERICIN-INDUCED CUTANEOUS PHOTOSENSITIZATION SO CLINICAL RESEARCH LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,WELLMAN LABS PHOTOMED,BOSTON,MA 02114. BETH ISRAEL HOSP,DIV INFECT DIS,BOSTON,MA 02215. NR 0 TC 1 Z9 1 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 SN 0009-9279 J9 CLIN RES JI Clin. Res. PD APR PY 1993 VL 41 IS 2 BP A502 EP A502 PG 1 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA KW761 UT WOS:A1993KW76102218 ER PT J AU HYLEK, E SINGER, D AF HYLEK, E SINGER, D TI RISK-FACTORS FOR INTRACRANIAL HEMORRHAGE IN OUTPATIENTS TAKING WARFARIN SO CLINICAL RESEARCH LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,GEN MED UNIT,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 1 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 SN 0009-9279 J9 CLIN RES JI Clin. Res. PD APR PY 1993 VL 41 IS 2 BP A519 EP A519 PG 1 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA KW761 UT WOS:A1993KW76102318 ER PT J AU INGELFINGER, JR DIAMANT, D TANG, SS AF INGELFINGER, JR DIAMANT, D TANG, SS TI ANGIOTENSIN-II (ANG-II) INCREASES PRODUCTION OF ANGIOTENSINOGEN (ANG-N) IN A CULTURED MURINE RENAL PROXIMAL TUBULE CELL-LINE SO CLINICAL RESEARCH LA English DT Meeting Abstract C1 HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DIV PEDIAT NEPHROL,BOSTON,MA 02114. NR 0 TC 3 Z9 3 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 SN 0009-9279 J9 CLIN RES JI Clin. Res. PD APR PY 1993 VL 41 IS 2 BP A285 EP A285 PG 1 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA KW761 UT WOS:A1993KW76100940 ER PT J AU KAMEOKA, J TANAKA, T NOJIMA, Y SCHLOSSMAN, SF MORIMOTO, C AF KAMEOKA, J TANAKA, T NOJIMA, Y SCHLOSSMAN, SF MORIMOTO, C TI CD26 IS ASSOCIATED WITH ADENOSINE-DEAMINASE SO CLINICAL RESEARCH LA English DT Meeting Abstract C1 HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV TUMOR IMMUNOL,BOSTON,MA 02115. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 SN 0009-9279 J9 CLIN RES JI Clin. Res. PD APR PY 1993 VL 41 IS 2 BP A278 EP A278 PG 1 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA KW761 UT WOS:A1993KW76100901 ER PT J AU KERBER, CA LAWRENCE, VA DHANDA, R AF KERBER, CA LAWRENCE, VA DHANDA, R TI CAN THE AMERICAN SOCIETY OF ANESTHESIOLOGISTS PHYSICAL STATUS CLASSIFICATION PREDICT OPERATIVE RISK SO CLINICAL RESEARCH LA English DT Meeting Abstract C1 AUDIE L MURPHY MEM VET ADM MED CTR,SAN ANTONIO,TX 78284. NR 0 TC 0 Z9 0 U1 1 U2 1 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 SN 0009-9279 J9 CLIN RES JI Clin. Res. PD APR PY 1993 VL 41 IS 2 BP A520 EP A520 PG 1 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA KW761 UT WOS:A1993KW76102322 ER PT J AU KOCHEVAR, IE MORAN, M FLOTTE, TJ GRANSTEIN, RD AF KOCHEVAR, IE MORAN, M FLOTTE, TJ GRANSTEIN, RD TI DIFFERENTIAL INCREASE IN SKIN MAST-CELLS INDUCED BY CHRONIC UVB EXPOSURE OF C3H/HEN AND C3H/HEJ MICE SO CLINICAL RESEARCH LA English DT Meeting Abstract C1 HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEPT DERMATOL,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 1 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 SN 0009-9279 J9 CLIN RES JI Clin. Res. PD APR PY 1993 VL 41 IS 2 BP A502 EP A502 PG 1 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA KW761 UT WOS:A1993KW76102221 ER PT J AU KOLLIAS, N GILLIES, R MUCCINI, JA PHILLIPS, SB BILDEN, P DRAKE, LA AF KOLLIAS, N GILLIES, R MUCCINI, JA PHILLIPS, SB BILDEN, P DRAKE, LA TI QUANTITATIVE MEASUREMENT OF ERYTHEMA RESULTING FROM TRETINOIN CREAM 0.025-PERCENT TREATMENT OF PHOTODAMAGED SKIN SO CLINICAL RESEARCH LA English DT Meeting Abstract C1 HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DERMATOL CLIN INVEST UNIT,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 SN 0009-9279 J9 CLIN RES JI Clin. Res. PD APR PY 1993 VL 41 IS 2 BP A421 EP A421 PG 1 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA KW761 UT WOS:A1993KW76101730 ER PT J AU KOLLIAS, N KOCHEVAR, IE FLOTTE, T NGUYEN, C GILLIES, R MORAN, M EHAMA, R FUJII, S AF KOLLIAS, N KOCHEVAR, IE FLOTTE, T NGUYEN, C GILLIES, R MORAN, M EHAMA, R FUJII, S TI THE EFFECTS OF RETINOIC ACID ON RHINO MOUSE SKIN MEASURED BY EXCITATION FLUORESCENCE SPECTROSCOPY SO CLINICAL RESEARCH LA English DT Meeting Abstract C1 HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,WELLMAN LABS PHOTOMED,BOSTON,MA 02114. SHISEIDO CO LTD,TOKYO,JAPAN. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 SN 0009-9279 J9 CLIN RES JI Clin. Res. PD APR PY 1993 VL 41 IS 2 BP A403 EP A403 PG 1 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA KW761 UT WOS:A1993KW76101622 ER PT J AU KOLLIAS, N GILLIES, R ANDERSON, RR AF KOLLIAS, N GILLIES, R ANDERSON, RR TI FLUORESCENCE-SPECTRA OF HUMAN SKIN - PRELIMINARY-REPORT SO CLINICAL RESEARCH LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,WELLMAN LABS PHOTOMED,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 SN 0009-9279 J9 CLIN RES JI Clin. Res. PD APR PY 1993 VL 41 IS 2 BP A402 EP A402 PG 1 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA KW761 UT WOS:A1993KW76101621 ER PT J AU KRUSKALL, MS MARCUSBAGLEY, D AWDEH, Z EISENBARTH, GS BRINK, SJ KATZ, AJ HAUSER, SL AHMED, AR BING, DH YUNIS, EJ SCHUR, PH ALPER, CA AF KRUSKALL, MS MARCUSBAGLEY, D AWDEH, Z EISENBARTH, GS BRINK, SJ KATZ, AJ HAUSER, SL AHMED, AR BING, DH YUNIS, EJ SCHUR, PH ALPER, CA TI MANY INDIVIDUALS WITH THE MHC CONSERVED EXTENDED [HLA-B8, SC01, DR3] HAPLOTYPE HAVE IMMUNOGLOBULIN DEFICIENCIES SO CLINICAL RESEARCH LA English DT Meeting Abstract C1 HARVARD UNIV,SCH MED,CTR BLOOD RES,BOSTON,MA 02115. HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02115. HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115. HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115. NR 0 TC 6 Z9 6 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 SN 0009-9279 J9 CLIN RES JI Clin. Res. PD APR PY 1993 VL 41 IS 2 BP A277 EP A277 PG 1 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA KW761 UT WOS:A1993KW76100896 ER PT J AU KUO, NT FREEH, R SMITH, RJ VADLAMUDI, SR JOHNSTON, V KLIEGMAN, RM PRZYBYLSKI, RJ AF KUO, NT FREEH, R SMITH, RJ VADLAMUDI, SR JOHNSTON, V KLIEGMAN, RM PRZYBYLSKI, RJ TI INSULIN RESISTANCE IN NEWBORNS - INSULIN-RECEPTORS AND GLUCOSE TRANSPORTERS SO CLINICAL RESEARCH LA English DT Meeting Abstract C1 HARVARD UNIV,JOSLIN DIABET CTR,BOSTON,MA 02115. CASE WESTERN RESERVE UNIV,DEPT ANAT,CLEVELAND,OH 44106. CASE WESTERN RESERVE UNIV,DEPT PEDIAT,CLEVELAND,OH 44106. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 SN 0009-9279 J9 CLIN RES JI Clin. Res. PD APR PY 1993 VL 41 IS 2 BP A304 EP A304 PG 1 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA KW761 UT WOS:A1993KW76101053 ER PT J AU LAWRENCE, VA CORNELL, JE MULROW, CD DHANDA, R HILSENBECK, SG AF LAWRENCE, VA CORNELL, JE MULROW, CD DHANDA, R HILSENBECK, SG TI COMORBIDITY AND RISK OF POSTOPERATIVE COMPLICATIONS SO CLINICAL RESEARCH LA English DT Meeting Abstract C1 AUDIE L MURPHY MEM VET ADM MED CTR,SAN ANTONIO,TX 78284. UNIV TEXAS,HLTH SCI CTR,SAN ANTONIO,TX 78284. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 SN 0009-9279 J9 CLIN RES JI Clin. Res. PD APR PY 1993 VL 41 IS 2 BP A520 EP A520 PG 1 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA KW761 UT WOS:A1993KW76102325 ER PT J AU LEECH, CA HOLZ, GG HABENER, JF AF LEECH, CA HOLZ, GG HABENER, JF TI BIDIRECTIONAL CROSSTALK IN PANCREATIC BETA-CELL SIGNAL TRANSDUCTION PATHWAYS REVEALED USING PATCH CLAMP AND INTRACELLULAR CALCIUM IMAGING SO CLINICAL RESEARCH LA English DT Meeting Abstract C1 HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,HOWARD HUGHES MED LAB,MOLEC ENDOCRINOL LAB,BOSTON,MA 02114. RI Holz, George/A-3386-2012 NR 0 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 SN 0009-9279 J9 CLIN RES JI Clin. Res. PD APR PY 1993 VL 41 IS 2 BP A130 EP A130 PG 1 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA KW761 UT WOS:A1993KW76100094 ER PT J AU LENCER, WI DEALMEIDA, JB AUSIELLO, DA MADARA, JL AF LENCER, WI DEALMEIDA, JB AUSIELLO, DA MADARA, JL TI ENTRY OF CHOLERA-TOXIN (CT) INTO INTESTINAL EPITHELIAL-CELLS - ROLE OF VESICULAR TRAFFIC SO CLINICAL RESEARCH LA English DT Meeting Abstract C1 CHILDRENS HOSP MED CTR,BOSTON,MA 02115. MASSACHUSETTS GEN HOSP,RENAL UNIT,BOSTON,MA 02114. HARVARD UNIV,SCH MED,BOSTON,MA 02115. BRIGHAM & WOMENS HOSP,BOSTON,MA 02115. NR 1 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 SN 0009-9279 J9 CLIN RES JI Clin. Res. PD APR PY 1993 VL 41 IS 2 BP A263 EP A263 PG 1 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA KW761 UT WOS:A1993KW76100826 ER PT J AU LERNER, EA YOUSSEF, DE GREVELINK, SA AF LERNER, EA YOUSSEF, DE GREVELINK, SA TI MAXADILAN, A POTENT CUTANEOUS VASODILATOR FROM SAND FLY SALIVARY-GLANDS SO CLINICAL RESEARCH LA English DT Meeting Abstract C1 HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,CUTANEOUS BIOL RES CTR,BOSTON,MA 02114. HARVARD UNIV,SCH MED,DEPT DERMATOL,BOSTON,MA 02115. NR 1 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 SN 0009-9279 J9 CLIN RES JI Clin. Res. PD APR PY 1993 VL 41 IS 2 BP A497 EP A497 PG 1 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA KW761 UT WOS:A1993KW76102188 ER PT J AU LEVITSKY, LL STONESTREET, B MINK, K ZHENG, QG AF LEVITSKY, LL STONESTREET, B MINK, K ZHENG, QG TI GLYCOGENIC RATE IN THE OVINE FETUS DIRECTLY CORRELATES WITH AVAILABILITY OF GLUCOSE (G) AND ALTERNATIVE SUBSTRATE SO CLINICAL RESEARCH LA English DT Meeting Abstract C1 HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,CHILDRENS SERV,BOSTON,MA 02114. BROWN UNIV,WOMEN & INFANTS HOSP,DEPT PEDIAT,PROVIDENCE,RI 02908. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 SN 0009-9279 J9 CLIN RES JI Clin. Res. PD APR PY 1993 VL 41 IS 2 BP A303 EP A303 PG 1 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA KW761 UT WOS:A1993KW76101051 ER PT J AU LINDGREN, AM GALLO, RL HOSOI, J GRANSTEIN, RD AF LINDGREN, AM GALLO, RL HOSOI, J GRANSTEIN, RD TI INHIBITION OF MURINE CONTACT HYPERSENSITIVITY BY ANALOGS OF AMILORIDE SO CLINICAL RESEARCH LA English DT Meeting Abstract C1 HARVARD UNIV,MASSACHUSETTS GEN HOSP,CUTANEOUS BIOL RES CTR,BOSTON,MA 02114. RI Gallo, Richard/A-8931-2009 NR 0 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 SN 0009-9279 J9 CLIN RES JI Clin. Res. PD APR PY 1993 VL 41 IS 2 BP A470 EP A470 PG 1 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA KW761 UT WOS:A1993KW76102027 ER PT J AU MANGIONE, CM ORAV, EJ LAWRENCE, MG PHILLIPS, RS SEDDON, JM GOLDMAN, L AF MANGIONE, CM ORAV, EJ LAWRENCE, MG PHILLIPS, RS SEDDON, JM GOLDMAN, L TI PREDICTING VISUAL FUNCTION AFTER CATARACT-EXTRACTION - A PROSPECTIVELY VALIDATED MODEL SO CLINICAL RESEARCH LA English DT Meeting Abstract C1 BRIGHAM & WOMENS HOSP,BOSTON,MA 02115. MASSACHUSETTS EYE & EAR INFIRM,BOSTON,MA 02114. BETH ISRAEL HOSP,BOSTON,MA 02215. HARVARD UNIV,SCH MED,BOSTON,MA 02115. HARVARD UNIV,SCH PUBL HLTH,BOSTON,MA 02115. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 SN 0009-9279 J9 CLIN RES JI Clin. Res. PD APR PY 1993 VL 41 IS 2 BP A179 EP A179 PG 1 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA KW761 UT WOS:A1993KW76100380 ER PT J AU MCALOONDYKE, M EARNHARDT, R HANKS, JB PRUETT, T MINAKER, KL SHAPIRO, M BROWN, R HABENER, JF ANDERSEN, DK GINGERICH, RL ELAHI, D AF MCALOONDYKE, M EARNHARDT, R HANKS, JB PRUETT, T MINAKER, KL SHAPIRO, M BROWN, R HABENER, JF ANDERSEN, DK GINGERICH, RL ELAHI, D TI INSULINOTROPIC EFFECT OF GLP-1 IN PORTALLY OR SYSTEMICALLY DRAINED PANCREAS TRANSPLANT PATIENTS SO CLINICAL RESEARCH LA English DT Meeting Abstract C1 BETH ISRAEL HOSP,BOSTON,MA 02215. UVA,CHARLOTTESVILLE,VA. MASSACHUSETTS GEN HOSP,BOSTON,MA 02114. UNIV CHICAGO,CHICAGO,IL 60637. BARNES HOSP,ST LOUIS,MO 63110. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 SN 0009-9279 J9 CLIN RES JI Clin. Res. PD APR PY 1993 VL 41 IS 2 BP A157 EP A157 PG 1 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA KW761 UT WOS:A1993KW76100253 ER PT J AU MCGEHEE, RE HABENER, JF AF MCGEHEE, RE HABENER, JF TI CLONING AND CHARACTERIZATION OF A 3T3-L1 ADIPOCYTE CDNA-ENCODING A NUCLEAR-PROTEIN THAT CONTAINS A NOVEL SEQUENCE-SPECIFIC DNA-BINDING DOMAIN SO CLINICAL RESEARCH LA English DT Meeting Abstract C1 HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,HOWARD HUGHES MED INST,DEPT MOLEC ENDOCRINOL,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 SN 0009-9279 J9 CLIN RES JI Clin. Res. PD APR PY 1993 VL 41 IS 2 BP A202 EP A202 PG 1 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA KW761 UT WOS:A1993KW76100493 ER PT J AU MEYER, GS SINGER, DE FIFER, MA AF MEYER, GS SINGER, DE FIFER, MA TI CLINICAL CHARACTERISTICS OF PATIENTS WITH ELEVATED PULMONARY CAPILLARY WEDGE PRESSURES IN THE PRESENCE OF NORMAL SYSTOLIC FUNCTION SO CLINICAL RESEARCH LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,DEPT MED,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 SN 0009-9279 J9 CLIN RES JI Clin. Res. PD APR PY 1993 VL 41 IS 2 BP A117 EP A117 PG 1 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA KW761 UT WOS:A1993KW76100014 ER PT J AU MISHICHITA, M VIDEM, V ARNAOUT, MA AF MISHICHITA, M VIDEM, V ARNAOUT, MA TI A NOVEL DIVALENT CATION-BINDING SITE IN THE A-DOMAIN OF THE BETA-2 INTEGRIN CR3 (CD11B/CD18) IS ESSENTIAL FOR LIGAND-BINDING SO CLINICAL RESEARCH LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,DEPT MED,LEUKOCYTE BIOL & INFLAMMAT PROGRAM,BOSTON,MA 02114. HARVARD UNIV,SCH MED,BOSTON,MA 02115. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 SN 0009-9279 J9 CLIN RES JI Clin. Res. PD APR PY 1993 VL 41 IS 2 BP A262 EP A262 PG 1 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA KW761 UT WOS:A1993KW76100821 ER PT J AU MORT, E NORDBERG, P GUADAGNOLI, E VINEYARD, G BROOKS, D CLEARY, P MCNEIL, B AF MORT, E NORDBERG, P GUADAGNOLI, E VINEYARD, G BROOKS, D CLEARY, P MCNEIL, B TI CLINICAL AND FUNCTIONAL STATUS OUTCOMES AFTER LAPAROSCOPIC AND OPEN CHOLECYSTECTOMY SO CLINICAL RESEARCH LA English DT Meeting Abstract C1 HARVARD UNIV,SCH MED,DEPT HLTH CARE POLICY,BOSTON,MA 02115. MASSACHUSETTS GEN HOSP,GEN INTERNAL MED UNIT,BOSTON,MA 02114. BRIGHAM & WOMENS HOSP,DEPT SURG,BOSTON,MA 02115. NR 0 TC 0 Z9 0 U1 0 U2 1 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 SN 0009-9279 J9 CLIN RES JI Clin. Res. PD APR PY 1993 VL 41 IS 2 BP A545 EP A545 PG 1 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA KW761 UT WOS:A1993KW76102470 ER PT J AU MOY, RL MCHUGH, T UYEMURA, K MODLIN, RL AF MOY, RL MCHUGH, T UYEMURA, K MODLIN, RL TI THE LOCAL IMMUNE-RESPONSE IN SQUAMOUS-CELL CARCINOMA CONSISTS OF A DISTINCT TYPE-2 CYTOKINE PATTERN SO CLINICAL RESEARCH LA English DT Meeting Abstract C1 UNIV CALIF LOS ANGELES, DIV DERMATOL, LOS ANGELES, CA USA. W LOS ANGELES VET ADM HOSP, LOS ANGELES, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 USA SN 0009-9279 J9 CLIN RES JI Clin. Res. PD APR PY 1993 VL 41 IS 2 BP A422 EP A422 PG 1 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA KW761 UT WOS:A1993KW76101740 ER PT J AU MULROW, CD GERETY, MB CORNELL, JE LAWRENCE, VA KANTEN, DN AF MULROW, CD GERETY, MB CORNELL, JE LAWRENCE, VA KANTEN, DN TI RELATIONSHIPS BETWEEN DISEASE, FUNCTION, AND PERCEIVED HEALTH IN VERY FRAIL ELDERS SO CLINICAL RESEARCH LA English DT Meeting Abstract C1 AUDIE L MURPHY MEM VET ADM MED CTR,GRECC,SAN ANTONIO,TX 78284. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 SN 0009-9279 J9 CLIN RES JI Clin. Res. PD APR PY 1993 VL 41 IS 2 BP A530 EP A530 PG 1 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA KW761 UT WOS:A1993KW76102380 ER PT J AU NAGAYA, T JAMESON, JL AF NAGAYA, T JAMESON, JL TI RECEPTOR DIMERIZATION IS REQUIRED FOR DOMINANT NEGATIVE INHIBITION BY THYROID-HORMONE RESISTANCE MUTANTS SO CLINICAL RESEARCH LA English DT Meeting Abstract C1 HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,THYROID UNIT,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 SN 0009-9279 J9 CLIN RES JI Clin. Res. PD APR PY 1993 VL 41 IS 2 BP A192 EP A192 PG 1 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA KW761 UT WOS:A1993KW76100444 ER PT J AU NGUYEN, Q DAVISBOUTTE, W TONG, A HUANG, L UYEMURA, K MODLIN, R MOY, R AF NGUYEN, Q DAVISBOUTTE, W TONG, A HUANG, L UYEMURA, K MODLIN, R MOY, R TI THE EFFECTS OF INTERFERON-ALPHA AND INTERLEUKIN-2 ON CYTOKINE PATTERNS IN A BASAL-CELL CARCINOMA SKIN EXPLANT MODEL SO CLINICAL RESEARCH LA English DT Meeting Abstract C1 UNIV CALIF LOS ANGELES, W LOS ANGELES VET ADM MED CTR, JONSSON COMPREHENS CANC CTR, DIV DERMATOL, LOS ANGELES, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 USA SN 0009-9279 J9 CLIN RES JI Clin. Res. PD APR PY 1993 VL 41 IS 2 BP A465 EP A465 PG 1 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA KW761 UT WOS:A1993KW76101996 ER PT J AU NISHIYAMA, T MCDONOUGH, AM BURGESON, RE AF NISHIYAMA, T MCDONOUGH, AM BURGESON, RE TI COLLAGEN TYPE-XII AND TYPE-XIV MAY MEDIATE INTERACTIONS BETWEEN BANDED COLLAGEN-FIBERS SO CLINICAL RESEARCH LA English DT Meeting Abstract C1 HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,MGH HARVARD CUTANEOUS BIOL RES CTR,BOSTON,MA 02114. RI Nishiyama, Toshio/C-5434-2013 NR 0 TC 0 Z9 0 U1 0 U2 1 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 SN 0009-9279 J9 CLIN RES JI Clin. Res. PD APR PY 1993 VL 41 IS 2 BP A435 EP A435 PG 1 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA KW761 UT WOS:A1993KW76101815 ER PT J AU ODAY, SJ WEEKS, JC COOK, EF PETERSON, LM LYNN, J WENGER, N REDING, D HARRELL, F FULKERSON, W DAWSON, NV CONNORS, A KNAUS, W PHILLIPS, RS AF ODAY, SJ WEEKS, JC COOK, EF PETERSON, LM LYNN, J WENGER, N REDING, D HARRELL, F FULKERSON, W DAWSON, NV CONNORS, A KNAUS, W PHILLIPS, RS TI RELATIONSHIP BETWEEN CANCER-PATIENTS PREDICTIONS OF PROGNOSIS AND THEIR TREATMENT PREFERENCES SO CLINICAL RESEARCH LA English DT Meeting Abstract C1 BETH ISRAEL HOSP, BOSTON, MA 02215 USA. HARVARD UNIV, SCH MED, DANA FARBER CANC INST, BOSTON, MA 02115 USA. DARTMOUTH COLL, HITCHCOCK MED CTR, DARTMOUTH MED SCH, HANOVER, NH 03756 USA. GEORGE WASHINGTON UNIV, WASHINGTON, DC 20052 USA. UNIV CALIF LOS ANGELES, MED CTR, LOS ANGELES, CA USA. MARSHFIELD CLIN FDN MED RES & EDUC, MARSHFIELD, WI 54449 USA. CASE WESTERN RESERVE UNIV, CLEVELAND, OH 44106 USA. DUKE UNIV, DURHAM, NC 27706 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 USA SN 0009-9279 J9 CLIN RES JI Clin. Res. PD APR PY 1993 VL 41 IS 2 BP A579 EP A579 PG 1 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA KW761 UT WOS:A1993KW76102679 ER PT J AU PHILLIPS, SB MUCCINI, JA BILDEN, PF LUCCHINA, LC UYEYAMA, RK KOLLIAS, N GILLIES, R DRAKE, LA AF PHILLIPS, SB MUCCINI, JA BILDEN, PF LUCCHINA, LC UYEYAMA, RK KOLLIAS, N GILLIES, R DRAKE, LA TI SPECTROSCOPIC EVALUATION OF THE CHANGE IN ERYTHEMA ACCOMPANYING TREATMENT OF PSORIATIC PLAQUES WITH A TOPICAL STEROID SO CLINICAL RESEARCH LA English DT Meeting Abstract C1 HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DERMATOL CLIN INVEST UNIT,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 SN 0009-9279 J9 CLIN RES JI Clin. Res. PD APR PY 1993 VL 41 IS 2 BP A423 EP A423 PG 1 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA KW761 UT WOS:A1993KW76101745 ER PT J AU REDDY, SV NECKARS, L DALLAS, M WILLIAMS, R ROODMAN, GD AF REDDY, SV NECKARS, L DALLAS, M WILLIAMS, R ROODMAN, GD TI ANTISENSE CONSTRUCTS TO IL-6 MESSENGER-RNA INHIBIT BONE-RESORPTION BY OSTEOCLASTS (OCL) FROM GIANT-CELL TUMORS (GCT) OF BONE SO CLINICAL RESEARCH LA English DT Meeting Abstract C1 AUDIE L MURPHY MEM VET ADM MED CTR, SAN ANTONIO, TX 78284 USA. UNIV TEXAS SAN ANTONIO, SAN ANTONIO, TX 78285 USA. NIH, BETHESDA, MD 20892 USA. NR 1 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 USA SN 0009-9279 J9 CLIN RES JI Clin. Res. PD APR PY 1993 VL 41 IS 2 BP A184 EP A184 PG 1 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA KW761 UT WOS:A1993KW76100403 ER PT J AU RIGOTTI, NA MCKOOL, KM AF RIGOTTI, NA MCKOOL, KM TI WHO STOPS SMOKING AFTER CORONARY-ARTERY BYPASS GRAFT-SURGERY - 5-YEAR FOLLOW-UP OF A RANDOMIZED INTERVENTION TRIAL SO CLINICAL RESEARCH LA English DT Meeting Abstract C1 HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,GEN INTERNAL MED UNIT,BOSTON,MA 02114. HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,PREVENT CARDIOL UNIT,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 1 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 SN 0009-9279 J9 CLIN RES JI Clin. Res. PD APR PY 1993 VL 41 IS 2 BP A572 EP A572 PG 1 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA KW761 UT WOS:A1993KW76102634 ER PT J AU ROTHMAN, DL MAGNUSSON, I CLINE, GW GERARD, DP KAHN, CR SHULMAN, RG SHULMAN, GI AF ROTHMAN, DL MAGNUSSON, I CLINE, GW GERARD, DP KAHN, CR SHULMAN, RG SHULMAN, GI TI MUSCLE GLUCOSE TRANSPORT/PHOSPHORYLATION IS REDUCED IN SUBJECTS WITH A HIGH-RISK OF DEVELOPING NON-INSULIN-DEPENDENT DIABETES-MELLITUS (NIDDM) SO CLINICAL RESEARCH LA English DT Meeting Abstract C1 YALE UNIV,SCH MED,DEPT INTERNAL MED,NEW HAVEN,CT 06510. YALE UNIV,SCH MED,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06510. JOSLIN DIABET CTR,BOSTON,MA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 SN 0009-9279 J9 CLIN RES JI Clin. Res. PD APR PY 1993 VL 41 IS 2 BP A204 EP A204 PG 1 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA KW761 UT WOS:A1993KW76100504 ER PT J AU SEMIGRAN, GE TRUDEAU, NR SEMIGRAN, MJ BOUCHER, CA AF SEMIGRAN, GE TRUDEAU, NR SEMIGRAN, MJ BOUCHER, CA TI COMPARATIVE PROGNOSTIC VALUE OF EXERCISE THALLIUM TESTING IN MEN WITH NORMAL REST ELECTROCARDIOGRAMS SO CLINICAL RESEARCH LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,CARDIAC UNIT,BOSTON,MA 02114. HARVARD UNIV,SCH MED,BOSTON,MA 02115. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 SN 0009-9279 J9 CLIN RES JI Clin. Res. PD APR PY 1993 VL 41 IS 2 BP A286 EP A286 PG 1 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA KW761 UT WOS:A1993KW76100947 ER PT J AU SILVA, P EPSTEIN, FH SOLOMON, RJ AF SILVA, P EPSTEIN, FH SOLOMON, RJ TI C-TYPE NATRIURETIC PEPTIDE (CNP) STIMULATES CHLORIDE SECRETION BY THE RECTAL GLAND OF THE SHARK VIA A DUAL MECHANISM OF ACTION INVOLVING PROTEIN-KINASE-C SO CLINICAL RESEARCH LA English DT Meeting Abstract C1 NEW ENGLAND DEACONESS HOSP,JOSLIN DIABET CTR,BOSTON,MA 02215. NEW ENGLAND DEACONESS HOSP,DEPT MED,BOSTON,MA 02215. BETH ISRAEL HOSP,DEPT MED,BOSTON,MA 02215. MT DESERT ISL BIOL LAB,SALSBURY COVE,ME 04672. NR 0 TC 1 Z9 1 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 SN 0009-9279 J9 CLIN RES JI Clin. Res. PD APR PY 1993 VL 41 IS 2 BP A327 EP A327 PG 1 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA KW761 UT WOS:A1993KW76101192 ER PT J AU STRUCKE, RJ GADENNE, ASJ WAGNER, M BLEICHER, PA BIGBY, M AF STRUCKE, RJ GADENNE, ASJ WAGNER, M BLEICHER, PA BIGBY, M TI GAMMA-DELTA T-CELLS IN LICHEN-PLANUS HAVE A LIMITED T-CELL RECEPTOR REPERTOIRE SO CLINICAL RESEARCH LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,CUTANEOUS BIOL RES CTR,DEPT DERMATOL,BOSTON,MA 02114. HARVARD UNIV,SCH MED,BOSTON,MA 02115. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 SN 0009-9279 J9 CLIN RES JI Clin. Res. PD APR PY 1993 VL 41 IS 2 BP A472 EP A472 PG 1 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA KW761 UT WOS:A1993KW76102041 ER PT J AU TAN, KC GRABBE, S HOSOI, J GRANSTEIN, RD AF TAN, KC GRABBE, S HOSOI, J GRANSTEIN, RD TI EPIDERMAL-CELL (EC) PRESENTATION OF TUMOR-ASSOCIATED ANTIGENS (TAA) FOR TOLERANCE SO CLINICAL RESEARCH LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,MGH HARVARD CUTANEOUS BIOL RES CTR,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 SN 0009-9279 J9 CLIN RES JI Clin. Res. PD APR PY 1993 VL 41 IS 2 BP A461 EP A461 PG 1 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA KW761 UT WOS:A1993KW76101970 ER PT J AU TIERNEY, MR WORTHINGTON, K HOPKINS, CC AF TIERNEY, MR WORTHINGTON, K HOPKINS, CC TI THE EPIDEMIOLOGY OF NEEDLESTICK AND SHARP INJURIES AND COST SAVINGS OF PREVENTABLE INJURIES AT A MAJOR TEACHING HOSPITAL SO CLINICAL RESEARCH LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 SN 0009-9279 J9 CLIN RES JI Clin. Res. PD APR PY 1993 VL 41 IS 2 BP A246 EP A246 PG 1 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA KW761 UT WOS:A1993KW76100733 ER PT J AU WANG, CY THOMPSON, CB PETRYNAIK, B KAELIN, WG LEIDEN, JM AF WANG, CY THOMPSON, CB PETRYNAIK, B KAELIN, WG LEIDEN, JM TI THE ETS-RELATED TRANSCRIPTION FACTOR, ELF-1 IS REGULATED BY BINDING TO THE PRODUCT OF THE RETINOBLASTOMA GENE SO CLINICAL RESEARCH LA English DT Meeting Abstract C1 UNIV CHICAGO,DEPT MED,CHICAGO,IL 60637. UNIV MICHIGAN,MED CTR,HOWARD HUGHES MED INST,ANN ARBOR,MI 48109. UNIV MICHIGAN,MED CTR,DEPT INTERNAL MED,ANN ARBOR,MI 48109. UNIV CHICAGO,DEPT PATHOL,CHICAGO,IL 60637. HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 SN 0009-9279 J9 CLIN RES JI Clin. Res. PD APR PY 1993 VL 41 IS 2 BP A266 EP A266 PG 1 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA KW761 UT WOS:A1993KW76100837 ER PT J AU WANG, M MINN, J BOLON, DL CIAMARRA, A FINBERG, RW AMBROSINO, DM AF WANG, M MINN, J BOLON, DL CIAMARRA, A FINBERG, RW AMBROSINO, DM TI T-CELL INFLUENCES ON HUMAN-IGG SUBCLASS CONCENTRATIONS IN SCID MICE SO CLINICAL RESEARCH LA English DT Meeting Abstract C1 HARVARD UNIV,SCH MED,DANA FARBER CANC INST,INFECT DIS LAB,BOSTON,MA 02115. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 SN 0009-9279 J9 CLIN RES JI Clin. Res. PD APR PY 1993 VL 41 IS 2 BP A321 EP A321 PG 1 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA KW761 UT WOS:A1993KW76101153 ER PT J AU WEINSTEIN, GD GREEN, L DRAKE, LA ELIAS, PM KRUEGER, GG LAZARUS, GS LOWE, NJ LEWKAYA, DA LUE, J SEFTON, J CHANDRARATNA, RAS AF WEINSTEIN, GD GREEN, L DRAKE, LA ELIAS, PM KRUEGER, GG LAZARUS, GS LOWE, NJ LEWKAYA, DA LUE, J SEFTON, J CHANDRARATNA, RAS TI NEW TOPICAL RETINOID GEL FOR THERAPY OF PSORIASIS - DOSE-RANGING STUDY OF AGN-190168 SO CLINICAL RESEARCH LA English DT Meeting Abstract C1 CALIF DERMATOL & PSORIASIS CTR,SANTA MONICA,CA. UNIV CALIF IRVINE,IRVINE,CA 92717. UNIV UTAH,HLTH SCI CTR,SALT LAKE CITY,UT 84112. UNIV PENN,PHILADELPHIA,PA 19104. MASSACHUSETTS GEN HOSP,BOSTON,MA 02114. FT MILEY VA HOSP,SAN FRANCISCO,CA. ALLERGAN HERBERT,DEPT CLIN RES,IRVINE,CA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 SN 0009-9279 J9 CLIN RES JI Clin. Res. PD APR PY 1993 VL 41 IS 2 BP A425 EP A425 PG 1 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA KW761 UT WOS:A1993KW76101758 ER PT J AU WENNBERG, DE ATLAS, SJ COLEY, CM DIENSTAG, JL SINGER, DE AF WENNBERG, DE ATLAS, SJ COLEY, CM DIENSTAG, JL SINGER, DE TI COST-EFFECTIVENESS OF PREOPERATIVE AUTOLOGOUS BLOOD DONATION IN ELECTIVE SURGERY SO CLINICAL RESEARCH LA English DT Meeting Abstract C1 MAINE MED CTR,PORTLAND,ME 04102. MASSACHUSETTS GEN HOSP,BOSTON,MA 02114. NR 0 TC 1 Z9 1 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 SN 0009-9279 J9 CLIN RES JI Clin. Res. PD APR PY 1993 VL 41 IS 2 BP A268 EP A268 PG 1 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA KW761 UT WOS:A1993KW76100851 ER PT J AU WILLIAMS, J MULROW, C GERETY, M AGUILAR, C MEDINA, A MURPHY, AL AF WILLIAMS, J MULROW, C GERETY, M AGUILAR, C MEDINA, A MURPHY, AL TI FACTORS ASSOCIATED WITH DEPRESSIVE SYMPTOMS IN MEXICAN-AMERICANS SO CLINICAL RESEARCH LA English DT Meeting Abstract C1 AUDIE L MURPHY MEM VET ADM MED CTR,SAN ANTONIO,TX. UNIV TEXAS,HLTH SCI CTR,SAN ANTONIO,TX 78284. RI Williams, Jr., John/A-3696-2008 OI Williams, Jr., John/0000-0002-5267-5558 NR 0 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 SN 0009-9279 J9 CLIN RES JI Clin. Res. PD APR PY 1993 VL 41 IS 2 BP A591 EP A591 PG 1 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA KW761 UT WOS:A1993KW76102748 ER PT J AU WILLIAMS, J MULROW, C GERETY, M DAVIS, J AF WILLIAMS, J MULROW, C GERETY, M DAVIS, J TI SOCIAL NEEDS AND SUBTHRESHOLD DEPRESSION SO CLINICAL RESEARCH LA English DT Meeting Abstract C1 UNIV TEXAS,HLTH SCI CTR,SAN ANTONIO,TX 78284. AUDIE L MURPHY MEM VET ADM MED CTR,SAN ANTONIO,TX 78284. RI Williams, Jr., John/A-3696-2008 OI Williams, Jr., John/0000-0002-5267-5558 NR 0 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 SN 0009-9279 J9 CLIN RES JI Clin. Res. PD APR PY 1993 VL 41 IS 2 BP A583 EP A583 PG 1 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA KW761 UT WOS:A1993KW76102702 ER PT J AU WILLIAMS, JW KERBER, C MULROW, CD GERETY, MB AGUILLAR, C AF WILLIAMS, JW KERBER, C MULROW, CD GERETY, MB AGUILLAR, C TI DIAGNOSING DEPRESSIVE-DISORDERS - OPERATING CHARACTERISTICS OF THE MEDICAL OUTCOMES STUDY DEPRESSION SCREEN SO CLINICAL RESEARCH LA English DT Meeting Abstract C1 AUDIE L MURPHY MEM VET ADM MED CTR,SAN ANTONIO,TX 78284. UNIV TEXAS,HLTH SCI CTR,SAN ANTONIO,TX 78284. RI Williams, Jr., John/A-3696-2008 OI Williams, Jr., John/0000-0002-5267-5558 NR 0 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 SN 0009-9279 J9 CLIN RES JI Clin. Res. PD APR PY 1993 VL 41 IS 2 BP A583 EP A583 PG 1 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA KW761 UT WOS:A1993KW76102701 ER PT J AU WILLIAMS, JW SIMEL, DL AF WILLIAMS, JW SIMEL, DL TI DIAGNOSTIC AND TREATMENT VARIABILITY FOR MANAGING ACUTE SINUSITIS SO CLINICAL RESEARCH LA English DT Meeting Abstract C1 DURHAM VET AFFAIRS MED CTR,DURHAM,NC. AUDIE L MURPHY MEM VET ADM MED CTR,SAN ANTONIO,TX 78284. DUKE UNIV,DURHAM,NC 27706. UNIV TEXAS,HLTH SCI CTR,SAN ANTONIO,TX 78284. RI Williams, Jr., John/A-3696-2008 OI Williams, Jr., John/0000-0002-5267-5558 NR 0 TC 4 Z9 4 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 SN 0009-9279 J9 CLIN RES JI Clin. Res. PD APR PY 1993 VL 41 IS 2 BP A566 EP A566 PG 1 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA KW761 UT WOS:A1993KW76102596 ER PT J AU WILLIAMS, WJ YUAN, L FINKELMAN, M SIBER, GR CROSS, AS AF WILLIAMS, WJ YUAN, L FINKELMAN, M SIBER, GR CROSS, AS TI EFFICACY OF ENDOTOXIN NEUTRALIZING PROTEIN IN A MOUSE MODEL OF SEPSIS SO CLINICAL RESEARCH LA English DT Meeting Abstract C1 WALTER REED ARMY INST RES,WASHINGTON,DC 20307. ASSOCIATES CAPE COD INC,FALMOUTH,MA. HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 SN 0009-9279 J9 CLIN RES JI Clin. Res. PD APR PY 1993 VL 41 IS 2 BP A173 EP A173 PG 1 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA KW761 UT WOS:A1993KW76100345 ER PT J AU YOHN, J SMITH, C STEVENS, T MORELLI, J DORMISH, J KANE, M ZAMORA, M AF YOHN, J SMITH, C STEVENS, T MORELLI, J DORMISH, J KANE, M ZAMORA, M TI IDENTIFICATION OF FUNCTIONAL ENDOTHELIN-1 RECEPTORS IN CULTURED HUMAN-MALIGNANT MELANOMA-CELLS SO CLINICAL RESEARCH LA English DT Meeting Abstract C1 CU SCH MED,DENVER VAMC,DEPT DERMATOL,DENVER,CO. CU SCH MED,DENVER VAMC,DEPT MED,DENVER,CO. CU CANC CTR,DENVER,CO. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 SN 0009-9279 J9 CLIN RES JI Clin. Res. PD APR PY 1993 VL 41 IS 2 BP A493 EP A493 PG 1 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA KW761 UT WOS:A1993KW76102164 ER PT J AU BEACHE, GM WEDEEN, VJ DINSMORE, RE AF BEACHE, GM WEDEEN, VJ DINSMORE, RE TI MAGNETIC-RESONANCE-IMAGING EVALUATION OF LEFT-VENTRICULAR DIMENSIONS AND FUNCTION AND PERICARDIAL AND MYOCARDIAL-DISEASE SO CORONARY ARTERY DISEASE LA English DT Article DE MAGNETIC RESONANCE IMAGING; LEFT VENTRICULAR FUNCTION; PERICARDITIS, CONSTRICTIVE ID EJECTION-FRACTION DETERMINATION; GATED CARDIAC MRI; CINE MR; INFARCT SIZE; INTERSTUDY REPRODUCIBILITY; HUMAN-HEART; MASS; MOTION; ECHOCARDIOGRAPHY; EXPERIENCE C1 MASSACHUSETTS GEN HOSP,DEPT RADIOL,DIV CARDIAC RADIOL,50 BLOSSOM ST,BOSTON,MA 02114. FU NCI NIH HHS [2T32 CA09502] NR 39 TC 9 Z9 9 U1 0 U2 0 PU RAPID SCIENCE PUBLISHERS PI LONDON PA 2-6 BOUNDARY ROW, LONDON, ENGLAND SE1 8NH SN 0954-6928 J9 CORONARY ARTERY DIS JI Coronary Artery Dis. PD APR PY 1993 VL 4 IS 4 BP 328 EP 333 DI 10.1097/00019501-199304000-00003 PG 6 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA KX364 UT WOS:A1993KX36400003 PM 8261204 ER PT J AU SCHUSSHEIM, AE KANTOR, HL AF SCHUSSHEIM, AE KANTOR, HL TI CARDIAC NUCLEAR-MAGNETIC-RESONANCE SPECTROSCOPY - INVESTIGATIONS OF PHYSIOLOGY AND DIAGNOSTIC-TECHNIQUES SO CORONARY ARTERY DISEASE LA English DT Article DE NUCLEAR MAGNETIC RESONANCE; SPECTROSCOPY; METABOLISM; MAGNETIC RESONANCE SPECTROSCOPY ID PERFUSED RAT-HEART; TRANSMURAL METABOLITE DISTRIBUTION; ENERGY PHOSPHATE-METABOLISM; CYTOSOLIC FREE CALCIUM; P-31 NMR-SPECTROSCOPY; SKELETAL-MUSCLE; MYOCARDIAL ISCHEMIA; MR SPECTROSCOPY; BLOOD-FLOW; C-13 NMR C1 MASSACHUSETTS GEN HOSP,CARDIAC UNIT,BOSTON,MA 02114. HARVARD UNIV,SCH MED,BOSTON,MA 02115. NR 48 TC 1 Z9 1 U1 0 U2 1 PU RAPID SCIENCE PUBLISHERS PI LONDON PA 2-6 BOUNDARY ROW, LONDON, ENGLAND SE1 8NH SN 0954-6928 J9 CORONARY ARTERY DIS JI Coronary Artery Dis. PD APR PY 1993 VL 4 IS 4 BP 361 EP 369 DI 10.1097/00019501-199304000-00008 PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA KX364 UT WOS:A1993KX36400008 PM 8261209 ER PT J AU CHEN, JZ ALT, FW AF CHEN, JZ ALT, FW TI GENE REARRANGEMENT AND B-CELL DEVELOPMENT SO CURRENT OPINION IN IMMUNOLOGY LA English DT Review ID LIGHT-CHAIN GENES; PRE-B; IMMUNOGLOBULIN GENES; ALLELIC EXCLUSION; GERM-LINE; T-CELLS; HEAVY; EXPRESSION; RECEPTOR; SEGMENTS AB The differentiation of B lymphocytes from their progenitors progresses through a series of successive stages that are defined by sequential rearrangement of Ig loci and surface expression of various stage-specific markers, including Ig heavy and light chain proteins. Considerable evidence suggests that the appearance of cells with an orderly progression of Ig gene rearrangements is linked to the expression of the rearranged Ig gene products. Recent experiments have clarified our understanding of mechanisms by which rearrangement of Ig gene segments is controlled and how Ig gene products participate in the regulation of the B-cell differentiation program. C1 HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115. CTR BLOOD RES,BOSTON,MA 02115. RP CHEN, JZ (reprint author), CHILDRENS HOSP MED CTR,HOWARD HUGUES MED INST,300 LONGWOOD AVE,BOSTON,MA 02115, USA. FU NIAID NIH HHS [AI20047]; PHS HHS [U01 A131541] NR 73 TC 71 Z9 71 U1 0 U2 5 PU CURRENT BIOLOGY LTD PI LONDON PA 34-42 CLEVELAND STREET, LONDON, ENGLAND W1P 6LB SN 0952-7915 J9 CURR OPIN IMMUNOL JI Curr. Opin. Immunol. PD APR PY 1993 VL 5 IS 2 BP 194 EP 200 DI 10.1016/0952-7915(93)90004-C PG 7 WC Immunology SC Immunology GA KY909 UT WOS:A1993KY90900004 PM 8507397 ER PT J AU KIRCHHAUSEN, T AF KIRCHHAUSEN, T TI COATED PITS AND COATED VESICLES - SORTING IT ALL OUT SO CURRENT OPINION IN STRUCTURAL BIOLOGY LA English DT Article ID ASSEMBLY PROTEIN AP-2; CLATHRIN-ASSOCIATED PROTEIN; PLASMA-MEMBRANE; HEAVY-CHAIN; LIGHT-CHAIN; SACCHAROMYCES-CEREVISIAE; BINDING DOMAIN; COMPLEX AP-2; BOVINE BRAIN; CELL-GROWTH AB Clathrin-coated structures are involved in the first steps of membrane vesiculation which lead to receptor sorting and directed traffic. This review focuses on our current understanding of clathrin and its associated proteins, the major components of the coat. Recent experiments provide new insights into the interactions between these proteins. C1 CTR BLOOD RES,BOSTON,MA. HARVARD UNIV,SCH MED,BOSTON,MA 02115. NR 59 TC 81 Z9 82 U1 0 U2 1 PU CURRENT BIOLOGY LTD PI LONDON PA 34-42 CLEVELAND STREET, LONDON, ENGLAND W1P 6LB SN 0959-440X J9 CURR OPIN STRUC BIOL JI Curr. Opin. Struct. Biol. PD APR PY 1993 VL 3 IS 2 BP 182 EP 188 DI 10.1016/S0959-440X(05)80150-2 PG 7 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA LU405 UT WOS:A1993LU40500004 ER PT J AU JIKKO, A AOBA, T MURAKAMI, H TAKANO, Y IWAMOTO, M KATO, Y AF JIKKO, A AOBA, T MURAKAMI, H TAKANO, Y IWAMOTO, M KATO, Y TI CHARACTERIZATION OF THE MINERALIZATION PROCESS IN CULTURES OF RABBIT GROWTH PLATE CHONDROCYTES SO DEVELOPMENTAL BIOLOGY LA English DT Article ID ALKALINE-PHOSPHATASE; ENDOCHONDRAL OSSIFICATION; TERMINAL DIFFERENTIATION; CHICK CHONDROCYTES; MATRIX VESICLES; CELL-CULTURE; CALCIFICATION; CARTILAGE; INVITRO; INHIBITION C1 OSAKA UNIV,FAC DENT,DEPT RADIOL,SUITA,OSAKA 565,JAPAN. FORSYTH DENT CTR,BOSTON,MA 02115. OSAKA CITY UNIV,SCH MED,DEPT PEDIAT,OSAKA 558,JAPAN. HIROSHIMA UNIV,SCH DENT,DEPT BIOCHEM,HIROSHIMA 730,JAPAN. NIIGATA UNIV,FAC DENT,DEPT ANAT,NIIGATA 95021,JAPAN. FU NIDCR NIH HHS [DE08670] NR 30 TC 38 Z9 39 U1 0 U2 1 PU ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 SN 0012-1606 J9 DEV BIOL JI Dev. Biol. PD APR PY 1993 VL 156 IS 2 BP 372 EP 380 DI 10.1006/dbio.1993.1084 PG 9 WC Developmental Biology SC Developmental Biology GA KV142 UT WOS:A1993KV14200006 PM 8462737 ER PT J AU COLWELL, JA AF COLWELL, JA TI IS IT TIME TO INTRODUCE METFORMIN IN THE UNITED-STATES SO DIABETES CARE LA English DT Note ID INSULIN C1 MED UNIV S CAROLINA, DIV ENDOCRINOL DIABET METAB, CHARLESTON, SC 29425 USA. RP COLWELL, JA (reprint author), MED UNIV S CAROLINA, RALPH H JOHNSON DEPT VET AFFAIRS MED CTR, 171 ASHLEY AVE, CHARLESTON, SC 29425 USA. NR 16 TC 12 Z9 13 U1 0 U2 1 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 EI 1935-5548 J9 DIABETES CARE JI Diabetes Care PD APR PY 1993 VL 16 IS 4 BP 653 EP 655 PG 3 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA KU330 UT WOS:A1993KU33000020 PM 8462396 ER PT J AU EDER, M GRIFFIN, JD ERNST, TJ AF EDER, M GRIFFIN, JD ERNST, TJ TI THE HUMAN GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR RECEPTOR IS CAPABLE OF INITIATING SIGNAL TRANSDUCTION IN NIH3T3 CELLS SO EMBO JOURNAL LA English DT Article DE GM-CSF RECEPTOR; MAP KINASE; RAF-1; SIGNAL TRANSDUCTION; TYROSINE KINASE ID PROTEIN-KINASE CASCADES; GM-CSF RECEPTORS; TYROSINE PHOSPHORYLATION; IL-2 RECEPTOR; BETA-CHAIN; ERYTHROPOIETIN RECEPTOR; HEMATOPOIETIC-CELLS; CYTOPLASMIC REGION; EXPRESSION CLONING; LIGAND-BINDING AB The ability of the receptor for the hematopoietic cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF) to function in non-hematopoietic cells is unknown. NIH3T3 fibroblasts were transfected with cDNAs encoding the alpha and beta subunit of the human GM-CSF receptor and a series of stable transformants were isolated that bound GM-CSF with either low (K(D) = 860 - >1000 pM) or high affinity (K(D) = 20-80 pM). Low affinity receptors were not functional. However, the reconstituted high affinity receptors were found to be capable of activating a number of signal transduction pathways, including tyrosine kinase activity, phosphorylation of Raf-1, and the transient induction of c-fos and c-myc mRNAs. The activation of protein tyrosine phosphorylation by GM-CSF in NIH3T3 cells was rapid (<1 min) and transient (peaking at 5-20 min) and resulted in the phosphorylation of proteins of estimated molecular weights of 42, 44, 52/53 and 58-60 kDa. Some of these proteins co-migrated with proteins from myeloid cells that were phosphorylated on tyrosine residues in response to GM-CSF. In particular, p42 and p44 were identified as mitogen-activated protein kinases (MAP kinases), and the phosphorylation on tyrosine residues of p42 and p44 MAP kinases occurred at the same time as the phosphorylation of Raf-1. However, despite evidence for activation of many mitogenic signal transduction molecules, GM-CSF did not induce significant proliferation of transfected NIH3T3 cells. These results suggest that murine fibroblasts contain signal transducing molecules that can effectively interact with the human GM-CSF receptor, and that are sufficient to activate at least some of the same signal transduction pathways this receptor activates in myeloid cells, including activation of one or more tyrosine kinase(s). However, the level of activation of signal transduction is either below a threshold of necessary activity or at least one mitogenic signal necessary for proliferation is missing. C1 HARVARD UNIV,SCH MED,BOSTON,MA 02115. RP EDER, M (reprint author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV TUMOR IMMUNOL,44 BINNEY ST,BOSTON,MA 02115, USA. FU NCI NIH HHS [CA34183, CA36167] NR 56 TC 46 Z9 46 U1 0 U2 0 PU OXFORD UNIV PRESS UNITED KINGDOM PI OXFORD PA WALTON ST JOURNALS DEPT, OXFORD, ENGLAND OX2 6DP SN 0261-4189 J9 EMBO J JI Embo J. PD APR PY 1993 VL 12 IS 4 BP 1647 EP 1656 PG 10 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA KW390 UT WOS:A1993KW39000040 PM 7682177 ER PT J AU LEE, MM DONAHOE, PK AF LEE, MM DONAHOE, PK TI MULLERIAN INHIBITING SUBSTANCE - A GONADAL HORMONE WITH MULTIPLE FUNCTIONS SO ENDOCRINE REVIEWS LA English DT Review ID GROWTH-FACTOR-BETA; HUMAN OVARIAN-CANCER; FETAL-RAT LUNG; TESTICULAR DESCENT; DUCT REGRESSION; GRANULOSA-CELLS; TYROSINE KINASE; OOCYTE MEIOSIS; COLONY GROWTH; SERUM LEVELS AB MULLERIAN inhibiting substance (MIS) is the gonadal hormone that causes regression of the Mullerian ducts, the anlagen of the female internal reproductive structures, during male embryogenesis. MIS is a member of the large transforming growth factor-beta (TGFbeta) multigene family of glycoproteins that are involved in the regulation of growth and differentiation. The proteins in this gene family are all produced as dimeric precursors and undergo posttranslational processing for activation, requiring cleavage and dissociation to release bioactive C-terminal fragments. Similarly, the 140 kilodalton (kDa) disulfide-linked homodimer of MIS is proteolytically cleaved to generate its active C-terminal fragments. The sexually dimorphic expression of MIS in Sertoli cells of the testis and granulosa cells of the ovary is critical for normal differentiation of the internal reproductive tract structures. A number of extra-Mullerian functions such as control of germ cell maturation and gonadal morphogenesis, induction of the abdominal phase of testicular descent, suppression of lung maturation, and growth inhibition of transformed cells have also been proposed for this growth-inhibitory, hormone and will be discussed. This article will summarize the current understanding of the biology and multiple functions of MIS including its activation, regulation, and mechanism of action and discuss areas of interest in ongoing research. C1 MASSACHUSETTS GEN HOSP, PEDIAT SURG SERV, BOSTON, MA 02114 USA. RP MASSACHUSETTS GEN HOSP, PEDIAT SURG RES LAB, PEDIAT ENDOCRINE UNIT, WRN-1133, 32 FRUIT ST, BOSTON, MA 02114 USA. OI Lee, Mary/0000-0002-7204-4884 FU NCI NIH HHS [CA-17393]; NIDDK NIH HHS [DK-02129] NR 106 TC 234 Z9 244 U1 1 U2 10 PU ENDOCRINE SOC PI WASHINGTON PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA SN 0163-769X EI 1945-7189 J9 ENDOCR REV JI Endocr. Rev. PD APR PY 1993 VL 14 IS 2 BP 152 EP 164 DI 10.1210/er.14.2.152 PG 13 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA KY239 UT WOS:A1993KY23900002 PM 8325249 ER PT J AU JAMESON, JL HOLLENBERG, AN AF JAMESON, JL HOLLENBERG, AN TI REGULATION OF CHORIONIC-GONADOTROPIN GENE-EXPRESSION SO ENDOCRINE REVIEWS LA English DT Review ID HORMONE ALPHA-SUBUNIT; MESSENGER-RIBONUCLEIC-ACID; AMP RESPONSE ELEMENT; TRANSCRIPTION FACTOR CREB; EPIDERMAL GROWTH-FACTOR; PHOSPHOENOLPYRUVATE CARBOXYKINASE GTP; HUMAN CHORIOCARCINOMA CELLS; PROTEIN-BINDING DOMAINS; STEADY-STATE LEVELS; CG-BETA-GENE C1 HARVARD UNIV,SCH MED,BOSTON,MA 02115. RP JAMESON, JL (reprint author), MASSACHUSETTS GEN HOSP,THYROID UNIT,JACKSON 1021,BOSTON,MA 02114, USA. OI Jameson, James/0000-0001-9538-4059 FU NICHD NIH HHS [HD-23519] NR 148 TC 153 Z9 158 U1 0 U2 3 PU ENDOCRINE SOC PI BETHESDA PA 4350 EAST WEST HIGHWAY SUITE 500, BETHESDA, MD 20814-4110 SN 0163-769X J9 ENDOCR REV JI Endocr. Rev. PD APR PY 1993 VL 14 IS 2 BP 203 EP 221 DI 10.1210/er.14.2.203 PG 19 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA KY239 UT WOS:A1993KY23900006 PM 8325253 ER PT J AU MYERS, MG SUN, XJ CHEATHAM, B JACHNA, BR GLASHEEN, EM BACKER, JM WHITE, MF AF MYERS, MG SUN, XJ CHEATHAM, B JACHNA, BR GLASHEEN, EM BACKER, JM WHITE, MF TI IRS-1 IS A COMMON ELEMENT IN INSULIN AND INSULIN-LIKE GROWTH FACTOR-I SIGNALING TO THE PHOSPHATIDYLINOSITOL 3'-KINASE SO ENDOCRINOLOGY LA English DT Article ID RECEPTOR TYROSINE KINASES; PDGF RECEPTOR; INTACT-CELLS; PHOSPHORYLATION; ONCOGENES; PROTEINS; BINDING; SUBSTRATE; AUTOPHOSPHORYLATION; TRANSDUCTION AB IRS-1 is a unique cytosolic protein that becomes tyrosine phosphorylated during insulin stimulation of intact cells and immediately associates with the phosphatidylinositol 3'-kinase (PtdIns 3'-kinase). The insulin-like growth factor-I (IGF-I) receptor also mediated the tyrosine phosphorylation of IRS-1 and increased the amount of Ptdlns 3'-kinase activity bound to IRS-1 in Chinese hamster ovary cells. Purified insulin receptor and IGF-1 receptor phosphorylated recombinant baculovirus-produced IRS-1 on similar sites in vitro, and phosphorylated baculovirus-produced IRS-1 bound Ptdlns 3'-kinase activity from lysates of quiescent cells. Treatment of cells with IGF-1 activated the PtdIns 3'-kinase, suggesting that IGF-1 activates the Ptdlns 3'-kinase through IRS-1 binding to p85 in a manner similar to insulin. Chinese hamster ovary cells overexpressing IRS-1 demonstrated increased tyrosine phosphorylation of IRS-1, and more PtdIns 3'-kinase activity associated with IRS-1 in these cells. These data demonstrate that IRS-1 is a common element for signal transmission by the IGF-I and insulin receptors. C1 HARVARD UNIV, SCH MED, JOSLIN DIABET CTR, DIV RES, 1 JOSLIN PL, BOSTON, MA 02115 USA. HARVARD UNIV, SCH MED, PROGRAM CELL & DEV BIOL, BOSTON, MA 02115 USA. FU NIDDK NIH HHS [DK-36836, DK-38712, DK-43808] NR 48 TC 321 Z9 325 U1 0 U2 7 PU ENDOCRINE SOC PI CHEVY CHASE PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA SN 0013-7227 EI 1945-7170 J9 ENDOCRINOLOGY JI Endocrinology PD APR PY 1993 VL 132 IS 4 BP 1421 EP 1430 DI 10.1210/en.132.4.1421 PG 10 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA KV629 UT WOS:A1993KV62900002 PM 8384986 ER PT J AU GUERIN, SL ANZIVINO, MJ ROY, RJ MOORE, DD AF GUERIN, SL ANZIVINO, MJ ROY, RJ MOORE, DD TI EXPRESSION OF THE RAT GROWTH-HORMONE GENE IS UNDER THE INFLUENCE OF A CELL-TYPE-SPECIFIC SILENCER ELEMENT SO EUROPEAN JOURNAL OF BIOCHEMISTRY LA English DT Article ID NUCLEAR FACTOR-I; TRANSCRIPTION FACTOR; BINDING PROTEINS; PROMOTER; IDENTIFICATION; ACTIVATION; REPRESSION; ENHANCER; FAMILY; SITE AB We have previously shown that a cell-type-specific negative-regulatory element, or silencer, acts to specifically restrict rat-growth-hormone(rGH)-promoter activity to pituitary cells. Here we report a detailed characterization of this element. The activity of the silencer is dependent on its position relative to the promoter. The negative regulatory effect can be diminished by cotransfection with a high-copy-number, silencer-containing competitor plasmid, suggesting that the function of the element is mediated by specific binding of a trans-acting negative-regulatory factor. The minimal region required for silencer function is contained between positions -309 and -266 relative to the start of the rGH mRNA. The specific interaction of a nuclear protein from non-pituitary cells with this rGH DNA segment was shown by DNaseI as well as dimethylsulfate methylation-interference footprinting. A detailed examination of the DNA-binding site for that protein clearly suggest that it belongs to the NF1 family of transcription factors. C1 UNIV VIRGINIA,DEPT BIOL,CHARLOTTESVILLE,VA 22903. MASSACHUSETTS GEN HOSP,DEPT MOLEC BIOL,BOSTON,MA 02114. RP GUERIN, SL (reprint author), CHUL,RES CTR,MOLEC ENDOCRINOL LAB,2705 LAURIER BLVD,ST FOY G1V 4G2,PQ,CANADA. NR 27 TC 18 Z9 18 U1 0 U2 0 PU SPRINGER VERLAG PI NEW YORK PA 175 FIFTH AVE, NEW YORK, NY 10010 SN 0014-2956 J9 EUR J BIOCHEM JI Eur. J. Biochem. PD APR 1 PY 1993 VL 213 IS 1 BP 399 EP 404 DI 10.1111/j.1432-1033.1993.tb17774.x PG 6 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA KW053 UT WOS:A1993KW05300045 PM 8477711 ER PT J AU MARCHISIO, PC CREMONA, O SAVOIA, P PELLEGRINI, G ORTONNE, JP VERRANDO, P BURGESON, RE CANCEDDA, R DELUCA, M AF MARCHISIO, PC CREMONA, O SAVOIA, P PELLEGRINI, G ORTONNE, JP VERRANDO, P BURGESON, RE CANCEDDA, R DELUCA, M TI THE BASEMENT-MEMBRANE PROTEIN BM-600 NICEIN CODISTRIBUTES WITH KALININ AND THE INTEGRIN-ALPHA-6-BETA-4 IN HUMAN CULTURED KERATINOCYTES SO EXPERIMENTAL CELL RESEARCH LA English DT Article ID JUNCTIONAL EPIDERMOLYSIS-BULLOSA; MONOCLONAL-ANTIBODY GB3; EXTRACELLULAR-MATRIX; ADHESION RECEPTORS; FOCAL ADHESIONS; HUMAN-CELLS; INTEGRIN; ALPHA-6-BETA-4; FIBRONECTIN; EXPRESSION C1 IST NAZL RIC CANC,I-16132 GENOA,ITALY. UER MED & PHARM,RECH DERMATOL LAB,NICE,FRANCE. MASSACHUSETTS GEN HOSP,CUTANEOUS BIOL RES CTR,CAMBRIDGE,MA. RP MARCHISIO, PC (reprint author), UNIV TURIN,DIPARTIMENTO SCI BIOMED & ONCOL UMANA,C SO MASSIMO AZEGLIO 52,I-10126 TURIN,ITALY. RI De Luca, Michele/N-5883-2014; Pellegrini, Graziella/E-1189-2015 OI De Luca, Michele/0000-0002-0850-8445; Pellegrini, Graziella/0000-0001-9861-0736 NR 39 TC 45 Z9 45 U1 0 U2 1 PU ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 SN 0014-4827 J9 EXP CELL RES JI Exp. Cell Res. PD APR PY 1993 VL 205 IS 2 BP 205 EP 212 DI 10.1006/excr.1993.1078 PG 8 WC Oncology; Cell Biology SC Oncology; Cell Biology GA KZ288 UT WOS:A1993KZ28800002 PM 8482332 ER PT J AU COLE, DG GROWDON, JH DIFIGLIA, M AF COLE, DG GROWDON, JH DIFIGLIA, M TI LEVODOPA INDUCTION OF FOS IMMUNOREACTIVITY IN RAT-BRAIN FOLLOWING PARTIAL AND COMPLETE LESIONS OF THE SUBSTANTIA-NIGRA SO EXPERIMENTAL NEUROLOGY LA English DT Article ID C-FOS; ZONA INCERTA; DOPAMINE; NEURONS; BINDING; SUPERSENSITIVITY; ACTIVATION; STRIATUM C1 MASSACHUSETTS GEN HOSP,MGH E,DEPT NEUROL,BOSTON,MA 02129. RP COLE, DG (reprint author), MASSACHUSETTS GEN HOSP,MGH E,CELLULAR NEUROBIOL LAB,BOSTON,MA 02129, USA. FU AHRQ HHS [HS 16367] NR 25 TC 23 Z9 24 U1 1 U2 1 PU ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 SN 0014-4886 J9 EXP NEUROL JI Exp. Neurol. PD APR PY 1993 VL 120 IS 2 BP 223 EP 232 DI 10.1006/exnr.1993.1057 PG 10 WC Neurosciences SC Neurosciences & Neurology GA LE438 UT WOS:A1993LE43800008 PM 8491280 ER PT J AU LEE, J MORGAN, JR TOMPKINS, RG YARMUSH, ML AF LEE, J MORGAN, JR TOMPKINS, RG YARMUSH, ML TI PROLINE-MEDIATED ENHANCEMENT OF HEPATOCYTE FUNCTION IN A COLLAGEN GEL SANDWICH CULTURE CONFIGURATION SO FASEB JOURNAL LA English DT Note DE PROLINE; CIS-HYDROXYPROLINE; COLLAGEN; HEPATOCYTES; ALBUMIN; PRIMARY CULTURE ID CELL-MATRIX INTERACTIONS; RAT HEPATOCYTES; AMINO-ACIDS; POLYPEPTIDES; LIPOGENESIS; PROCOLLAGEN AB Isolated rat primary hepatocytes were cultured between two layers of gelled collagen in a sandwich configuration that reinstates the cellular polarity necessary for long-term function in vitro. Maintenance of hepatocyte function, as measured by the secretion of albumin, was shown to be dependent on both the sandwich gel configuration and the continued presence of L-proline in the culture media. Cis-hydroxyproline, an analog of proline known to prevent the proper folding of triple helical collagen molecules, inhibited the response of sandwiched hepatocytes to proline in a dose-dependent and reversible manner. The addition of cis-hydroxyproline to cultures established for 7 days also resulted in the inhibition of hepatocyte function. These data support the hypothesis that continued collagen synthesis by hepatocytes is critical for hepatocyte function in the sandwich gel configuration. C1 MASSACHUSETTS GEN HOSP,SURG SERV,BOSTON,MA 02114. SHRINERS BURNS INST,SURG SERV,BOSTON,MA 02114. RP LEE, J (reprint author), RUTGERS STATE UNIV,DEPT CHEM & BIOCHEM ENGN,BRETT BOWERS RD,PISCATAWAY,NJ 08854, USA. OI Morgan, Jeffrey/0000-0002-7546-3443 FU NIDDK NIH HHS [DK 43371] NR 26 TC 39 Z9 42 U1 0 U2 2 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 SN 0892-6638 J9 FASEB J JI Faseb J. PD APR 1 PY 1993 VL 7 IS 6 BP 586 EP 591 PG 6 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA KY009 UT WOS:A1993KY00900013 PM 8472895 ER PT J AU CURTIS, MA SLANEY, JM CARMAN, RJ PEMBERTON, PA AF CURTIS, MA SLANEY, JM CARMAN, RJ PEMBERTON, PA TI INTERACTION OF A TRYPSIN-LIKE-ENZYME OF PORPHYROMONAS-GINGIVALIS W83 WITH ANTITHROMBIN-III SO FEMS MICROBIOLOGY LETTERS LA English DT Article DE TRYPSIN-LIKE ENZYME; ANTITHROMBIN-III; COMPLEX STABILIZATION; INACTIVATION; PORPHYROMONAS-GINGIVALIS ID HUMAN-PLASMA; PERIODONTAL-DISEASES; INHIBITOR; PROTEINS AB We have previously observed that trypsin-like activity in' Porphyromonas gingivalis culture supernatants is inhibitable by the plasma arg-serpin antithrombin III (ATIII). This report demonstrates that a partially purified P. gingivalis trypsin-like enzyme (M(r) 47000) is inhibited by ATIII with an association rate constant (k(ass)) of 5.65 x 10(4) M-1 s-1 but does not form SDS-stable complexes. Heparin enhances the k(ass) and stabilizes the complexes but in either case such inhibition is temporary and results in ATIII inactivation by reactive centre proteolysis between R393-S394 . In the absence of heparin this is accompanied by N-terminal cleavage between K-39-I-40. C1 CTR BLOOD RES,BOSTON,MA. RP CURTIS, MA (reprint author), UNIV LONDON LONDON HOSP,COLL MED,MRC,DENT RES UNIT,LONDON E1 1BB,ENGLAND. NR 18 TC 6 Z9 6 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0378-1097 J9 FEMS MICROBIOL LETT JI FEMS Microbiol. Lett. PD APR 1 PY 1993 VL 108 IS 2 BP 169 EP 174 DI 10.1016/0378-1097(93)90580-U PG 6 WC Microbiology SC Microbiology GA KW346 UT WOS:A1993KW34600008 PM 8486244 ER PT J AU WARSHAW, AL AF WARSHAW, AL TI DAMAGE PREVENTION VERSUS DAMAGE CONTROL IN ACUTE-PANCREATITIS SO GASTROENTEROLOGY LA English DT Editorial Material ID TAUROCHOLATE-INDUCED PANCREATITIS; GABEXATE MESILATE; PROTEASE INHIBITORS; DUCT OBSTRUCTION; SECRETION; MICE; RATS; CHOLECYSTOKININ; PATHOGENESIS; ACTIVATION RP WARSHAW, AL (reprint author), HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,WACC-336,BOSTON,MA 02144, USA. NR 42 TC 18 Z9 18 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD APR PY 1993 VL 104 IS 4 BP 1216 EP 1219 PG 4 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA LM684 UT WOS:A1993LM68400039 PM 8462813 ER PT J AU BABYATSKY, MW WANG, TC WONG, H WALSH, JH BRAND, SJ AF BABYATSKY, MW WANG, TC WONG, H WALSH, JH BRAND, SJ TI REGULATION OF A GASTRIN TRANSGENE BY ACHLORHYDRIA AND SOMATOSTATIN SO GASTROENTEROLOGY LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,GASTROENTEROL UNIT,BOSTON,MA 02114. UNIV CALIF LOS ANGELES,CURE,LOS ANGELES,CA 90024. NR 2 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD APR PY 1993 VL 104 IS 4 SU S BP A811 EP A811 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA KX957 UT WOS:A1993KX95703220 ER PT J AU BABYATSKY, MW WANG, TC UPCHURCH, B OATES, PS BRAND, SJ AF BABYATSKY, MW WANG, TC UPCHURCH, B OATES, PS BRAND, SJ TI C0-EXPRESSION OF A GASTRIN TRANSGENE IN NONTRANSFORMED PYY CELLS OF THE ILEUM AND COLON SO GASTROENTEROLOGY LA English DT Meeting Abstract C1 NEMC,MASSACHUSETTS GEN HOSP,GI UNITS,BOSTON,MA. NR 1 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD APR PY 1993 VL 104 IS 4 SU S BP A811 EP A811 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA KX957 UT WOS:A1993KX95703218 ER PT J AU BABYATSKY, MW BRAND, SJ KARMELI, F PODOLSKY, DK WALSH, JH WONG, H RACHMILEWITZ, D AF BABYATSKY, MW BRAND, SJ KARMELI, F PODOLSKY, DK WALSH, JH WONG, H RACHMILEWITZ, D TI ENHANCED SOMATOSTATIN EXPRESSION MODULATES GASTRIC INJURY AND EXPERIMENTAL COLITIS SO GASTROENTEROLOGY LA English DT Meeting Abstract C1 UNIV CALIF LOS ANGELES, CURE, LOS ANGELES, CA USA. MASSACHUSETTS GEN HOSP, CTR STUDY INFLAMMATORY BOWEL DIS, NERPRC, GASTROINTESTINAL UNIT, BOSTON, MA 02114 USA. NR 0 TC 2 Z9 2 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD APR PY 1993 VL 104 IS 4 SU S BP A663 EP A663 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA KX957 UT WOS:A1993KX95702632 ER PT J AU BASSI, DG FOITZIK, T LEWANDROWSKI, KB FERNANDEZDELCASTILLO, C WARSHAW, AL RATTNER, DW AF BASSI, DG FOITZIK, T LEWANDROWSKI, KB FERNANDEZDELCASTILLO, C WARSHAW, AL RATTNER, DW TI EFFECT OF PENTOXIFYLLINE ON PROGRESSION OF SEVERE ACUTE-PANCREATITIS IN THE RAT SO GASTROENTEROLOGY LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,DEPT SURG,BOSTON,MA 02114. MASSACHUSETTS GEN HOSP,DEPT PATHOL,BOSTON,MA 02114. HARVARD UNIV,SCH MED,BOSTON,MA 02115. NR 0 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD APR PY 1993 VL 104 IS 4 SU S BP A1029 EP A1029 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA KX957 UT WOS:A1993KX95704083 ER PT J AU BRUGGE, WR SHIFFMAN, ML FURTH, EL MACDERMOTT, RP MALET, PF AF BRUGGE, WR SHIFFMAN, ML FURTH, EL MACDERMOTT, RP MALET, PF TI URSODIOL REDUCES GALLBLADDER BILE MUCIN AND IMMUNOGLOBULINS IN GALLSTONE PATIENTS SO GASTROENTEROLOGY LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,BOSTON,MA 02114. STRONG MEM HOSP,ROCHESTER,NY 14642. HOSP UNIV PENN,PHILADELPHIA,PA 19104. NR 0 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD APR PY 1993 VL 104 IS 4 SU S BP A351 EP A351 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA KX957 UT WOS:A1993KX95701394 ER PT J AU BRUGGE, WR CHEY, WY MALET, PF AF BRUGGE, WR CHEY, WY MALET, PF TI URSODIOL REDUCES CHRONIC SYMPTOMS OF CHOLELITHIASIS SO GASTROENTEROLOGY LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,BOSTON,MA 02114. STRONG MEM HOSP,ROCHESTER,NY 14642. HOSP UNIV PENN,PHILADELPHIA,PA 19104. NR 0 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD APR PY 1993 VL 104 IS 4 SU S BP A351 EP A351 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA KX957 UT WOS:A1993KX95701392 ER PT J AU CHANG, TI AF CHANG, TI TI ORALLY INTRODUCED PROTEIN ANTIGENS ARE DETECTABLE IN THE PEYERS-PATCHES AND SPLEEN BY A T-CELL ACTIVATION ASSAY SO GASTROENTEROLOGY LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,COMBINED PROGRAM PEDIAT GASTROENTEROL & NUTR,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD APR PY 1993 VL 104 IS 4 SU S BP A680 EP A680 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA KX957 UT WOS:A1993KX95702702 ER PT J AU CHUNG, DC TILLOTSON, LG BUNDGAARD, J BRAND, SJ AF CHUNG, DC TILLOTSON, LG BUNDGAARD, J BRAND, SJ TI IDENTIFICATION OF STOMACH-SPECIFIC CIS-REGULATORY ELEMENTS CONTROLLING GASTRIN TRANSCRIPTION SO GASTROENTEROLOGY LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,GASTROINTESTINAL UNIT,BOSTON,MA 02114. RIGSHOSP,DEPT CLIN CHEM,DK-2100 COPENHAGEN,DENMARK. NR 0 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD APR PY 1993 VL 104 IS 4 SU S BP A818 EP A818 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA KX957 UT WOS:A1993KX95703247 ER PT J AU COLEY, CM BARRY, MJ SPECHLER, SJ WILLIFORD, WO MULLEY, AG AF COLEY, CM BARRY, MJ SPECHLER, SJ WILLIFORD, WO MULLEY, AG TI INITIAL MEDICAL V SURGICAL THERAPY FOR COMPLICATED OR CHRONIC GASTROESOPHAGEAL REFLUX DISEASE (GERD) - A COST-EFFECTIVENESS ANALYSIS SO GASTROENTEROLOGY LA English DT Meeting Abstract C1 VA COOPERAT STUDIES PROGRAM,BOSTON,MA. MASSACHUSETTS GEN HOSP,BOSTON,MA 02114. NR 0 TC 32 Z9 32 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD APR PY 1993 VL 104 IS 4 SU S BP A5 EP A5 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA KX957 UT WOS:A1993KX95700016 ER PT J AU DIGNASS, AU PODOLSKY, DK AF DIGNASS, AU PODOLSKY, DK TI TRANSFORMING GROWTH-FACTOR-BETA PLAYS A CENTRAL ROLE IN THE MODULATION OF CYTOKINE MEDIATED INTESTINAL EPITHELIAL-CELL RESTITUTION IN AN INVITRO WOUNDING MODEL SO GASTROENTEROLOGY LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,MGH NERPRC CTR STUDY INFLAMMATORY BOWEL DIS,GASTROINTESTINAL UNIT,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD APR PY 1993 VL 104 IS 4 SU S BP A693 EP A693 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA KX957 UT WOS:A1993KX95702750 ER PT J AU DIGNASS, AU PODOLSKY, DK AF DIGNASS, AU PODOLSKY, DK TI INTERLEUKIN-2 EXPRESSION BY INTESTINAL EPITHELIAL-CELL LINES AND MODULATION OF INTESTINAL EPITHELIAL-CELL RESTITUTION SO GASTROENTEROLOGY LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,MGH NERPRC CTR STUDY INFLAMMATORY BOWEL DIS,GASTROINTESTINAL UNIT,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD APR PY 1993 VL 104 IS 4 SU S BP A692 EP A692 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA KX957 UT WOS:A1993KX95702749 ER PT J AU DIGNASS, AU STOW, JL PODOLSKY, DK AF DIGNASS, AU STOW, JL PODOLSKY, DK TI TRANSFORMING GROWTH-FACTOR-BETA-1 MODULATION OF INTESTINAL EPITHELIAL INJURY IN AN INVIVO MODEL OF ACUTE EPITHELIAL-CELL INJURY IN RAT SMALL-INTESTINE SO GASTROENTEROLOGY LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,NERPRC,CTR STUDY INFLAMMATORY BOWEL DIS,BOSTON,MA 02114. MASSACHUSETTS GEN HOSP,GASTROINTESTINAL UNIT,BOSTON,MA 02114. MASSACHUSETTS GEN HOSP,RENAL UNIT,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD APR PY 1993 VL 104 IS 4 SU S BP A617 EP A617 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA KX957 UT WOS:A1993KX95702452 ER PT J AU FOITZIK, T BASSI, DG LEWANDROWSKI, K FERNANDEZDELCASTILLO, C RATTNER, DW WARSHAW, AL AF FOITZIK, T BASSI, DG LEWANDROWSKI, K FERNANDEZDELCASTILLO, C RATTNER, DW WARSHAW, AL TI TRYPSINOGEN ACTIVATION PEPTIDES (TAP) PARALLEL THE TIME COURSE OF HISTOLOGICAL INJURY EARLY IN EXPERIMENTAL ACUTE-PANCREATITIS SO GASTROENTEROLOGY LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,DEPT SURG,BOSTON,MA 02114. MASSACHUSETTS GEN HOSP,DEPT PATHOL,BOSTON,MA 02114. HARVARD UNIV,SCH MED,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD APR PY 1993 VL 104 IS 4 SU S BP A1039 EP A1039 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA KX957 UT WOS:A1993KX95704123 ER PT J AU LENCER, WI DEALMEIDA, JB AUSIELLO, DA MADARA, JL AF LENCER, WI DEALMEIDA, JB AUSIELLO, DA MADARA, JL TI ENTRY OF CHOLERA-TOXIN INTO INTESTINAL EPITHELIAL-CELLS - ROLE OF VESICULAR TRAFFIC SO GASTROENTEROLOGY LA English DT Meeting Abstract C1 CHILDRENS HOSP MED CTR,BOSTON,MA 02115. MASSACHUSETTS GEN HOSP,RENAL UNIT,BOSTON,MA 02114. BRIGHAM & WOMENS HOSP,BOSTON,MA 02115. HARVARD UNIV,SCH MED,BOSTON,MA 02115. NR 1 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD APR PY 1993 VL 104 IS 4 SU S BP A259 EP A259 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA KX957 UT WOS:A1993KX95701025 ER PT J AU MAHIDA, YR CIACCI, C DEBEAUMONT, M GESPACH, C PODOLSKY, DK AF MAHIDA, YR CIACCI, C DEBEAUMONT, M GESPACH, C PODOLSKY, DK TI EXPRESSION AND RESPONSIVENESS TO TGF-BETA OF THE ESK1 CELL-LINE ESTABLISHED AFTER INFECTION OF RAT SMALL INTESTINAL EPITHELIAL-CELLS BY RECOMBINANT RETROVIRUSES CARRYING THE SV40 LARGE T ONCOGENE SO GASTROENTEROLOGY LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,NERPRC,CTR STUDY INFLAMMATORY BOWEL DIS,BOSTON,MA 02114. MASSACHUSETTS GEN HOSP,GASTROINTESTINAL UNIT,BOSTON,MA 02114. HOP ST ANTOINE,INSERM,U55,F-75571 PARIS 12,FRANCE. RI ciacci, carolina/A-2594-2012 OI ciacci, carolina/0000-0002-7426-1145 NR 0 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD APR PY 1993 VL 104 IS 4 SU S BP A262 EP A262 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA KX957 UT WOS:A1993KX95701040 ER PT J AU MCCORMICK, BA COLGAN, SP MILLER, SI MADARA, JL AF MCCORMICK, BA COLGAN, SP MILLER, SI MADARA, JL TI APICAL BINDING OF SALMONELLA TO INTESTINAL EPITHELIA MODULATES NEUTROPHIL-EPITHELIAL INTERACTIONS SO GASTROENTEROLOGY LA English DT Meeting Abstract C1 HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115. MASSACHUSETTS GEN HOSP,DEPT INFECT DIS,BOSTON,MA 02114. MASSACHUSETTS GEN HOSP,CTR STUDY IBDA,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD APR PY 1993 VL 104 IS 4 SU S BP A740 EP A740 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA KX957 UT WOS:A1993KX95702940 ER PT J AU MURGUE, B TSUNEKAWA, S PODOLSKY, DK AF MURGUE, B TSUNEKAWA, S PODOLSKY, DK TI MOLECULAR-CLONING OF A NOVEL FORM OF FIBROBLAST GROWTH-FACTOR RECEPTOR-3 (FGFR-3) WITH A UNIQUE LIGAND-BINDING DOMAIN IN HT-29 CELLS SO GASTROENTEROLOGY LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,GI UNIT,BOSTON,MA 02114. NR 0 TC 1 Z9 1 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD APR PY 1993 VL 104 IS 4 SU S BP A842 EP A842 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA KX957 UT WOS:A1993KX95703341 ER PT J AU NANJI, AA ZHAO, S SADRZADEH, SMH KHETTRY, U WAXMAN, DJ AF NANJI, AA ZHAO, S SADRZADEH, SMH KHETTRY, U WAXMAN, DJ TI CIMETIDINE PREVENTS EXPERIMENTAL ALCOHOLIC LIVER-INJURY IN THE INTRAGASTRIC FEEDING RAT MODEL SO GASTROENTEROLOGY LA English DT Meeting Abstract C1 NEW ENGLAND DEACONESS HOSP,DEPT PATHOL,BOSTON,MA 02215. HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115. NR 0 TC 1 Z9 1 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD APR PY 1993 VL 104 IS 4 SU S BP A962 EP A962 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA KX957 UT WOS:A1993KX95703820 ER PT J AU OHNING, GV LLOYD, KCK WONG, HC WALSH, JH AF OHNING, GV LLOYD, KCK WONG, HC WALSH, JH TI ENDOGENOUS SOMATOSTATIN REGULATES GASTRIN-RELEASE WITHOUT AFFECTING ANTRAL GASTRIN CONTENT IN FASTED RATS - DEMONSTRATION BY SOMATOSTATIN IMMUNONEUTRALIZATION SO GASTROENTEROLOGY LA English DT Meeting Abstract C1 W LOS ANGELES VAMC,DDC,CURE,LOS ANGELES,CA. UNIV CALIF LOS ANGELES,DEPT MED,LOS ANGELES,CA 90024. NR 0 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD APR PY 1993 VL 104 IS 4 SU S BP A844 EP A844 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA KX957 UT WOS:A1993KX95703352 ER PT J AU PODOLSKY, DK LOBB, R KING, N BENJAMIN, CD PEPINSKY, B SEHGAL, P DEBEAUMONT, M AF PODOLSKY, DK LOBB, R KING, N BENJAMIN, CD PEPINSKY, B SEHGAL, P DEBEAUMONT, M TI ATTENUATION OF COLITIS IN THE COTTON TOP TAMARIN BY ANTI-VLA4 MONOCLONAL-ANTIBODY SO GASTROENTEROLOGY LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,GASTROINTESTINAL UNIT,BOSTON,MA 02114. MGH NERPRC,CTR STUDY INFLAMMATORY BOWEL DIS,BOSTON,MA. BIOGEN INC,CAMBRIDGE,MA. NEW ENGLAND REG PRIMATE RES CTR,SOUTHBOROUGH,MA 01772. NR 0 TC 1 Z9 1 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD APR PY 1993 VL 104 IS 4 SU S BP A764 EP A764 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA KX957 UT WOS:A1993KX95703034 ER PT J AU RACHMILEWITZ, D STAMLER, JS KARMELI, F MULLINS, ME SINGEL, DJ LOSCALZO, J XAVIER, RJ PODOLSKY, DK AF RACHMILEWITZ, D STAMLER, JS KARMELI, F MULLINS, ME SINGEL, DJ LOSCALZO, J XAVIER, RJ PODOLSKY, DK TI PEROXYNITRITE INDUCED EXPERIMENTAL COLITIS-A NEW MODEL INDICATING POSSIBLE CONTRIBUTION OF THE NO RADICAL TO THE PATHOGENESIS OF COLONIC INFLAMMATION SO GASTROENTEROLOGY LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,GI UNIT,BOSTON,MA 02114. MASSACHUSETTS GEN HOSP,CTR STUDY INFLAMMATORY BOWEL DIS,BOSTON,MA 02114. BRIGHAM & WOMENS HOSP,DIV RESP & CARDIOVASC,BOSTON,MA 02115. HARVARD UNIV,DEPT CHEM,CAMBRIDGE,MA 02138. NR 0 TC 4 Z9 4 U1 0 U2 2 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD APR PY 1993 VL 104 IS 4 SU S BP A766 EP A766 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA KX957 UT WOS:A1993KX95703043 ER PT J AU RACHMILEWITZ, D STAMLER, JS BACHWICH, D KARMELI, F ACKERMAN, Z LOSCALZO, J PODOLSKY, DK AF RACHMILEWITZ, D STAMLER, JS BACHWICH, D KARMELI, F ACKERMAN, Z LOSCALZO, J PODOLSKY, DK TI ENHANCED COLONIC NO GENERATION AND STIMULATED NO SYNTHASE ACTIVITY IN EXPERIMENTAL COLITIS AND IN ACTIVE INFLAMMATORY BOWEL-DISEASE SO GASTROENTEROLOGY LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,GI UNIT,BOSTON,MA 02114. MASSACHUSETTS GEN HOSP,CTR STUDY INFLAMMATORY BOWEL DIS,BOSTON,MA 02114. BRIGHAM & WOMENS HOSP,DIV RESP & CARDIOVASC,BOSTON,MA 02115. HADASSAH UNIV HOSP,DEPT MED,IL-91120 JERUSALEM,ISRAEL. NR 0 TC 4 Z9 4 U1 0 U2 2 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD APR PY 1993 VL 104 IS 4 SU S BP A766 EP A766 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA KX957 UT WOS:A1993KX95703041 ER PT J AU ROSENBERG, IM DEBEAUMONT, M PODOLSKY, DK AF ROSENBERG, IM DEBEAUMONT, M PODOLSKY, DK TI A MONOCLONAL-ANTIBODY RAISED AGAINST HUMAN ULCERATIVE-COLITIS MUCOSA RECOGNIZES THE MRP COMPLEX OF PROTEINS, OVERPRODUCED IN ACTIVATED NEUTROPHILS AND INFLAMED EPITHELIA SO GASTROENTEROLOGY LA English DT Meeting Abstract C1 HARVARD UNIV,SCH MED,DEPT MED,GASTROINTESTINAL UNIT,BOSTON,MA 02115. MASSACHUSETTS GEN HOSP,BOSTON,MA 02114. MGH NER PRC,CTR STUDY INFLAMMATORY BOWEL DIS,BOSTON,MA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD APR PY 1993 VL 104 IS 4 SU S BP A772 EP A772 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA KX957 UT WOS:A1993KX95703066 ER PT J AU RUSTGI, AK HATEBOER, G BERNARDS, R AF RUSTGI, AK HATEBOER, G BERNARDS, R TI THE C-MYC ONCOPROTEIN BINDS TO THE TATA-BINDING PROTEIN (TBP) INVITRO AND INVIVO SO GASTROENTEROLOGY LA English DT Meeting Abstract C1 HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,GASTROINTESTINAL UNIT,BOSTON,MA 02114. HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,CTR CANC,BOSTON,MA 02114. NETHERLANDS CANC INST,1066 CX AMSTERDAM,NETHERLANDS. NR 0 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD APR PY 1993 VL 104 IS 4 SU S BP A445 EP A445 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA KX957 UT WOS:A1993KX95701767 ER PT J AU SANDS, BE PODOLSKY, DK AF SANDS, BE PODOLSKY, DK TI MOLECULAR-CLONING OF THE INTESTINAL TREFOIL FACTOR GENE - GENOMIC ORGANIZATION AND CHARACTERIZATION OF 5 FLANKING REGION SO GASTROENTEROLOGY LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,GI UNIT,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 1 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD APR PY 1993 VL 104 IS 4 SU S BP A278 EP A278 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA KX957 UT WOS:A1993KX95701104 ER PT J AU SCHIFFRIN, EJ TROP, M CARTER, EA AF SCHIFFRIN, EJ TROP, M CARTER, EA TI CONTINUOUS INFUSION OF LIPOPOLYSACCHARIDE PRODUCES CHRONIC INTESTINAL INFLAMMATION IN GERM FREE RATS SO GASTROENTEROLOGY LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,COMBINED PROGRAM PEDIAT GASTROENTEROL,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD APR PY 1993 VL 104 IS 4 SU S BP A776 EP A776 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA KX957 UT WOS:A1993KX95703082 ER PT J AU SCHMIDT, J HUCH, K SINN, HP MITHOFER, K KLAR, E WARSHAW, AL BUHR, HJ AF SCHMIDT, J HUCH, K SINN, HP MITHOFER, K KLAR, E WARSHAW, AL BUHR, HJ TI EFFECT OF HYPERONCOTIC DEXTRANS AFTER DELAYED ONSET OF THERAPY IN ACUTE EXPERIMENTAL PANCREATITIS SO GASTROENTEROLOGY LA English DT Meeting Abstract C1 UNIV HEIDELBERG,DEPT SURG,W-6900 HEIDELBERG,GERMANY. UNIV HEIDELBERG,DEPT PATHOL,W-6900 HEIDELBERG,GERMANY. MASSACHUSETTS GEN HOSP,DEPT SURG,BOSTON,MA 02114. RI Sinn, Hans-Peter/C-5661-2008 NR 0 TC 1 Z9 1 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD APR PY 1993 VL 104 IS 4 SU S BP A334 EP A334 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA KX957 UT WOS:A1993KX95701326 ER PT J AU SEE, JA JENSEN, DM JUTABHA, R MACHICADO, GA HIRABAYASHI, K AF SEE, JA JENSEN, DM JUTABHA, R MACHICADO, GA HIRABAYASHI, K TI A RANDOMIZED CONTROLLED-STUDY OF METRONIDAZOLE IN HEALING ULCERATIONS AFTER COAGULATION IN THE RIGHT COLON OF DOGS SO GASTROENTEROLOGY LA English DT Meeting Abstract C1 UNIV CALIF LOS ANGELES, CURE, LOS ANGELES, CA USA. W LOS ANGELES VA MED CTR, LOS ANGELES, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD APR PY 1993 VL 104 IS 4 SU S BP A279 EP A279 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA KX957 UT WOS:A1993KX95701108 ER PT J AU SOHN, UD KIM, DK BEHAR, J BIANCANI, P AF SOHN, UD KIM, DK BEHAR, J BIANCANI, P TI PHOSPHOLIPASE-D (PLD) AND PHOSPHOLIPASE-A2 (PLA2) SYNERGISM IN ACH-INDUCED CONTRACTION OF ESOPHAGEAL CIRCULAR SMOOTH-MUSCLE SO GASTROENTEROLOGY LA English DT Meeting Abstract C1 HARVARD UNIV,BOSTON,MA 02115. MASSACHUSETTS GEN HOSP,BOSTON,MA 02114. RHODE ISL HOSP,PROVIDENCE,RI 02902. BROWN UNIV,PROVIDENCE,RI 02912. NR 0 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD APR PY 1993 VL 104 IS 4 SU S BP A586 EP A586 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA KX957 UT WOS:A1993KX95702328 ER PT J AU STOKER, TW CASANOVA, JE SANDERSON, IR SCHIFFRIN, EJ ISRAEL, EJ CARTER, EA AF STOKER, TW CASANOVA, JE SANDERSON, IR SCHIFFRIN, EJ ISRAEL, EJ CARTER, EA TI DIET AND DISEASE RESPONSE IN AN ANIMAL-MODEL FOR INFLAMMATORY BOWEL-DISEASE SO GASTROENTEROLOGY LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,COMBINED PROGRAM PEDIAT GASTROENTEROL & NUTR,BOSTON,MA 02114. NR 0 TC 1 Z9 1 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD APR PY 1993 VL 104 IS 4 SU S BP A1063 EP A1063 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA KX957 UT WOS:A1993KX95704220 ER PT J AU TILLOTSON, LG BRAND, SJ AF TILLOTSON, LG BRAND, SJ TI IDENTIFICATION OF A POSITIVE ELEMENT IN THE HUMAN GASTRIN GENE PROMOTER IMPORTANT FOR PANCREATIC ISLET-SPECIFIC EXPRESSION SO GASTROENTEROLOGY LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,GI UNIT,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD APR PY 1993 VL 104 IS 4 SU S BP A859 EP A859 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA KX957 UT WOS:A1993KX95703410 ER PT J AU TILLOTSON, LG CHUNG, DC BRAND, SJ AF TILLOTSON, LG CHUNG, DC BRAND, SJ TI DIFFERENTIAL TRANSCRIPTIONAL REGULATION OF GASTRIN EXPRESSION IN COLON-TUMOR CELLS SO GASTROENTEROLOGY LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,GASTROINTESTINAL UNIT,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD APR PY 1993 VL 104 IS 4 SU S BP A456 EP A456 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA KX957 UT WOS:A1993KX95701812 ER PT J AU TOGAWA, K CHIECOBIANCO, L PERRACCHIA, A RUSTGI, AK AF TOGAWA, K CHIECOBIANCO, L PERRACCHIA, A RUSTGI, AK TI HUMAN PAPILLOMAVIRUS DNA-SEQUENCES IN ESOPHAGEAL SQUAMOUS-CELL CARCINOMAS FROM HIGH-RISK AREAS SO GASTROENTEROLOGY LA English DT Meeting Abstract C1 HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,GASTROINTESTINAL UNIT,BOSTON,MA 02114. HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,CTR CANC,BOSTON,MA 02114. UNIV TURIN,I-10124 TURIN,ITALY. NR 0 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD APR PY 1993 VL 104 IS 4 SU S BP A457 EP A457 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA KX957 UT WOS:A1993KX95701816 ER PT J AU VONJAN, NCS CARTER, EA CLARK, BD HATZ, RA KRAEMLING, HJ AF VONJAN, NCS CARTER, EA CLARK, BD HATZ, RA KRAEMLING, HJ TI EFFECT OF THERMAL-INJURY AND ETHANOL ON GASTRIC-EMPTYING, GASTRIC INTERLEUKIN-1-ALPHA (IL-1), AND SERUM GASTRIN IN THE RAT SO GASTROENTEROLOGY LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,BOSTON,MA 02114. TUFTS UNIV,NEW ENGLAND MED CTR,SCH MED,BOSTON,MA 02111. KLINIKUM,GROSSHADERN,DEPT SURG,MUNICH,GERMANY. NR 0 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD APR PY 1993 VL 104 IS 4 SU S BP A1065 EP A1065 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA KX957 UT WOS:A1993KX95704228 ER PT J AU WANG, TC CHULAK, MB JIANG, J AF WANG, TC CHULAK, MB JIANG, J TI RAT HISTIDINE-DECARBOXYLASE (HDC) GENE-EXPRESSION IS REGULATED BY A HOMEOBOX-LIKE ENHANCER IN GASTRIC CELL-LINES SO GASTROENTEROLOGY LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,GASTROINTESTINAL UNIT,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD APR PY 1993 VL 104 IS 4 SU S BP A862 EP A862 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA KX957 UT WOS:A1993KX95703423 ER PT J AU WINKELSTEIN, A WINTER, H LANDERS, C TARGAN, S AF WINKELSTEIN, A WINTER, H LANDERS, C TARGAN, S TI ANTINEUTROPHIL CYTOPLASMIC ANTIBODY AS MEASURED BY ELISA IS SENSITIVE AND SPECIFIC FOR CHILDHOOD ULCERATIVE-COLITIS SO GASTROENTEROLOGY LA English DT Meeting Abstract C1 CEDARS SINAI MED CTR,CTR INFLAMMATORY BOWEL DIS,LOS ANGELES,CA 90048. BOSTON CITY HOSP,BOSTON,MA 02118. MASSACHUSETTS GEN HOSP,BOSTON,MA 02114. NR 0 TC 1 Z9 1 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD APR PY 1993 VL 104 IS 4 SU S BP A802 EP A802 PG 1 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA KX957 UT WOS:A1993KX95703184 ER PT J AU LU, XY CHOU, TB WILLIAMS, NG ROBERTS, T PERRIMON, N AF LU, XY CHOU, TB WILLIAMS, NG ROBERTS, T PERRIMON, N TI CONTROL OF CELL FATE DETERMINATION BY P21RAS/RAS1, AN ESSENTIAL COMPONENT OF TORSO SIGNALING IN DROSOPHILA SO GENES & DEVELOPMENT LA English DT Article DE DROSOPHILA; KINASE; RAS; SOS; SIGNAL TRANSDUCTION; PATTERN FORMATION ID GUANINE-NUCLEOTIDE EXCHANGE; RECEPTOR TYROSINE KINASE; EMBRYONIC TERMINI; PATTERN-FORMATION; VULVAR INDUCTION; PROTO-ONCOGENE; GENE TAILLESS; RAS PROTEIN; MUTATIONS; GROWTH AB Determination of cell fate at the posterior termini of the Drosophila embryo is specified by the activation of the torso (tor) receptor tyrosine kinase. This signaling pathway is mediated by the serine/threonine kinase D-raf and a protein tyrosine phosphatase corkscrew (csw). We found that expression of an activated form of Ras1 during oogenesis resulted in embryos with tor gain-of-function phenotypes. To demonstrate that p21ras/Ras1 mediates tor signaling, we injected mammalian p21ras variants into early Drosophila embryos. We found that the injection of activated p21v-ras rescued the maternal-effect phenotypes of both tor and csw null mutations. These rescuing effects of p21v-ras are dependent on the presence of maternally derived D-raf activity. In addition, wild-type embryos show a terminal-class phenotype resembling csw when injected with p21rasN17, a dominant-negative form of p21ras. Furthermore, we have analyzed the maternal-effect phenotype of Son of sevenless (Sos), a positive regulator of Ras1, and showed that embryos derived from germ cells lacking Sos+ activity exhibit a terminal-class phenotype. Our study demonstrates that the Drosophila p21ras, encoded by Ras1, is an intrinsic component of the tor signaling pathway, where it is both necessary and sufficient in specifying posterior terminal cell fates. p21ras/Ras1 operates upstream of the D-raf kinase in this signaling pathway. C1 HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115. HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115. HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115. RP LU, XY (reprint author), HARVARD UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT GENET,BOSTON,MA 02115, USA. RI Perrimon, Norbert/F-9766-2011; OI CHOU, TZE-BIN/0000-0003-2453-0164 FU NICHD NIH HHS [HD24926] NR 62 TC 100 Z9 100 U1 0 U2 3 PU COLD SPRING HARBOR LAB PRESS PI PLAINVIEW PA 1 BUNGTOWN RD, PLAINVIEW, NY 11724 SN 0890-9369 J9 GENE DEV JI Genes Dev. PD APR PY 1993 VL 7 IS 4 BP 621 EP 632 DI 10.1101/gad.7.4.621 PG 12 WC Cell Biology; Developmental Biology; Genetics & Heredity SC Cell Biology; Developmental Biology; Genetics & Heredity GA KW758 UT WOS:A1993KW75800009 PM 8458578 ER PT J AU PARKER, S ANGELICO, MC LAFFEL, L KROLEWSKI, AS AF PARKER, S ANGELICO, MC LAFFEL, L KROLEWSKI, AS TI APPLICATION OF DENATURING GRADIENT GEL-ELECTROPHORESIS TO DETECT DNA-SEQUENCE DIFFERENCES ENCODING APOLIPOPROTEIN-E ISOFORMS SO GENOMICS LA English DT Note ID POLYMORPHISM; GENE C1 JOSLIN DIABET CTR,DIV RES,EPIDEMIOL & GENET SECT,1 JOSLIN PL,BOSTON,MA 02215. HARVARD UNIV,SCH MED,BOSTON,MA 02115. FU NIDDK NIH HHS [DK 41526] NR 12 TC 10 Z9 10 U1 0 U2 2 PU ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 SN 0888-7543 J9 GENOMICS JI Genomics PD APR PY 1993 VL 16 IS 1 BP 245 EP 247 DI 10.1006/geno.1993.1166 PG 3 WC Biotechnology & Applied Microbiology; Genetics & Heredity SC Biotechnology & Applied Microbiology; Genetics & Heredity GA KW205 UT WOS:A1993KW20500034 PM 8486365 ER PT J AU KURBAN, RS KURBAN, AK AF KURBAN, RS KURBAN, AK TI COMMON SKIN DISORDERS OF AGING - DIAGNOSIS AND TREATMENT SO GERIATRICS LA English DT Article ID KERATOSES AB The incidence of skin disorders increases with age because of changes in skin structures and a lifetime accumulation of environmental insults. Photoaging, resulting from exposure to harmful ultraviolet wavelengths in sunlight, is responsible for many common skin disorders, from wrinkles to melanoma. Older patients also see their physicians with complaints of various types of dermatitis, including contact and seborrheic. Although skin disorders vary in severity, they all adversely affect an older patient's health and/or quality of life. Early recognition, prevention, and treatment of skin diseases by the primary care physician is therefore an important element in the overall care of the middle-aged and older patient. C1 PENN STATE UNIV,MILTON S HERSHEY MED CTR,HERSHEY,PA 17033. BOSTON UNIV,SCH MED,BOSTON,MA 02118. BOSTON UNIV,MED CTR,BOSTON,MA 02215. RP KURBAN, RS (reprint author), HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,BOSTON,MA 02114, USA. NR 10 TC 7 Z9 7 U1 0 U2 2 PU ADVANSTAR COMMUNICATIONS PI DULUTH PA 131 W FIRST ST, DULUTH, MN 55802 SN 0016-867X J9 GERIATRICS JI Geriatrics PD APR PY 1993 VL 48 IS 4 BP 30 EP & PG 0 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA KX053 UT WOS:A1993KX05300002 PM 8462882 ER PT J AU BERKOWITZ, RS AF BERKOWITZ, RS TI CA125 MEASUREMENT IN EPITHELIAL OVARIAN-CANCER - A 10-YEAR ANNIVERSARY OF CLINICAL INVESTIGATION SO GYNECOLOGIC ONCOLOGY LA English DT Editorial Material ID SERUM CA-125 LEVELS C1 HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DEPT OBSTET & GYNECOL,BOSTON,MA 02115. RP BERKOWITZ, RS (reprint author), HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DIV GYNECOL ONCOL,BOSTON,MA 02115, USA. NR 9 TC 8 Z9 8 U1 0 U2 0 PU ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 SN 0090-8258 J9 GYNECOL ONCOL JI Gynecol. Oncol. PD APR PY 1993 VL 49 IS 1 BP 1 EP 2 DI 10.1006/gyno.1993.1075 PG 2 WC Oncology; Obstetrics & Gynecology SC Oncology; Obstetrics & Gynecology GA LB923 UT WOS:A1993LB92300001 PM 8482551 ER PT J AU SEIDEN, MV SKLAR, J AF SEIDEN, MV SKLAR, J TI MOLECULAR GENETIC-ANALYSIS OF POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDERS SO HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA LA English DT Article ID EPSTEIN-BARR-VIRUS; BONE-MARROW TRANSPLANTATION; B-CELL LYMPHOMA; COMBINED IMMUNODEFICIENCY; ACYCLOVIR THERAPY; CONSTANT-REGION; CLONAL ANALYSIS; RECIPIENTS; DISEASES; LATENT C1 BRIGHAM & WOMENS HOSP,DIV DIAGNOST MOLEC BIOL,BOSTON,MA 02115. BRIGHAM & WOMENS HOSP,DIV MOLEC ONCOL,BOSTON,MA 02115. HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115. MASSACHUSETTS GEN HOSP,BOSTON,MA 02114. HARVARD UNIV,SCH MED,BOSTON,MA 02115. NR 54 TC 33 Z9 33 U1 0 U2 1 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 SN 0889-8588 J9 HEMATOL ONCOL CLIN N JI Hematol. Oncol. Clin. North Am. PD APR PY 1993 VL 7 IS 2 BP 447 EP 465 PG 19 WC Oncology; Hematology SC Oncology; Hematology GA KV656 UT WOS:A1993KV65600010 PM 8385661 ER PT J AU OBERLEY, TD COURSIN, DB CIHLA, HP OBERLEY, LW ELSAYYAD, N HO, YS AF OBERLEY, TD COURSIN, DB CIHLA, HP OBERLEY, LW ELSAYYAD, N HO, YS TI IMMUNOLOCALIZATION OF MANGANESE SUPEROXIDE-DISMUTASE IN NORMAL AND TRANSGENIC MICE EXPRESSING THE HUMAN ENZYME SO HISTOCHEMICAL JOURNAL LA English DT Article ID SYRIAN-HAMSTER TISSUES; IMMUNOHISTOCHEMICAL LOCALIZATION; ANTIOXIDANT ENZYMES; KIDNEY DEVELOPMENT; XANTHINE-OXIDASE; CELLS; RADICALS AB The localization of manganese superoxide dismutase (MnSOD) was determined using immunohistochemistry of various tissues of normal and transgenic mice which express the human enzyme, with emphasis on studies of mouse kidney and lung. Mouse kidney and lung were studied using both frozen section analysis and paraffin sections following fixation in a variety of fixatives. Formalin fixation resulted in a loss of antigenicity, while fixation in zinc formalin or B5 fixative gave results similar to those from frozen sections. Immunoperoxidase studies using antibodies to MnSOD showed greater staining in transgenic kidney or lung than in identical tissues in normal mice when appropriate fixation was used. In contrast, equal immunostaining was obtained in kidney or lung from normal and transgenic mice when antibodies to catalase or copper zinc superoxide dismutase were utilized. Immunogold ultrastructural analysis of MnSOD localization for lung and kidney was also performed. As compared to normal mice, transgenic mice exhibited greater staining of the mitochondria of kidney interstitial fibroblasts and glomerular, endothelial, and smooth muscle cells. In the lungs of transgenic animals, all cells showed increased staining; smooth muscle cells demonstrated the most marked increase in immunolabelling. The results indicate that these transgenic mice overexpress MnSOD in their mitochondria, and that this occurs selectively in at least some mesenchymal tissues. C1 UNIV WISCONSIN,SCH MED,DEPT PATHOL,MADISON,WI 53706. UNIV WISCONSIN,SCH MED,DEPT MED,MADISON,WI 53706. UNIV WISCONSIN,SCH MED,DEPT ANESTHESIOL,MADISON,WI 53706. UNIV IOWA,RADIAT RES LAB,IOWA CITY,IA 52242. DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27710. RP OBERLEY, TD (reprint author), WILLIAM S MIDDLETON MEM VET ADM MED CTR,LAB SERV,PATHOL SECT,2500 OVERLOOK TERRACE,MADISON,WI 53705, USA. FU NCI NIH HHS [CA-41267]; NHLBI NIH HHS [HL-39585, HL-44571] NR 29 TC 38 Z9 38 U1 0 U2 0 PU CHAPMAN HALL LTD PI LONDON PA 2-6 BOUNDARY ROW, LONDON, ENGLAND SE1 8HN SN 0018-2214 J9 HISTOCHEM J JI Histochem.J. PD APR PY 1993 VL 25 IS 4 BP 267 EP 279 DI 10.1007/BF00159118 PG 13 WC Cell Biology SC Cell Biology GA KY964 UT WOS:A1993KY96400002 PM 8491667 ER PT J AU TESAR, GE AF TESAR, GE TI THE AGITATED PATIENT .1. EVALUATION AND BEHAVIORAL-MANAGEMENT SO HOSPITAL AND COMMUNITY PSYCHIATRY LA English DT Article RP TESAR, GE (reprint author), MASSACHUSETTS GEN HOSP,ACUTE PSYCHIAT SERV,15 PARKMAN ST,ACC-815,BOSTON,MA 02114, USA. NR 9 TC 12 Z9 12 U1 0 U2 0 PU AMER PSYCHIATRIC ASSOCIATION PI WASHINGTON PA 1400 K ST NW, WASHINGTON, DC 20005 SN 0022-1597 J9 HOSP COMMUNITY PSYCH PD APR PY 1993 VL 44 IS 4 BP 329 EP 331 PG 3 WC Public, Environmental & Occupational Health; Psychiatry SC Public, Environmental & Occupational Health; Psychiatry GA KV461 UT WOS:A1993KV46100004 PM 8462938 ER PT J AU TAGLE, DA BLANCHARDMCQUATE, KL VALDES, J CASTILLA, L MACDONALD, ME GUSELLA, JF COLLINS, FS AF TAGLE, DA BLANCHARDMCQUATE, KL VALDES, J CASTILLA, L MACDONALD, ME GUSELLA, JF COLLINS, FS TI DINUCLEOTIDE REPEAT POLYMORPHISM IN THE HUNTINGTONS-DISEASE REGION AT THE D4S182 LOCUS SO HUMAN MOLECULAR GENETICS LA English DT Article C1 UNIV MICHIGAN,MED CTR,DEPT HUMAN GENET,ANN ARBOR,MI 48109. UNIV MICHIGAN,MED CTR,DEPT BIOL,ANN ARBOR,MI 48109. UNIV MICHIGAN,MED CTR,DEPT INTERNAL MED,ANN ARBOR,MI 48109. HOWARD HUGHES MED INST,ANN ARBOR,MI 48109. MASSACHUSETTS GEN HOSP,NEUROGENET LAB,BOSTON,MA 02114. HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115. FU NHGRI NIH HHS [HG00067-01] NR 2 TC 2 Z9 2 U1 0 U2 1 PU OXFORD UNIV PRESS UNITED KINGDOM PI OXFORD PA WALTON ST JOURNALS DEPT, OXFORD, ENGLAND OX2 6DP SN 0964-6906 J9 HUM MOL GENET JI Hum. Mol. Genet. PD APR PY 1993 VL 2 IS 4 BP 489 EP 489 DI 10.1093/hmg/2.4.489 PG 1 WC Biochemistry & Molecular Biology; Genetics & Heredity SC Biochemistry & Molecular Biology; Genetics & Heredity GA KW632 UT WOS:A1993KW63200031 PM 8504314 ER PT J AU ROSENBERG, AE OCONNELL, JX OJEMANN, RG PLATA, MJ PALMER, WE AF ROSENBERG, AE OCONNELL, JX OJEMANN, RG PLATA, MJ PALMER, WE TI GIANT CYSTIC ARACHNOID GRANULATIONS - A RARE CAUSE OF LYTIC SKULL LESIONS SO HUMAN PATHOLOGY LA English DT Article DE ARACHNOID GRANULATIONS; PACCHIONIAN GRANULATIONS; SKULL C1 CHARLESTON AREA MED CTR,DEPT PATHOL,CHARLESTON,WV. MASSACHUSETTS GEN HOSP,DEPT NEUROSURG,BOSTON,MA 02114. MASSACHUSETTS GEN HOSP,DEPT RADIOL,BOSTON,MA 02114. RP ROSENBERG, AE (reprint author), MASSACHUSETTS GEN HOSP,DEPT PATHOL,BOSTON,MA 02114, USA. NR 17 TC 17 Z9 17 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 SN 0046-8177 J9 HUM PATHOL JI Hum. Pathol. PD APR PY 1993 VL 24 IS 4 BP 438 EP 441 DI 10.1016/0046-8177(93)90094-W PG 4 WC Pathology SC Pathology GA KX354 UT WOS:A1993KX35400016 PM 8491484 ER PT J AU SCHUPPIN, GT BONNERWEIR, S MONTANA, E KAISER, N WEIR, GC AF SCHUPPIN, GT BONNERWEIR, S MONTANA, E KAISER, N WEIR, GC TI REPLICATION OF ADULT PANCREATIC-BETA-CELLS CULTURED ON BOVINE CORNEAL ENDOTHELIAL-CELL EXTRACELLULAR-MATRIX SO IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY-ANIMAL LA English DT Article DE DIABETES; INSULIN; EPITHELIUM; GLUCOSE; CORNEA ID DEOXYRIBONUCLEIC-ACID SYNTHESIS; GROWTH FACTOR-I; B-CELL; PLACENTAL-LACTOGEN; MONOLAYER-CULTURE; DNA-REPLICATION; ISLETS; INSULIN; RAT; HORMONE AB A valuable system has been developed to study replication of adult beta cells. Isolated islets from adult rats were partially dispersed and plated on dishes coated with extracellular matrix from bovine-corneal endothelial cells. Within 24 h islet cells attached to the matrix and formed a monolayer. The proportion of insulin-, glucagon-, and somatostatin-containing cells in the cultures was characteristic of whole islets. Function of beta cells was assessed by measuring glucose-stimulated insulin release. Insulin release from 7-day-old cultures increased 19-fold after a 16.7 mM glucose challenge indicating that beta-cell function was normal. Cellular replication in the cultures was assessed using the thymidine analogue 5-bromo-2'-deoxyuridine (BrdU). BrdU incorporation was noted in insulin-, glucagon-, and somatostatin-containing cells and also in non-endocrine cells. Among endocrine cells, the majority of BrdU labeling occurred in beta cells. Beta-cell replication potential was assessed using different concentrations of glucose. The incorporation of BrdU into beta cells was affected in a dose-dependent manner by glucose; over a 10-fold increase of beta-cell BrdU labeling was observed when glucose concentration was raised from 5.5 to 16.7 mM. The system proved advantageous for studying the replication potential of adult beta cells. C1 NEW ENGLAND DEACONESS HOSP,BOSTON,MA 02215. BRIGHAM & WOMENS HOSP,BOSTON,MA 02115. HARVARD UNIV,SCH MED,BOSTON,MA 02115. HEBREW UNIV JERUSALEM,HADASSAH MED CTR,DEPT ENDOCRINOL & METAB,JERUSALEM,ISRAEL. RP SCHUPPIN, GT (reprint author), JOSLIN DIABET CTR,1 JOSLIN PL,BOSTON,MA 02215, USA. FU NIDDK NIH HHS [DK 35449, DK 36836] NR 31 TC 22 Z9 22 U1 0 U2 0 PU SOC IN VITRO BIOLOGY PI UPPER MARLBORO PA 9315 LARGO DR W #255, UPPER MARLBORO, MD 20774-4755 SN 1071-2690 J9 IN VITRO CELL DEV-AN JI In Vitro Cell. Dev. Biol.-Anim. PD APR PY 1993 VL 29A IS 4 BP 339 EP 344 PG 6 WC Cell Biology; Developmental Biology SC Cell Biology; Developmental Biology GA LD071 UT WOS:A1993LD07100016 PM 8320184 ER PT J AU ROTHSTEIN, DM DASILVA, A SUGITA, K YAMAMOTO, M PRASAD, KVS MORIMOTO, C SCHLOSSMAN, SF RUDD, CE AF ROTHSTEIN, DM DASILVA, A SUGITA, K YAMAMOTO, M PRASAD, KVS MORIMOTO, C SCHLOSSMAN, SF RUDD, CE TI HUMAN CD4/CD45RA+ AND CD4/CD45RA- T-CELL SUBSETS EXPRESS CD4-P56(LCK) COMPLEXES, CD4-ASSOCIATED LIPID KINASES, TCR/CD3-P59(FYN) COMPLEXES, AND SHARE SIMILAR TYROSINE KINASE SUBSTRATES SO INTERNATIONAL IMMUNOLOGY LA English DT Article DE T-CELL SUBSETS; TYROSINE KINASES; TYROSINE PHOSPHATASES ID HUMAN LYMPHOCYTES-T; LEUKOCYTE-COMMON ANTIGEN; RECEPTOR-MEDIATED ACTIVATION; SIGNAL TRANSDUCTION; MONOCLONAL-ANTIBODY; PHOSPHATIDYLINOSITOL KINASE; ALTERNATIVE PATHWAY; CROSS-LINKING; INDUCER CELLS; CD2 PATHWAY AB T cell activation appears to be regulated by an interplay between protein tyrosine kinases (PTKs) and protein tyrosine phosphatases (PTPases). p56lck and p59fyn have been found to associate with CD4 and TCR - CD3 respectively. The CD45 family of transmembrane PTPases has been shown to be able to regulate the activities of these receptor-associated PTKs in vitro. In man, CD45 contains five different isoforms whose distribution defines subsets of T cells having distinct activation requirements and in vitro functions. Several groups have reported a physical interaction between distinct isoforms of CD45 and CD2, CD4, and the TCR - CD3 complex. Given the potential regulatory interaction between CD45 and PTKs in CD4+ subsets expressing different CD45 isoforms, we have examined CD4 associated and TCR - CD3- associated PTK activities, associated phosphatidyl inositol (PI) kinases and substrates of tyrosine phosphorylation in CD45RA+ and CD45RA- CD4+ T cell lines derived from peripheral blood. Both subsets express CD4-associated p56lck and TCR - CD3-associated p59fyn kinases which exhibit identical in vitro phosphorylation at the Y-394 and Y-420 autophosphorylation sites respectively. Further, both subsets exhibited PI kinases activity associated with CD4-p56lck. Consistent with these observations, anti-CD3 crosslinking induced the phosphorylation of a similar spectrum of intracellular substrates in these CD45RA+ and CD45RA- CD4+ T cell lines. These observations indicate that despite the possible interaction between CD45 isoforms and CD4 or TCR - CD3, the mere expression of the CD45RA isoform does not in and of itself alter the presence of receptor-associated kinases or their intracellular targets. C1 HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115. HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DIV NEPHROL,BOSTON,MA 02115. HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115. RP ROTHSTEIN, DM (reprint author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV TUMOR IMMUNOL,44 BINNEY ST,BOSTON,MA 02115, USA. FU NCI NIH HHS [CA51887-2]; NIAMS NIH HHS [AR33713]; NIDDK NIH HHS [1KO8DK02011-01A1] NR 84 TC 17 Z9 17 U1 0 U2 0 PU OXFORD UNIV PRESS UNITED KINGDOM PI OXFORD PA WALTON ST JOURNALS DEPT, OXFORD, ENGLAND OX2 6DP SN 0953-8178 J9 INT IMMUNOL JI Int. Immunol. PD APR PY 1993 VL 5 IS 4 BP 409 EP 418 DI 10.1093/intimm/5.4.409 PG 10 WC Immunology SC Immunology GA KY320 UT WOS:A1993KY32000011 PM 8388247 ER PT J AU VIRELLA, G VIRELLA, I LEMAN, RB PRYOR, MB LOPESVIRELLA, MF AF VIRELLA, G VIRELLA, I LEMAN, RB PRYOR, MB LOPESVIRELLA, MF TI ANTI-OXIDIZED LOW-DENSITY-LIPOPROTEIN ANTIBODIES IN PATIENTS WITH CORONARY HEART-DISEASE AND NORMAL HEALTHY-VOLUNTEERS SO INTERNATIONAL JOURNAL OF CLINICAL & LABORATORY RESEARCH LA English DT Article DE ANTI-LOW-DENSITY LIPOPROTEIN ANTIBODIES; IMMUNE COMPLEXES; CORONARY HEART DISEASE; ATHEROSCLEROSIS; AUTOIMMUNITY ID FOAM CELL-FORMATION; CIRCULATING IMMUNE-COMPLEXES; VASCULAR DISEASES; AUTOANTIBODIES; PEROXIDATION; FIBROBLASTS; DEGRADATION; XANTHOMA; PLASMA; INVIVO AB We have developed a solid-phase enzyme immunoassay for anti-oxidized low-density lipoprotein antibodies. Most sera showed some degree of non-specific binding to plates coated with oxidized low-density lipoprotein and the autoantibodies to oxidized low-density lipoprotein often appeared to have a relatively low affinity. To differentiate between specific and non-specific binding each sample was tested untreated and after absorption with oxidized low-density lipoprotein. The optical densities obtained with dilutions of the absorbed sample were considered to reflect non-specific binding and were subtracted from values obtained with identical dilutions of the unabsorbed sample, to yield corrected values from which the concentrations of anti-oxidized low-density lipoprotein antibody were calculated. Similar absorptions with native low-density lipoprotein and oxidized human serum albumin failed to induce a significant reduction in binding to immobilized oxidized low-density lipoprotein proving that the antibodies measured by this assay are primarily specific for oxidized low-density lipoprotein. We studied sera from two groups of individuals: (1) 33 subjects submitted to coronary angiography and split into two subgroups depending on the degree of coronary stenosis and (2) 64 healthy individuals also split into two subgroups according to lipid levels. Anti-oxidized low-density lipoprotein antibodies were detected both in patients and healthy individuals. Higher levels were detected in patients with moderate coronary disease and hyperlipemic healthy individuals, but the differences between patients and healthy volunteers or between their respective subgroups did not reach statistical significance. Our results suggest that autoantibodies to oxidized low-density lipoprotein are relatively frequent in both symptomatic and asymptomatic individuals. The investigation of their potential role as a risk factor will require mass screening and long-term follow-up. C1 MED UNIV S CAROLINA,DEPT MED,DIV CARDIOL,CHARLESTON,SC 29425. MED UNIV S CAROLINA,DEPT MED,DIV ENDOCRINOL METAB NUTR,CHARLESTON,SC 29425. RALPH H JOHNSON DEPT VET AFFAIRS MED CTR,CHARLESTON,SC 29425. RP VIRELLA, G (reprint author), MED UNIV S CAROLINA,DEPT MICROBIOL & IMMUNOL,171 ASHLEY ST,CHARLESTON,SC 29425, USA. NR 33 TC 130 Z9 135 U1 0 U2 0 PU SPRINGER VERLAG PI NEW YORK PA 175 FIFTH AVE, NEW YORK, NY 10010 SN 0940-5437 J9 INT J CLIN LAB RES JI Int. J. Clin. Lab. Res. PD APR PY 1993 VL 23 IS 2 BP 95 EP 101 DI 10.1007/BF02592290 PG 7 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA LC695 UT WOS:A1993LC69500008 PM 8518420 ER PT J AU ROSENBLATT, KA THOMAS, DB BERRY, G MACLENNAN, R SHEARMAN, R JELIHOVSKY, T BOOTH, JC MOLINA, R MARTINEZ, L SALES, O DABANCENS, A CHEN, ZH TAO, Y HU, YW MODAN, B RON, E ALFANDARY, E CUEVAS, HR SALAZAR, SB PALET, A ONTIVEROS, P APELO, RA DELACRUZ, JR BAENS, J JAVIER, B PARDTHAISONG, T MARTIN, N THEETRANONT, C BOOSIRI, B CHUTIVONGSE, S VIRUTAMASEN, P WONGSRICHANALAI, C JIMAKORN, P KOETSAWANG, S RACHAWAT, D KOETSAWANG, A SCULLY, RE YOUNG, RH THOMAS, DB ROSENBLATT, KA NOONAN, EA HOLCK, S FARLEY, T MEIRIK, O AF ROSENBLATT, KA THOMAS, DB BERRY, G MACLENNAN, R SHEARMAN, R JELIHOVSKY, T BOOTH, JC MOLINA, R MARTINEZ, L SALES, O DABANCENS, A CHEN, ZH TAO, Y HU, YW MODAN, B RON, E ALFANDARY, E CUEVAS, HR SALAZAR, SB PALET, A ONTIVEROS, P APELO, RA DELACRUZ, JR BAENS, J JAVIER, B PARDTHAISONG, T MARTIN, N THEETRANONT, C BOOSIRI, B CHUTIVONGSE, S VIRUTAMASEN, P WONGSRICHANALAI, C JIMAKORN, P KOETSAWANG, S RACHAWAT, D KOETSAWANG, A SCULLY, RE YOUNG, RH THOMAS, DB ROSENBLATT, KA NOONAN, EA HOLCK, S FARLEY, T MEIRIK, O TI LACTATION AND THE RISK OF EPITHELIAL OVARIAN-CANCER SO INTERNATIONAL JOURNAL OF EPIDEMIOLOGY LA English DT Article ID DETERMINANTS; OVULATION; HISTORY; EVENTS AB The relationship between lactation and the development of epithelial ovarian cancer was assessed in data from seven countries that were collected for a multinational hospital-based case-control study conducted between 1979 and 1988. Three hundred and ninety-three cases of ovarian cancer were compared to 2565 controls matched on age, hospital, and year of interview. A non-significant reduction in risk with short-term lactation was observed but no further reduction in risk was seen with long-term lactation. The reduction in risk associated with months of lactation was not as great as the reduction with months of pregnancy, which may be a result of lactation being a less effective form of ovulation suppression than pregnancy. The short-term lactation that takes place in developed countries, may provide as great a reduction in risk as the long-term lactation practised in the developing countries included in this study. C1 UNIV SYDNEY,DEPT PUBL HLTH,SYDNEY,NSW 2006,AUSTRALIA. UNIV CHILE,HOSP JOSE JOAQUIM AGUIRRE,FAC MED,DEPT OBSTET & GYNECOL,SANTIAGO,CHILE. HOSP SALVADOR,MINIST HLTH,DEPT OBSTET & GYNECOL,SANTIAGO,CHILE. SHANGHAI INST PLANNED PARENTHOOD RES,SHANGHAI,PEOPLES R CHINA. CHAIM SHEBA MED CTR,DEPT CLIN EPIDEMIOL,IL-52621 TEL HASHOMER,ISRAEL. HOSP GEN MEXICO CITY,MEXICO CITY,MEXICO. UNIV PHILIPPINES,COLL MED,MANILA,PHILIPPINES. CHULALONGKORN UNIV,FAC MED,DEPT OBSTET & GYNECOL,WHO,COLLABORATING CTR RES HUMAN REPROD,BANGKOK 5,THAILAND. MAHIDOL UNIV,SIRIRAJ HOSP,FAC MED,DEPT OBSTET & GYNECOL,FAMILY PLANNING RES UNIT,BANGKOK 10700,THAILAND. MASSACHUSETTS GEN HOSP,DEPT PATHOL,BOSTON,MA 02114. FRED HUTCHINSON CANC RES CTR,DIV PUBL HLTH SCI,SEATTLE,WA 98104. WHO,CH-1211 GENEVA 27,SWITZERLAND. FU NCIPC CDC HHS [NICHD-CE-84-16] NR 21 TC 88 Z9 90 U1 0 U2 2 PU OXFORD UNIV PRESS UNITED KINGDOM PI OXFORD PA WALTON ST JOURNALS DEPT, OXFORD, ENGLAND OX2 6DP SN 0300-5771 J9 INT J EPIDEMIOL JI Int. J. Epidemiol. PD APR PY 1993 VL 22 IS 2 BP 192 EP 197 DI 10.1093/ije/22.2.192 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA LA513 UT WOS:A1993LA51300002 PM 8505173 ER PT J AU YOUNG, RH AF YOUNG, RH TI SERTOLI-LEYDIG CELL TUMORS OF THE OVARY - REVIEW WITH EMPHASIS ON HISTORICAL ASPECTS AND UNUSUAL VARIANTS SO INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY LA English DT Article; Proceedings Paper CT ROBERT MEYER MEMORIAL SYMP CY MAY 13-15, 1992 CL HUMBOLDT UNIV, CHARITE HOSP & MED SCH, BERLIN, GERMANY HO HUMBOLDT UNIV, CHARITE HOSP & MED SCH DE OVARY; SERTOLI-LEYDIG CELL TUMOR; HETEROLOGOUS ELEMENTS; RETIFORM PATTERN; BIZARRE NUCLEI; PREGNANCY-RELATED CHANGES ID PEUTZ-JEGHERS SYNDROME; SERUM ALPHA-FETOPROTEIN; CORD-STROMAL TUMORS; CLINICOPATHOLOGICAL ANALYSIS; HETEROLOGOUS ELEMENTS; RETIFORM PATTERN; ANNULAR TUBULES; DIFFERENTIATION; ANDROBLASTOMA AB Among the many contributions to gynecological pathology of Dr. Robert Meyer were his observations on Sertoli-Leydig cell tumors and the formulation of a classification of them that is the basis of the one used today. Selected variants in this category of tumors are reviewed here. Sertoli cell tumors are of interest clinically because, in contrast to other tumors in this category, they tend to be estrogenic rather than androgenic. They are important for the pathologist to be aware of, because other neoplasms of diverse types may mimic them. Heterologous Sertoli-Leydig cell tumors are noteworthy; since they may feature mucinous epithelium, carcinoid, skeletal muscle, and/or cartilage, they may present a confusing histologic picture that could result in a misdiagnosis. Similarly, the recently recognized retiform variant of Sertoli-Leydig cell tumor is apt to be misdiagnosed because its pattern of slit-like glandular spaces and papillae is often confused with tumors in the common epithelial category. These retiform lesions are also less often androgenic than are other Sertoli-Leydig cell tumors. Finally, neoplasms with bizarre nuclei and tumors that occur in pregnancy, which often have prominent intercellular edema, are briefly discussed. C1 HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115. RP YOUNG, RH (reprint author), MASSACHUSETTS GEN HOSP,JAMES HOMER WRIGHT PATHOL LABS,DEPT PATHOL,BOSTON,MA 02114, USA. NR 39 TC 21 Z9 22 U1 0 U2 1 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0277-1691 J9 INT J GYNECOL PATHOL JI Int. J. Gynecol. Pathol. PD APR PY 1993 VL 12 IS 2 BP 141 EP 147 DI 10.1097/00004347-199304000-00009 PG 7 WC Obstetrics & Gynecology; Pathology SC Obstetrics & Gynecology; Pathology GA KU815 UT WOS:A1993KU81500009 PM 8463038 ER PT J AU SCULLY, RE AF SCULLY, RE TI SMALL-CELL CARCINOMA OF HYPERCALCEMIC TYPE SO INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY LA English DT Article; Proceedings Paper CT ROBERT MEYER MEMORIAL SYMP CY MAY 13-15, 1992 CL HUMBOLDT UNIV, CHARITE HOSP & MED SCH, BERLIN, GERMANY HO HUMBOLDT UNIV, CHARITE HOSP & MED SCH DE OVARY; CARCINOMA; SMALL CELL; HYPERCALCEMIA; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY ID CLINICOPATHOLOGICAL ANALYSIS; OVARY; TUMOR; YOUNG; LUNG AB The small cell carcinoma of the ovary that is associated with paraendocrine hypercalcemia in two thirds of cases is characterized typically by poorly differentiated small cells with scanty cytoplasm, although larger cells with abundant cytoplasm are frequently observed as well, usually as a minor component of the tumor. The tumor almost always occurs in women in the second to fourth decade, usually presenting at a stage higher than stage 1A. It must be distinguished from other primary and metastatic small cell carcinomas that may involve the ovary. The tumor differs in its histologic, electron microscopic, immunohistochemical, and flow cytometric features from the pulmonary type of small cell carcinoma that may metastasize to the ovary from the lung and other organs or rarely may be primary in the ovary. The cell lineage of the small cell carcinoma remains a mystery. The tumor is highly malignant, with only a 30% survival rate in Stage 1A cases. It may be responsive to radiation therapy and combination chemotherapy, but long-term survival is rare once the tumor has spread beyond the ovary. C1 MASSACHUSETTS GEN HOSP,JAMES HOMER WRIGHT LABS,DEPT PATHOL,32 FRUIT ST,BOSTON,MA 02114. HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115. NR 24 TC 34 Z9 37 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0277-1691 J9 INT J GYNECOL PATHOL JI Int. J. Gynecol. Pathol. PD APR PY 1993 VL 12 IS 2 BP 148 EP 152 DI 10.1097/00004347-199304000-00010 PG 5 WC Obstetrics & Gynecology; Pathology SC Obstetrics & Gynecology; Pathology GA KU815 UT WOS:A1993KU81500010 PM 8385068 ER PT J AU MACKLIS, RM BERESFORD, BA LIN, JY ATCHER, RW HUMM, JL AF MACKLIS, RM BERESFORD, BA LIN, JY ATCHER, RW HUMM, JL TI MURINE HEMATOPOIETIC ABLATION BY ALPHA-PARTICLE-EMITTING RADIOPHARMACEUTICALS - A POTENTIAL PREPARATIVE REGIMEN FOR BONE-MARROW TRANSPLANTATION SO INTERNATIONAL JOURNAL OF ONCOLOGY LA English DT Article DE ALPHA-PARTICLES; RADIOBIOLOGY; BONE MARROW; HORMESIS AB Although short-lived alpha-particle-emitting radiopharmaceuticals are currently under evaluation for biologically targeted radiotherapy, very little is known about the dose-response kinetics of the hematosuppression produced by low level or transient exposure to these compounds while in the circulation. We have used hematopoietic progenitor cell colony-forming-unit assays to establish the dose-response curve for Bi-212 alpha particle radiation delivered in vitro, and have compared it to the dose-response curves for equivalent doses of Y-90 beta and Cs-137 gamma radiation. We then evaluated the dose-response effects for these radiopharmaceuticals after in vivo injection in mice. Both in vitro and in vivo, the Bi-212 was extremely hematosuppressive (50% inhibitory dose 20-30 cGy in culture) but this myelosuppression was transient at low or intermediate doses. Serum froin mice recovering from Bi-212-induced hematosuppression produced significant stimulation of naive syngeneic marrow progenitor cells, supporting the existence of a physiologic feedback mechanism that involves a poorly defined humoral factor released after radiation injury. Short-lived alpha emitters may be well suited to the development of tumor-seeking radiopharmaceuticals that can be used in the preparation of patients for autologous and allogeneic marrow transplantation. C1 ARGONNE NATL LAB,DIV BIOL,ARGONNE,IL 60439. ARGONNE NATL LAB,DIV CHEM,ARGONNE,IL 60439. RP MACKLIS, RM (reprint author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,HARVARD JOINT CTR RADIAT THERAPY,50 BINNEY ST,BOSTON,MA 02115, USA. OI Atcher, Robert/0000-0003-4656-2247 NR 16 TC 8 Z9 8 U1 0 U2 0 PU INT JOURNAL ONCOLOGY PI ATHENS PA C/O PROFESSOR D A SPANDIDOS, EDITORIAL OFFICE, 1, S MERKOURI ST, ATHENS 116 35, GREECE SN 1019-6439 J9 INT J ONCOL JI Int. J. Oncol. PD APR PY 1993 VL 2 IS 4 BP 711 EP 715 PG 5 WC Oncology SC Oncology GA KU308 UT WOS:A1993KU30800035 PM 21573615 ER PT J AU BERSON, EL AF BERSON, EL TI REMARKS ON ACCEPTANCE OF THE FRIEDENWALD AWARD SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Editorial Material RP BERSON, EL (reprint author), HARVARD UNIV,MASSACHUSETTS EYE & EAR INFIRM,SCH MED,BERMAN GUND LAB STUDY RETINAL DEGENERAT,BOSTON,MA 02114, USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD APR PY 1993 VL 34 IS 5 BP 1658 EP 1658 PG 1 WC Ophthalmology SC Ophthalmology GA KX212 UT WOS:A1993KX21200002 ER PT J AU BERSON, EL AF BERSON, EL TI RETINITIS-PIGMENTOSA - THE FRIEDENWALD LECTURE SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Review ID BOVINE RHODOPSIN GENE; SYNDROME TYPE-II; RETINAL DEGENERATION; OCULAR FINDINGS; CONE ELECTRORETINOGRAMS; TRANSVERSION MUTATION; ALPHA-TRANSDUCIN; TEMPORAL ASPECTS; BINDING PROTEIN; PHYTANIC-ACID RP BERSON, EL (reprint author), HARVARD UNIV, MASSACHUSETTS EYE & EAR INFIRM, SCH MED, BERMAN GUND LAB STUDY RETINAL DEGENERAT, BOSTON, MA 02114 USA. FU NEI NIH HHS [EY00169, EY02014] NR 129 TC 440 Z9 455 U1 1 U2 8 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD APR PY 1993 VL 34 IS 5 BP 1659 EP 1676 PG 18 WC Ophthalmology SC Ophthalmology GA KX212 UT WOS:A1993KX21200003 PM 8473105 ER PT J AU PAGE, AE ALLAN, C JASTY, M HARRIGAN, TP BRAGDON, CR HARRIS, WH AF PAGE, AE ALLAN, C JASTY, M HARRIGAN, TP BRAGDON, CR HARRIS, WH TI DETERMINATION OF LOADING PARAMETERS IN THE CANINE HIP INVIVO SO JOURNAL OF BIOMECHANICS LA English DT Article ID STRAIN-MEASUREMENTS; FORCES; REPLACEMENT; SHEEP; FEMUR; BONE AB The loading parameters in the canine hip were determined from multiple studies, involving the collection of kinematic and force plate data in vivo joint reaction force from an instrumented hip replacement prosthesis, and in vivo femoral cortical bone strain gauge data in different dogs. In the middle of the stance phase of gait the canine femur was flexed 110-degrees with respect to the pelvis and formed a 20-degrees angle relative to the floor. At this point in the gait cycle, a line passing from the superior to the inferior aspect of the pubic symphysis was parallel to the floor. The joint reaction force measurements showed that the net force vector during midstance was directed inferiorly, posteriorly, and laterally, with a peak magnitude of up to 1.65 times the body weight. A torsional moment of 1.6 N m is exerted about the femoral shaft. In vivo strain data showed that during gait peak compressive strains of -300 to -502 microstrain were produced on the medial aspect of the femoral cortex and peak tensile strains of +250 to +458 midstrain were produced on the femoral cortex. At the midstance phase of gait, principal cortical bone strains were rotated up to 29-degrees relative to the long axis of the femur, suggesting torsional loads on the femur. These data in combination provide valuable insights on the loading parameters of the canine hip which can be used in future applications of the canine as a model for evaluating mechanically based phenomena such as bone ingrowth and remodeling or hip prostheses. C1 MASSACHUSETTS GEN HOSP,HIP & IMPLANT UNIT,BOSTON,MA 02114. RP PAGE, AE (reprint author), MASSACHUSETTS GEN HOSP,ORTHOPAED BIOMECH LAB,BOSTON,MA 02181, USA. FU NIAMS NIH HHS [AR35828] NR 25 TC 49 Z9 51 U1 3 U2 6 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 0021-9290 J9 J BIOMECH JI J. Biomech. PD APR-MAY PY 1993 VL 26 IS 4-5 BP 571 EP 579 DI 10.1016/0021-9290(93)90018-A PG 9 WC Biophysics; Engineering, Biomedical SC Biophysics; Engineering GA KX576 UT WOS:A1993KX57600018 PM 8478358 ER PT J AU OCONNELL, JX ROSENTHAL, DI MANKIN, HJ GUDGER, GK DICKERSIN, GR SCHILLER, AL ROSENBERG, AE AF OCONNELL, JX ROSENTHAL, DI MANKIN, HJ GUDGER, GK DICKERSIN, GR SCHILLER, AL ROSENBERG, AE TI A UNIQUE MULTIFOCAL OSTEOBLASTOMA-LIKE TUMOR OF THE BONES OF A SINGLE LOWER-EXTREMITY - REPORT OF A CASE SO JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME LA English DT Article ID HEMANGIOENDOTHELIOMA ANGIOSARCOMA C1 HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEPT RADIOL,BOSTON,MA 02114. HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEPT ORTHOPED SURG,BOSTON,MA 02114. RP OCONNELL, JX (reprint author), HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEPT PATHOL,BOSTON,MA 02114, USA. NR 10 TC 8 Z9 8 U1 0 U2 0 PU JOURNAL BONE JOINT SURGERY INC PI NEEDHAM PA 20 PICKERING ST, NEEDHAM, MA 02192 SN 0021-9355 J9 J BONE JOINT SURG AM JI J. Bone Joint Surg.-Am. Vol. PD APR PY 1993 VL 75A IS 4 BP 597 EP 602 PG 6 WC Orthopedics; Surgery SC Orthopedics; Surgery GA KZ590 UT WOS:A1993KZ59000015 PM 8478388 ER PT J AU KIM, YH ONUNAIN, S TROUTON, T SOSASUAREZ, G LEVINE, RA GARAN, H RUSKIN, JN AF KIM, YH ONUNAIN, S TROUTON, T SOSASUAREZ, G LEVINE, RA GARAN, H RUSKIN, JN TI PSEUDO-PACEMAKER SYNDROME FOLLOWING INADVERTENT FAST PATHWAY ABLATION FOR ATRIOVENTRICULAR NODAL REENTRANT TACHYCARDIA SO JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY LA English DT Article DE ATRIOVENTRICULAR NODAL REENTRANT TACHYCARDIA; RADIOFREQUENCY ABLATION; PSEUDO-PACEMAKER SYNDROME AB Atrioventricular nodal reentrant tachycardia that is refractory to drug treatment has recently been treated with radiofrequency catheter ablation. In this case report we describe a patient with atrioventricular nodal reentrant tachycardia in whom radiofrequency ablation of slow pathway was attempted, with inadvertent damage to the fast pathway. The patient developed marked first-degree atrioventricular block associated with symptoms mimicking pacemaker syndrome. C1 MASSACHUSETTS GEN HOSP,CARDIAC UNIT,CARDIAC ARRHYTHMIA SERV,BOSTON,MA 02114. NR 0 TC 34 Z9 34 U1 0 U2 0 PU FUTURA PUBL CO PI ARMONK PA 135 BEDFORD RD, PO BOX 418, ARMONK, NY 10504-0418 SN 1045-3873 J9 J CARDIOVASC ELECTR JI J. Cardiovasc. Electrophysiol. PD APR PY 1993 VL 4 IS 2 BP 178 EP 182 DI 10.1111/j.1540-8167.1993.tb01221.x PG 5 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA KY816 UT WOS:A1993KY81600006 PM 8269289 ER PT J AU GIRARD, MT MATSUBARA, M KUBLIN, C TESSIER, MJ CINTRON, C FINI, ME AF GIRARD, MT MATSUBARA, M KUBLIN, C TESSIER, MJ CINTRON, C FINI, ME TI STROMAL FIBROBLASTS SYNTHESIZE COLLAGENASE AND STROMELYSIN DURING LONG-TERM TISSUE REMODELING SO JOURNAL OF CELL SCIENCE LA English DT Article DE COLLAGENASE; EXTRACELLULAR MATRIX; METALLOPROTEINASE; WOUND HEALING; TISSUE REMODELING, CORNEA ID RABBIT CORNEA; CELL COLLAGENASE; METALLOPROTEINASES; KERATINOCYTES; SCARS AB The process of connective tissue remodeling is an important mechanism contributing to tissue morphogenesis in development and homeostasis. Although it has long been known that remodeling tissues actively mediate collagenolysis, little is understood about the molecular mechanisms controlling this cell-regulated process. In this study, we examined the biosynthesis of collagenase and the related metalloproteinase, stromelysin, during remodeling of repair tissue deposited after mechanical injury to the rabbit cornea. Neither enzyme was synthesized by uninjured corneas; however, synthesis and secretion was detectable within one day after injury. Collagenase accumulated in its latent form while stromelysin appeared to be partially activated. Enzymes were synthesized by cells having a fibroblast phenotype. These cells were found within the stroma. New synthesis was correlated with accumulation of enzyme-specific mRNA. Highest levels of enzyme synthesis were observed in the repair tissue. However, stromal cells outside of the repairing area also synthesized both enzymes. The level of synthesis decreased in a gradient radiating from the repair tissue. Total synthetic levels in a given area of cornea were dependent on both the number of cells expressing enzyme and the rate of enzyme synthesis. Synthesis of collagenase was detected in repair tissue as long as nine months after injury. Our findings provide direct support for the hypothesis that new collagenase synthesis by cells in repair tissue is the first step in collagen degradation during long-term tissue remodeling. C1 MASSACHUSETTS GEN HOSP,MGH HARVARD CUTANEOUS BIOL RES CTR,BOSTON,MA 02129. SCHEPENS EYE RES INST,BOSTON,MA 02114. HARVARD UNIV,SCH MED,DEPT OPHTHALMOL,BOSTON,MA 02115. FU NEI NIH HHS [EY01199, EY08408] NR 47 TC 116 Z9 117 U1 1 U2 2 PU COMPANY OF BIOLOGISTS LTD PI CAMBRIDGE PA BIDDER BUILDING CAMBRIDGE COMMERCIAL PARK COWLEY RD, CAMBRIDGE, CAMBS, ENGLAND CB4 4DL SN 0021-9533 J9 J CELL SCI JI J. Cell Sci. PD APR PY 1993 VL 104 BP 1001 EP 1011 PN 4 PG 11 WC Cell Biology SC Cell Biology GA LA762 UT WOS:A1993LA76200006 PM 8314885 ER PT J AU RABENECK, L AF RABENECK, L TI DIAGNOSTIC WORK-UP STRATEGIES FOR PATIENTS WITH HIV-RELATED CHRONIC DIARRHEA - WHAT IS THE END RESULT SO JOURNAL OF CLINICAL GASTROENTEROLOGY LA English DT Article DE HIV; DIARRHEA; DIAGNOSTIC TESTS; ACQUIRED IMMUNODEFICIENCY SYNDROME ID ACQUIRED-IMMUNODEFICIENCY-SYNDROME; HOMOSEXUAL MEN; INTESTINAL INFECTIONS; SYNDROME AIDS; DISEASE; COMPLEX; TRIAL AB The intensity of diagnostic workup of patients with human immunodeficiency virus (HIV)-related chronic diarrhea is controversial. In the ideal setting in which an enteric pathogen is detected with minimal evaluation (stool tests) and in which specific treatment clears the diarrhea, eradicates the pathogen, and improves the patient's quality of life, the need for diagnostic workup is clear. However, problems frequently occur in the evaluation and treatment of patients that preclude such a straightforward approach. They are (a) failure to detect enteric pathogens; (b) detection of organisms of uncertain significance; (c) lack of effective treatment; (d) the presence of a severe coexisting illness that is the major determinant of the patient's outcome; and (e) lack of evidence that detecting enteric pathogens leads to improvement in broad patient outcomes, such as quality of life. I discuss these, problems and examine the two opposing diagnostic workup strategies-minimal and intensive evaluation-that have been advocated. My main conclusion is that both approaches fall short, and that clinicians lack the information needed to guide clinical decision making. I urge investigators to analyze the full effects of alternative diagnostic interventions on broad patient outcomes so that clinical guidelines can be developed to assist the evaluation of patients. RP RABENECK, L (reprint author), VET ADM MED CTR 111D,BAYLOR COLL MED,DEPT MED,2002 HOLCOMBE BLVD,HOUSTON,TX 77030, USA. NR 32 TC 16 Z9 17 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0192-0790 J9 J CLIN GASTROENTEROL JI J. Clin. Gastroenterol. PD APR PY 1993 VL 16 IS 3 BP 245 EP 250 DI 10.1097/00004836-199304000-00018 PG 6 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA KW992 UT WOS:A1993KW99200017 PM 8505500 ER PT J AU BASILE, JN LIEL, Y SHARY, J BELL, NH AF BASILE, JN LIEL, Y SHARY, J BELL, NH TI INCREASED CALCIUM INTAKE DOES NOT SUPPRESS CIRCULATING 1,25-DIHYDROXYVITAMIN-D IN NORMOCALCEMIC PATIENTS WITH SARCOIDOSIS SO JOURNAL OF CLINICAL INVESTIGATION LA English DT Article DE SARCOIDOSIS; CALCIUM; 1,25-DIHYDROXYVITAMIN-D; 25-HYDROXYVITAMIN-D; ANGIOTENSIN-CONVERTING ENZYME ID CULTURED ALVEOLAR MACROPHAGES; DIETARY CALCIUM; VITAMIN-D; SERUM; METABOLISM; HUMANS; ASSAY; HYPERPARATHYROIDISM; CHROMATOGRAPHY; PHOSPHATE AB Ca absorption is regulated by 1,25(OH)2D, and serum values vary inversely with Ca intake. In sarcoidosis, 1,25(OH)2D is produced by alveolar macrophages in response to gamma-interferon, and patients may develop hypercalcemia after prolonged exposure to sunlight and increased dermal production of vitamin D3. To determine if increased Ca intake suppresses serum 1,25(OH)2D in normocalcemic patients and to identify those at risk, 17 normal subjects and 11 patients were studied on a metabolic ward for two and one-half days while receiving first 400 and then 1,000 mg/d of Ca. On the low Ca intake, serum angiotensin-converting enzyme (ACE), an index of disease activity, was higher in only three of the patients than in the controls, mean serum 1,25(OH)2D was higher in the patients, and mean serum total Ca, serum Ca++, and urinary Ca were not different in the two groups. On the higher Ca intake, mean urinary Ca increased in both groups, but mean serum 1,25(OH)2D was suppressed only in the normal subjects. Thus, 1,25(OH)2D production is abnormally regulated, indicating that (a) normocalcemic patients with sarcoidosis are at risk for developing abnormal Ca metabolism, and (b) a better index of disease activity is provided by the oral Ca suppression test than by serum ACE. C1 RALPH H JOHNSON DEPT VET AFFAIRS MED CTR,109 BEE ST,CHARLESTON,SC 29401. MED UNIV S CAROLINA,DEPT MED,CHARLESTON,SC 29425. FU NCRR NIH HHS [M01 RR01070]; NIAMS NIH HHS [AR36066] NR 24 TC 26 Z9 26 U1 0 U2 0 PU ROCKEFELLER UNIV PRESS PI NEW YORK PA 1114 FIRST AVE, 4TH FL, NEW YORK, NY 10021 SN 0021-9738 J9 J CLIN INVEST JI J. Clin. Invest. PD APR PY 1993 VL 91 IS 4 BP 1396 EP 1398 DI 10.1172/JCI116342 PG 3 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA KY052 UT WOS:A1993KY05200021 PM 8386185 ER PT J AU HARTSHORN, KL SASTRY, K WHITE, MR ANDERS, EM SUPER, M EZEKOWITZ, RA TAUBER, AI AF HARTSHORN, KL SASTRY, K WHITE, MR ANDERS, EM SUPER, M EZEKOWITZ, RA TAUBER, AI TI HUMAN MANNOSE-BINDING PROTEIN FUNCTIONS AS AN OPSONIN FOR INFLUENZA-A VIRUSES SO JOURNAL OF CLINICAL INVESTIGATION LA English DT Article DE NEUTROPHILS; HEMAGGLUTINATION; RECOMBINANT PROTEINS; MANNOSE-BINDING PROTEIN; INFLUENZA-A VIRUS ID ACUTE-PHASE REACTANT; HUMAN NEUTROPHIL; HEMAGGLUTININ; LECTINS; IMMUNITY; SUBTYPE; MODEL AB Influenza A viruses (IAVs) cause substantial morbidity and mortality in yearly epidemics, which result from the ability of the virus to alter the antigenicity of its envelope proteins. Despite the rapid replication of this virus and its ability to infect a wide variety of cell types, viremia is rare and the infection is generally limited to the upper respiratory tract. The preimmune host defense response against IAV is generally, therefore, successful. We have previously provided (and summarized) evidence that neutrophils contribute to defense against IAV, although neutrophil dysfunction and local tissue damage may be less salutory byproducts of this response. Here we provide evidence that the serum lectin mannose-binding protein directly inhibits hemagglutinin activity and infectivity of several strains of IAV. In addition mannose-binding protein acts as an opsonin, enhancing neutrophil reactivity against IAV. Opsonization of IAV by mannose-binding protein also protects the neutrophil from IAV-induced dysfunction. These effects are observed with physiologically relevant concentrations of mannose-binding protein. Two different allelic forms of recombinant mannose-binding protein are found to have similar effects. We believe, on the basis of these data, that mannose-binding protein alone and in conjunction with phagocytic cells is an important constituent of natural immunity (i.e., preimmune defense) against IAV. C1 BOSTON UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02118. BOSTON CITY HOSP,DEPT MED,BOSTON,MA 02118. HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115. HARVARD UNIV,CHILDRENS HOSP,DEPT PEDIAT,DIV HEMATOL ONCOL,BOSTON,MA 02115. HARVARD UNIV,CHILDRENS HOSP,DEPT PEDIAT,DIV INFECT DIS,BOSTON,MA 02115. UNIV MELBOURNE,DEPT MICROBIOL,PARKVILLE,VIC 3052,AUSTRALIA. RP HARTSHORN, KL (reprint author), BOSTON UNIV,SCH MED,DEPT MED,80 E CONCORD ST,BOSTON,MA 02118, USA. FU NHLBI NIH HHS [HL-335565-08]; NIAID NIH HHS [AI-29550-03] NR 29 TC 155 Z9 158 U1 0 U2 1 PU ROCKEFELLER UNIV PRESS PI NEW YORK PA 1114 FIRST AVE, 4TH FL, NEW YORK, NY 10021 SN 0021-9738 J9 J CLIN INVEST JI J. Clin. Invest. PD APR PY 1993 VL 91 IS 4 BP 1414 EP 1420 DI 10.1172/JCI116345 PG 7 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA KY052 UT WOS:A1993KY05200024 PM 7682571 ER PT J AU BAJORIN, DF SAROSDY, MF PFISTER, DG MAZUMDAR, M MOTZER, RJ SCHER, HI GELLER, NL FAIR, WR HERR, H SOGANI, P SHEINFELD, J RUSSO, P VLAMIS, V CAREY, R VOGELZANG, NJ CRAWFORD, ED BOSL, GJ AF BAJORIN, DF SAROSDY, MF PFISTER, DG MAZUMDAR, M MOTZER, RJ SCHER, HI GELLER, NL FAIR, WR HERR, H SOGANI, P SHEINFELD, J RUSSO, P VLAMIS, V CAREY, R VOGELZANG, NJ CRAWFORD, ED BOSL, GJ TI RANDOMIZED TRIAL OF ETOPOSIDE AND CISPLATIN VERSUS ETOPOSIDE AND CARBOPLATIN IN PATIENTS WITH GOOD-RISK GERM-CELL TUMORS - A MULTIINSTITUTIONAL STUDY SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Article ID TESTICULAR CANCER; COMBINATION CHEMOTHERAPY; RAYNAUDS-PHENOMENON; COMPLETE RESPONSE; CLINICAL-TRIALS; POOR-RISK; BLEOMYCIN; VINBLASTINE; TOXICITY; SEMINOMA C1 SW ONCOL GRP,SAN ANTONIO,TX. MEM SLOAN KETTERING CANC CTR,DEPT SURG,UROL SERV,NEW YORK,NY 10021. CORNELL UNIV,MED CTR,COLL MED,DEPT BIOSTAT & EPIDEMIOL,NEW YORK,NY 10021. CORNELL UNIV,MED CTR,COLL MED,DEPT MED,NEW YORK,NY 10021. MASSACHUSETTS GEN HOSP,DEPT MED,BOSTON,MA 02114. RP BAJORIN, DF (reprint author), MEM SLOAN KETTERING CANC CTR,DEPT MED,DIV SOLID TUMOR ONCOL,GENITOURINARY ONCOL SERV,NEW YORK,NY 10021, USA. FU NCI NIH HHS [CA-05826, CM-57332, CM-07337] NR 35 TC 246 Z9 247 U1 0 U2 2 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD APR PY 1993 VL 11 IS 4 BP 598 EP 606 PG 9 WC Oncology SC Oncology GA KV515 UT WOS:A1993KV51500003 PM 8386751 ER PT J AU ZERBINI, C GELBER, RD WEINBERG, D SALLAN, SE BARNES, P KUPSKY, W SCOTT, RM TARBELL, NJ AF ZERBINI, C GELBER, RD WEINBERG, D SALLAN, SE BARNES, P KUPSKY, W SCOTT, RM TARBELL, NJ TI PROGNOSTIC FACTORS IN MEDULLOBLASTOMA, INCLUDING DNA PLOIDY SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Article ID FLOW-CYTOMETRY; RADIATION-THERAPY; IMAGE-ANALYSIS; CHILDHOOD; PATTERNS; SURVIVAL; CHILDREN; ANEUPLOIDY; FAILURE; TUMORS C1 CHILDRENS HOSP MED CTR,DEPT RADIAT ONCOL,300 LONGWOOD AVE,BOSTON,MA 02115. JOINT CTR RADIAT THERAPY,BOSTON,MA. CHILDRENS HOSP MED CTR,DEPT PATHOL,BOSTON,MA 02115. CHILDRENS HOSP MED CTR,DEPT SURG,BOSTON,MA 02115. CHILDRENS HOSP MED CTR,DEPT RADIOL,BOSTON,MA 02115. HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV BIOSTAT,BOSTON,MA 02115. HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DEPT PEDIAT,BOSTON,MA 02115. BRIGHAM & WOMENS HOSP,CTR BRAIN TUMOR,BOSTON,MA 02115. BRIGHAM & WOMENS HOSP,DEPT PATHOL,BOSTON,MA 02115. HARVARD UNIV,SCH PUBL HLTH,DEPT BIOSTAT,BOSTON,MA 02115. HARVARD UNIV,SCH MED,BOSTON,MA 02115. RI Zerbini, Maria Claudia/D-1586-2012 OI Zerbini, Maria Claudia/0000-0002-7408-9816 FU NCI NIH HHS [CA 06516] NR 32 TC 60 Z9 60 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD APR PY 1993 VL 11 IS 4 BP 616 EP 622 PG 7 WC Oncology SC Oncology GA KV515 UT WOS:A1993KV51500005 PM 8478656 ER PT J AU GROSSBARD, ML LAMBERT, JM GOLDMACHER, VS SPECTOR, NL KINSELLA, J ELISEO, L CORAL, F TAYLOR, JA BLATTLER, WA EPSTEIN, CL NADLER, LM AF GROSSBARD, ML LAMBERT, JM GOLDMACHER, VS SPECTOR, NL KINSELLA, J ELISEO, L CORAL, F TAYLOR, JA BLATTLER, WA EPSTEIN, CL NADLER, LM TI ANTI-B4-BLOCKED RICIN - A PHASE-I TRIAL OF 7-DAY CONTINUOUS INFUSION IN PATIENTS WITH B-CELL NEOPLASMS SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Article ID A-CHAIN IMMUNOTOXIN; ANTIBODY-RICIN; MECHANISMS; LYMPHOMAS C1 IMMUNOGEN INC,CAMBRIDGE,MA. HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115. RP GROSSBARD, ML (reprint author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV TUMOR IMMUNOL,44 BINNEY ST,BOSTON,MA 02115, USA. OI Grossbard, Michael/0000-0002-3919-3028 FU NCI NIH HHS [1K12CA01730, CA34183, CA55207] NR 23 TC 150 Z9 152 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD APR PY 1993 VL 11 IS 4 BP 726 EP 737 PG 12 WC Oncology SC Oncology GA KV515 UT WOS:A1993KV51500019 PM 7683045 ER PT J AU SHIVDASANI, RA HESS, JL SKARIN, AT PINKUS, GS AF SHIVDASANI, RA HESS, JL SKARIN, AT PINKUS, GS TI INTERMEDIATE LYMPHOCYTIC LYMPHOMA - CLINICAL AND PATHOLOGICAL FEATURES OF A RECENTLY CHARACTERIZED SUBTYPE OF NON-HODGKINS-LYMPHOMA SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Review ID MANTLE-ZONE LYMPHOMA; SINGLE-AGENT CHEMOTHERAPY; CLEAVED CELL LYMPHOMA; LOW-GRADE LYMPHOMAS; B-CELL; MALIGNANT-LYMPHOMA; CENTROCYTIC LYMPHOMA; CHROMOSOMAL-ABNORMALITIES; GASTROINTESTINAL-TRACT; CYTOGENETIC ANALYSIS C1 BRIGHAM & WOMENS HOSP,DEPT PATHOL,BOSTON,MA 02115. HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115. HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115. RP SHIVDASANI, RA (reprint author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV MED ONCOL,BOSTON,MA 02115, USA. NR 75 TC 88 Z9 88 U1 0 U2 1 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 SN 0732-183X J9 J CLIN ONCOL JI J. Clin. Oncol. PD APR PY 1993 VL 11 IS 4 BP 802 EP 811 PG 10 WC Oncology SC Oncology GA KV515 UT WOS:A1993KV51500028 PM 8478674 ER PT J AU SICHEL, DA COHEN, LS DIMMOCK, JA ROSENBAUM, JF AF SICHEL, DA COHEN, LS DIMMOCK, JA ROSENBAUM, JF TI POSTPARTUM OBSESSIVE-COMPULSIVE DISORDER - A CASE SERIES SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article ID RAT-BRAIN; DEPRESSION; PREGNANCY AB Background: The puerperium has typically been a period of risk for the development of psychiatric illness. Although postpartum depressive illness has been discussed extensively in the literature, obsessive compulsive disorder during pregnancy and puerperium has received little attention . Method: Fifteen women with new-onset obsessive compulsive symptoms during the puerperium were retrospectively evaluated by chart review; all met DSM-III-R criteria for obsessive compulsive disorder. Distinctive features of their clinical presentation, pharmacotherapy received. and status at 1-year follow-up were recorded. Results: Patients were noted to have a characteristic constellation of symptoms comprised of disabling intrusive obsessional thoughts to harm their babies. Obsessive rituals were not observed in any of the patients described. Patients frequently developed secondary depression and appeared to be exquisitely responsive to serotonin selective reuptake inhibitors. Conclusion: The puerperium may be a period of risk for development of new-onset obsessive compulsive disorder. Clinicians caring for puerperal women need to be aware of the impact of these symptoms on maternal and fetal well-being. RP SICHEL, DA (reprint author), MASSACHUSETTS GEN HOSP,DEPT PSYCHIAT,CLIN PSYCHOPHARMACOL UNIT,BOSTON,MA 02114, USA. NR 25 TC 89 Z9 92 U1 3 U2 7 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 240008, MEMPHIS, TN 38124 SN 0160-6689 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PD APR PY 1993 VL 54 IS 4 BP 156 EP 159 PG 4 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA LC105 UT WOS:A1993LC10500005 PM 8486594 ER PT J AU BRUIJN, JA BERWICK, M MIHM, MC BARNHILL, RL AF BRUIJN, JA BERWICK, M MIHM, MC BARNHILL, RL TI COMMON ACQUIRED MELANOCYTIC NEVI, DYSPLASTIC MELANOCYTIC NEVI AND MALIGNANT MELANOMAS - AN IMAGE-ANALYSIS CYTOMETRIC STUDY SO JOURNAL OF CUTANEOUS PATHOLOGY LA English DT Article AB We used computerized image analysis cytometry to analyze 10 melanocytic lesions from each of the following categories: common acquired nevi, melanocytic nevi with architectural features of dysplasia, dysplastic melanocytic nevi (DMN) with slight atypia, DMN with moderate atypia, DMN with severe atypia, and superficial spreading melanomas. The nuclei of at least 50 consecutive nevomelanocytes in the most atypical zones were digitized at X1000 under oil immersion, without knowledge of diagnosis by one observer. Grading of atypia was based on current practices as described in the literature, The results showed significant differences (p < 0.05) in nuclear area and standard deviation of nuclear area between melanoma and DMN with severe atypia, and between DMN with severe atypia and all other categories of nevi. There were no differences among any lesions with respect to nuclear shape. No differences in nuclear area were found among DMN with moderate, or slight atypia, nevi with features of dysplasia, and typical nevi. These results show for the first time objective distinction of low-grade (slight-moderate atypia), and high-grade or severe atypia in pre-malignant nevomelanocytic lesions of the skin. C1 LEIDEN UNIV,DEPT PATHOL,2300 RA LEIDEN,NETHERLANDS. YALE UNIV,SCH MED,DEPT EPIDEMIOL & PUBL HLTH,NEW HAVEN,CT 06510. BRIGHAM & WOMENS HOSP,DIV DERMATOPATHOL,BOSTON,MA 02115. MASSACHUSETTS GEN HOSP,BOSTON,MA 02114. HARVARD UNIV,SCH MED,BOSTON,MA 02115. RI Berwick, Marianne/E-9608-2010; OI Berwick, Marianne/0000-0001-5062-2180 NR 12 TC 13 Z9 13 U1 0 U2 1 PU MUNKSGAARD INT PUBL LTD PI COPENHAGEN PA 35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK SN 0303-6987 J9 J CUTAN PATHOL JI J. Cutan. Pathol. PD APR PY 1993 VL 20 IS 2 BP 121 EP 125 DI 10.1111/j.1600-0560.1993.tb00227.x PG 5 WC Dermatology; Pathology SC Dermatology; Pathology GA LB657 UT WOS:A1993LB65700004 PM 8320355 ER PT J AU KANG, SW BARNHILL, RL MIHM, MC SOBER, AJ AF KANG, SW BARNHILL, RL MIHM, MC SOBER, AJ TI HISTOLOGIC REGRESSION IN MALIGNANT-MELANOMA - AN INTEROBSERVER CONCORDANCE STUDY SO JOURNAL OF CUTANEOUS PATHOLOGY LA English DT Article ID PROGNOSTIC IMPORTANCE; DIAGNOSIS; LESION AB Histologic evidence for regression as a prognostic indicator in melanoma has shown conflicting results. To assess if melanoma regression is a consistently identifiable histologic feature, an interobserver concordance study was undertaken. Fifty histologic slides of melanoma with Breslow thickness of 1 mm or less were non-randomly selected from the Massachusetts General Hospital Melanoma Registry. The selection was in favor of those with regression present in 44 of 50 slides (88%). Two dermatopathologists working independently evaluated a 2 mm wide bracketed area in each tissue section and then the remainder of the non-bracketed tissue section for regression. Before and after each slide review, the evaluators were required to read criteria for early, intermediate, and late regression explicitly outlined. The overall concordance rate for the presence and absence of regression was 96% (48/50) in the bracketed area and 90% for the outside area. When the group with regression was subdivided into three stages, interobserver agreement fell to 86% for the bracketed, and 66% for the outside area. In at least 30% of cases where regression was detected in the bracketed area, both reviewers observed two or more stages of regression in the remainder of tissue section. Therefore, subdividing the process is impractical and unrealistic. Consistent histologic identification of regression in melanoma requires a simple and systematic approach which should be applied to future studies that include melanoma regression as a prognostic factor. C1 HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEPT DERMATOL,BOSTON,MA 02114. HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEPT PATHOL,BOSTON,MA 02114. FU NIAMS NIH HHS [5T 32 AR07098-16] NR 10 TC 44 Z9 45 U1 0 U2 0 PU MUNKSGAARD INT PUBL LTD PI COPENHAGEN PA 35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK SN 0303-6987 J9 J CUTAN PATHOL JI J. Cutan. Pathol. PD APR PY 1993 VL 20 IS 2 BP 126 EP 129 DI 10.1111/j.1600-0560.1993.tb00228.x PG 4 WC Dermatology; Pathology SC Dermatology; Pathology GA LB657 UT WOS:A1993LB65700005 PM 8320356 ER PT J AU DOVER, JS KILMER, SL ANDERSON, RR AF DOVER, JS KILMER, SL ANDERSON, RR TI WHATS NEW IN CUTANEOUS LASER-SURGERY SO JOURNAL OF DERMATOLOGIC SURGERY AND ONCOLOGY LA English DT Article ID SWITCHED RUBY-LASER; PORT-WINE STAINS; ARGON-LASER; SELECTIVE PHOTOTHERMOLYSIS; EXPERIENCE; THERAPY; TATTOOS; PULSES C1 HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEPT DERMATOL,BOSTON,MA 02114. RP DOVER, JS (reprint author), NEW ENGLAND DEACONESS HOSP,DEPT DERMATOL,110 FRANCIS ST,BOSTON,MA 02215, USA. NR 23 TC 6 Z9 6 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 SN 0148-0812 J9 J DERMATOL SURG ONC PD APR PY 1993 VL 19 IS 4 BP 295 EP 298 PG 4 WC Oncology; Dermatology; Surgery SC Oncology; Dermatology; Surgery GA KZ689 UT WOS:A1993KZ68900002 PM 8478468 ER PT J AU KILMER, SL ANDERSON, RR AF KILMER, SL ANDERSON, RR TI CLINICAL USE OF THE Q-SWITCHED RUBY AND THE Q-SWITCHED NDYAG (1064 NM AND 532 NM) LASERS FOR TREATMENT OF TATTOOS SO JOURNAL OF DERMATOLOGIC SURGERY AND ONCOLOGY LA English DT Article ID CARBON-DIOXIDE LASER; SELECTIVE PHOTOTHERMOLYSIS; DECORATIVE TATTOOS; REMOVAL; CO2-LASER; PULSES AB BACKGROUND. The desire to remove tattoos has probably been around as long as their existence. Recent technological advances in lasers have finally made it possible to remove tattoos without leaving an equally undesirable scar. OBJECTIVE. The purpose of this article is to review the use of the Q-switched ruby (694 nm) and the Q-switched Nd:YAG (532 and 1064 nm) lasers for effective removal of tattoo ink, with cosmetically appealing results. RESULTS. The Q-switched ruby laser (694 nm) effectively removes blue-black and green ink, may treat other colors less efficiently, and is frequently associated with transient pigmentary changes, including rare depigmentation. The Q-switched Nd:YAG laser at 1064 nm quickly removes black ink, as well as other colors less efficiently; pigmentary changes are much less frequent, correlating with its lower absorption by melanin. The 532-nm wavelength treats red ink effectively, but also leads to temporary hypopigmentation. Transient textural changes may be noted at all three wavelengths discussed, but scarring is rare. CONCLUSIONS. Q-switched lasers can remove tattoos without residual scarring. Efficacy of ink removal is dependent on the wavelength used for the targeted pigment. RP KILMER, SL (reprint author), HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEPT DERMATOL,WELLMAN LABS PHOTOMED,50 BLOSSOM ST,BOSTON,MA 02114, USA. NR 27 TC 128 Z9 131 U1 0 U2 11 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 SN 0148-0812 J9 J DERMATOL SURG ONC PD APR PY 1993 VL 19 IS 4 BP 330 EP 338 PG 9 WC Oncology; Dermatology; Surgery SC Oncology; Dermatology; Surgery GA KZ689 UT WOS:A1993KZ68900006 PM 8478472 ER PT J AU FAUST, EA SAFFRAN, DC TOKSOZ, D WILLIAMS, DA WITTE, ON AF FAUST, EA SAFFRAN, DC TOKSOZ, D WILLIAMS, DA WITTE, ON TI DISTINCTIVE GROWTH REQUIREMENTS AND GENE-EXPRESSION PATTERNS DISTINGUISH PROGENITOR B-CELLS FROM PRE-B-CELLS SO JOURNAL OF EXPERIMENTAL MEDICINE LA English DT Article ID BONE-MARROW; RESTRICTED EXPRESSION; MURINE INTERLEUKIN-7; V(D)J RECOMBINATION; TYROSINE KINASE; LEUKEMIA-VIRUS; DIFFERENTIATION; PRECURSORS; INVITRO; LINEAGE AB Long-term bone marrow cultures have been useful in determining gene expression patterns in pre-B cells and in the identification of cytokines such as interleukin 7 (IL-7). We have developed a culture system to selectively grow populations of B lineage restricted progenitors (pro-B cells) from murine bone marrow. Pro-B cells do not grow in response to IL-7, Steel locus factor (SLF), or a combination of the two. c-kit, the SLF receptor, and the IL-7 receptor are both expressed by pro-B cells, indicating that the lack of response is not simply due to the absence of receptors. Furthermore, SLF is not necessary for the growth of pro-B cells since they could be expanded on a stromal line derived from Steel mice that produces no SLF. IL-7 responsiveness in pre-B cells is associated with an increase in n-myc expression and is correlated with immunoglobulin (Ig) gene rearrangements. Although members of the ets family of transcription factors and the Pim-1 kinase are expressed by pro-B cells, n-myc is not expressed. Pro-B cells maintain Ig genes in the germline configuration, which is correlated with a low level of recombination activating genes 1 and 2 (Rag-1 and 2) mRNA expression, but high expression of sterile mu and terminal deoxynucleotidyl transferase. Pro-B cells are unable to grow separated from the stromal layer by a porous membrane, indicating that stromal contact is required for growth. These results suggest that pro-B cells are dependent on alternative growth signals derived from bone marrow stroma and can be distinguished from pre-B cells by specific patterns of gene expression. C1 UNIV CALIF LOS ANGELES,HOWARD HUGHES MED INST,5-748 MACDONALD BLDG,10833 LE CONTE AVE,LOS ANGELES,CA 90024. UNIV CALIF LOS ANGELES,DEPT MICROBIOL & MOLEC GENET,LOS ANGELES,CA 90024. CHILDRENS HOSP MED CTR,HOWARD HUGHES MED INST,BOSTON,MA 02115. HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115. INDIANA UNIV,SCH MED,HERMAN B WELLS CTR PEDIAT RES,HOWARD HUGHES MED INST,INDIANAPOLIS,IN 46202. FU NIAID NIH HHS [AI-076126] NR 59 TC 63 Z9 63 U1 0 U2 1 PU ROCKEFELLER UNIV PRESS PI NEW YORK PA 1114 FIRST AVE, 4TH FL, NEW YORK, NY 10021 SN 0022-1007 J9 J EXP MED JI J. Exp. Med. PD APR 1 PY 1993 VL 177 IS 4 BP 915 EP 923 DI 10.1084/jem.177.4.915 PG 9 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA KU080 UT WOS:A1993KU08000005 PM 7681470 ER PT J AU RODEWALD, HR AWAD, K MOINGEON, P DADAMIO, L RABINOWITZ, D SHINKAI, Y ALT, FW REINHERZ, EL AF RODEWALD, HR AWAD, K MOINGEON, P DADAMIO, L RABINOWITZ, D SHINKAI, Y ALT, FW REINHERZ, EL TI FC-GAMMA-RII/III AND CD2 EXPRESSION MARK DISTINCT SUBPOPULATIONS OF IMMATURE CD4-CD8-MURINE THYMOCYTES - INVIVO DEVELOPMENTAL KINETICS AND T-CELL RECEPTOR BETA-CHAIN REARRANGEMENT STATUS SO JOURNAL OF EXPERIMENTAL MEDICINE LA English DT Article ID NATURAL-KILLER-CELLS; MONOCLONAL-ANTIBODIES; B-CELLS; INTERLEUKIN-2 RECEPTOR; V(D)J RECOMBINATION; MOLECULAR-GENETICS; ANTIGEN RECEPTOR; TRANSGENIC MICE; PRECURSOR CELLS; MURINE CD2 AB We have recently identified a dominant wave of CD4-CD8- (double-negative [DN]) thymocytes in early murine fetal development that express low affinity Fcgamma receptors (FcgammaRII/III) and contain precursors for Tialpha/beta lineage T cells. Here we show that FcgammaRII/III is expressed in very immature CD4low single-positive (SP) thymocytes and that FcgammaRII/III expression is downregulated within the DN subpopulation and before the CD3-CD8low SP stage in T cell receptor (TCR)-alpha/beta lineage-committed thymocytes. DN FcgammaRII/III+ thymocytes also contain a small fraction of TCR-gamma/delta lineage cells in addition to TCR-alpha/beta progenitors. Fetal day 15.5 DN TCR-alpha/beta lineage progenitors can be subdivided into three major subpopulations as characterized by cell surface expression of FcgammaRII/III vs. CD2 (FcgammaRII/III+CD2-, FcgammaRII/III+CD2+, FcgammaRII/III-CD2+). Phenotypic analysis during fetal development as well as adoptive transfer of isolated fetal thymocyte subpopulations derived from C57Bl/6 (Ly5.1) mice into normal, nonirradiated Ly5.2 congenic recipient mice identifies one early differentiation sequence (FcgammaRII/III+CD2- --> FcgammaRII/III+CD2+ --> FcgammaRII/III-CD2+) that precedes the entry of DN thymocytes into the CD4+CD8+ double-positive (DP) TCR(low/-) stage. Unseparated day 15.5 fetal thymocytes develop into DP thymocytes within 2.5 d and remain at the DP stage for >48 h before being selected into either CD4+ or CD8+ SP thymocytes. In contrast, FcgammaRII/III+CD2- DN thymocytes follow this same developmental pathway but are delayed by approximately 24 h before entering the DP compartment, while FcgammaRII/III-CD2+ display accelerated development by approximately 24 h compared with total day 15.5 thymocytes. FCgammaRII/III-CD2+ are also more developmentally advanced than FcgammaRII/III+CD2- fetal thymocytes with respect to their TCR beta chain V(D)J rearrangement. At day 15.5 in gestation, beta chain V(D)J rearrangement is mostly, if not entirely, restricted to the FcgammaRII/III-CD2+ subset of DN fetal thymocytes. Consistent with this analysis in fetal thymocytes, >90% of adult thymocytes derived from mice carrying a disrupting mutation at the recombination-activating gene 2 locus (RAG-2-/-) on both alleles are developmentally arrested at the DN CD2- stage. In addition, there is a fivefold increase in the relative percentage of thymocytes expressing FcgammaRII/III in TCR and immunoglobulin gene rearrangement-incompetent homozygous RAG-2-/- mice (15% FcgammaRII/III+) versus rearrangement-competent heterozygous RAG-2+/- mice (<3% FcgammaRII/III+). Thus, FcgammaRII/III expression defines an early DN stage preceding V(beta)(D(beta))J(beta) rearrangement, which in turn is followed by surface expression of CD2. Loss of FcgammaRII/III and acquisition of CD2 expression characterize a late DN stage immediately before the conversion into DP thymocytes. C1 HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115. HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115. HARVARD UNIV,SCH PUBL HLTH,DEPT BIOSTAT,BOSTON,MA 02115. CHILDRENS HOSP MED CTR,HOWARD HUGHES MED INST,BOSTON,MA 02115. RP RODEWALD, HR (reprint author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,IMMUNOBIOL LAB,44 BINNEY ST,BOSTON,MA 02115, USA. RI Shinkai, Yoichi/N-3909-2014 OI Shinkai, Yoichi/0000-0002-6051-2484 FU NIAID NIH HHS [AI-21226, AI-19807, AI-20047] NR 66 TC 86 Z9 86 U1 1 U2 4 PU ROCKEFELLER UNIV PRESS PI NEW YORK PA 1114 FIRST AVE, 4TH FL, NEW YORK, NY 10021 SN 0022-1007 J9 J EXP MED JI J. Exp. Med. PD APR 1 PY 1993 VL 177 IS 4 BP 1079 EP 1092 DI 10.1084/jem.177.4.1079 PG 14 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA KU080 UT WOS:A1993KU08000021 PM 8096236 ER PT J AU DEFOUGEROLLES, AR KLICKSTEIN, LB SPRINGER, TA AF DEFOUGEROLLES, AR KLICKSTEIN, LB SPRINGER, TA TI CLONING AND EXPRESSION OF INTERCELLULAR-ADHESION MOLECULE-3 REVEALS STRONG HOMOLOGY TO OTHER IMMUNOGLOBULIN FAMILY COUNTER-RECEPTORS FOR LYMPHOCYTE FUNCTION-ASSOCIATED ANTIGEN-1 SO JOURNAL OF EXPERIMENTAL MEDICINE LA English DT Note ID AMINO-ACID-SEQUENCE; ICAM-1; LFA-1; PROTEIN; ACTIVATION; DISTINCT; BINDING; SYSTEM; CDNA; GENE AB Based on protein sequence, we have isolated a cDNA for intercellular adhesion molecule 3 (ICAM-3), the most recently defined counter-receptor for lymphocyte function-associated antigen 1 (LFA-1). Expression of the cDNA yields a product that reacts with monoclonal antibody to ICAM-3 and functions as a ligand for LFA-1. The deduced 518-amino acid sequence of the predicted mature. protein defines a highly glycosylated type I integral membrane protein with five immunoglobulin (Ig)-like domains. The five Ig-like domains of ICAM-3 are highly homologous with those of human ICAM-1 (52% identity) and human ICAM-2 (37% identity). C1 CTR BLOOD RES,200 LONGWOOD AVE,BOSTON,MA 02115. HARVARD UNIV,SCH MED,DEPT PATHOL,COMM IMMUNOL,BOSTON,MA 02115. FU NCI NIH HHS [CA-31798] NR 29 TC 105 Z9 107 U1 0 U2 0 PU ROCKEFELLER UNIV PRESS PI NEW YORK PA 1114 FIRST AVE, 4TH FL, NEW YORK, NY 10021 SN 0022-1007 J9 J EXP MED JI J. Exp. Med. PD APR 1 PY 1993 VL 177 IS 4 BP 1187 EP 1192 DI 10.1084/jem.177.4.1187 PG 6 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA KU080 UT WOS:A1993KU08000032 PM 8459213 ER PT J AU DUTZ, JP FRUMAN, DA BURAKOFF, SJ BIERER, BE AF DUTZ, JP FRUMAN, DA BURAKOFF, SJ BIERER, BE TI A ROLE FOR CALCINEURIN IN DEGRANULATION OF MURINE CYTOTOXIC T-LYMPHOCYTES SO JOURNAL OF IMMUNOLOGY LA English DT Article ID INDUCED CELL-DEATH; CYCLOSPORINE-A; SERINE ESTERASE; ACTIVATION; REQUIREMENTS; IMMUNOPHILIN; FRAGMENTATION; TRANSCRIPTION; HYBRIDOMAS; EXOCYTOSIS AB The immunosuppressive drugs cyclosporin A (CsA) and FK506 bind to distinct families of intracellular proteins, cyclophilins, and FK506 binding proteins (FKBP) respectively, termed immunophilins. Immunosuppressant-immunophilin complexes bind to and inhibit the activity of calcineurin, a calcium-dependent serine/threonine phosphatase. CsA is known to inhibit degranulation in CTL as assessed by N benzyloxylcarbonyl-L-lysine thiobenzyl ester-esterase release assays. We have investigated whether calcineurin phosphatase activity is involved in this degranulation. Both CsA and FK506 are shown to inhibit N benzyloxylcarbonyl-L-lysine thiobenzyl ester-esterase release in murine CTL clones induced either by cognate target or by PMA and the calcium ionophore A23187. Inhibition is concentration dependent and is observed at drug concentrations that specifically inhibit cellular calcineurin. The FK506-binding immunophilin FKBP12, as well as calcineurin, are shown to be present in these cells by immunoblotting analysis. Rapamycin, a macrolide antibiotic thought to compete with FK506 for binding to common FKBP receptor sites, antagonizes the effects of FK506 on both degranulation and calcineurin activity. Neither the degranulation nor the effect of the immunosuppressants is affected by the protein synthesis inhibitor cycloheximide. These observations suggest a role for calcineurin in CTL degranulation. Thus, in addition to its previously described role in lymphokine gene activation, calcineurin also appears to be involved in T cell activation processes which do not require protein synthesis. C1 HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV PEDIAT ONCOL,44 BINNEY ST,BOSTON,MA 02115. MIT,CTR CANC RES,CAMBRIDGE,MA 02139. BRIGHAM & WOMENS HOSP,DIV HEMATOL ONCOL,BOSTON,MA 02115. HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02115. HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115. FU NCI NIH HHS [P01-CA 39542, R35-CA 42504, CA 14051] NR 37 TC 50 Z9 50 U1 0 U2 1 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 SN 0022-1767 J9 J IMMUNOL JI J. Immunol. PD APR 1 PY 1993 VL 150 IS 7 BP 2591 EP 2598 PG 8 WC Immunology SC Immunology GA KT805 UT WOS:A1993KT80500004 PM 7681074 ER PT J AU HAHN, WC BURAKOFF, SJ BIERER, BE AF HAHN, WC BURAKOFF, SJ BIERER, BE TI SIGNAL TRANSDUCTION PATHWAYS INVOLVED IN T-CELL RECEPTOR-INDUCED REGULATION OF CD2 AVIDITY FOR CD58 SO JOURNAL OF IMMUNOLOGY LA English DT Article ID FUNCTION-ASSOCIATED ANTIGEN-3; HUMAN LYMPHOCYTES-T; CYTOPLASMIC FREE CALCIUM; PROTEIN-TYROSINE KINASE; PHOSPHOLIPASE C-GAMMA-1; SURFACE MOLECULES; INTERLEUKIN-2 PRODUCTION; INOSITOL PHOSPHATES; ALTERNATIVE PATHWAY; ADHESION PATHWAYS AB Through physiologic interactions with its ligands CD58 (lymphocyte function-associated Ag-3, LFA-3) and CD59, the T cell glycoprotein CD2 plays a role in T cell signaling and promotes lymphocyte adhesion. We have recently demonstrated that the interaction of CD2 with CD58 is dynamic: TCR stimulation or treatment with the phorbol ester PMA rapidly up-regulates CD2 ligand avidity, and this regulation requires the carboxyl-terminal asparagine residue of the CD2 cytoplasmic domain. Here we have analyzed the regulation of CD2 avidity for CD58, as assessed by the binding of CD2+ cells to purified CD58 and by the formation of rosettes between CD2+ cells and SRBC. In murine T cell hybridomas transfected with human CD2, we show that, unlike CD2-mediated IL-2 production, cell surface expression of the TCR-CD3 structure is not required for up-regulation of CD2 ligand avidity. TCR-initiated up-regulation of CD2 avidity requires the activity of both protein tyrosine kinases and protein kinase C. Agents which elevate intracellular levels of cAMP also up-regulate CD2 ligand avidity and act either distal to or independently of protein kinase C and protein tyrosine kinases. Cell lines expressing single amino acid substitutions of the carboxyl-terminal asparagine of CD2 are incapable of avidity regulation by TCR signaling, PMA treatment, or elevation of intracellular cAMP levels, demonstrating that each of these stimuli utilizes a common structural element for regulating CD2 avidity. The response to both cAMP and phorbol ester treatment distinguishes the regulation of CD2 avidity from that of a second major adhesion pathway, LFA-1 (CD11a/CD18)/ICAM-1 (CD54) and from that of the TCR coreceptor CD8. These observations identify the signaling events involved in the regulation of CD2 avidity and help to define the signal transduction processes that participate in ''inside-out'' signaling. C1 HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV PEDIAT ONCOL,DANA 1610B,44 BINNEY ST,BOSTON,MA 02115. BRIGHAM & WOMENS HOSP,DEPT MED,DIV HEMATOL ONCOL,BOSTON,MA 02115. HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02115. HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115. FU NIAID NIH HHS [AI31868, AI28554] NR 72 TC 43 Z9 43 U1 0 U2 0 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 SN 0022-1767 J9 J IMMUNOL JI J. Immunol. PD APR 1 PY 1993 VL 150 IS 7 BP 2607 EP 2619 PG 13 WC Immunology SC Immunology GA KT805 UT WOS:A1993KT80500006 PM 7681075 ER PT J AU ASAHINA, A HOSOI, J BRUVERS, S MURPHY, GF GRANSTEIN, RD AF ASAHINA, A HOSOI, J BRUVERS, S MURPHY, GF GRANSTEIN, RD TI REGULATION OF LANGERHANS CELL (LC) PROTEIN ANTIGEN PRESENTATION BY CALCITONIN GENE-RELATED PEPTIDE (CGRP), GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR (GM-CSF) AND TUMOR-NECROSIS-FACTOR-ALPHA (TNF-ALPHA SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,MASSACHUSETTS GEN HOSP HARVARD CUTANEOUS BIOL RES CTR,BOSTON,MA 02114. UNIV PENN,DEPT DERMATOL,PHILADELPHIA,PA 19104. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL SCIENCE INC PI CAMBRIDGE PA 238 MAIN ST, CAMBRIDGE, MA 02142 SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD APR PY 1993 VL 100 IS 4 BP 489 EP 489 PG 1 WC Dermatology SC Dermatology GA KW395 UT WOS:A1993KW39500307 ER PT J AU SMITH, C YOHN, J STEVENS, T MORELLI, J DORMISH, J KANE, M ZAMORA, M AF SMITH, C YOHN, J STEVENS, T MORELLI, J DORMISH, J KANE, M ZAMORA, M TI EVIDENCE FOR AN ENDOTHELIN-1 AUTOCRINE SYSTEM IN NORMAL HUMAN KERATINOCYTES SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract C1 UNIV COLORADO,SCH MED,DEPT DERMATOL,DENVER,CO 80202. UNIV COLORADO,SCH MED,DEPT CHEM,DENVER,CO 80202. DENVER VAMC,DENVER,CO. UNIV COLORADO,CTR CANC,DENVER,CO 80202. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL SCIENCE INC PI CAMBRIDGE PA 238 MAIN ST, CAMBRIDGE, MA 02142 SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD APR PY 1993 VL 100 IS 4 BP 494 EP 494 PG 1 WC Dermatology SC Dermatology GA KW395 UT WOS:A1993KW39500332 ER PT J AU YOHN, J SMITH, C STEVENS, T MORELLI, J DORMISH, J KANE, M ZAMORA, M AF YOHN, J SMITH, C STEVENS, T MORELLI, J DORMISH, J KANE, M ZAMORA, M TI IDENTIFICATION OF FUNCTIONAL ENDOTHELIN-1 RECEPTORS IN CULTURED HUMAN-MALIGNANT MELANOMA-CELLS SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract C1 UNIV COLORADO,SCH MED,DEPT DERMATOL,DENVER,CO 80202. UNIV COLORADO,SCH MED,DEPT MED,DENVER,CO 80202. DENVER VAMC,DENVER,CO. UNIV COLORADO,CTR CANC,DENVER,CO 80202. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL SCIENCE INC PI CAMBRIDGE PA 238 MAIN ST, CAMBRIDGE, MA 02142 SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD APR PY 1993 VL 100 IS 4 BP 494 EP 494 PG 1 WC Dermatology SC Dermatology GA KW395 UT WOS:A1993KW39500335 ER PT J AU HIBINO, T TAKAHASHI, T HORII, I GOETINCK, PF AF HIBINO, T TAKAHASHI, T HORII, I GOETINCK, PF TI EGF-LIKE DOMAIN OF UROKINASE PLASMINOGEN-ACTIVATOR (MU-PA) PLAYS AN ESSENTIAL ROLE IN KERATINOCYTE GROWTH-STIMULATION SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,CUTANEOUS BIOL RES CTR,BOSTON,MA 02129. SHISEIDO RES CTR,YOKOHAMA,JAPAN. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL SCIENCE INC PI CAMBRIDGE PA 238 MAIN ST, CAMBRIDGE, MA 02142 SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD APR PY 1993 VL 100 IS 4 BP 500 EP 500 PG 1 WC Dermatology SC Dermatology GA KW395 UT WOS:A1993KW39500373 ER PT J AU NISHIYAMA, T MCDONOUGH, AM BURGESON, RE AF NISHIYAMA, T MCDONOUGH, AM BURGESON, RE TI COLLAGEN TYPES-XII AND TYPE-XIV MAY MEDIATE INTERACTIONS BETWEEN BANDED COLLAGEN-FIBERS SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract C1 HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,HARVARD CUTANEOUS BIOL RES CTR,BOSTON,MA 02114. RI Nishiyama, Toshio/C-5434-2013 NR 0 TC 0 Z9 0 U1 0 U2 1 PU BLACKWELL SCIENCE INC PI CAMBRIDGE PA 238 MAIN ST, CAMBRIDGE, MA 02142 SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD APR PY 1993 VL 100 IS 4 BP 505 EP 505 PG 1 WC Dermatology SC Dermatology GA KW395 UT WOS:A1993KW39500398 ER PT J AU GALLO, RL POVSIC, T KIM, C PAGE, C ERIKSSON, E BERNFIELD, M AF GALLO, RL POVSIC, T KIM, C PAGE, C ERIKSSON, E BERNFIELD, M TI THE SYNDECANS, CO-RECEPTORS FOR MATRIX AND GROWTH-FACTORS, ARE INDUCED SELECTIVELY BY AN ACTIVITY IN WOUND FLUID SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract C1 HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,HARVARD CUTANEOUS BIOL RES CTR,BOSTON,MA 02114. HARVARD UNIV,SCH MED,BRIGHAM CHILDRENS DIV PLAST SURG,BOSTON,MA 02115. HARVARD UNIV,SCH MED,JOINT PROGRAM NEONATOL,BOSTON,MA 02115. RI Gallo, Richard/A-8931-2009 NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL SCIENCE INC PI CAMBRIDGE PA 238 MAIN ST, CAMBRIDGE, MA 02142 SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD APR PY 1993 VL 100 IS 4 BP 506 EP 506 PG 1 WC Dermatology SC Dermatology GA KW395 UT WOS:A1993KW39500404 ER PT J AU GRANSTEIN, RD EGAN, C VIGLIONE, MI HOSOI, J MURPHY, GF AF GRANSTEIN, RD EGAN, C VIGLIONE, MI HOSOI, J MURPHY, GF TI LANGERHANS CELLS (LC) AND CALCITONIN GENE-RELATED PEPTIDE (CGRP)-CONTAINING EPIDERMAL AXONS ARE ANATOMICALLY ASSOCIATED SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract C1 HARVARD UNIV,MASSACHUSETTS GEN HOSP,CUTANEOUS BIOL RES CTR,BOSTON,MA 02114. UNIV PENN,DEPT DERMATOL,PHILADELPHIA,PA 19104. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL SCIENCE INC PI CAMBRIDGE PA 238 MAIN ST, CAMBRIDGE, MA 02142 SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD APR PY 1993 VL 100 IS 4 BP 520 EP 520 PG 1 WC Dermatology SC Dermatology GA KW395 UT WOS:A1993KW39500490 ER PT J AU KOLLIAS, N KOCHEVAR, IE FLOTTE, T NGUYEN, C GILLIES, R MORAN, M EHAMA, R FUJII, S AF KOLLIAS, N KOCHEVAR, IE FLOTTE, T NGUYEN, C GILLIES, R MORAN, M EHAMA, R FUJII, S TI THE EFFECTS OF RETINOIC ACID ON RHINO MOUSE SKIN MEASURED BY EXCITATION FLUORESCENCE SPECTROSCOPY SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract C1 HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,WELLMAN LABS PHOTOMED,BOSTON,MA 02114. SHISEIDO CO LTD,TOKYO,JAPAN. NR 0 TC 4 Z9 4 U1 0 U2 0 PU BLACKWELL SCIENCE INC PI CAMBRIDGE PA 238 MAIN ST, CAMBRIDGE, MA 02142 SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD APR PY 1993 VL 100 IS 4 BP 530 EP 530 PG 1 WC Dermatology SC Dermatology GA KW395 UT WOS:A1993KW39500552 ER PT J AU KOLLIAS, N GILLIES, R ANDERSON, RR AF KOLLIAS, N GILLIES, R ANDERSON, RR TI FLUORESCENCE-SPECTRA OF HUMAN SKIN - PRELIMINARY-REPORT SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,WELLMAN LABS PHOTOMED,BOSTON,MA 02114. NR 0 TC 4 Z9 4 U1 0 U2 0 PU BLACKWELL SCIENCE INC PI CAMBRIDGE PA 238 MAIN ST, CAMBRIDGE, MA 02142 SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD APR PY 1993 VL 100 IS 4 BP 530 EP 530 PG 1 WC Dermatology SC Dermatology GA KW395 UT WOS:A1993KW39500549 ER PT J AU AHMED, AR MOHIMAN, A NEUMAN, R FOSTER, CS AF AHMED, AR MOHIMAN, A NEUMAN, R FOSTER, CS TI THE AUTOANTIGEN CHARACTERIZING OCULAR CICATRICAL PEMPHIGOID SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract C1 HARVARD UNIV,MASSACHUSETTS EYE & EAR INFIRM,SCH MED,CTR BLOOD RES,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL SCIENCE INC PI CAMBRIDGE PA 238 MAIN ST, CAMBRIDGE, MA 02142 SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD APR PY 1993 VL 100 IS 4 BP 531 EP 531 PG 1 WC Dermatology SC Dermatology GA KW395 UT WOS:A1993KW39500556 ER PT J AU MOY, RL MCHUGH, T UYEMURA, K MODLIN, RL AF MOY, RL MCHUGH, T UYEMURA, K MODLIN, RL TI THE LOCAL IMMUNE-RESPONSE IN SQUAMOUS-CELL CARCINOMA CONSISTS OF A DISTINCT TYPE-2 CYTOKINE PATTERN SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract C1 UNIV CALIF LOS ANGELES, DIV DERMATOL, LOS ANGELES, CA USA. W LOS ANGELES VET ADM HOSP, LOS ANGELES, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD APR PY 1993 VL 100 IS 4 BP 537 EP 537 PG 1 WC Dermatology SC Dermatology GA KW395 UT WOS:A1993KW39500595 ER PT J AU KOLLIAS, N GILLIES, R MUCCINI, JA PHILLIPS, SB BILDEN, P DRAKE, LA AF KOLLIAS, N GILLIES, R MUCCINI, JA PHILLIPS, SB BILDEN, P DRAKE, LA TI QUANTITATIVE MEASUREMENT OF ERYTHEMA RESULTING FROM TRETINOIN CREAM 0.025-PERCENT TREATMENT OF PHOTODAMAGED SKIN SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract C1 HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DERMATOL CLIN INVEST UNIT,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL SCIENCE INC PI CAMBRIDGE PA 238 MAIN ST, CAMBRIDGE, MA 02142 SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD APR PY 1993 VL 100 IS 4 BP 539 EP 539 PG 1 WC Dermatology SC Dermatology GA KW395 UT WOS:A1993KW39500606 ER PT J AU PHILLIPS, SB MUCCINI, JA BILDEN, PF LUCCHINA, LC UYEYAMA, RK KOLLIAS, N GILLIES, R DRAKE, LA AF PHILLIPS, SB MUCCINI, JA BILDEN, PF LUCCHINA, LC UYEYAMA, RK KOLLIAS, N GILLIES, R DRAKE, LA TI SPECTROSCOPIC EVALUATION OF THE CHANGE IN ERYTHEMA ACCOMPANYING TREATMENT OF PSORIATIC PLAQUES WITH A TOPICAL STEROID SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract C1 HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DERMATOL CLIN INVEST UNIT,BOSTON,MA 02114. NR 0 TC 1 Z9 1 U1 0 U2 0 PU BLACKWELL SCIENCE INC PI CAMBRIDGE PA 238 MAIN ST, CAMBRIDGE, MA 02142 SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD APR PY 1993 VL 100 IS 4 BP 543 EP 543 PG 1 WC Dermatology SC Dermatology GA KW395 UT WOS:A1993KW39500626 ER PT J AU WEINSTEIN, GD GREEN, L DRAKE, LA ELIAS, PM KRUEGER, GG LAZARUS, GS LOWE, NJ LEWKAYA, DA LUE, J SEFTON, J CHANDRARATNA, RAS AF WEINSTEIN, GD GREEN, L DRAKE, LA ELIAS, PM KRUEGER, GG LAZARUS, GS LOWE, NJ LEWKAYA, DA LUE, J SEFTON, J CHANDRARATNA, RAS TI NEW TOPICAL RETINOID GEL FOR THERAPY OF PSORIASIS - DOSE-RANGING STUDY OF AGN 190168 SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract C1 UNIV CALIF IRVINE,IRVINE,CA 92717. MASSACHUSETTS GEN HOSP,BOSTON,MA 02114. FT MILEY VA HOSP,SAN FRANCISCO,CA. UNIV UTAH,HLTH SCI CTR,SALT LAKE CITY,UT 84112. UNIV PENN,PHILADELPHIA,PA 19104. SO CALIF DERMATOL & PSORIASIS CTR,SANTA MONICA,CA. ALLERGAN HERBERT,CLIN RES DEPT,IRVINE,CA. NR 0 TC 10 Z9 10 U1 0 U2 0 PU BLACKWELL SCIENCE INC PI CAMBRIDGE PA 238 MAIN ST, CAMBRIDGE, MA 02142 SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD APR PY 1993 VL 100 IS 4 BP 544 EP 544 PG 1 WC Dermatology SC Dermatology GA KW395 UT WOS:A1993KW39500632 ER PT J AU BARNHILL, RL FANDREY, K KANG, S HYMAN, B AF BARNHILL, RL FANDREY, K KANG, S HYMAN, B TI TUMOR VASCULARITY AS A PROGNOSTIC FACTOR IN CUTANEOUS MALIGNANT-MELANOMA SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract C1 HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT DERMATOL,BOSTON,MA 02115. HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT NEUROL,BOSTON,MA 02115. HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT PATHOL,BOSTON,MA 02115. HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL SCIENCE INC PI CAMBRIDGE PA 238 MAIN ST, CAMBRIDGE, MA 02142 SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD APR PY 1993 VL 100 IS 4 BP 547 EP 547 PG 1 WC Dermatology SC Dermatology GA KW395 UT WOS:A1993KW39500651 ER PT J AU FALLON, J PRESS, W NADIRE, K COMPTON, C AF FALLON, J PRESS, W NADIRE, K COMPTON, C TI MORPHOMETRICAL STUDY OF ANCHORING FIBRIL REGENERATION DURING EPITHELIAL WOUND-HEALING SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,DEPT PATHOL,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL SCIENCE INC PI CAMBRIDGE PA 238 MAIN ST, CAMBRIDGE, MA 02142 SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD APR PY 1993 VL 100 IS 4 BP 548 EP 548 PG 1 WC Dermatology SC Dermatology GA KW395 UT WOS:A1993KW39500661 ER PT J AU HOSOI, I GRABBE, S GRANSTEIN, RD AF HOSOI, I GRABBE, S GRANSTEIN, RD TI EFFECTS OF HYDROCORTISONE ON PRESENTATION OF TUMOR-ASSOCIATED ANTIGENS BY MURINE EPIDERMAL ANTIGEN PRESENTING CELLS SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract C1 HARVARD UNIV,MASSACHUSETTS GEN HOSP,MGH HARVARD CUTANEOUS BIOL RES CTR,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL SCIENCE INC PI CAMBRIDGE PA 238 MAIN ST, CAMBRIDGE, MA 02142 SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD APR PY 1993 VL 100 IS 4 BP 564 EP 564 PG 1 WC Dermatology SC Dermatology GA KW395 UT WOS:A1993KW39500752 ER PT J AU TAN, KC GRABBE, S HOSOI, J GRANSTEIN, RD AF TAN, KC GRABBE, S HOSOI, J GRANSTEIN, RD TI EPIDERMAL-CELL (EC) PRESENTATION OF TUMOR-ASSOCIATED ANTIGENS (TAA) FOR TOLERANCE SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,MASSACHUSETTS GEN HOSP HARVARD CUTANEOUS BIOL RES CTR,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL SCIENCE INC PI CAMBRIDGE PA 238 MAIN ST, CAMBRIDGE, MA 02142 SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD APR PY 1993 VL 100 IS 4 BP 565 EP 565 PG 1 WC Dermatology SC Dermatology GA KW395 UT WOS:A1993KW39500762 ER PT J AU NGUYEN, Q DAVISBOUTTE, W TONG, A HUANG, L UYEMURA, K MODLIN, R MOY, R AF NGUYEN, Q DAVISBOUTTE, W TONG, A HUANG, L UYEMURA, K MODLIN, R MOY, R TI THE EFFECTS OF INTERFERON-ALPHA AND INTERLEUKIN-2 ON CYTOKINE PATTERNS IN A BASAL-CELL CARCINOMA SKIN EXPLANT MODEL SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract C1 UCLA DIV DERMATOL,W LOS ANGELES VA MED CTR,JONSSON COMPREHENS CANC CTR,LOS ANGELES,CA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL SCIENCE INC PI CAMBRIDGE PA 238 MAIN ST, CAMBRIDGE, MA 02142 SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD APR PY 1993 VL 100 IS 4 BP 570 EP 570 PG 1 WC Dermatology SC Dermatology GA KW395 UT WOS:A1993KW39500793 ER PT J AU STRUCKE, RJ GADENNE, ASJ WAGNER, M BLEICHER, PA BIGBY, M AF STRUCKE, RJ GADENNE, ASJ WAGNER, M BLEICHER, PA BIGBY, M TI GAMMA-DELTA T-CELLS IN LICHEN-PLANUS HAVE A LIMITED T-CELL RECEPTOR REPERTOIRE SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,CUTANEOUS BIOL RES CTR,DEPT DERMATOL,BOSTON,MA 02114. HARVARD UNIV,SCH MED,BOSTON,MA 02115. NR 0 TC 1 Z9 1 U1 0 U2 0 PU BLACKWELL SCIENCE INC PI CAMBRIDGE PA 238 MAIN ST, CAMBRIDGE, MA 02142 SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD APR PY 1993 VL 100 IS 4 BP 573 EP 573 PG 1 WC Dermatology SC Dermatology GA KW395 UT WOS:A1993KW39500810 ER PT J AU GRABBE, S GRANSTEIN, RD AF GRABBE, S GRANSTEIN, RD TI DIFFERENTIAL MODULATION OF PRIMARY AND SECONDARY EPIDERMAL-CELL ALLOANTIGEN PRESENTATION BY CYTOKINES SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract C1 UNIV MUNSTER,HAUTKLIN,W-4400 MUNSTER,GERMANY. MASSACHUSETTS GEN HOSP,HARVARD CUTANEOUS BIOL RES CTR,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL SCIENCE INC PI CAMBRIDGE PA 238 MAIN ST, CAMBRIDGE, MA 02142 SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD APR PY 1993 VL 100 IS 4 BP 574 EP 574 PG 1 WC Dermatology SC Dermatology GA KW395 UT WOS:A1993KW39500815 ER PT J AU LINDGREN, AM GALLO, RL HOSOI, J GRANSTEIN, RD AF LINDGREN, AM GALLO, RL HOSOI, J GRANSTEIN, RD TI INHIBITION OF MURINE CONTACT HYPERSENSITIVITY BY ANALOGS OF AMILORIDE SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,HARVARD CUTANEOUS BIOL RES CTR,BOSTON,MA 02114. RI Gallo, Richard/A-8931-2009 NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL SCIENCE INC PI CAMBRIDGE PA 238 MAIN ST, CAMBRIDGE, MA 02142 SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD APR PY 1993 VL 100 IS 4 BP 574 EP 574 PG 1 WC Dermatology SC Dermatology GA KW395 UT WOS:A1993KW39500817 ER PT J AU DEKKER, SK VINK, J VERMEER, BJ BRUIJN, JA MIHM, MC BYERS, HR AF DEKKER, SK VINK, J VERMEER, BJ BRUIJN, JA MIHM, MC BYERS, HR TI TNF-ALPHA AND IL-1-ALPHA MODULATES MELANOMA INTEGRIN EXPRESSION AND CELL-MIGRATION SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract C1 HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEPT PATHOL,DIV DERMATOPATHOL,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL SCIENCE INC PI CAMBRIDGE PA 238 MAIN ST, CAMBRIDGE, MA 02142 SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD APR PY 1993 VL 100 IS 4 BP 588 EP 588 PG 1 WC Dermatology SC Dermatology GA KW395 UT WOS:A1993KW39500900 ER PT J AU BOUFFARD, D DUNCAN, LM HOWARD, CA MIHM, MC BYERS, HR AF BOUFFARD, D DUNCAN, LM HOWARD, CA MIHM, MC BYERS, HR TI ACTIN-BINDING PROTEIN EXPRESSION IN BENIGN AND MALIGNANT MELANOCYTIC PROLIFERATIONS SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract C1 HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DIV DERMATOPATHOL,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL SCIENCE INC PI CAMBRIDGE PA 238 MAIN ST, CAMBRIDGE, MA 02142 SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD APR PY 1993 VL 100 IS 4 BP 590 EP 590 PG 1 WC Dermatology SC Dermatology GA KW395 UT WOS:A1993KW39500909 ER PT J AU LERNER, EA YOUSSEF, DE GREVELINK, SA AF LERNER, EA YOUSSEF, DE GREVELINK, SA TI MAXADILAN, A POTENT CUTANEOUS VASODILATOR FROM SAND FLY SALIVARY-GLANDS SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,CUTANEOUS BIOL RES CTR,BOSTON,MA 02114. HARVARD UNIV,SCH MED,DEPT DERMATOL,BOSTON,MA 02115. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL SCIENCE INC PI CAMBRIDGE PA 238 MAIN ST, CAMBRIDGE, MA 02142 SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD APR PY 1993 VL 100 IS 4 BP 593 EP 593 PG 1 WC Dermatology SC Dermatology GA KW395 UT WOS:A1993KW39500927 ER PT J AU KOCHEVAR, IE MORAN, M FLOTTE, TJ GRANSTEIN, RD AF KOCHEVAR, IE MORAN, M FLOTTE, TJ GRANSTEIN, RD TI DIFFERENTIAL INCREASE IN SKIN MAST-CELLS INDUCED BY CHRONIC UVB EXPOSURE OF C3H/HEN AND C3H/HEJ MICE SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract C1 HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEPT DERMATOL,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU BLACKWELL SCIENCE INC PI CAMBRIDGE PA 238 MAIN ST, CAMBRIDGE, MA 02142 SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD APR PY 1993 VL 100 IS 4 BP 598 EP 598 PG 1 WC Dermatology SC Dermatology GA KW395 UT WOS:A1993KW39500960 ER PT J AU HRUZA, LL KOLLIAS, N LUI, H GULICK, R FLOTTE, TJ WIMBERLY, J CRUMPACKER, C ANDERSON, RR AF HRUZA, LL KOLLIAS, N LUI, H GULICK, R FLOTTE, TJ WIMBERLY, J CRUMPACKER, C ANDERSON, RR TI HYPERICIN-INDUCED CUTANEOUS PHOTOSENSITIZATION SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,WELLMAN LABS PHOTOMED,BOSTON,MA 02114. BETH ISRAEL HOSP,DIV INFECT DIS,BOSTON,MA 02215. NR 0 TC 1 Z9 1 U1 0 U2 0 PU BLACKWELL SCIENCE INC PI CAMBRIDGE PA 238 MAIN ST, CAMBRIDGE, MA 02142 SN 0022-202X J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD APR PY 1993 VL 100 IS 4 BP 600 EP 600 PG 1 WC Dermatology SC Dermatology GA KW395 UT WOS:A1993KW39500973 ER PT J AU PAPISOV, MI BOGDANOV, A SCHAFFER, B NOSSIFF, N SHEN, T WEISSLEDER, R BRADY, TJ AF PAPISOV, MI BOGDANOV, A SCHAFFER, B NOSSIFF, N SHEN, T WEISSLEDER, R BRADY, TJ TI COLLOIDAL MAGNETIC-RESONANCE CONTRAST AGENTS - EFFECT OF PARTICLE SURFACE ON BIODISTRIBUTION SO JOURNAL OF MAGNETISM AND MAGNETIC MATERIALS LA English DT Article; Proceedings Paper CT 6TH INTERNATIONAL CONF ON MAGNETIC FLUIDS ( ICMF 6 ) CY JUL 20-24, 1992 CL PARIS, FRANCE SP FRENCH MINIST RES & TECHNOL, FRENCH GEN DIRECT ARMAMENT, UNIV PIERRE & MARIE CURIE, UNIV PARIS 7, UNESCO, LAB GUERBET, JAPAN SOC MAGNET FLUID RES, EXXON, FERROFLUIDICS, BIOL & IND AB Surface structure of dextran-coated superparamagnetic particles is studied as a biodistribution-defining factor. Colloidal particle and polymer molecule of the same size and similar outer structure are shown to possess similar biokinetics and biodistribution. A dense dextran layer on the particle surface is identified as a structure responsible for particle accumulation in the lymph nodes. C1 HARVARD UNIV,SCH MED,BOSTON,MA 02129. RP PAPISOV, MI (reprint author), MASSACHUSETTS GEN HOSP,DEPT RADIOL,CTR NMR,MGH E,BLDG 149,13TH ST,BOSTON,MA 02129, USA. NR 11 TC 89 Z9 92 U1 0 U2 10 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0304-8853 J9 J MAGN MAGN MATER JI J. Magn. Magn. Mater. PD APR PY 1993 VL 122 IS 1-3 BP 383 EP 386 DI 10.1016/0304-8853(93)91115-N PG 4 WC Materials Science, Multidisciplinary; Physics, Condensed Matter SC Materials Science; Physics GA LD485 UT WOS:A1993LD48500091 ER PT J AU SAKURAI, SY PENNEY, JB YOUNG, AB AF SAKURAI, SY PENNEY, JB YOUNG, AB TI REGIONALLY DISTINCT N-METHYL-D-ASPARTATE RECEPTORS DISTINGUISHED BY QUANTITATIVE AUTORADIOGRAPHY OF [H-3] MK-801 BINDING IN RAT-BRAIN SO JOURNAL OF NEUROCHEMISTRY LA English DT Article DE 3-(2-CARBOXYPIPERAZIN-4-YL)-PROPYL-1-PHOSPHONIC ACID; GLUTAMATE; 7-CHLOROKYNURENIC ACID; MK-801; PHENCYCLIDINE; N-METHYL-D-ASPARATE RECEPTOR ID H-3 MK-801 BINDING; AMINO-ACID RECEPTORS; CENTRAL-NERVOUS-SYSTEM; NMDA-RECEPTOR; L-GLUTAMATE; 7-CHLOROKYNURENIC ACID; CORTICAL-NEURONS; MULTIPLE STATES; ION CHANNEL; GLYCINE AB Quantitative autoradiography of [H-3]MK-801 binding was used to characterize regional differences in N-methyl-D-aspartate (NMDA) receptor pharmacology in rat CNS. Regionally distinct populations of NMDA receptors were distinguished on the basis of regulation of [H-3]MK-801 binding by the NMDA antagonist 3-(2-carboxypiperazin-4-yl)-propyl-1-phosphonic acid (CPP). CPP inhibited [H-3]MK-801 binding in outer cortex (OC) and medial cortex (MC) with apparent K(i) values of 0.32-0.48 muM, whereas in the medial striatum (MS), lateral striatum (LS), CA1, and dentate gyrus (DG) of hippocampus, apparent K(i) values were 1.1- 1.6 muM. In medial thalamus (MT) and lateral thalamus (LT) the apparent K(i) values were 0.78 muM. In the presence of added glutamate (3 muM), the relative differences in apparent K(i) values between regions maintained a similar relationship with the exception of the OC. Inhibition of [H-3]-MK-801 binding by the glycine site antagonist 7-chlorokynurenic acid (7-ClKyn) distinguished at least two populations of NMDA receptors that differed from populations defined by CPP displacement. 7-ClKyn inhibited [H-3]MK-801 binding in OC, MC, MS, and LS with apparent K(i) values of 6.3-8.6 muM, whereas in CA1, DG, LT, and MT, K(i) values were 11.4-13.6 muM. In the presence of added glycine (I muM), the relative differences in apparent K(i) values were maintained. Under conditions of differential receptor activation, regional differences in NMDA receptor pharmacology can be detected using [H-3]MK-801 binding. C1 MASSACHUSETTS GEN HOSP,DEPT NEUROL,NEUROL SERV,FRUIT ST,BOSTON,MA 02114. UNIV MICHIGAN,DEPT NEUROL,ANN ARBOR,MI 48109. FU NIA NIH HHS [AG08671]; NINDS NIH HHS [NS19613] NR 53 TC 85 Z9 85 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0022-3042 J9 J NEUROCHEM JI J. Neurochem. PD APR PY 1993 VL 60 IS 4 BP 1344 EP 1353 DI 10.1111/j.1471-4159.1993.tb03295.x PG 10 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA KT837 UT WOS:A1993KT83700019 PM 8095974 ER PT J AU HALEY, EC KASSELL, NF TORNER, JC SPETZLER, RF ZABRAMSKI, J CULICCHIA, F CARTER, LP FEINBERG, W URBINA, C LOPEZ, L BROWN, D TALLMAN, D SELMAN, WR HARRINGTON, F WARF, B BARNETT, GH LITTLE, J PALMER, J SOLOMON, RA LENNIHAN, L FINK, M BECKFORD, A FRIEDMAN, AH BOWMAN, M GENTRY, A CAMPBELL, RL SHAPIRO, S FARLOW, M KAY, S HORNER, T LEIPZIG, T REDELMAN, K NAUTA, HJ PREZIOSI, T HANLEY, D BOREL, C SALIBI, S HEROS, RC KISTLER, JP DIEBOLD, P MUIZELAAR, JP TURNER, R KAMSHEH, W BOUMA, G MUIZELAAR, JP MOHR, G BOJANOWSKI, M BERNIER, G DUQUETTE, P LAPLANTE, P MURALI, R CRISAFULLI, C MERKEL, C ROSNER, MJ MAHALEY, MS ARONIN, PA MORAWETZ, RB ROSNER, S BROCKSILLERS, R WEIR, BKA PETRUK, K ARONYK, K FINDLAY, JM MCKEAN, J BROAD, R ALLEN, P SCHINDEL, D DURITY, F CAMERON, DA WOODHURST, WB FAIRHOLM, DJ BOROZNY, M MARTIN, NA BECKER, DP FRAZER, J MOORE, S THOMAS, K LAMOND, RG MARSHALL, L ROTHROCK, J BENEDICT, B MOORE, S PITTS, LH WILSON, C ANDREWS, B ROSEGAY, H DAMRON, S ROSS, A TEW, JM YEH, HS VANLOVEREN, H MCMAHON, N DAY, AL FRIEDMAN, W SYPERT, G GUIN, P ADAMS, HP BECK, D GODERSKY, J BILLER, J LOFTUS, C MITCHELL, V YOUNG, B DEMPSEY, R TIBBS, P PHILLIPS, R SHIELDS, CB GARRETSON, H GUARNASCHELLI, J DAWSON, K WEST, M ANDERSON, B FEWER, D GLADISH, D SALCMAN, M RIGAMONTI, D KULIK, S CHANDLER, WF GREENBERG, H GUNDEN, C SMITH, RR HAERER, AF BROWN, R ORO, J WATTS, C GUMERLOCK, MK BYER, J BELSHE, B VOLLMER, DG POWERS, S DACEY, R BAKER, ML RICHARD, MT RUSSELL, NA BENOIT, B DASILVA, VF SREERANA, VS POLIS, T BRACCIO, D FLAMM, ES REIVICH, M KUSHNER, M FARBER, R PARROTT, S YONAS, H SEKHAR, L BISSONETTE, K BISSONETTE, D GIANNOTTA, SL WEISS, M APUZZO, M FISHER, M MARTIN, E DELAROSA, S SIMARD, JM EISENBERG, H KAPLAR, B KENT, T ALDRICH, F TURNER, B GROTTA, J KOPANICKY, D YATSU, F DEGRAPA, T BRATINA, P BATJER, HH SAMSON, D PLAZIER, L HEILBRUN, MP HOOD, R GOODMAN, S ALLEN, B SUNDERLAND, P KASSELL, NF HALEY, EC PARKS, K WINN, HR GRADY, S MAYBERG, M VAN, M BURNAL, C DUFF, TA LEVINE, R DUNLAVYTACHON, ML GRUBB, RL COXE, W LANDAU, W RICH, K LEVIN, A HOBBS, V ADAMS, HP FLAMM, ES DRAKE, CG DYKEN, ML FRANKOWSKI, RF KURTZKE, JF WEIR, BKA KASSELL, NF HALEY, EC TORNER, JC KONGABLE, GL ELDER, LJ HENRY, ML CAIL, WS LIGHTFOOT, AL MARRON, JA GERMANSON, TP TRUSKOWSKI, LL MATCHI, M AF HALEY, EC KASSELL, NF TORNER, JC SPETZLER, RF ZABRAMSKI, J CULICCHIA, F CARTER, LP FEINBERG, W URBINA, C LOPEZ, L BROWN, D TALLMAN, D SELMAN, WR HARRINGTON, F WARF, B BARNETT, GH LITTLE, J PALMER, J SOLOMON, RA LENNIHAN, L FINK, M BECKFORD, A FRIEDMAN, AH BOWMAN, M GENTRY, A CAMPBELL, RL SHAPIRO, S FARLOW, M KAY, S HORNER, T LEIPZIG, T REDELMAN, K NAUTA, HJ PREZIOSI, T HANLEY, D BOREL, C SALIBI, S HEROS, RC KISTLER, JP DIEBOLD, P MUIZELAAR, JP TURNER, R KAMSHEH, W BOUMA, G MUIZELAAR, JP MOHR, G BOJANOWSKI, M BERNIER, G DUQUETTE, P LAPLANTE, P MURALI, R CRISAFULLI, C MERKEL, C ROSNER, MJ MAHALEY, MS ARONIN, PA MORAWETZ, RB ROSNER, S BROCKSILLERS, R WEIR, BKA PETRUK, K ARONYK, K FINDLAY, JM MCKEAN, J BROAD, R ALLEN, P SCHINDEL, D DURITY, F CAMERON, DA WOODHURST, WB FAIRHOLM, DJ BOROZNY, M MARTIN, NA BECKER, DP FRAZER, J MOORE, S THOMAS, K LAMOND, RG MARSHALL, L ROTHROCK, J BENEDICT, B MOORE, S PITTS, LH WILSON, C ANDREWS, B ROSEGAY, H DAMRON, S ROSS, A TEW, JM YEH, HS VANLOVEREN, H MCMAHON, N DAY, AL FRIEDMAN, W SYPERT, G GUIN, P ADAMS, HP BECK, D GODERSKY, J BILLER, J LOFTUS, C MITCHELL, V YOUNG, B DEMPSEY, R TIBBS, P PHILLIPS, R SHIELDS, CB GARRETSON, H GUARNASCHELLI, J DAWSON, K WEST, M ANDERSON, B FEWER, D GLADISH, D SALCMAN, M RIGAMONTI, D KULIK, S CHANDLER, WF GREENBERG, H GUNDEN, C SMITH, RR HAERER, AF BROWN, R ORO, J WATTS, C GUMERLOCK, MK BYER, J BELSHE, B VOLLMER, DG POWERS, S DACEY, R BAKER, ML RICHARD, MT RUSSELL, NA BENOIT, B DASILVA, VF SREERANA, VS POLIS, T BRACCIO, D FLAMM, ES REIVICH, M KUSHNER, M FARBER, R PARROTT, S YONAS, H SEKHAR, L BISSONETTE, K BISSONETTE, D GIANNOTTA, SL WEISS, M APUZZO, M FISHER, M MARTIN, E DELAROSA, S SIMARD, JM EISENBERG, H KAPLAR, B KENT, T ALDRICH, F TURNER, B GROTTA, J KOPANICKY, D YATSU, F DEGRAPA, T BRATINA, P BATJER, HH SAMSON, D PLAZIER, L HEILBRUN, MP HOOD, R GOODMAN, S ALLEN, B SUNDERLAND, P KASSELL, NF HALEY, EC PARKS, K WINN, HR GRADY, S MAYBERG, M VAN, M BURNAL, C DUFF, TA LEVINE, R DUNLAVYTACHON, ML GRUBB, RL COXE, W LANDAU, W RICH, K LEVIN, A HOBBS, V ADAMS, HP FLAMM, ES DRAKE, CG DYKEN, ML FRANKOWSKI, RF KURTZKE, JF WEIR, BKA KASSELL, NF HALEY, EC TORNER, JC KONGABLE, GL ELDER, LJ HENRY, ML CAIL, WS LIGHTFOOT, AL MARRON, JA GERMANSON, TP TRUSKOWSKI, LL MATCHI, M TI A RANDOMIZED CONTROLLED TRIAL OF HIGH-DOSE INTRAVENOUS NICARDIPINE IN ANEURYSMAL SUBARACHNOID HEMORRHAGE - A REPORT OF THE COOPERATIVE ANEURYSM STUDY SO JOURNAL OF NEUROSURGERY LA English DT Article DE NICARDIPINE; SUBARACHNOID HEMORRHAGE; CEREBRAL VASOSPASM; CEREBRAL ANEURYSM ID ARTERIAL-HYPERTENSION; CEREBRAL INFARCTION; NIMODIPINE; VASOSPASM; MANAGEMENT AB Because of their action as cerebral vasodilators, dihydropyridine calcium antagonists have received intense scrutiny for their potential benefit in ameliorating the devastating consequences of delayed cerebral vasospasm following aneurysmal subarachnoid hemorrhage (SAH). From October, 1987, to September, 1989, 41 North American neurosurgical centers in the Cooperative Aneurysm Study accrued 906 patients with recent (Days 0 to 7) aneurysmal SAH into a prospective randomized double-blind placebo-controlled trial of high-dose intravenous nicardipine to test whether treatment with this agent improved overall outcome. Eligible patients received 0. 15 mg/kg/hr of either nicardipine or placebo by continuous infusion for up to 14 days following hemorrhage. The 449 patients randomly assigned to the nicardipine-treated group and the 457 patients assigned to the placebo-treated group were balanced with regard to prognostic factors for ischemic deficits from vasospasm and for overall outcome. Other medical and surgical interventions were used with similar frequency in both groups, except that antihypertensive agents were used less frequently in the nicardipine-treated patients (26% of the nicardipine-treated group vs. 43 % of the placebo-treated group, p < 0.001), and more patients in the placebo-treated group had intentional hypervolemia, induced hypertension, and/or hemodilution administered therapeutically for symptomatic vasospasm (38% of the placebo-treated group vs. 25% of the nicardipine-treated group, p < 0.001). The incidence of symptomatic vasospasm during the treatment period was higher in the placebo-treated group (46%) than in the nicardipine-treated group (32%) (p < 0.001). Despite the reduction in symptomatic vasospasm in the nicardipine-treated group, overall outcome at 3 months was similar between the two groups. Fifty-five percent of nicardipine-treated patients were rated as having a good recovery according to the Glasgow Outcome Scale at follow-up review and 17% were dead, compared to 56% and 18%, respectively, in the placebo-treated group (not statistically significant). These data suggest that high-dose intravenous nicardipine treatment is associated with a reduced incidence of symptomatic vasospasm in patients with recent aneurysmal SAH, but not with an improvement in overall outcome at 3 months when compared to standard management in North America. It is postulated that, while nicardipine prevents vasospasm, hypertensive/hypervolemic therapy may be effective in reversing ischemic deficits from vasospasm once they occur. C1 UNIV VIRGINIA,HLTH SCI CTR,DEPT NEUROL SURG,CHARLOTTESVILLE,VA 22908. BARROW NEUROL INST,PHOENIX,AZ. UNIV ARIZONA,TUCSON,AZ 85721. CASE WESTERN RESERVE UNIV,CLEVELAND,OH 44106. CLEVELAND CLIN EDUC FDN,CLEVELAND,OH 44106. COLUMBIA PRESBYTERIAN MED CTR,NEW YORK,NY 10032. DUKE UNIV,DURHAM,NC 27706. INDIANA UNIV,INDIANAPOLIS,IN 46204. INDIANAPOLIS NEUROSURG GRP,INDIANAPOLIS,IN. JOHNS HOPKINS UNIV,BALTIMORE,MD 21218. MASSACHUSETTS GEN HOSP,BOSTON,MA 02114. VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,RICHMOND,VA 23298. NOTRE DAME HOSP,MONTREAL,PQ,CANADA. ST VINCENTS HOSP & MED CTR,NEW YORK,NY 10011. UNIV ALABAMA,BIRMINGHAM,AL 35294. UNIV ALBERTA,EDMONTON T6G 2E1,ALBERTA,CANADA. UNIV BRITISH COLUMBIA,VANCOUVER V6T 1W5,BC,CANADA. UNIV CALIF LOS ANGELES,LOS ANGELES,CA 90024. UNIV CALIF SAN DIEGO,LA JOLLA,CA 92093. UNIV CALIF SAN FRANCISCO,SAN FRANCISCO,CA 94143. UNIV CINCINNATI,CINCINNATI,OH 45221. UNIV FLORIDA,GAINESVILLE,FL 32611. UNIV IOWA,IOWA CITY,IA 52242. UNIV KENTUCKY,LEXINGTON,KY 40506. UNIV LOUISVILLE,LOUISVILLE,KY 40292. UNIV MANITOBA,WINNIPEG R3T 2N2,MANITOBA,CANADA. UNIV MARYLAND,COLL PK,MD 20742. UNIV MICHIGAN,ANN ARBOR,MI 48109. UNIV MISSISSIPPI,JACKSON,MS 39216. UNIV MISSOURI,COLUMBIA,MO 65201. UNIV N CAROLINA,CHAPEL HILL,NC 27514. UNIV OTTAWA,OTTAWA K1N 6N5,ONTARIO,CANADA. UNIV PENN,PHILADELPHIA,PA 19104. UNIV PITTSBURGH,PITTSBURGH,PA 15260. UNIV SO CALIF,LOS ANGELES,CA 90089. UNIV TEXAS,MED BRANCH,GALVESTON,TX 77550. UNIV TEXAS,HOUSTON,TX 77025. UNIV TEXAS,DALLAS,TX 75230. UNIV UTAH,SALT LAKE CITY,UT 84112. UNIV VIRGINIA,CHARLOTTESVILLE,VA 22903. UNIV WASHINGTON,SEATTLE,WA 98195. UNIV WISCONSIN,MADISON,WI 53706. WASHINGTON UNIV,ST LOUIS,MO 63130. UNIV IOWA,IOWA CITY,IA 52242. UNIV PENN,PHILADELPHIA,PA 19104. UNIV WESTERN ONTARIO,LONDON N6A 3K7,ONTARIO,CANADA. INDIANA UNIV,BLOOMINGTON,IN 47401. UNIV TEXAS,HOUSTON,TX 77025. GEORGETOWN UNIV,WASHINGTON,DC 20057. UNIV ALBERTA,EDMONTON T6G 2E1,ALBERTA,CANADA. UNIV VIRGINIA,CHARLOTTESVILLE,VA 22903. RP HALEY, EC (reprint author), UNIV VIRGINIA,HLTH SCI CTR,DEPT NEUROL,CENT REGISTRY,BOX 394,CHARLOTTESVILLE,VA 22908, USA. FU NINDS NIH HHS [NS 24806] NR 29 TC 212 Z9 214 U1 1 U2 14 PU AMER ASSOC NEUROLOGICAL SURGEONS PI CHARLOTTESVILLE PA UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903 SN 0022-3085 J9 J NEUROSURG JI J. Neurosurg. PD APR PY 1993 VL 78 IS 4 BP 537 EP 547 DI 10.3171/jns.1993.78.4.0537 PG 11 WC Clinical Neurology; Surgery SC Neurosciences & Neurology; Surgery GA KT984 UT WOS:A1993KT98400002 PM 8450326 ER PT J AU HALEY, EC KASSELL, NF TORNER, JC SPETZLER, RF ZABRAMSKI, J CULICCHIA, F CARTER, LP FEINBERG, W URBINA, C LOPEZ, L BROWN, D TALLMAN, D SELMAN, WR HARRINGTON, F WARF, B BARNETT, GH LITTLE, J PALMER, J SOLOMON, RA LENNIHAN, L FINK, M BECKFORD, A FRIEDMAN, AH BOWMAN, M GENTRY, A CAMPBELL, RL SHAPIRO, S FARLOW, M KAY, S HORNER, T LEIPZIG, T REDELMAN, K NAUTA, HJ PREZIOSI, T HANLEY, D BOREL, C SALIBI, S HEROS, RC KISTLER, JP DIEBOLD, P MUIZELAAR, JP TURNER, R KAMSHEH, W BOUMA, G MOHR, G BOJANOWSKI, M BERNIER, G DUQUETTE, P LAPLANTE, P MURALI, R CRISAFULLI, C MERKEL, C ROSNER, MJ MAHALEY, MS ARONIN, PA MORAWETZ, RB ROSNER, S BROCKSILLERS, R WEIR, BKA PETRUK, K ARONYK, K FINDLAY, JM MCKEAN, J BROAD, R ALLEN, P SCHINDEL, D DURITY, F CAMERON, DA WOODHURST, WB FAIRHOLM, DJ BOROZNY, M MARTIN, NA BECKER, DP FRAZER, J MOORE, S THOMAS, K LAMOND, RG MARSHALL, L ROTHROCK, J BENEDICT, B MOORE, S PITTS, LH WILSON, C ANDREWS, B ROSEGAY, H DAMRON, S ROSS, A TEW, JM YEH, HS VANLOVEREN, H MCMAHON, N DAY, AL FRIEDMAN, W SYPERT, G GUIN, P ADAMS, HP BECK, D GODERSKY, J BILLER, J LOFTUS, C MITCHELL, V YOUNG, B DEMPSEY, R TIBBS, P PHILLIPS, R SHIELDS, CB GARRETSON, H GUARNASCHELLI, J DAWSON, K WEST, M ANDERSON, B FEWER, D GLADISH, D SALCMAN, M RIGAMONTI, D KULIK, S CHANDLER, WF GREENBERG, H GUNDEN, C SMITH, RR HAERER, AF BROWN, R ORO, J WATTS, C GUMERLOCK, MK BYER, J BELSHE, B VOLLMER, DG POWERS, S DACEY, R BAKER, ML RICHARD, MT RUSSELL, NA BENOIT, B DASILVA, VF SREERANA, VS POLIS, T BRACCIO, D FLAMM, ES REIVICH, M KUSHNER, M FARBER, R PARROTT, S YONAS, H SEKHAR, L BISSONETTE, K BISSONETTE, D GIANNOTTA, SL WEISS, M APUZZO, M FISHER, M MARTIN, E DELAROSA, S SIMARD, JM EISENBERG, H KAPLAR, B KENT, T ALDRICH, F TURNER, B GROTTA, J KOPANICKY, D YATSU, F DEGRAPA, T BRATINA, P BATJER, HH SAMSON, D PLAZIER, L HEILBRUN, MP CALL, G HOOD, R GOODMAN, S ALLEN, B SUNDERLAND, P KASSELL, NF HALEY, FC PARKS, K WINN, HR GRADY, S MAYBERG, M VAN, M BURNAL, C DUFF, TA LEVINE, R DUNLAVYTACHON, ML GRUBB, RL COXE, W LANDAU, W RICH, K LEVIN, A HOBBS, V ADAMS, HP FLAMM, ES DRAKE, CG DYKEN, ML FRANKOWSKI, RF KURTZKE, JF WEIR, BKA KASSELL, NF HALEY, EC TORNER, JC KONGABLE, GL ELDER, LJ HENRY, ML CAIL, WS LIGHTFOOT, AL MARRON, JA GERMANSON, TP TRUSKOWSKI, LL MATCHI, M AF HALEY, EC KASSELL, NF TORNER, JC SPETZLER, RF ZABRAMSKI, J CULICCHIA, F CARTER, LP FEINBERG, W URBINA, C LOPEZ, L BROWN, D TALLMAN, D SELMAN, WR HARRINGTON, F WARF, B BARNETT, GH LITTLE, J PALMER, J SOLOMON, RA LENNIHAN, L FINK, M BECKFORD, A FRIEDMAN, AH BOWMAN, M GENTRY, A CAMPBELL, RL SHAPIRO, S FARLOW, M KAY, S HORNER, T LEIPZIG, T REDELMAN, K NAUTA, HJ PREZIOSI, T HANLEY, D BOREL, C SALIBI, S HEROS, RC KISTLER, JP DIEBOLD, P MUIZELAAR, JP TURNER, R KAMSHEH, W BOUMA, G MOHR, G BOJANOWSKI, M BERNIER, G DUQUETTE, P LAPLANTE, P MURALI, R CRISAFULLI, C MERKEL, C ROSNER, MJ MAHALEY, MS ARONIN, PA MORAWETZ, RB ROSNER, S BROCKSILLERS, R WEIR, BKA PETRUK, K ARONYK, K FINDLAY, JM MCKEAN, J BROAD, R ALLEN, P SCHINDEL, D DURITY, F CAMERON, DA WOODHURST, WB FAIRHOLM, DJ BOROZNY, M MARTIN, NA BECKER, DP FRAZER, J MOORE, S THOMAS, K LAMOND, RG MARSHALL, L ROTHROCK, J BENEDICT, B MOORE, S PITTS, LH WILSON, C ANDREWS, B ROSEGAY, H DAMRON, S ROSS, A TEW, JM YEH, HS VANLOVEREN, H MCMAHON, N DAY, AL FRIEDMAN, W SYPERT, G GUIN, P ADAMS, HP BECK, D GODERSKY, J BILLER, J LOFTUS, C MITCHELL, V YOUNG, B DEMPSEY, R TIBBS, P PHILLIPS, R SHIELDS, CB GARRETSON, H GUARNASCHELLI, J DAWSON, K WEST, M ANDERSON, B FEWER, D GLADISH, D SALCMAN, M RIGAMONTI, D KULIK, S CHANDLER, WF GREENBERG, H GUNDEN, C SMITH, RR HAERER, AF BROWN, R ORO, J WATTS, C GUMERLOCK, MK BYER, J BELSHE, B VOLLMER, DG POWERS, S DACEY, R BAKER, ML RICHARD, MT RUSSELL, NA BENOIT, B DASILVA, VF SREERANA, VS POLIS, T BRACCIO, D FLAMM, ES REIVICH, M KUSHNER, M FARBER, R PARROTT, S YONAS, H SEKHAR, L BISSONETTE, K BISSONETTE, D GIANNOTTA, SL WEISS, M APUZZO, M FISHER, M MARTIN, E DELAROSA, S SIMARD, JM EISENBERG, H KAPLAR, B KENT, T ALDRICH, F TURNER, B GROTTA, J KOPANICKY, D YATSU, F DEGRAPA, T BRATINA, P BATJER, HH SAMSON, D PLAZIER, L HEILBRUN, MP CALL, G HOOD, R GOODMAN, S ALLEN, B SUNDERLAND, P KASSELL, NF HALEY, FC PARKS, K WINN, HR GRADY, S MAYBERG, M VAN, M BURNAL, C DUFF, TA LEVINE, R DUNLAVYTACHON, ML GRUBB, RL COXE, W LANDAU, W RICH, K LEVIN, A HOBBS, V ADAMS, HP FLAMM, ES DRAKE, CG DYKEN, ML FRANKOWSKI, RF KURTZKE, JF WEIR, BKA KASSELL, NF HALEY, EC TORNER, JC KONGABLE, GL ELDER, LJ HENRY, ML CAIL, WS LIGHTFOOT, AL MARRON, JA GERMANSON, TP TRUSKOWSKI, LL MATCHI, M TI A RANDOMIZED TRIAL OF NICARDIPINE IN SUBARACHNOID HEMORRHAGE - ANGIOGRAPHIC AND TRANSCRANIAL DOPPLER ULTRASOUND RESULTS - A REPORT OF THE COOPERATIVE ANEURYSM STUDY SO JOURNAL OF NEUROSURGERY LA English DT Article DE NICARDIPINE; CALCIUM ANTAGONIST; SUBARACHNOID HEMORRHAGE; CEREBRAL VASOSPASM; TRANSCRANIAL DOPPLER ULTRASOUND ID CALCIUM-ANTAGONISTS; CEREBRAL-ISCHEMIA; NIMODIPINE; VASOSPASM; SPASM AB Calcium antagonist drugs were proposed for use in patients with recent aneurysmal subarachnoid hemorrhage (SAH) because of their ability to block the effects of a wide variety of vasoconstrictor substances on cerebral arteries in vitro. It was suggested that these agents might, therefore, be useful in ameliorating cerebral vasospasm and its ischemic consequences which frequently complicate SAH. This hypothesis was tested in an arm of a randomized double-blind placebo-controlled trial of high-dose intravenous nicardipine in patients with recently ruptured aneurysms. Participating investigators were required to send selected copies of all admission and follow-up angiograms obtained between Days 7 and 11 following hemorrhage (the peak period of risk for vasospasm) to the Central Registry of the Cooperative Aneurysm Study for blinded interpretation and review for the presence and severity of angiographic vasospasm. In centers with transcranial Doppler ultrasound (TCD) capabilities, middle cerebral artery (MCA) mean flow velocities were measured and recorded. Angiograms obtained between Days 7 and 11 were available for 103 (23%) of 449 patients receiving nicardipine and 121 (26%) of 457 receiving placebo. There was a balance of prognostic factors for vasospasm between the groups. Fifty-one percent of placebo-treated patients had moderate or severe vasospasm on ''Day 7-11 angiograms'' compared to 33% of nicardipine-treated patients. This difference is statistically significant (p < 0.01). Sixty-seven (49%) of 13 7 placebo-treated patients examined with TCD between Days 7 and 11 had mean MCA flow velocities exceeding 120 cm/sec compared to 26 (23%) of 112 nicardipine-treated patients (significant difference, p < 0.001). These data suggest that high-dose intravenous nicardipine reduces the incidence and severity of delayed cerebral arterial narrowing in patients following aneurysmal SAH. C1 UNIV VIRGINIA,HLTH SCI CTR,DEPT NEUROL SURG,CHARLOTTESVILLE,VA 22908. BARROW NEUROL INST,PHOENIX,AZ. UNIV ARIZONA,TUCSON,AZ 85721. CASE WESTERN RESERVE UNIV,CLEVELAND,OH 44106. CLEVELAND CLIN EDUC FDN,CLEVELAND,OH 44106. COLUMBIA PRESBYTERIAN MED CTR,NEW YORK,NY 10032. DUKE UNIV,DURHAM,NC 27706. INDIANA UNIV,INDIANAPOLIS,IN 46204. INDIANAPOLIS NEUROSURG GRP,INDIANAPOLIS,IN. JOHNS HOPKINS UNIV,BALTIMORE,MD 21218. MASSACHUSETTS GEN HOSP,BOSTON,MA 02114. VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,RICHMOND,VA 23298. NOTRE DAME HOSP,MONTREAL,PQ,CANADA. ST VINCENTS HOSP & MED CTR,NEW YORK,NY 10011. UNIV ALABAMA,BIRMINGHAM,AL 35294. UNIV ALBERTA,EDMONTON T6G 2E1,ALBERTA,CANADA. UNIV BRITISH COLUMBIA,VANCOUVER V6T 1W5,BC,CANADA. UNIV CALIF LOS ANGELES,LOS ANGELES,CA 90024. UNIV CALIF SAN DIEGO,LA JOLLA,CA 92093. UNIV CALIF SAN FRANCISCO,SAN FRANCISCO,CA 94143. UNIV CINCINNATI,CINCINNATI,OH 45221. UNIV FLORIDA,GAINESVILLE,FL 32611. UNIV IOWA,IOWA CITY,IA 52242. UNIV KENTUCKY,LEXINGTON,KY 40506. UNIV LOUISVILLE,LOUISVILLE,KY 40292. UNIV MANITOBA,WINNIPEG R3T 2N2,MANITOBA,CANADA. UNIV MARYLAND,COLL PK,MD 20742. UNIV MICHIGAN,ANN ARBOR,MI 48109. UNIV MISSISSIPPI,JACKSON,MS 39216. UNIV MISSOURI,COLUMBIA,MO 65201. UNIV N CAROLINA,CHAPEL HILL,NC 27514. UNIV OTTAWA,OTTAWA K1N 6N5,ONTARIO,CANADA. UNIV PENN,PHILADELPHIA,PA 19104. UNIV PITTSBURGH,PITTSBURGH,PA 15260. UNIV SO CALIF,LOS ANGELES,CA 90089. UNIV TEXAS,MED BRANCH,GALVESTON,TX 77550. UNIV TEXAS,HOUSTON,TX 77025. UNIV TEXAS,DALLAS,TX 75230. UNIV UTAH,SALT LAKE CITY,UT 84112. UNIV VIRGINIA,CHARLOTTESVILLE,VA 22903. UNIV WASHINGTON,SEATTLE,WA 98195. UNIV WISCONSIN,MADISON,WI 53706. WASHINGTON UNIV,ST LOUIS,MO 63130. UNIV IOWA,IOWA CITY,IA 52242. UNIV PENN,PHILADELPHIA,PA 19104. UNIV WESTERN ONTARIO,LONDON N6A 3K7,ONTARIO,CANADA. INDIANA UNIV,BLOOMINGTON,IN 47401. UNIV TEXAS,HOUSTON,TX 77025. GEORGETOWN UNIV,WASHINGTON,DC 20057. UNIV ALBERTA,EDMONTON T6G 2E1,ALBERTA,CANADA. UNIV VIRGINIA,CHARLOTTESVILLE,VA 22903. RP HALEY, EC (reprint author), UNIV VIRGINIA,HLTH SCI CTR,DEPT NEUROL,CENT REGISTRY,BOX 394,CHARLOTTESVILLE,VA 22908, USA. FU NINDS NIH HHS [NS 24806] NR 20 TC 103 Z9 104 U1 0 U2 6 PU AMER ASSOC NEUROLOGICAL SURGEONS PI CHARLOTTESVILLE PA UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903 SN 0022-3085 J9 J NEUROSURG JI J. Neurosurg. PD APR PY 1993 VL 78 IS 4 BP 548 EP 553 DI 10.3171/jns.1993.78.4.0548 PG 6 WC Clinical Neurology; Surgery SC Neurosciences & Neurology; Surgery GA KT984 UT WOS:A1993KT98400003 PM 8450327 ER PT J AU LEVASSEUR, JE PATTERSON, JL GARCIA, CI MOSKOWITZ, MA CHOI, SC KONTOS, HA AF LEVASSEUR, JE PATTERSON, JL GARCIA, CI MOSKOWITZ, MA CHOI, SC KONTOS, HA TI EFFECT OF NEONATAL CAPSAICIN TREATMENT ON NEUROGENIC PULMONARY-EDEMA FROM FLUID-PERCUSSION BRAIN INJURY IN THE ADULT-RAT SO JOURNAL OF NEUROSURGERY LA English DT Article DE NEUROGENIC PULMONARY EDEMA; PULMONARY PRESSURE; PROMETHAZINE; RANITIDINE; CAPSAICIN; PRIMARY AFFERENT FIBER ID SUBSTANCE-P; NEURONS AB The frequent occurrence of acute death from pulmonary failure in experimental head injury studies on Sprague-Dawley rats prompted an investigation into the manner in which acute neurogenic pulmonary edema develops in these animals as a result of an applied fluid pressure pulse to the cerebral hemispheres. Studies were performed in adult animals using histamine H-1 and H-2 blocking agents, or in adult animals treated as neonates with capsaicin to destroy unmyelinated C-fibers. Recordings were made of either the pulmonary arterial or the right ventricular pressure, and the left atrial and femoral arterial pressures before, during, and after injury to provide a record of the hemodynamic response throughout the development of neurogenic pulmonary edema. Head injury triggered the almost immediate development of pressure transients with and without neurogenic pulmonary edema. All rats, regardless of treatment, reacted with nearly identical systemic arterial pressure responses; however, the pulmonary responses followed a time course that was independent of systemic arterial pressure changes. Acute neurogenic pulmonary edema was always associated with a substantial increase in pulmonary arterial and left atrial pressures: conversely, pressure increases of similar magnitude were not always associated with edema. Histamine H-1 and H-2 blockers significantly reduced the pulmonary pressure surges only in rats free of neurogenic pulmonary edema. All capsaicin-treated rats showed suppressed pulmonary pressure responses, normal lung water content, elevated lung surface tension, and significantly reduced levels of immunoreactive substance P in the spinal cord and vagus nerve. While the pressures cannot clarify how edema influences the observed hemodynamics, they do not support the view that edema is the direct consequence of pulmonary hypertension. It is proposed that neurogenic pulmonary edema is a functional disturbance provoked by adverse stimuli from outside the lungs and that in the rat the primary afferent fiber is essential to the production of this entity. C1 VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT BIOSTAT,RICHMOND,VA 23298. HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,NEUROSURG SERV,STROKE RES LAB,BOSTON,MA 02114. RP LEVASSEUR, JE (reprint author), VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT MED,DIV CARDIOL,POB 282,RICHMOND,VA 23298, USA. RI Moskowitz, Michael/D-9916-2011 NR 26 TC 10 Z9 12 U1 0 U2 1 PU AMER ASSOC NEUROLOGICAL SURGEONS PI CHARLOTTESVILLE PA UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903 SN 0022-3085 J9 J NEUROSURG JI J. Neurosurg. PD APR PY 1993 VL 78 IS 4 BP 610 EP 618 DI 10.3171/jns.1993.78.4.0610 PG 9 WC Clinical Neurology; Surgery SC Neurosciences & Neurology; Surgery GA KT984 UT WOS:A1993KT98400013 PM 7680709 ER PT J AU SCOTT, JA PALMER, EL AF SCOTT, JA PALMER, EL TI DO DIAGNOSTIC ALGORITHMS ALWAYS PRODUCE A UNIFORM LUNG-SCAN INTERPRETATION SO JOURNAL OF NUCLEAR MEDICINE LA English DT Article ID VENTILATION-PERFUSION; PULMONARY-EMBOLISM; QUALITY ASSURANCE; NUCLEAR-MEDICINE AB Several algorithms have been devised to assist in the interpretation of ventilation-perfusion (V/Q) scans performed to diagnose pulmonary embolism. The degree to which adherence to a single algorithm facilitates diagnostic homogeneity among different readers, however, has been little investigated. We evaluated the individual variability in V/Q lung scan interpretation in a large, academic nuclear medicine division to determine the degree of interpretive heterogeneity among a group of physicians all using the same image interpretation algorithm. Ventilation-perfusion scan interpretive patterns and the diagnostic accuracy of individual physicians were evaluated using quantitative parameters to establish group norms and to detect variations from these norms. The performance of each reader was tracked over a 4 yr period. There was a significant variation in V/Q interpretive patterns and diagnostic accuracy between readers despite the attempted use of a uniform diagnostic algorithm. Subgroups of interpretive styles could be defined based on the percentage of intermediate (including both indeterminate and intermediate categories) scans read. Although there was significant variation in diagnostic accuracy among readers, there was no obvious correlation between accuracy and reading style except that the most nonstandard diagnostic patterns were associated with the most variable diagnostic accuracy. These data show a measurable variation in interpretive patterns and accuracy among multiple readers of V/Q scans despite attempted group adherence to an established diagnostic algorithm. C1 MASSACHUSETTS GEN HOSP,DIV NUCL MED,BOSTON,MA 02114. RP SCOTT, JA (reprint author), MASSACHUSETTS GEN HOSP,DEPT RADIOL,BOSTON,MA 02114, USA. NR 9 TC 13 Z9 13 U1 0 U2 0 PU SOC NUCLEAR MEDICINE INC PI RESTON PA 1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 SN 0161-5505 J9 J NUCL MED JI J. Nucl. Med. PD APR PY 1993 VL 34 IS 4 BP 661 EP 665 PG 5 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA KV038 UT WOS:A1993KV03800020 PM 8455085 ER PT J AU VEERAPEN, K SCHUMACHER, HR VANLINTHOUDT, D NEILSON, EG WANG, F AF VEERAPEN, K SCHUMACHER, HR VANLINTHOUDT, D NEILSON, EG WANG, F TI TOPHACEOUS GOUT IN YOUNG-PATIENTS WITH SYSTEMIC LUPUS-ERYTHEMATOSUS SO JOURNAL OF RHEUMATOLOGY LA English DT Article DE TOPHUS; GOUT; SYSTEMIC LUPUS ERYTHEMATOSUS ID COEXISTENT GOUT; DEPOSITION; DISEASE AB Systemic lupus erythematosus (SLE) and gout have been associated infrequently. We describe 3 young adults with SLE who developed tophaceous gout relatively early in the course of their disease. All were underexcretors of uric acid but were studied after the development of renal disease; 2 were treated with diuretics. In 2 cases, gout became obvious while lupus was quiescent. C1 VET AFFAIRS MED CTR,CTR ARTHRIT IMMUNOL,PHILADELPHIA,PA 19104. UNIV HOSP KUALA LUMPUR,DEPT MED,KUALA LUMPUR,MALAYSIA. UNIV PENN,SCH MED,DEPT MED,PHILADELPHIA,PA 19104. NR 17 TC 6 Z9 6 U1 0 U2 1 PU J RHEUMATOL PUBL CO PI TORONTO PA 920 YONGE ST, SUITE 115, TORONTO ON M4W 3C7, CANADA SN 0315-162X J9 J RHEUMATOL JI J. Rheumatol. PD APR PY 1993 VL 20 IS 4 BP 721 EP 724 PG 4 WC Rheumatology SC Rheumatology GA KY515 UT WOS:A1993KY51500024 PM 8496872 ER PT J AU SADOSKI, C SUIT, HD ROSENBERG, A MANKIN, H EFIRD, J AF SADOSKI, C SUIT, HD ROSENBERG, A MANKIN, H EFIRD, J TI PREOPERATIVE RADIATION, SURGICAL MARGINS, AND LOCAL-CONTROL OF EXTREMITY SARCOMAS OF SOFT-TISSUES SO JOURNAL OF SURGICAL ONCOLOGY LA English DT Article DE SOFT TISSUE SARCOMA; EXTREMITIES; PREOPERATIVE RADIATION THERAPY ID POSTOPERATIVE IRRADIATION; SURVIVAL; SURGERY; THERAPY; FAILURE AB The relationship between status of the surgical margin and local control of soft tissue sarcoma of the extremities by preoperative radiation therapy has been assessed in 132 consecutive patients from 1974 to 1988. The 5-year actuarial local control rate was 94% for all patients; the rates were 97% and 82% for the 104 tumors with negative margins and the 28 tumors with positive margins, respectively. The local control rate was independent of the extent of the negative margin. For primary sarcomas, the local control rates were 96%, 97%, and 100%, respectively, for margins that were negative at less-than-or-equal-to 1 mm or > 1 mm, or the specimens were negative for tumor; for positive margins the result was 83%. The overall local control rate was lower (not significant) for recurrent than for primary sarcomas: 88% vs. 94%. On the other hand, when stratifying by margin status, no difference was observed in local control results, i.e.: (1) 97% and 91 % for primary and recurrent tumors with negative margins, respectively, and (2) 83% and 80% for primary and recurrent tumors with positive margins, respectively. Local control was not significantly higher in those patients who were treated by surgical resection (S), radiation (RT), and re-excision of the previous tumor bed than in those whose radiation therapy was started after the biopsy and followed by one surgical resection. For primary sarcomas that were resected with negative margins the results were: 100% of 15 patients treated by S-RT-S and 96% of 75 patients treated by RT-S. C1 HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEPT RADIAT ONCOL,COX 3,100 BLOSSOM ST,BOSTON,MA 02114. HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEPT PATHOL,BOSTON,MA 02114. HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEPT ORTHOPAED,BOSTON,MA 02114. NR 29 TC 168 Z9 172 U1 0 U2 0 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012 SN 0022-4790 J9 J SURG ONCOL JI J. Surg. Oncol. PD APR PY 1993 VL 52 IS 4 BP 223 EP 230 DI 10.1002/jso.2930520405 PG 8 WC Oncology; Surgery SC Oncology; Surgery GA KY457 UT WOS:A1993KY45700004 PM 8468983 ER PT J AU DRAKE, LA CEILLEY, RI CORNELISON, RL DOBES, WA DORNER, W GOLTZ, RW LEWIS, CW SALASCHE, SJ TURNER, MLC SALASCHE, S DINEHART, SM POLLACK, SV SKOUGE, JW AF DRAKE, LA CEILLEY, RI CORNELISON, RL DOBES, WA DORNER, W GOLTZ, RW LEWIS, CW SALASCHE, SJ TURNER, MLC SALASCHE, S DINEHART, SM POLLACK, SV SKOUGE, JW TI GUIDELINES OF CARE FOR CUTANEOUS SQUAMOUS-CELL CARCINOMA SO JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY LA English DT Article ID SKIN-CANCER AB This report reflects the best data available at the time the report was prepared, but caution should be exercised in interpreting the data; the results of future studies may require alteration of the conclusions or recommendations set forth in this report. RP DRAKE, LA (reprint author), MASSACHUSETTS GEN HOSP,DEPT DERMATOL,WELLMAN 2,BOSTON,MA 02114, USA. NR 23 TC 18 Z9 18 U1 0 U2 0 PU MOSBY-YEAR BOOK INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 SN 0190-9622 J9 J AM ACAD DERMATOL JI J. Am. Acad. Dermatol. PD APR PY 1993 VL 28 IS 4 BP 628 EP 631 PG 4 WC Dermatology SC Dermatology GA KU482 UT WOS:A1993KU48200015 ER PT J AU DRAKE, LA CEILLEY, RI CORNELISON, RL DOBES, WA DORNER, W GOLTZ, RW LEWIS, CW SALASCHE, SJ TURNER, MLC MENTER, A SKINNER, RB ZANOLLI, MD DOBES, WL AF DRAKE, LA CEILLEY, RI CORNELISON, RL DOBES, WA DORNER, W GOLTZ, RW LEWIS, CW SALASCHE, SJ TURNER, MLC MENTER, A SKINNER, RB ZANOLLI, MD DOBES, WL TI GUIDELINES OF CARE FOR PSORIASIS SO JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY LA English DT Article ID ORAL METHOXSALEN-PHOTOCHEMOTHERAPY; CRUDE COAL-TAR; ULTRAVIOLET-B PHOTOTHERAPY; SERIAL LIVER BIOPSIES; ALPHA-HYDROXY-ACIDS; ETRETINATE THERAPY; GOECKERMAN REGIMEN; PUSTULAR PSORIASIS; METHOTREXATE; ANTHRALIN AB This report reflects the best data available at the time the report was prepared, but caution should be exercised in interpreting the data; the results of future studies may require alteration of the conclusions or recommendations set forth in this report. RP DRAKE, LA (reprint author), MASSACHUSETTS GEN HOSP,DEPT DERMATOL,WELLMAN 2,BOSTON,MA 02114, USA. RI menter md, alan/A-8250-2009 NR 83 TC 23 Z9 23 U1 1 U2 2 PU MOSBY-YEAR BOOK INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 SN 0190-9622 J9 J AM ACAD DERMATOL JI J. Am. Acad. Dermatol. PD APR PY 1993 VL 28 IS 4 BP 632 EP 637 PG 6 WC Dermatology SC Dermatology GA KU482 UT WOS:A1993KU48200016 ER PT J AU DRAKE, LA CEILLEY, RI CORNELISON, RL DOBES, WL DORNER, WA GOLTZ, RW LEWIS, CW SALASCHE, SJ TURNER, MLC TURNER, MLC ARROWSMITH, DR CATALANO, PM DAY, CL LEWIS, CW SOBER, AJ AF DRAKE, LA CEILLEY, RI CORNELISON, RL DOBES, WL DORNER, WA GOLTZ, RW LEWIS, CW SALASCHE, SJ TURNER, MLC TURNER, MLC ARROWSMITH, DR CATALANO, PM DAY, CL LEWIS, CW SOBER, AJ TI GUIDELINES OF CARE FOR MALIGNANT-MELANOMA SO JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY LA English DT Article ID THIN CUTANEOUS MELANOMA; RISK; IODOAMPHETAMINE; MARGIN AB This report reflects the best data available at the time the report was prepared, but caution should be exercised in interpreting the data; the results of future studies may require alteration of the conclusions or recommendations set forth in this report. RP DRAKE, LA (reprint author), MASSACHUSETTS GEN HOSP,DEPT DERMATOL,WELLMAN 2,BOSTON,MA 02114, USA. NR 15 TC 28 Z9 28 U1 0 U2 0 PU MOSBY-YEAR BOOK INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 SN 0190-9622 J9 J AM ACAD DERMATOL JI J. Am. Acad. Dermatol. PD APR PY 1993 VL 28 IS 4 BP 638 EP 641 PG 4 WC Dermatology SC Dermatology GA KU482 UT WOS:A1993KU48200017 ER PT J AU GOLD, HK TORRES, FW GARABEDIAN, HD WERNER, W JANG, IK KHAN, A HAGSTROM, JN YASUDA, T LEINBACH, RC NEWELL, JB BOVILL, EG STUMP, DC COLLEN, D AF GOLD, HK TORRES, FW GARABEDIAN, HD WERNER, W JANG, IK KHAN, A HAGSTROM, JN YASUDA, T LEINBACH, RC NEWELL, JB BOVILL, EG STUMP, DC COLLEN, D TI EVIDENCE FOR A REBOUND COAGULATION PHENOMENON AFTER CESSATION OF A 4-HOUR INFUSION OF A SPECIFIC THROMBIN INHIBITOR IN PATIENTS WITH UNSTABLE ANGINA-PECTORIS SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Article ID FIBRINOPEPTIDE-A; DOUBLE-BLIND; MYOCARDIAL-INFARCTION; PLASMINOGEN-ACTIVATOR; PLATELET-AGGREGATION; THROMBOLYTIC THERAPY; HEPARIN; ASPIRIN; TRIAL; NIFEDIPINE AB Objectives. In a Phase I clinical trial, we studied the antithrombotic and clinical effects of the synthetic competitive thrombin inhibitor, argatroban, in 43 patients with unstable angina pectoris. Background. Thrombin has a pivotal role in platelet-mediated thrombosis associated with atheromatous plaque rupture in patients with an acute ischemic coronary syndrome. However, the efficacy of conventional heparin therapy to prevent ischemic events is limited and has been surpassed by that of specific thrombin inhibitors in experimental models of arterial thrombosis. Methods. Intravenous infusion of the drug (0.5 to 5.0 mug/kg per min) for 4 h was monitored by sequential measurements of coagulation times and of indexes of thrombin activity in vivo followed by a 24-h clinical observation period. Results. Significant dose-related increases in plasma drug concentrations and activated partial thromboplastin times (aPTT), but no bleeding time prolongation or spontaneous bleeding, was observed. Myocardial ischemia did not occur during therapy but, surprisingly, 9 of the 43 patients experienced an episode of unstable angina 5.8 +/- 2.6 h (mean +/- SD) after infusion. This early recurrent angina was correlated significantly with a higher argatroban dose and with greater prolongation of aPTT but not with other demographic, clinical, laboratory and angiographic characteristics. Pretreatment plasma concentrations of thrombin-antithrombin III complex and fibrinopeptide A were elevated two to three times above normal values. During infusion, thrombin-antithrombin III complex levels remained unchanged, whereas a significant 2.3-fold decrease in fibrinopeptide A concentrations was observed. By contrast, 2 h after infusion, thrombin-antithrombin III complex concentrations increased 3.9-fold over baseline measurements together with return of fibrinopeptide A levels to values before treatment with argatroban. Conclusions. In patients with unstable angina, argatroban inhibits clotting (aPTT prolongation) and thrombin activity toward fibrinogen (fibrinopeptide A decrease), but in vivo thrombin (thrombin-antithrombin III complex) formation is not suppressed. However, cessation of infusion is associated with rebound thrombin (thrombin-antithrombin III complex) generation and with an early dose-related recurrence of unstable angina. Although the mechanism of this clinical and biochemical rebound phenomenon remains to be determined, its implication for the clinical use of specific thrombin inhibitors in the management of ischemic coronary syndromes may be significant. C1 GENENTECH INC,S SAN FRANCISCO,CA. HARVARD UNIV,SCH MED,BOSTON,MA 02115. UNIV VERMONT,COLL MED,DEPT BIOCHEM,BURLINGTON,VT 05405. UNIV VERMONT,COLL MED,DEPT PATHOL,BURLINGTON,VT 05405. RP GOLD, HK (reprint author), MASSACHUSETTS GEN HOSP,CARDIAC UNIT,WACC 4,ROOM 480,15 PARKMAN ST,BOSTON,MA 02114, USA. NR 43 TC 163 Z9 163 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD APR PY 1993 VL 21 IS 5 BP 1039 EP 1047 PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA KV708 UT WOS:A1993KV70800001 PM 8459055 ER PT J AU DEC, GW AF DEC, GW TI MYOCARDITIS MIMICKING MYOCARDIAL-INFARCTION - REPLY SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Letter RP DEC, GW (reprint author), MASSACHUSETTS GEN HOSP,CARDIAC TRANSPLANTAT PROGRAM,BULFINCH 1,BOSTON,MA 02114, USA. NR 3 TC 3 Z9 3 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD APR PY 1993 VL 21 IS 5 BP 1302 EP 1303 PG 2 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA KV708 UT WOS:A1993KV70800041 ER PT J AU DRINKA, PJ LANGER, EH VOEKS, SK GOODWIN, JS AF DRINKA, PJ LANGER, EH VOEKS, SK GOODWIN, JS TI LOW SERUM FOLIC-ACID LEVELS IN A NURSING-HOME POPULATION - A CLINICAL-EXPERIENCE SO JOURNAL OF THE AMERICAN COLLEGE OF NUTRITION LA English DT Article DE SERUM FOLIC ACID; NURSING HOME ID NUTRITIONAL-STATUS; FOLATE-DEFICIENCY; VITAMIN; ANEMIA AB Four hundred fifty-five residents of the Wisconsin Veterans Home had fasting serum specimens obtained for folic acid as part of standard practice. Twenty-nine percent were taking folic acid supplements. Six percent (n = 28) were taking phenytoin, a folate antagonist. No resident receiving a folate supplement (400 mcg/day) had a low serum folic acid level. This finding may be important for practitioners selecting a dose of folic acid for nursing home patients. Of the 325 residents not receiving a folate supplement, nine (3%) had low folic acid levels (<2.5 ng/mL). Two of the nine were receiving phenytoin. Five were characterized by staff as eating well. As low serum levels are preventable with a multivitamin, we believe that supplementation with a multivitamin containing 400 mcg folic acid/day should be considered in nursing home residents. C1 UNIV WISCONSIN,DEPT MED,MADISON,WI 53706. WILLIAM S MIDDLETON MEM VET ADM MED CTR,MADISON,WI. UNIV WISCONSIN,SCH MED,MADISON,WI 53706. RP DRINKA, PJ (reprint author), WISCONSIN VET HOME,KING,WI 54946, USA. NR 20 TC 3 Z9 3 U1 0 U2 0 PU AMER COLL NUTRITION PI NEW YORK PA C/O HOSP. JOINT DIS. 301 E. 17TH ST., NEW YORK, NY 10003 SN 0731-5724 J9 J AM COLL NUTR JI J. Am. Coll. Nutr. PD APR PY 1993 VL 12 IS 2 BP 186 EP 189 PG 4 WC Nutrition & Dietetics SC Nutrition & Dietetics GA KU485 UT WOS:A1993KU48500013 PM 8463516 ER PT J AU SWEET, MJ ZWILLING, L AF SWEET, MJ ZWILLING, L TI THE 1ST MEDICALIZATION - THE TAXONOMY AND ETIOLOGY OF QUEERNESS IN CLASSICAL INDIAN MEDICINE SO JOURNAL OF THE HISTORY OF SEXUALITY LA English DT Article C1 UNIV WISCONSIN,DEPT ENGLISH,MADISON,WI 53706. MIDDLETON VET ADM HOSP,MIDDLETON,WI. RP SWEET, MJ (reprint author), UNIV WISCONSIN,DEPT PSYCHIAT,MADISON,WI 53706, USA. NR 81 TC 15 Z9 15 U1 0 U2 0 PU UNIV CHICAGO PRESS PI CHICAGO PA 5720 S WOODLAWN AVE, CHICAGO, IL 60637 SN 1043-4070 J9 J HIST SEXUALITY JI J. Hist. Sex. PD APR PY 1993 VL 3 IS 4 BP 590 EP 607 PG 18 WC History; Sociology SC History; Sociology GA KR983 UT WOS:A1993KR98300003 PM 11623132 ER PT J AU ABBOTT, WM CALLOW, A MOORE, W RUTHERFORD, R VEITH, F WEINBERG, S AF ABBOTT, WM CALLOW, A MOORE, W RUTHERFORD, R VEITH, F WEINBERG, S TI EVALUATION AND PERFORMANCE STANDARDS FOR ARTERIAL PROSTHESES SO JOURNAL OF VASCULAR SURGERY LA English DT Article RP ABBOTT, WM (reprint author), MASSACHUSETTS GEN HOSP,15 PARKMAN ST,ACC-4,SUITE 458,BOSTON,MA 02114, USA. NR 0 TC 72 Z9 75 U1 3 U2 13 PU MOSBY-YEAR BOOK INC PI ST LOUIS PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 SN 0741-5214 J9 J VASC SURG JI J. Vasc. Surg. PD APR PY 1993 VL 17 IS 4 BP 746 EP 756 PG 11 WC Surgery; Peripheral Vascular Disease SC Surgery; Cardiovascular System & Cardiology GA KX198 UT WOS:A1993KX19800016 PM 8464095 ER PT J AU ROSE, RC BONNEZ, W REICHMAN, RC GARCEA, RL AF ROSE, RC BONNEZ, W REICHMAN, RC GARCEA, RL TI EXPRESSION OF HUMAN PAPILLOMAVIRUS TYPE-11 L1 PROTEIN IN INSECT CELLS - INVIVO AND INVITRO ASSEMBLY OF VIRUS-LIKE PARTICLES SO JOURNAL OF VIROLOGY LA English DT Article ID ANTIBODY-MEDIATED NEUTRALIZATION; OPEN READING FRAMES; RECOMBINANT BACULOVIRUS; CONDYLOMATA ACUMINATA; ESCHERICHIA-COLI; HUMAN-SERA; IDENTIFICATION; INFECTION; VP1 AB The L1 coat protein of human papillomavirus type 11 (HPV-11) was expressed in Sf-9 insect cells with the recombinant baculovirus vector Ac11L1. Viruslike particles (VLPs) were identified by electron microscopy in the nucleus and cytoplasm of Sf-9 cells infected with Ac11L1. The L1 protein was purified from Ac11L1-infected insect cells. The purified protein spontaneously assembled in vitro into various aggregates, including particles appearing similar to empty virions. Reaction of VLP-containing insect cell extracts with antisera directed against either denatured or nondenatured capsid epitopes in Western blot (immunoblot) and immuno-dot blot assays suggested that conformational epitopes present in native HPV-11 infectious virions were also present on the baculovirus-produced HPV-11 VLPs. Immuno-dot blot assays using human sera obtained from individuals with biopsy-proven condyloma accuminatum correlated closely with results previously obtained in HPV-11 whole virus particle-based enzyme-linked immunosorbent assays. These morphologic and immunologic similarities to native HPV-11 virions suggest that recombinant VLPs produced in the baculovirus system may be useful in seroepidemiology and pathogenesis studies of genital HPV infection and that they may also be potential candidates for vaccine development. C1 UNIV ROCHESTER,SCH MED & DENT,DEPT MICROBIOL & IMMUNOL,ROCHESTER,NY 14642. CHILDRENS HOSP MED CTR,DIV PEDIAT ONCOL,BOSTON,MA 02115. HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115. RP ROSE, RC (reprint author), UNIV ROCHESTER,SCH MED & DENT,DEPT MED,INFECT DIS UNIT,ROCHESTER,NY 14642, USA. FU NCI NIH HHS [R01 CA037667, CA37667]; NIAID NIH HHS [AI-82509] NR 40 TC 301 Z9 312 U1 1 U2 12 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171 SN 0022-538X J9 J VIROL JI J. Virol. PD APR PY 1993 VL 67 IS 4 BP 1936 EP 1944 PG 9 WC Virology SC Virology GA KT980 UT WOS:A1993KT98000024 PM 8383219 ER PT J AU CLOSS, EI RINKES, IHMB BADER, A YARMUSH, ML CUNNINGHAM, JM AF CLOSS, EI RINKES, IHMB BADER, A YARMUSH, ML CUNNINGHAM, JM TI RETROVIRAL INFECTION AND EXPRESSION OF CATIONIC AMINO-ACID TRANSPORTERS IN RODENT HEPATOCYTES SO JOURNAL OF VIROLOGY LA English DT Article ID MEDIATED GENE-TRANSFER; SANDWICH CONFIGURATION; EXTRACELLULAR-MATRIX; ADULT HEPATOCYTES; RECEPTOR GENE; CELLS; INVITRO; CHROMOSOME-8; FIBROBLASTS; SUBSTRATA AB The susceptibility of rodent hepatocytes to infection by mouse type C retroviruses was examined in vivo and in vitro and compared with the expression of two membrane proteins that function as transporters for the cationic amino acids CAT-1 and CAT-2. CAT-1 expression in rodents determines susceptibility to ecotropic retrovirus infection by serving as the virus receptor. Recently, it has been suggested that CAT-2 may be a receptor for amphotropic murine leukemia virus. In the present study, CAT-1 expression was observed in Hepa1, a cell line derived from a murine hepatoma, and in rat hepatocytes propagated on collagen monolayers in vitro but not in intact or regenerating rat liver in vivo. The expression of CAT-1 correlated with susceptibility to infection by an ecotropic retrovirus encoding beta-galactosidase. CAT-2 expression was observed in hepatocytes in vitro and in vivo, consistent with reports of infection of regenerating and cultured hepatocytes by amphotropic retroviruses. However, introduction of murine CAT-2 into nonpermissive Chinese hamster cells was not sufficient to confer susceptibility to amphotropic retrovirus infection, using a protocol that could easily demonstrate CAT-1-dependent infection by an ecotropic virus. Our data establish CAT-1 as a major determinant of ecotropic retrovirus infection in rodent hepatocytes and suggest that CAT-2 is not a receptor for viruses in the amphotropic subgroup. C1 BRIGHAM & WOMENS HOSP,DEPT MED,DIV HEMATOL ONCOL,BOSTON,MA 02115. BRIGHAM & WOMENS HOSP,HOWARD HUGHES MED INST,BOSTON,MA 02115. MASSACHUSETTS GEN HOSP,SURG SERV,BOSTON,MA 02114. SHRINERS BURN INST,BOSTON,MA 02114. RUTGERS STATE UNIV,DEPT CHEM & BIOCHEM ENGN,PISCATAWAY,NJ 08854. NR 33 TC 40 Z9 40 U1 0 U2 0 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171 SN 0022-538X J9 J VIROL JI J. Virol. PD APR PY 1993 VL 67 IS 4 BP 2097 EP 2102 PG 6 WC Virology SC Virology GA KT980 UT WOS:A1993KT98000042 PM 8383231 ER PT J AU HALLAQ, Y BECKER, TC MANNO, CS LAPOSATA, M AF HALLAQ, Y BECKER, TC MANNO, CS LAPOSATA, M TI USE OF ACETYL-CHLORIDE METHANOL FOR ASSUMED SELECTIVE METHYLATION OF PLASMA NONESTERIFIED FATTY-ACIDS RESULTS IN SIGNIFICANT METHYLATION OF ESTERIFIED FATTY-ACIDS SO LIPIDS LA English DT Article ID COLORIMETRIC METHOD AB The albumin-bound nonesterified fatty acid pool in plasma, which represents a very small percentage of total plasma fatty acids, has previously been quantitated by a variety of methods. In the present study we determined that the nonesterified fatty acid concentrations in the plasma, quantitated by a popular method using acetyl chloride and methanol which is reported to be specific for methylation of nonesterified fatty acids in the presence of esterified f atty acids (i.e., without prior isolation of the plasma nonesterified fatty acids), were significantly overestimated due to cleavage and methylation of esterified fatty acids. Quantitation of the contaminating fatty acid from the esterified pool demonstrated that the amount of fatty acid cleaved from the esterified pool was enough to exceed the entire mass of nonesterified fatty acids. As an established method for comparison, we isolated nonesterified fatty acids from the plasma by thin-layer chromatography prior to methylation, using a number of simple precautions to limit oxidation. By performing all thin-layer chromatography steps in an atmosphere of nitrogen and by including fatty acid standards in the plasma with 0, 1, 2 or 4 double bonds, we were able to accurately and reproducibly determine the concentration of nonesterified fatty acids in the plasma, including arachidonate. We demonstrated that no oxidation occurred in the thin-layer chromatographic isolation of nonesterified fatty acids and that the coefficients of variation for repeat measurements of the same sample were <11% using our reference method. Our data indicate that the use of acetyl chloride and methanol for assumed selective methylation of plasma nonesterified fatty acids results in significant methylation of esterified fatty acids. C1 MASSACHUSETTS GEN HOSP,DEPT PATHOL,ROOM 235,GRAY BLDG,BOSTON,MA 02114. HARVARD UNIV,SCH MED,BOSTON,MA 02115. UNIV PENN,SCH MED,PHILADELPHIA,PA 19104. CHILDRENS HOSP PENN,DEPT PEDIAT,DIV HEMATOL,PHILADELPHIA,PA 19104. FU NIDDK NIH HHS [DK-43159] NR 12 TC 14 Z9 15 U1 1 U2 5 PU AMER OIL CHEMISTS SOC PI CHAMPAIGN PA 1608 BROADMOOR DRIVE, CHAMPAIGN, IL 61821-0489 SN 0024-4201 J9 LIPIDS JI Lipids PD APR PY 1993 VL 28 IS 4 BP 355 EP 360 DI 10.1007/BF02536323 PG 6 WC Biochemistry & Molecular Biology; Nutrition & Dietetics SC Biochemistry & Molecular Biology; Nutrition & Dietetics GA KW586 UT WOS:A1993KW58600015 PM 8487628 ER PT J AU WEISSKOFF, RM CHESLER, D BOXERMAN, JL ROSEN, BR AF WEISSKOFF, RM CHESLER, D BOXERMAN, JL ROSEN, BR TI PITFALLS IN MR MEASUREMENT OF TISSUE BLOOD-FLOW WITH INTRAVASCULAR TRACERS - WHICH MEAN TRANSIT-TIME SO MAGNETIC RESONANCE IN MEDICINE LA English DT Note DE PERFUSION; CONTRAST AGENTS; FLOW ID MAGNETIC-SUSCEPTIBILITY; COMPUTED-TOMOGRAPHY; CONTRAST; DIFFUSION; VOLUME; FIELDS; NMR AB Measuring tissue blood flow with NMR imaging of intravascular tracers is more difficult than measurements of tissue blood volume. One major obstacle to the application of the Central Volume Principle is the direct measurement of the mean transit time. In this note, we demonstrate that mean transit time (MTT), which relates tissue blood volume to blood flow via the Central Volume Principle, is not the first moment of the concentration-time curve for MR or CT imaging of purely intravascular tracers. However, while first moment methods cannot be used by themselves to determine absolute flow, we show that transit curves may provide a useful relative measure of flow, for example, by considering ratios of the first moments. C1 HARVARD UNIV,SCH MED,BOSTON,MA. RP WEISSKOFF, RM (reprint author), MASSACHUSETTS GEN HOSP,CTR NMR,DEPT RADIOL,2ND FLOOR,BLDG 149,13TH ST,BOSTON,MA 02129, USA. FU NCI NIH HHS [R01-CA40303, 5PO1CA48729-02]; NHLBI NIH HHS [R01-HL39810] NR 22 TC 273 Z9 274 U1 0 U2 7 PU WILLIAMS & WILKINS PI BALTIMORE PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 SN 0740-3194 J9 MAGNET RESON MED JI Magn.Reson.Med. PD APR PY 1993 VL 29 IS 4 BP 553 EP 559 DI 10.1002/mrm.1910290420 PG 7 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA KU346 UT WOS:A1993KU34600019 PM 8464373 ER PT J AU FINE, MJ SINGER, DE PHELPS, AL HANUSA, BH KAPOOR, WN AF FINE, MJ SINGER, DE PHELPS, AL HANUSA, BH KAPOOR, WN TI DIFFERENCES IN LENGTH OF HOSPITAL STAY IN PATIENTS WITH COMMUNITY-ACQUIRED PNEUMONIA - A PROSPECTIVE 4-HOSPITAL STUDY SO MEDICAL CARE LA English DT Note ID MORTALITY; QUALITY C1 UNIV PITTSBURGH,DEPT BIOSTAT,PITTSBURGH,PA 15261. MASSACHUSETTS GEN HOSP,DEPT MED,GEN INTERNAL MED UNIT,BOSTON,MA 02114. RP FINE, MJ (reprint author), UNIV PITTSBURGH,DEPT MED,DIV GEN MED,167 LOTHROP HALL,190 LOTHROP ST,PITTSBURGH,PA 15261, USA. FU AHRQ HHS [R01 HS06468] NR 27 TC 70 Z9 72 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0025-7079 J9 MED CARE JI Med. Care PD APR PY 1993 VL 31 IS 4 BP 371 EP 380 DI 10.1097/00005650-199304000-00008 PG 10 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA KX026 UT WOS:A1993KX02600008 PM 8464253 ER PT J AU PONICHTERAMULCARE, JA AF PONICHTERAMULCARE, JA TI EXERCISE AND MULTIPLE-SCLEROSIS SO MEDICINE AND SCIENCE IN SPORTS AND EXERCISE LA English DT Article DE MUSCLE STRENGTH; AEROBIC EXERCISE CAPACITY; AUTONOMIC CARDIOVASCULAR REFLEXES; REHABILITATION ID HEART-RATE; MUSCLE; TEMPERATURE; CONDUCTION; IMPAIRMENT; SCALE AB Multiple sclerosis (MS) is a neurological disease characterized by a variety of potentially debilitating symptoms. The manner in which the disease affects each individual is unique: however, many individuals with MS have a normal life expectancy and remain ambulatory throughout their lives. Very little research has focused on understanding how MS affects basic physiologic responses during exercise. Four general topics have been addressed: autonomic control of heart rate (HR) and arterial blood pressure (BP), cardiorespiratory fitness. skeletal muscle function, and symptom instability under thermal stress. Abnormalities in cardiovascular reflexes have been observed in some MS individuals during quiescent testing; however, HR and BP responses during exercise have not confirmed such findings. Deficits in cardiorespiratory fitness appear to be present in moderately impaired individuals, which are not always present in minimally impaired persons. Similarly, abnormalities in skeletal muscle function have been reported in some individuals with MS, while absent in others. Training appears to improve both cardiorespiratory illness and skeletal muscle function. Findings appear to be indirectly influenced by the level of physical impairment of the experimental sample. This factor needs to be considered in sample selection, as well as in analyzing and reporting data. Elicitation of symptoms in response to thermal stressors has been documented by several investigators using unreliable techniques to measure core temperature. The use of more valid methods during rest and exercise have not confirmed the relationship between symptoms and core temperature changes. It may be that thermal sensitivity, although typically reported by most MS individuals, is a symptom that is very unique to each individual and sample selection may have indirectly contaminated results in past research. Considerations for future research are discussed. C1 WRIGHT STATE UNIV,SCH MED,US DEPT VET AFFAIRS,DAYTON VET ADM MED CTR,DAYTON,OH 45428. NR 57 TC 54 Z9 55 U1 1 U2 5 PU WILLIAMS & WILKINS PI BALTIMORE PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 SN 0195-9131 J9 MED SCI SPORT EXER JI Med. Sci. Sports Exerc. PD APR PY 1993 VL 25 IS 4 BP 451 EP 465 PG 15 WC Sport Sciences SC Sport Sciences GA KW796 UT WOS:A1993KW79600006 PM 8479299 ER PT J AU KOLACZYNSKI, JW CARTER, R SOPRANO, KJ MOSCICKI, R BODEN, G AF KOLACZYNSKI, JW CARTER, R SOPRANO, KJ MOSCICKI, R BODEN, G TI INSULIN BINDING AND DEGRADATION BY RAT-LIVER KUPFFER AND ENDOTHELIAL-CELLS SO METABOLISM-CLINICAL AND EXPERIMENTAL LA English DT Article ID I-123 INSULIN; HEPATOCYTES; RECEPTOR; INVIVO; METABOLISM; ANTIBODIES; EXTRACTION; DENSITY C1 MASSACHUSETTS GEN HOSP,DEPT CLIN IMMUNOL,BOSTON,MA 02114. TEMPLE UNIV,HLTH SCI CTR,SCH MED,DEPT MICROBIOL & IMMUNOL,PHILADELPHIA,PA 19140. TEMPLE UNIV,HLTH SCI CTR,SCH MED,DIV ENDOCRINOL & METAB,GEN CLIN RES CTR,PHILADELPHIA,PA 19140. FU NCRR NIH HHS [RR-349]; NIA NIH HHS [AG-07088] NR 28 TC 10 Z9 10 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 SN 0026-0495 J9 METABOLISM JI Metab.-Clin. Exp. PD APR PY 1993 VL 42 IS 4 BP 477 EP 481 DI 10.1016/0026-0495(93)90106-X PG 5 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA KW798 UT WOS:A1993KW79800013 PM 8487671 ER PT J AU CIMINO, JJ BARNETT, GO AF CIMINO, JJ BARNETT, GO TI AUTOMATIC KNOWLEDGE ACQUISITION FROM MEDLINE SO METHODS OF INFORMATION IN MEDICINE LA English DT Article DE COMPUTER REASONING; KNOWLEDGE ACQUISITION; KNOWLEDGE BASES; MEDLINE ID MEDICINE AB Construction of medical knowledge bases for use in expert systems is an arduous task. We propose a procedure for obtaining medical knowledge via automated analysis of citations found in the National Library of Medicine's MEDLINE(R) database. In this method, simple pattern of keywords and subheading co-occurrences are detected in the keyword descriptor portion of the citations. Each pattern corresponds to a fact, expressed as a semantic relationship between medical concepts. We have constructed a set of 504 pattern-matching rules and applied it to a set of 673 MEDLINE(R) citations to produce 2,795 such facts. The results are presented of an analysis of the syntactic and semantic features of these facts to understand the kinds of knowledge than can be obtained through our method and speculate on the potential uses and pitfalls for knowledge of this type. C1 HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,COMP SCI LAB,BOSTON,MA 02114. RP CIMINO, JJ (reprint author), COLUMBIA PRESBYTERIAN MED CTR,CTR MED INFORMAT,ATCHLEY PAVIL,ROOM 1310,NEW YORK,NY 10032, USA. OI Cimino, James/0000-0003-4101-1622 FU NLM NIH HHS [T15-LM07037-4, N01-LM-8-3513] NR 25 TC 23 Z9 28 U1 0 U2 2 PU F K SCHATTAUER VERLAG GMBH PI STUTTGART PA P O BOX 10 45 45, LENZHALDE 3, D-70040 STUTTGART, GERMANY SN 0026-1270 J9 METHOD INFORM MED JI Methods Inf. Med. PD APR PY 1993 VL 32 IS 2 BP 120 EP 130 PG 11 WC Computer Science, Information Systems; Health Care Sciences & Services; Medical Informatics SC Computer Science; Health Care Sciences & Services; Medical Informatics GA LA068 UT WOS:A1993LA06800006 PM 8321130 ER PT J AU ARCECI, RJ KING, AAJ SIMON, MC ORKIN, SH WILSON, DB AF ARCECI, RJ KING, AAJ SIMON, MC ORKIN, SH WILSON, DB TI MOUSE GATA-4 - A RETINOIC ACID-INDUCIBLE GATA-BINDING TRANSCRIPTION FACTOR EXPRESSED IN ENDODERMALLY DERIVED TISSUES AND HEART SO MOLECULAR AND CELLULAR BIOLOGY LA English DT Article ID PUTATIVE ZINC FINGER; NITROGEN REGULATORY GENE; DNA-BINDING; ASPERGILLUS-NIDULANS; NEUROSPORA-CRASSA; ENDOTHELIAL-CELLS; PROTEIN; GLOBIN; PROMOTER; RECEPTOR AB We report the cDNA cloning and characterization of mouse GATA-4, a new member of the family of zinc finger transcription factors that bind a core GATA motif. GATA-4 cDNA was identified by screening a 6.5-day mouse embryo library with oligonucleotide probes corresponding to a highly conserved region of the finger domains. Like other proteins of the family, GATA-4 is approximately 50 kDa in size and contains two zinc finger domains of the form C-X-N-C-(X17)-C-N-X-C. Cotransfection assays in heterologous cells demonstrate that GATA-4 trans activates reporter constructs containing GATA promoter elements. Northern (RNA) analysis and in situ hybridization show that GATA-4 mRNA is expressed in the heart, intestinal epithelium, primitive endoderm, and gonads. Retinoic acid-induced differentiation of mouse F9 cells into visceral or parietal endoderm is accompanied by increased expression of GATA-4 mRNA and protein. In vitro differentiation of embryonic stem cells into embryoid bodies is also associated with increased GATA-4 expression. We conclude that GATA-4 is a tissue-specific, retinoic acid-inducible, and developmentally regulated transcription factor. On the basis of its tissue distribution, we speculate that GATA-4 plays a role in gene expression in the heart, intestinal epithelium, primitive endoderm, and gonads. C1 BOSTON CHILDRENS HOSP,DIV PEDIAT HEMATOL ONCOL,BOSTON,MA 02115. HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115. HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02115. HOWARD HUGHES MED INST,BOSTON,MA 02115. RI Wilson, David/K-7433-2014 OI Wilson, David/0000-0002-1826-7745 NR 57 TC 560 Z9 573 U1 2 U2 9 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1325 MASSACHUSETTS AVENUE, NW, WASHINGTON, DC 20005-4171 SN 0270-7306 J9 MOL CELL BIOL JI Mol. Cell. Biol. PD APR PY 1993 VL 13 IS 4 BP 2235 EP 2246 PG 12 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA KT913 UT WOS:A1993KT91300025 PM 8455608 ER PT J AU SEGARS, JH MARKS, MS HIRSCHFELD, S DRIGGERS, PH MARTINEZ, E GRIPPO, JF BROWN, M WAHLI, W OZATO, K AF SEGARS, JH MARKS, MS HIRSCHFELD, S DRIGGERS, PH MARTINEZ, E GRIPPO, JF BROWN, M WAHLI, W OZATO, K TI INHIBITION OF ESTROGEN-RESPONSIVE GENE ACTIVATION BY THE RETINOID-X RECEPTOR-BETA - EVIDENCE FOR MULTIPLE INHIBITORY PATHWAYS SO MOLECULAR AND CELLULAR BIOLOGY LA English DT Article ID HUMAN-BREAST CANCER; 5' FLANKING REGION; THYROID-HORMONE; TRANSCRIPTIONAL ACTIVATION; GLUCOCORTICOID RECEPTORS; INVITRO TRANSCRIPTION; MAMMALIAN-CELLS; OVALBUMIN GENE; ACID RECEPTOR; V-ERBA AB The retinoid X receptor beta (RXRbeta; H-2RIIBP) forms heterodimers with various nuclear hormone receptors and binds multiple hormone response elements, including the estrogen response element (ERE). In this report, we show that endogenous RXRbeta contributes to ERE binding activity in nuclear extracts of the human breast cancer cell line MCF-7. To define a possible regulatory role of RXRbeta regarding estrogen-responsive transcription in breast cancer cells, RXRbeta and a reporter gene driven by the vitellogenin A2 ERE were transfected into estrogen-treated MCF-7 cells. RXRbeta inhibited ERE-driven reporter activity in a dose-dependent and element-specific fashion. This inhibition occurred in the absence of the RXR ligand 9-cis retinoic acid. The RXRbeta-induced inhibition was specific for estrogen receptor (ER)-mediated ERE activation because inhibition was observed in ER-negative MDA-MB-231 cells only following transfection of the estrogen-activated ER. No inhibition of the basal reporter activity was observed. The inhibition was not caused by simple competition of RXRbeta with the ER for ERE binding, since deletion mutants retaining DNA binding activity but lacking the N-terminal or C-terminal domain failed to inhibit reporter activity. In addition, cross-linking studies indicated the presence of an auxiliary nuclear factor present in MCF-7 cells that contributed to RXRbeta binding of the ERE. Studies using known heterodimerization partners of RXRbeta confirmed that RXRbeta/triiodothyronine receptor alpha heterodimers avidly bind the ERE but revealed the existence of another triiodothyronine-independent pathway of ERE inhibition. These results indicate that estrogen-responsive genes may be negatively regulated by RXRbeta through two distinct pathways. C1 NICHHD, MOLEC GROWTH REGULAT LAB, BETHESDA, MD 20892 USA. UNIV LAUSANNE, INST BIOL ANIM, CH-1015 LAUSANNE, SWITZERLAND. HOFFMANN LA ROCHE INC, DRUG METAB, NUTLEY, NJ 07110 USA. HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DEPT MED, BOSTON, MA 02115 USA. RI Wahli, Walter/B-1398-2009; Hirschfeld, Steven/E-2987-2016 OI Wahli, Walter/0000-0002-5966-9089; Hirschfeld, Steven/0000-0003-0627-7249 FU NICHD NIH HHS [HD00849-02] NR 80 TC 85 Z9 85 U1 0 U2 3 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0270-7306 J9 MOL CELL BIOL JI Mol. Cell. Biol. PD APR PY 1993 VL 13 IS 4 BP 2258 EP 2268 PG 11 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA KT913 UT WOS:A1993KT91300027 PM 8384307 ER PT J AU MCGEHEE, RE RON, D BRASIER, AR HABENER, JF AF MCGEHEE, RE RON, D BRASIER, AR HABENER, JF TI DIFFERENTIATION-SPECIFIC ELEMENT - A CIS-ACTING DEVELOPMENTAL SWITCH REQUIRED FOR THE SUSTAINED TRANSCRIPTIONAL EXPRESSION OF THE ANGIOTENSINOGEN GENE DURING HORMONAL-INDUCED DIFFERENTIATION OF 3T3-L1 FIBROBLASTS TO ADIPOCYTES SO MOLECULAR ENDOCRINOLOGY LA English DT Article ID ENHANCER BINDING-PROTEIN; ACUTE-PHASE RESPONSE; MESSENGER-RNA; CELL-LINE; HOMEODOMAIN; TISSUE; DOMAIN; RAT; SITE; POU AB The gene encoding angiotensinogen, the glycoprotein precursor for the vasopressor angiotensin II, is under coordinate tissue-specific, developmental, and hormonal regulation. We show here that the irreversible, developmentally regulated increase in angiotensinogen gene expression during the hormonal (dexamethasone, insulin, and isobutylmethylxanthine) differentiation of fibroblast-like 3T3-L1 cells into adipocytes is mediated by a 14-base pair cis-acting element located at -1000 in the 5'-flanking region of the gene. The sequence of this differentiation-specific element (DSE) is similar to sites that bind the homeotic and pou class of transcription factors found in the promoters of other genes known to be regulated during differentiation. Furthermore, we show that there are several high affinity DSE-specific binding proteins present in preadipocyte nuclear extracts that are competed with known homeotic and pou transcription factor DNA binding sequences. Thus the DSE appears to serve as a developmental switch for the expression of the angiotensinogen gene during the differentiation of fibroblasts to adipocytes and may be a binding site for one or more of the pou-homeodomain class of transcription factors. C1 HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,HOWARD HUGHES MED INST,MOLEC ENDOCRINOL LAB,BOSTON,MA 02114. NR 46 TC 51 Z9 51 U1 0 U2 0 PU ENDOCRINE SOC PI BETHESDA PA 4350 EAST WEST HIGHWAY SUITE 500, BETHESDA, MD 20814-4110 SN 0888-8809 J9 MOL ENDOCRINOL JI Mol. Endocrinol. PD APR PY 1993 VL 7 IS 4 BP 551 EP 560 DI 10.1210/me.7.4.551 PG 10 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA LA064 UT WOS:A1993LA06400009 PM 7684818 ER PT J AU HANRATTY, WP DEAROLF, CR AF HANRATTY, WP DEAROLF, CR TI THE DROSOPHILA-TUMOROUS-LETHAL HEMATOPOIETIC ONCOGENE IS A DOMINANT MUTATION IN THE HOPSCOTCH LOCUS SO MOLECULAR & GENERAL GENETICS LA English DT Article DE DROSOPHILA-MELANOGASTER; TUMOROUS-LETHAL GENE; HOPSCOTCH GENE; HEMATOPOIESIS ID FINE CYTOGENETICAL ANALYSIS; MELANOGASTER X-CHROMOSOME; ADJOINING REGIONS; BAND 10A1-2; MUTANTS AB The Drosophila Tumorous-lethal (Tum-l) mutation acts as an activated oncogene, causing hematopoietic neoplasms, overproliferation, and premature differentiation. Tum-l is a dominant mutation in the hopscotch (hop) locus, which is required for cell division and for proper embryonic segmentation. The Tum-l temperature-sensitive period for melanotic tumor formation includes most of larval and pupal development. C1 HARVARD UNIV,SCH MED,DANA FARBER CANC INST,ROOM JF 209,44 BINNEY ST,BOSTON,MA 02115. UNIV SO MISSISSIPPI,DEPT BIOL SCI,HATTIESBURG,MS 39406. HARVARD UNIV,SCH MED,DEPT RADIAT ONCOL,BOSTON,MA 02115. FU NCI NIH HHS [CA24488] NR 22 TC 105 Z9 105 U1 0 U2 4 PU SPRINGER VERLAG PI NEW YORK PA 175 FIFTH AVE, NEW YORK, NY 10010 SN 0026-8925 J9 MOL GEN GENET JI Mol. Gen. Genet. PD APR PY 1993 VL 238 IS 1-2 BP 33 EP 37 PG 5 WC Biochemistry & Molecular Biology; Genetics & Heredity SC Biochemistry & Molecular Biology; Genetics & Heredity GA KY630 UT WOS:A1993KY63000005 PM 8479437 ER PT J AU WARD, JM MARTYN, JAJ AF WARD, JM MARTYN, JAJ TI BURN INJURY-INDUCED NICOTINIC ACETYLCHOLINE-RECEPTOR CHANGES ON MUSCLE MEMBRANE SO MUSCLE & NERVE LA English DT Article DE MUSCLE-TYPE ACETYLCHOLINE RECEPTOR; BURN INJURY; THERMAL INJURY; D-TUBOCURARINE; ALPHA-BUNGAROTOXIN ID SKELETAL-MUSCLE; THERMAL-INJURY; HYPERMETABOLIC RESPONSE; PEDIATRIC-PATIENTS; ATRACURIUM; PHARMACODYNAMICS; STIMULATION; RATS AB Patients with thermal injury show pharmacological responses akin to those seen following denervation of motor nerve where there is an increase in the number of muscle-type acetylcholine receptors (AChR). This study in the rat, examined the effect of 20%, 30%, and 50% body surface area burn injury on gastrocnemius and diaphragm AChR number, quantitated by [I-125]alpha-bungarotoxin (alpha-BGT). Pharmacodynamic responses to D-tubocurarine were evaluated in the gastrocnemius muscle. AChR from gastrocnemius muscle were significantly increased in all burn groups at 14 days after burn. After 28 days, the AChR had returned to control in the 20% and 30% burn groups, but persisted in the 50% burn group AChR from diaphragm did not show significant changes between groups. Resistance to D-tubocurarine was not seen in burn groups compared with controls. Burn trauma causes increases of AChR at sites distant from the area of injury. Diaphragm muscle may be less sensitive than gastrocnemius to mediators which upregulate AChR. C1 HARVARD UNIV,SCH MED,DEPT ANAESTHESIA,BOSTON,MA 02115. SHRINERS BURN INST,BOSTON,MA. MASSACHUSETTS GEN HOSP,ANESTHESIA SERV,BOSTON,MA 02114. FU NIGMS NIH HHS [GM31569] NR 35 TC 29 Z9 29 U1 0 U2 1 PU JOHN WILEY & SONS INC PI NEW YORK PA 605 THIRD AVE, NEW YORK, NY 10158-0012 SN 0148-639X J9 MUSCLE NERVE JI Muscle Nerve PD APR PY 1993 VL 16 IS 4 BP 348 EP 354 DI 10.1002/mus.880160403 PG 7 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA KW181 UT WOS:A1993KW18100002 PM 8455647 ER PT J AU FRIM, DM UHLER, TA SHORT, MP EZZEDINE, ZD KLAGSBRUN, M BREAKEFIELD, XO ISACSON, O AF FRIM, DM UHLER, TA SHORT, MP EZZEDINE, ZD KLAGSBRUN, M BREAKEFIELD, XO ISACSON, O TI EFFECTS OF BIOLOGICALLY DELIVERED NGF, BDNF AND BFGF ON STRIATAL EXCITOTOXIC LESIONS SO NEUROREPORT LA English DT Article DE BDNF; BFGF; EXCITOTOXICITY; GENETICALLY ENGINEERED CELLS; NEURAL TRANSPLANTATION; NEUROPROTECTION; NEUROTROPHIC FACTOR; NGF; RAT; STRIATUM ID NERVE GROWTH-FACTOR; DOPAMINERGIC-NEURONS; CELLS; BRAIN; DEGENERATION; SYSTEM AB IMMORTALIZED rat fibroblasts, genetically altered to secrete NGF, BDNF, and bFGF, were implanted in rat brain near the striatum 7 days before striatal infusion of excitotoxic quantities of an NMDA-receptor agonist. Analysis of striatal damage 7 days after lesioning revealed that implantation of NGF-secreting cells reduced the size of the excitotoxic lesions by more than 80% when compared with control cells, while implanting of bFGF-secreting cells caused a 30% decrease in excitotoxic lesion size. BDNF-secreting fibroblasts caused no protective sparing in the striatum in this lesion model. This finding shows that biological delivery of NGF and bFGF by grafting of genetically altered cells protects against glutamate toxicity in the adult striatum while grafting of BDNF-producing cells does not. Such observations begin to define a spectrum of neurotrophic agents able to mitigate the cell loss seen in neurodegeneration. C1 MCLEAN HOSP,NEUROREGENERAT LAB,BELMONT,MA 02178. HARVARD UNIV,SCH MED,PROGRAM NEUROSCI,BOSTON,MA 02115. HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC BIOL,BOSTON,MA 02115. CHILDRENS HOSP MED CTR,DEPT SURG,BOSTON,MA 02115. MASSACHUSETTS GEN HOSP,NEUROL SERV,BOSTON,MA 02114. MASSACHUSETTS GEN HOSP,NEUROSURG SERV,BOSTON,MA 02114. MASSACHUSETTS GEN HOSP,NEUROGENET UNIT,BOSTON,MA 02114. FU NINDS NIH HHS [NS 24279, NS 29178, NS 30064] NR 25 TC 145 Z9 148 U1 0 U2 0 PU RAPID SCIENCE PUBLISHERS PI LONDON PA 2-6 BOUNDARY ROW, LONDON, ENGLAND SE1 8NH SN 0959-4965 J9 NEUROREPORT JI Neuroreport PD APR PY 1993 VL 4 IS 4 BP 367 EP 370 DI 10.1097/00001756-199304000-00006 PG 4 WC Neurosciences SC Neurosciences & Neurology GA KW546 UT WOS:A1993KW54600006 PM 8098961 ER PT J AU BROUILLET, E BEAL, MF AF BROUILLET, E BEAL, MF TI NMDA ANTAGONISTS PARTIALLY PROTECT AGAINST MPTP INDUCED NEUROTOXICITY IN MICE SO NEUROREPORT LA English DT Article DE MPTP; MPP+; EXCITOTOXICITY; NMDA RECEPTORS; MK-801; CGP39551; LY274614; PARKINSONS DISEASE ID RECEPTOR; INHIBITION; GLUTAMATE; TOXICITY; DISEASE; BRAIN; MPP+; ACID AB RECENT studies show that N-methyl-D-aspartate (NMDA) antagonists protect against neurotoxicity induced by local injections of 1-methyl-4-phenylpyridinium (MPP+) in both the substantia nigra and the striatum. The present studies examined whether either systemic administration of the non-competitive NMDA antagonist MK-801 or the competitive NMDA antagonists CGP39551 and LY274614 would protect against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) dopaminergic toxicity in mice. Administration of MK-801, CGP39551 or LY274614 for 24 hours partially but significantly attenuated striatal dopamine (DA) depletions induced by MPTP at both 24 h and 1 week. These results support the hypothesis that MPTP neurotoxicity involves a secondary excitotoxic mechanism mediated by NMDA receptors. Such a mechanism may play a role in the etiology of Parkinson's disease. C1 MASSACHUSETTS GEN HOSP,NEUROL SERV,NEUROCHEM LAB,BOSTON,MA 02114. HARVARD UNIV,SCH MED,BOSTON,MA 02114. RI Brouillet, Emmanuel/B-4784-2014 OI Brouillet, Emmanuel/0000-0001-6322-7403 FU NINDS NIH HHS [NS 10828]; PHS HHS [16367] NR 25 TC 80 Z9 81 U1 1 U2 3 PU RAPID SCIENCE PUBLISHERS PI LONDON PA 2-6 BOUNDARY ROW, LONDON, ENGLAND SE1 8NH SN 0959-4965 J9 NEUROREPORT JI Neuroreport PD APR PY 1993 VL 4 IS 4 BP 387 EP 390 DI 10.1097/00001756-199304000-00011 PG 4 WC Neurosciences SC Neurosciences & Neurology GA KW546 UT WOS:A1993KW54600011 PM 8499594 ER PT J AU MARKERT, JM MALICK, A COEN, DM MARTUZA, RL KORNBLITH, PL HINTON, DR AF MARKERT, JM MALICK, A COEN, DM MARTUZA, RL KORNBLITH, PL HINTON, DR TI REDUCTION AND ELIMINATION OF ENCEPHALITIS IN AN EXPERIMENTAL GLIOMA THERAPY MODEL WITH ATTENUATED HERPES-SIMPLEX MUTANTS THAT RETAIN SUSCEPTIBILITY TO ACYCLOVIR SO NEUROSURGERY LA English DT Article DE BRAIN NEOPLASM; ENCEPHALITIS; GENETIC ENGINEERING; GLIOMA; HERPES SIMPLEX ID DNA POLYMERASE GENE; RADIATION-THERAPY; MALIGNANT GLIOMA; VIRUS MUTANTS; THYMIDINE; PATHOGENICITY; RADIOTHERAPY; MUTATIONS; NEUROVIRULENCE; ASTROCYTOMAS AB MALIGNANT GLIOMAS ARE the most common malignant brain tumors and are almost universally fatal. A genetically engineered herpes simplex virus-1 mutant with decreased neurovirulence, dlsptk, has been shown to kill human glioma cells in culture and in animal models. However, intracranial inoculation of dlsptk is limited by fatal encephalitis at higher doses. Therefore, additional engineered and recombinant herpes simplex mutants with demonstrated reduced neurovirulence (AraA(r)9 , AraA(r)13, RE6, R3616) were examined as antiglioma agents. One long-term human glioma cell line and two early-passage human gliomas in culture were destroyed by all four viruses tested. In a subcutaneous glioma model, AraA(r)13, RE6, and R3616 retained substantial antineoplastic effects in nude mice when compared with controls (one-sided Wilcoxon rank test, P < 0.05 for one or more doses each). When tested in a nude mouse intracranial glioma model, both RE6 and R3616 significantly prolonged average survival without producing premature encephalitic deaths at two doses (log-rank statistic, P < 0.007). Histopathological studies of the brains of surviving animals revealed minimal focal encephalitis in two of three RE6-treated animals and no evidence of encephalitis in either one of three RE6-treated or in three of three R3616-treated animals. No evidence of residual tumor was seen in four of the six surviving animals. Additionally, both RE6 and R3616 were found to be susceptible to the common antiherpetic agent acyclovir, adding to their safety as potential antiglioma agents. Recombinant and engineered viruses that minimize host toxicity and maximize tumoricidal activity merit further study as antineoplastic agents. C1 GEORGETOWN UNIV,MED CTR,DEPT NEUROSURG,3800 RESERVOIR RD NW,WASHINGTON,DC 20007. HARVARD UNIV,MASSACHUSETTS GEN HOSP E,SCH MED,DEPT SURG NEUROSURG,BOSTON,MA. HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115. UNIV MICHIGAN,MED CTR,NEUROSURG SECT,ANN ARBOR,MI 48109. HARVARD UNIV,MASSACHUSSETTS GEN HOSP E,SCH MED,MOLEC NEUROGENET LAB,BOSTON,MA. FU NCRR NIH HHS [SO7RRO5381]; NIAID NIH HHS [R01-AI19838]; NINDS NIH HHS [NS24279] NR 35 TC 121 Z9 124 U1 0 U2 3 PU WILLIAMS & WILKINS PI BALTIMORE PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 SN 0148-396X J9 NEUROSURGERY JI Neurosurgery PD APR PY 1993 VL 32 IS 4 BP 597 EP 603 PG 7 WC Clinical Neurology; Surgery SC Neurosciences & Neurology; Surgery GA KV759 UT WOS:A1993KV75900016 PM 8386343 ER PT J AU BLACK, PM AF BLACK, PM TI MENINGIOMAS SO NEUROSURGERY LA English DT Article DE BRAIN NEOPLASMS; GROWTH FACTORS; MENINGIOMA; PROGESTERONE; RADIATION ID EPIDERMAL GROWTH-FACTOR; SEX STEROID-RECEPTORS; CAVERNOUS SINUS MENINGIOMAS; NERVE SHEATH MENINGIOMAS; SPINAL-CORD TUMORS; INTRACRANIAL MENINGIOMAS; PROGESTERONE RECEPTORS; RADIATION-THERAPY; MEDROXYPROGESTERONE ACETATE; CEREBELLOPONTINE ANGLE AB THIS ARTICLE REVIEWS the recent literature on the pathogenesis and pathology of meningiomas, contemporary techniques of surgical resection, and new nonsurgical treatments, including radiation and hormone therapy. Factors predisposing to meningioma formation include female sex, previous ionizing radiation, and Type 2 neurofibromatosis. The first factor may act through the expression of sex hormone receptors, especially the progesterone receptor, in these tumors; the other two probably act by causing a deletion on Chromosome 22. The pathological classifications of meningiomas include the traditional division into histological subtypes and the World Health Organization classification that selects characteristics that may lead to recurrence. There is an increasing emphasis on proliferative indices and other characteristics that may predict aggressive behavior in these tumors. On computed tomography, meningiomas are enhancing, well-marginated, dural-based lesions that may have considerable surrounding edema; the cause of the edema is uncertain but may result from secretory products of the tumor. Magnetic resonance imaging with enhancement will demonstrate these lesions accurately and can be used for three-dimensional reconstruction as well. Computed tomography and magnetic resonance imaging have largely replaced angiography in the preoperative diagnosis of meningiomas, but angiographic embolization may be a useful operative adjunct. Although meningioma surgery is sometimes thought of as benign and curative, the reported surgical mortality rate is as high as 14.3% and the reported 10-year survival rate after surgery varies from 43 to 77%. Surgery has advanced most in the management of suprasellar, cavernous sinus, clivus, tentorial, and posterior fossa meningiomas, because new approaches and a better understanding of anatomy have allowed more radical resection. There is still substantial morbidity associated with surgery in these regions, however, and the long-term recurrence rates are still unknown for these new radical techniques. For convexity, parasagittal, lateral sphenoid wing, and olfactory groove meningiomas, complete resection should be the goal and operative morbidity appears to be low. There is a high recurrence rate after surgery. With apparent total removal, the recurrence rate varies from 9 to 20% at 10 years, with subtotal resection varying from 18.4 to 50%. The degree of resection appears to be most important in recurrence, but histopathological features are also important. Recently, radiation therapy has been recognized as a useful adjunct to surgery, and with radio-surgical techniques may become more important in the future. Antiprogesterone therapy appears to have had some success as well, and it or other hormonal therapy may be another future option for residual or recurrent meningiomas C1 BRIGHAM & WOMENS HOSP,CHILDRENS HOSP,BOSTON,MA 02115. RP BLACK, PM (reprint author), BRIGHAM & WOMENS HOSP,CHILDRENS HOSP,DANA FARBER CANC INST,NEUROSURG SERV,300 LONGWOOD AVE,BOSTON,MA 02115, USA. NR 223 TC 221 Z9 227 U1 0 U2 12 PU WILLIAMS & WILKINS PI BALTIMORE PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 SN 0148-396X J9 NEUROSURGERY JI Neurosurgery PD APR PY 1993 VL 32 IS 4 BP 643 EP 657 PG 15 WC Clinical Neurology; Surgery SC Neurosciences & Neurology; Surgery GA KV759 UT WOS:A1993KV75900023 PM 8474655 ER PT J AU WINAWER, SJ ZAUBER, AG OBRIEN, MJ HO, MN GOTTLIEB, L STERNBERG, SS WAYE, JD BOND, J SCHAPIRO, M STEWART, ET PANISH, J ACKROYD, F KURTZ, RC SHIKE, M AF WINAWER, SJ ZAUBER, AG OBRIEN, MJ HO, MN GOTTLIEB, L STERNBERG, SS WAYE, JD BOND, J SCHAPIRO, M STEWART, ET PANISH, J ACKROYD, F KURTZ, RC SHIKE, M TI RANDOMIZED COMPARISON OF SURVEILLANCE INTERVALS AFTER COLONOSCOPIC REMOVAL OF NEWLY DIAGNOSED ADENOMATOUS POLYPS SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID COLORECTAL ADENOMAS; SUBSEQUENT CARCINOMA; FOLLOW-UP; RISK; CANCER; INDIVIDUALS; POLYPECTOMY; POPULATION; COLON AB Background. The identification and removal of adenomatous polyps and post-polypectomy surveillance are considered to be important for the control of colorectal cancer. In current practice, the intervals between colonoscopies after polypectomy are variable, often a year long, and not based on data from randomized clinical trials. We sought to determine whether follow-up colonoscopy at three years would detect important colonic lesions as well as follow-up colonoscopy at both one and three years. Methods. Patients were eligible if they had one or more adenomas, no previous polypectomy, and a complete colonoscopy and if all their polyps had been removed. They were randomly assigned to have follow-up colonoscopy at one and three years or at three years only. The two study end points were the detection of any adenoma, and the detection of adenomas with advanced pathological features (defined as those >1 cm in diameter and those with high-grade dysplasia or invasive cancer). Results. Of 2632 eligible patients, 1418 were randomly assigned to the two follow-up groups, 699 to the two-examination group and 719 to the one-examination group. The percentage of patients with adenomas in the group examined at one and three years was 41.7 percent, as compared with 32.0 percent in the group examined at three years (P = 0.006). The percentage of patients with adenomas with advanced pathological features was the same in both groups (3.3 percent). Conclusions. Colonoscopy performed three years after colonoscopic removal of adenomatous polyps detects important colonic lesions as effectively as follow-up colonoscopy after both one and three years. An interval of at least three years is recommended before follow-up examination after colonoscopic removal of newly diagnosed adenomatous polyps. Adoption of this recommendation nationally should reduce the cost of post-polypectomy surveillance and screening. C1 MEM SLOAN KETTERING CANC CTR,NATL POLYP STUDY HEADQUARTERS,NEW YORK,NY 10021. MT SINAI HOSP,NEW YORK,NY. VET AFFAIRS MED CTR,MINNEAPOLIS,MN. VALLEY PRESBYTERIAN HOSP,VAN NUYS,CA. CEDARS SINAI MED CTR,LOS ANGELES,CA 90048. MASSACHUSETTS GEN HOSP,BOSTON,MA 02114. BOSTON CITY HOSP,MALLORY INST PATHOL,BOSTON,MA 02118. MILWAUKEE CTY MED CTR,MILWAUKEE,WI. FU NCI NIH HHS [CA-26852] NR 28 TC 675 Z9 682 U1 1 U2 9 PU MASS MEDICAL SOC PI BOSTON PA 10 SHATTUCK, BOSTON, MA 02115 SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD APR 1 PY 1993 VL 328 IS 13 BP 901 EP 906 DI 10.1056/NEJM199304013281301 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA KU177 UT WOS:A1993KU17700001 PM 8446136 ER PT J AU MEINERT, C STERNBERG, A AMENDLIBERCCI, D DODGE, J GERCZAK, C HAYNES, V ISAACSON, M LEVINE, C MAGUIRE, M MEINERT, J TONASCIA, J TONASCIA, S WETZEL, D HAWKINS, B BONDS, B CANNER, J CONNOR, K DICKERSIN, K GUNTHER, G THOMAS, B TU, N XU, C SPAETH, G KATZ, LJ BECKERSHOFF, C DEPIANO, D SLAGLE, S BARONE, L GROSS, P JACKSON, M MORGANSTERN, S SAMMARTINO, M STRONG, C WILENSKY, J FROHLICHSTEIN, D BECKMAN, H CRABTREE, J CZEDIK, C SUNDERMEYER, S KURINIJ, N DUDLEY, P SURAN, A KRUG, J CHIAVELLI, M BERRY, I EVANS, C JOYNER, M KITTAY, R MELANSON, A STOUT, K WAY, R EPSTEIN, D BERSON, F LATINA, M MELAMED, S JOHNSON, E LINDERMEYER, A MCGEE, R PIVABOWE, D SMITH, TJ WILENSKY, J TESSLER, H FROHLICHSTEIN, D ANDERSON, J JEDNOCK, N PETERSON, R NAIL, C MILLMAN, K SIEGEL, H SPIGELMAN, V SPRINCZ, M BECKMAN, H CYRLIN, M CZEDIK, C RITCH, R PODOLSKY, M STEINBERGER, D STOCK, L ABDULAZIM, J JOHNSON, M KRANTZ, J SWEENEY, V CUNNINGHAM, J MARANAN, L TERRERO, A THEERTHAM, M SPAETH, G KATZ, LJ BECKERSHOFF, C DEPIANO, D MOLINEAUX, J NICHOLS, J PETRAKIS, P SLAGLE, J CAPRIOLI, J SIMMONS, S STRANG, S CAPONE, M SAMMARTINO, M SANDY, R WILSON, R WITTKOWSKI, D VELATHOMAS, MA HARBIN, T LEEF, D GOMEZ, S GEMMILL, M GILMAN, J MOORE, K SWORDS, R WRIGHT, J CAMPBELL, D CARLTON, S FRANK, MK LASALLE, J MAIO, M NICHOLAS, P SNIPES, C WEBER, P KAPETANSKY, F MCKINNEY, K CLARK, M MOORE, D SIMMONS, L JONES, S RADIUS, R KLEWIN, K SOPA, J GUNDERSEN, B RICHIE, M WIPPLINGER, W BAUER, D LANGE, C BENCE, D HELT, P KAVANAGH, J WOLF, C AF MEINERT, C STERNBERG, A AMENDLIBERCCI, D DODGE, J GERCZAK, C HAYNES, V ISAACSON, M LEVINE, C MAGUIRE, M MEINERT, J TONASCIA, J TONASCIA, S WETZEL, D HAWKINS, B BONDS, B CANNER, J CONNOR, K DICKERSIN, K GUNTHER, G THOMAS, B TU, N XU, C SPAETH, G KATZ, LJ BECKERSHOFF, C DEPIANO, D SLAGLE, S BARONE, L GROSS, P JACKSON, M MORGANSTERN, S SAMMARTINO, M STRONG, C WILENSKY, J FROHLICHSTEIN, D BECKMAN, H CRABTREE, J CZEDIK, C SUNDERMEYER, S KURINIJ, N DUDLEY, P SURAN, A KRUG, J CHIAVELLI, M BERRY, I EVANS, C JOYNER, M KITTAY, R MELANSON, A STOUT, K WAY, R EPSTEIN, D BERSON, F LATINA, M MELAMED, S JOHNSON, E LINDERMEYER, A MCGEE, R PIVABOWE, D SMITH, TJ WILENSKY, J TESSLER, H FROHLICHSTEIN, D ANDERSON, J JEDNOCK, N PETERSON, R NAIL, C MILLMAN, K SIEGEL, H SPIGELMAN, V SPRINCZ, M BECKMAN, H CYRLIN, M CZEDIK, C RITCH, R PODOLSKY, M STEINBERGER, D STOCK, L ABDULAZIM, J JOHNSON, M KRANTZ, J SWEENEY, V CUNNINGHAM, J MARANAN, L TERRERO, A THEERTHAM, M SPAETH, G KATZ, LJ BECKERSHOFF, C DEPIANO, D MOLINEAUX, J NICHOLS, J PETRAKIS, P SLAGLE, J CAPRIOLI, J SIMMONS, S STRANG, S CAPONE, M SAMMARTINO, M SANDY, R WILSON, R WITTKOWSKI, D VELATHOMAS, MA HARBIN, T LEEF, D GOMEZ, S GEMMILL, M GILMAN, J MOORE, K SWORDS, R WRIGHT, J CAMPBELL, D CARLTON, S FRANK, MK LASALLE, J MAIO, M NICHOLAS, P SNIPES, C WEBER, P KAPETANSKY, F MCKINNEY, K CLARK, M MOORE, D SIMMONS, L JONES, S RADIUS, R KLEWIN, K SOPA, J GUNDERSEN, B RICHIE, M WIPPLINGER, W BAUER, D LANGE, C BENCE, D HELT, P KAVANAGH, J WOLF, C TI THE GLAUCOMA LASER TRIAL (GLT) .5. SUBGROUP DIFFERENCES AT ENROLLMENT SO OPHTHALMIC SURGERY AND LASERS LA English DT Article ID OPEN-ANGLE GLAUCOMA; LONGITUDINAL DATA-ANALYSIS; VISUAL-FIELD DEFECTS; RISK-FACTORS; OCULAR HYPERTENSION; CLINICAL RESEARCH; PREVALENCE; CHARTS; RACE AB Data collected at enrollment on the 271 patients (542 eyes) who participated in the Glaucoma Laser Trial (GLT) were analyzed for subgroup differences. The subgrouping variables included four patient characteristics (race, sex, age, and history of a vascular disease) and one ocular characteristic (myopia). The strongest differences observed were between blacks and whites. As compared with the eyes of the white patients, those of the black patients had lower mean decibels per test location in the visual field (P < .001), greater mean defect (P < .001), number of abnormal test locations (P < .001), and corrected loss variance (P = .009), as well as greater cup depth (P < .001), and larger mean horizontal (P = .002) and vertical (P < .001) cup/disc ratios. C1 MASSACHUSETTS EYE & EAR INFIRM,BOSTON,MA 02114. UNIV ILLINOIS,EYE & EAR INFIRM,CTR VISUAL FIELD READING,CHICAGO,IL 60612. NEW YORK EYE & EAR INFIRM,NEW YORK,NY 10003. WILLS EYE HOSP & RES INST,CTR DISC STEREOPHOTOG READING,PHILADELPHIA,PA 19107. MED COLL WISCONSIN,MILWAUKEE,WI 53226. OHIO STATE UNIV,COLUMBUS,OH 43210. NEI,PROJECT OFF,BETHESDA,MD 20892. RP MEINERT, C (reprint author), JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT EPIDEMIOL,615 N WOLFE ST,BALTIMORE,MD 21205, USA. RI Dickersin, Kay/A-4576-2008 NR 33 TC 0 Z9 0 U1 0 U2 0 PU SLACK INC PI THOROFARE PA 6900 GROVE RD, THOROFARE, NJ 08086 SN 0022-023X J9 OPHTHALMIC SURG LAS JI Ophthalmic Surg. Lasers PD APR PY 1993 VL 24 IS 4 BP 232 EP 241 PG 10 WC Ophthalmology; Surgery SC Ophthalmology; Surgery GA KX368 UT WOS:A1993KX36800002 ER PT J AU ARK, J JUPITER, JB AF ARK, J JUPITER, JB TI THE RATIONALE FOR PRECISE MANAGEMENT OF DISTAL RADIUS FRACTURES SO ORTHOPEDIC CLINICS OF NORTH AMERICA LA English DT Article ID COLLES FRACTURE; EXTERNAL FIXATION; PLASTER C1 MASSACHUSETTS GEN HOSP,ORTHOPAED TRAUMA SERV,15 PARKMAN ST,BOSTON,MA 02114. HARVARD UNIV,SCH MED,DEPT ORTHOPAED SURG,BOSTON,MA 02115. NR 54 TC 42 Z9 46 U1 1 U2 1 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 SN 0030-5898 J9 ORTHOP CLIN N AM JI Orthop. Clin. North Am. PD APR PY 1993 VL 24 IS 2 BP 205 EP 210 PG 6 WC Orthopedics SC Orthopedics GA LA287 UT WOS:A1993LA28700002 PM 8479718 ER PT J AU CANNON, SC MCCLATCHEY, AI GUSELLA, JF AF CANNON, SC MCCLATCHEY, AI GUSELLA, JF TI MODIFICATION OF THE NA+ CURRENT CONDUCTED BY THE RAT SKELETAL-MUSCLE ALPHA-SUBUNIT BY COEXPRESSION WITH A HUMAN BRAIN BETA-SUBUNIT SO PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY LA English DT Note DE SODIUM CHANNEL; SKELETAL MUSCLE; XENOPUS ID SODIUM-CHANNEL AB Sodium channels are multimeric structures composed of alpha and beta subunits. Oocytes injected with RNA encoding only the alpha subunit express voltage-gated Na+ currents. The kinetics of inactivation, however, are abnormal. Co-injection of rat brain alpha and beta subunits modifies inactivation of I(Na) such that it closely resembles endogenous currents [1]. Here we show that a beta subunit derived from human brain directs the same functional modification of I(Na) expressed by a rat skeletal muscle ct subunit. This implies that functional domains for the interaction of alpha and beta subunits are highly conserved across both tissues and species. C1 HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEPT NEUROL,BOSTON,MA 02114. HARVARD UNIV,MASSACHUSETTS GEN HOSP,MOLEC NEUROGENET LAB,BOSTON,MA 02114. RP CANNON, SC (reprint author), HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,HOWARD HUGHES MED INST,WELLMAN 414,BOSTON,MA 02114, USA. FU NIAMS NIH HHS [AR-41025]; NINDS NIH HHS [NS-2224] NR 9 TC 79 Z9 81 U1 1 U2 2 PU SPRINGER VERLAG PI NEW YORK PA 175 FIFTH AVE, NEW YORK, NY 10010 SN 0031-6768 J9 PFLUG ARCH EUR J PHY JI Pflugers Arch. PD APR PY 1993 VL 423 IS 1-2 BP 155 EP 157 DI 10.1007/BF00374974 PG 3 WC Physiology SC Physiology GA KW828 UT WOS:A1993KW82800022 PM 7683789 ER PT J AU RITZMANN, RF KLING, A MELCHIOR, CL GLASKY, AJ AF RITZMANN, RF KLING, A MELCHIOR, CL GLASKY, AJ TI EFFECT OF AGE AND STRAIN ON WORKING MEMORY IN MICE AS MEASURED BY WIN-SHIFT PARADIGM SO PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR LA English DT Article DE WORKING MEMORY; MICE; AGE; STRAIN; MEMORY DEFICIT; PHYSOSTIGMINE; TACRINE ID RAT AB Working memory is disrupted in Alzheimer's disease and stroke; therefore, any therapeutic drug should restore deficits in working memory. The win-shift foraging paradigm has been demonstrated to be a model of working memory in rats. In the present study, this paradigm was adapted to mice because of the greater ease and economy of testing potential drugs in mice and the wider availability of strains of aged mice with naturally occurring working memory deficits. This study has demonstrated strain differences in the working memory trace and that age induces a deficit that can be detected at 11 months of age in mice. Tacrine and physostigmine enhance the memory trace in normal mice and physostigmine can reverse age-induced working memory deficits in subjects with mild and moderate deficits but not in subjects with severe deficits. C1 OLIVE VIEW MED CTR,EDUC & RES INST,SYLMAR,CA 91342. W LOS ANGELES VET ADM,LOS ANGELES,CA 90073. SEPULVEDA VET ADM,LOS ANGELES,CA 90073. RP RITZMANN, RF (reprint author), ADVANCED IMMUNO THERAPEUT,IRVINE,CA 92680, USA. FU NIAAA NIH HHS [NIAAA 08709]; PHS HHS [NIA 09911] NR 12 TC 16 Z9 16 U1 1 U2 1 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 0091-3057 J9 PHARMACOL BIOCHEM BE JI Pharmacol. Biochem. Behav. PD APR PY 1993 VL 44 IS 4 BP 805 EP 807 DI 10.1016/0091-3057(93)90009-I PG 3 WC Behavioral Sciences; Neurosciences; Pharmacology & Pharmacy SC Behavioral Sciences; Neurosciences & Neurology; Pharmacology & Pharmacy GA KU641 UT WOS:A1993KU64100009 PM 8469692 ER PT J AU JEVSEVAR, DS RILEY, PO HODGE, WA KREBS, DE AF JEVSEVAR, DS RILEY, PO HODGE, WA KREBS, DE TI KNEE KINEMATICS AND KINETICS DURING LOCOMOTOR ACTIVITIES OF DAILY LIVING IN SUBJECTS WITH KNEE ARTHROPLASTY AND IN HEALTHY CONTROL SUBJECTS SO PHYSICAL THERAPY LA English DT Article DE ACTIVITIES OF DAILY LIVING; DYNAMICS; KNEE; LOCOMOTION ID LOWER-LIMB MECHANICS; TORQUE; CHAIR; WALKING; MOTION; MODELS; GAIT; BODY AB Background and Purpose. Knee kinematics and kinetics have not been quantitatively studied during gait, stair negotiation, and rising from a chair in the same subjects, either among healthy control subjects or among subjects with knee joint impairments. Despite this paucity of data, rehabilitation goals often include achieving a specific peak knee torque at a specific, fixed angular velocity. Subjects. We compared the kinematic and kinetic performance of the knees in 15 subjects (19 knees) who bad undergone knee arthroplasty (KA group) and 11 healthy subjects (22 knees) who served as a control group. The KA group subjects ranged in age from 61 to 78 years, and the control group subjects ranged in age from 26 to 88 years The KA group subjects bad had knee osteoarthritis, were greater-than-or-equal-to 1 year postsurgery, and were considered fully rehabilitated. Methods. All subjects were analyzed during barefoot paced walking, stair ascent and descent, and arising from a chair Results. Compared with the control subjects, the KA group subjects bad significantly different knee sagittal range of motion, angular velocities, and maximum knee moments during loaded knee extension. Vertical ground reactions did not differ significantly between groups Both groups' maximum extension angular velocity exceeded 350-degrees/s during the swing phase of gait, but the maximum loaded extension velocity averaged only 140-degrees/s (during rising from a chair). Maximum knee flexion moments were approximately 10 to 15 N.m/%BW (knee moments normalized to percentage of body weight in newtons). Conclusion and Discussion. We concluded that locomotor ADLs demand relatively slow loaded angular velocities and low knee torques, a factor that should be considered in knee postarthroplasty exercise prescription. C1 MASSACHUSETTS GEN HOSP,INST HLTH PROFESS,101 MERRIMAC ST,BOSTON,MA 02114. ALLEGHENY GEN HOSP,MED COLL PENN,PITTSBURGH,PA 15212. MASSACHUSETTS GEN HOSP,BIOMOT LAB,BOSTON,MA 02114. RI Riley, Patrick/B-3053-2009 NR 32 TC 71 Z9 75 U1 0 U2 9 PU AMER PHYS THER ASSN PI ALEXANDRIA PA 1111 N FAIRFAX ST, ALEXANDRIA, VA 22314 SN 0031-9023 J9 PHYS THER JI Phys. Ther. PD APR PY 1993 VL 73 IS 4 BP 229 EP 242 PG 14 WC Orthopedics; Rehabilitation SC Orthopedics; Rehabilitation GA KW846 UT WOS:A1993KW84600006 PM 8456142 ER PT J AU KREBS, DE JEVSEVAR, DS RILEY, PO AF KREBS, DE JEVSEVAR, DS RILEY, PO TI KNEE KINEMATICS AND KINETICS DURING LOCOMOTOR ACTIVITIES OF DAILY LIVING IN SUBJECTS WITH KNEE ARTHROPLASTY AND IN HEALTHY CONTROL SUBJECTS - REPLY SO PHYSICAL THERAPY LA English DT Letter C1 ALLEGHENY GEN HOSP,MED COLL PENN,PITTSBURGH,PA 15212. MASSACHUSETTS GEN HOSP,BIOMOT LAB,BOSTON,MA 02114. RP KREBS, DE (reprint author), MASSACHUSETTS GEN HOSP,INST HLTH PROFESS,101 MERRIMAC ST,BOSTON,MA 02114, USA. RI Riley, Patrick/B-3053-2009 NR 5 TC 0 Z9 0 U1 0 U2 0 PU AMER PHYS THER ASSN PI ALEXANDRIA PA 1111 N FAIRFAX ST, ALEXANDRIA, VA 22314 SN 0031-9023 J9 PHYS THER JI Phys. Ther. PD APR PY 1993 VL 73 IS 4 BP 241 EP 242 PG 2 WC Orthopedics; Rehabilitation SC Orthopedics; Rehabilitation GA KW846 UT WOS:A1993KW84600008 ER PT J AU YAREMCHUK, MJ AF YAREMCHUK, MJ TI VASCULARIZED OSTEOCHONDRAL ALLOGRAFTS IN AN IMMUNOSUPPRESSED RAT MODEL - GRAFT MODULATION AND HOST IMMUNE TOLERANCE - DISCUSSION SO PLASTIC AND RECONSTRUCTIVE SURGERY LA English DT Discussion ID TRANSPLANTATION RP YAREMCHUK, MJ (reprint author), MASSACHUSETTS GEN HOSP,DIV PLAST RECONSTRUCT & CRANIOFACIAL SURG,CTR AMBULATORY CARE,BOSTON,MA 02114, USA. NR 8 TC 0 Z9 0 U1 0 U2 0 PU WILLIAMS & WILKINS PI BALTIMORE PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 SN 0032-1052 J9 PLAST RECONSTR SURG JI Plast. Reconstr. Surg. PD APR PY 1993 VL 91 IS 4 BP 606 EP 607 PG 2 WC Surgery SC Surgery GA KT700 UT WOS:A1993KT70000005 ER PT J AU KONONAS, TC BUCKY, LP HURLEY, C MAY, JW AF KONONAS, TC BUCKY, LP HURLEY, C MAY, JW TI THE FATE OF SUCTIONED AND SURGICALLY REMOVED FAT AFTER REIMPLANTATION FOR SOFT-TISSUE AUGMENTATION - A VOLUMETRIC AND HISTOLOGIC-STUDY IN THE RABBIT SO PLASTIC AND RECONSTRUCTIVE SURGERY LA English DT Article ID RETROSPECTIVE ANALYSIS; AUTOLOGOUS FAT; LIPOSUCTION; LIPECTOMY; SURVIVAL; GRAFTS AB The use of autologous fat transplantation has seen renewed popularity with the recent advent of liposuction as a body recontouring technique. However, clinicians are still faced with uncertainty concerning the ultimate volume maintenance of the transplanted fat graft at its recipient site. This study was initiated to examine and evaluate the changes in volume of suctioned versus surgically excised fat grafts over a 9-month period in the New Zealand White rabbit. Fat grafts of equal volume were harvested from the groin using standard suction and surgical techniques and transferred into isolated pockets in the ear. Results demonstrate that both suctioned and surgically removed fat grafts undergo significant volume reduction. However, surgically excised fat maintains its volume (42.2 percent; n = 16) better than suction-assisted fat grafts (31.6 percent; n = 16; p < 0.05). Histologic examination showed that fibrous connective tissue was more prevalent in the suctioned fat grafts than in the surgically removed fat grafts. C1 MASSACHUSETTS GEN HOSP,DEPT SURG,15 PARKMAN ST,ACC-453,BOSTON,MA 02114. MASSACHUSETTS GEN HOSP,PLAST SURG RES LAB,BOSTON,MA 02114. NR 49 TC 119 Z9 130 U1 0 U2 5 PU WILLIAMS & WILKINS PI BALTIMORE PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 SN 0032-1052 J9 PLAST RECONSTR SURG JI Plast. Reconstr. Surg. PD APR PY 1993 VL 91 IS 5 BP 763 EP 768 DI 10.1097/00006534-199304001-00001 PG 6 WC Surgery SC Surgery GA KV328 UT WOS:A1993KV32800001 PM 8460177 ER PT J AU ESKEY, CJ KORETSKY, AP DOMACH, MM JAIN, RK AF ESKEY, CJ KORETSKY, AP DOMACH, MM JAIN, RK TI ROLE OF OXYGEN VS GLUCOSE IN ENERGY-METABOLISM IN A MAMMARY-CARCINOMA PERFUSED EXVIVO - DIRECT MEASUREMENT BY P-31 NMR SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article ID NUCLEAR-MAGNETIC-RESONANCE; BLOOD-FLOW; MURINE TUMORS; SOLID TUMORS; INVIVO; SPECTROSCOPY; ENVIRONMENT; RESISTANCE; MODEL; CELLS AB The role of glycolysis vs. respiration in tumor energy metabolism has been studied, to date, primarily in vitro by using single cells, multicellular spheroids, or tissue slices. With the advent of in vivo NMR spectroscopy, several investigators have shown that tumor energy status depends on its blood flow. Since manipulation of blood flow alters both oxygen and glucose delivery to a solid tumor, these studies have not been able to separate the relative contribution of oxygen vs. glucose in energy metabolism in vivo. In the present study, we have overcome this problem by combining two methods: the tissue-isolated R3230AC mammary adenocarcinoma perfused ex vivo and P-31 NMR spectroscopy. The isolated tumor permits one to control the perfusion pressure as well as the metabolite concentrations in the perfusate. NMR spectroscopy permits one to measure the ratio of nucleoside triphosphate to inorganic phosphate (NTP/P(i)) and pH. Our results show that (i) the NTP/P(i) ratio ex vivo is similar to that observed in vivo prior to surgery, (ii) the NTP/P(i) ratio is insensitive to flow changes at high flow rates but is proportional to flow rate at flows comparable to those found in vivo, (iii) the NTP/P(i) ratio of these tumors is resistant to hypoxia and is not maintained when glucose is removed or replaced with glutamine, and (iv) although both O2 and glucose are consumed by these tumors, the effect of perfusate flow rate appears to be mediated largely through glucose delivery. The current approach not only provides information about the role of glycolysis vs. respiration in a rodent tumor but also is general and versatile enough to provide similar data in human tumors perfused ex vivo. C1 CARNEGIE MELLON UNIV,DEPT BIOL SCI,PITTSBURGH,PA 15213. CARNEGIE MELLON UNIV,CTR NUCL MAGNET RESONANCE,PITTSBURGH,PA 15213. HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEPT RADIAT ONCOL,STEELE LAB,BOSTON,MA 02114. RP ESKEY, CJ (reprint author), CARNEGIE MELLON UNIV,DEPT CHEM ENGN,PITTSBURGH,PA 15213, USA. RI Koretsky, Alan/C-7940-2015 OI Koretsky, Alan/0000-0002-8085-4756 FU NCI NIH HHS [CA-37239]; NCRR NIH HHS [RR-03631] NR 38 TC 54 Z9 55 U1 0 U2 1 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD APR 1 PY 1993 VL 90 IS 7 BP 2646 EP 2650 DI 10.1073/pnas.90.7.2646 PG 5 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA KV975 UT WOS:A1993KV97500020 PM 8464871 ER PT J AU BILLAUD, M ISSELBACHER, KJ BERNARDS, R AF BILLAUD, M ISSELBACHER, KJ BERNARDS, R TI A DOMINANT-NEGATIVE MUTANT OF MAX THAT INHIBITS SEQUENCE-SPECIFIC DNA-BINDING BY MYC PROTEINS SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article ID LOOP-HELIX PROTEINS; C-MYC; TRANSCRIPTION; CELLS; GENE; EXTRAMACROCHAETAE; NEUROBLASTOMA; AMPLIFICATION; DROSOPHILA; EXPRESSION AB Myc proteins are basic helix-loop-helix/leucine-zipper proteins that bind to specific DNA sequences. In vivo, Myc proteins have been found associated with Max, another basic helix-loop-helix/leucine-zipper protein. However, it is not known to what extent the dimerization of Myc with Max is required for the manifestation of the Myc-induced phenotype. To investigate this, we constructed a dominant-negative mutant of Max, named dMax, that inhibits sequence-specific DNA binding of Myc proteins. Using a rat neuroblastoma model system, we show that dMax reverts N-Myc-induced changes in cellular gene expression. A control mutant of dMax that contains a proline residue in the leucine-zipper region was unable to bind to N-Myc and did not revert the N-Myc-induced changes in cellular gene expression. These data support the hypothesis that N-Myc affects neuroblastoma gene expression through the formation of a DNA-binding heterodimeric complex with Max in vivo. C1 HARVARD UNIV,SCH MED,BOSTON,MA 02129. RP BILLAUD, M (reprint author), MASSACHUSETTS GEN HOSP,CTR CANC,DIV MOLEC GENET,149 13TH ST,BOSTON,MA 02129, USA. RI Billaud, Marc/M-6954-2013; OI Bernards, Rene/0000-0001-8677-3423 NR 35 TC 21 Z9 21 U1 0 U2 0 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD APR 1 PY 1993 VL 90 IS 7 BP 2739 EP 2743 DI 10.1073/pnas.90.7.2739 PG 5 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA KV975 UT WOS:A1993KV97500039 PM 8464883 ER PT J AU MARKOWITZ, JS AUCHINCLOSS, H GRUSBY, MJ GLIMCHER, LH AF MARKOWITZ, JS AUCHINCLOSS, H GRUSBY, MJ GLIMCHER, LH TI CLASS II-POSITIVE HEMATOPOIETIC-CELLS CANNOT MEDIATE POSITIVE SELECTION OF CD4+ T-LYMPHOCYTES IN CLASS-II-DEFICIENT MICE SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article ID ANTIGEN-PRESENTING CELLS; BONE-MARROW CHIMERAS; SELF-RECOGNITION; RESTRICTION SPECIFICITIES; GENE PHENOTYPE; H-2 ANTIGENS; NUDE-MICE; THYMUS; ALLOREACTIVITY; REPERTOIRE AB Generation of immunocompetent alpha/beta T-cell receptor-positive T cells from CD4+CD8+ thymocytes depends upon their interaction with thymic major histocompatibility complex (MHC) molecules. This process of positive selection provides mature T cells that can recognize antigens in the context of self-MHC proteins. Previous studies investigating haplotype restriction in thymic and bone-marrow chimeras concluded that radioresistant thymic cortical epithelium directs the positive selection of thymocytes. There is controversy, however, as to whether intra- or extrathymic radiosensitive bone marrow-derived macrophage and dendritic cells also can mediate positive selection. To determine whether CD4+ T cells can be positively selected by hematopoietic cells, we generated chimeric animals expressing MHC class II molecules on either bone marrow-derived or thymic stromal cells by using a recently produced strain of MHC class II-deficient mice. CD4+ T cells developed only when class II MHC molecules were expressed on radioresistant thymic cells. In contrast to what recently has been observed for the selection of CD8+ T lymphocytes, MHC class II-positive bone marrow-derived cells were unable to mediate the selection of CD4+ T cells when the thymic epithelium lacked MHC class II expression. These data suggest that CD4+ and CD8+ T cells may be generated by overlapping, but not identical, mechanisms. C1 HARVARD UNIV,SCH PUBL HLTH,DEPT CANC BIOL,BOSTON,MA 02115. MASSACHUSETTS GEN HOSP,DEPT SURG,BOSTON,MA 02114. HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115. FU NHLBI NIH HHS [HL36372]; NIAID NIH HHS [AI21569] NR 32 TC 87 Z9 87 U1 0 U2 0 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD APR 1 PY 1993 VL 90 IS 7 BP 2779 EP 2783 DI 10.1073/pnas.90.7.2779 PG 5 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA KV975 UT WOS:A1993KV97500047 PM 8464889 ER PT J AU GREGOR, P REEVES, RH JABS, EW YANG, XD DACKOWSKI, W ROCHELLE, JM BROWN, RH HAINES, JL OHARA, BF UHL, GR SELDIN, MF AF GREGOR, P REEVES, RH JABS, EW YANG, XD DACKOWSKI, W ROCHELLE, JM BROWN, RH HAINES, JL OHARA, BF UHL, GR SELDIN, MF TI CHROMOSOMAL LOCALIZATION OF GLUTAMATE RECEPTOR GENES - RELATIONSHIP TO FAMILIAL AMYOTROPHIC-LATERAL-SCLEROSIS AND OTHER NEUROLOGICAL DISORDERS OF MICE AND HUMANS SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article ID CONSERVED LINKAGE GROUP; MOLECULAR-CLONING; FUNCTIONAL EXPRESSION; MOUSE CHROMOSOME-16; ALZHEIMER-DISEASE; MESSENGER-RNA; X-CHROMOSOME; KAINATE; PROTEIN; SUBUNIT AB Receptors for the major excitatory neurotransmitter glutamate may play key roles in neurodegeneration. The mouse Glur-5 gene maps to chromosome 16 between App and Sod-1. The homologous human GLUR5 gene maps to the corresponding region of human chromosome 21, which contains the locus for familial amyotrophic lateral sclerosis. This location, and other features, render GLUR5 a possible candidate gene for familial amyotrophic lateral sclerosis. In addition, dosage imbalance of GLUR5 may have a role in the trisomy 21 (Down syndrome). Further characterization of the murine glutamate receptor family includes mapping of Glur-1 to the same region as neurological mutants spasmodic, shaker-2, tipsy, and vibrator on chromosome 11; Glur-2 near spastic on chromosome 3; Glur-6 near waltzer and Jackson circler on chromosome 10; and Glur-7 near clasper on chromosome 4. C1 JOHNS HOPKINS UNIV,SCH MED,DEPT PHYSIOL,BALTIMORE,MD 21205. JOHNS HOPKINS UNIV,SCH MED,DEPT PEDIAT & MED,BALTIMORE,MD 21205. JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROL & NEUROSCI,BALTIMORE,MD 21205. INTEGRATED GENET INC,FRAMINGHAM,MA 01701. DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27710. DUKE UNIV,MED CTR,DEPT MICROBIOL,DURHAM,NC 27710. MASSACHUSETTS GEN HOSP,DAY NEUROMUSCULAR RES CTR,BOSTON,MA 02129. MASSACHUSETTS GEN HOSP,MOLEC NEUROGENET UNIT,BOSTON,MA 02129. STANFORD UNIV,DEPT BIOL SCI,STANFORD,CA 94305. RP GREGOR, P (reprint author), NIDA,ADDICT RES CTR,MOLEC NEUROBIOL SECT,POB 5180,BALTIMORE,MD 21224, USA. RI Haines, Jonathan/C-3374-2012; OI Jabs, Ethylin/0000-0001-8983-5466 FU NHGRI NIH HHS [HG00324, HG00101, HG00465] NR 77 TC 55 Z9 56 U1 0 U2 1 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD APR 1 PY 1993 VL 90 IS 7 BP 3053 EP 3057 DI 10.1073/pnas.90.7.3053 PG 5 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA KV975 UT WOS:A1993KV97500103 PM 8464923 ER PT J AU TAGHIAN, A GIOIOSO, D BUDACH, W SUIT, H AF TAGHIAN, A GIOIOSO, D BUDACH, W SUIT, H TI IN VITRO SPLIT-DOSE RECOVERY OF GLIOBLASTOMA-MULTIFORME (RETRACTED ARTICLE. SEE VOL 146, PG 242, 1996) SO RADIATION RESEARCH LA English DT Article ID HUMAN-TUMOR CELLS; POTENTIALLY LETHAL DAMAGE; REPAIR; RADIOSENSITIVITY; RADIOCURABILITY; RADIORESISTANT; RADIOTHERAPY; PREDICT; LINES RP TAGHIAN, A (reprint author), HARVARD UNIV, MASSACHUSETTS GEN HOSP, SCH MED, DEPT RADIAT ONCOL, EDWIN L STEELE LAB RADIAT BIOL, BOSTON, MA 02114 USA. FU NCI NIH HHS [CA13311] NR 18 TC 16 Z9 16 U1 1 U2 3 PU RADIATION RESEARCH SOC PI LAWRENCE PA 810 E TENTH STREET, LAWRENCE, KS 66044 USA SN 0033-7587 J9 RADIAT RES JI Radiat. Res. PD APR PY 1993 VL 134 IS 1 BP 16 EP 21 DI 10.2307/3578497 PG 6 WC Biology; Biophysics; Radiology, Nuclear Medicine & Medical Imaging SC Life Sciences & Biomedicine - Other Topics; Biophysics; Radiology, Nuclear Medicine & Medical Imaging GA KY744 UT WOS:A1993KY74400003 PM 8386388 ER PT J AU MUELLER, PR AF MUELLER, PR TI PANCREATIC BIOPSY - STRIVING FOR EXCELLENCE SO RADIOLOGY LA English DT Editorial Material DE BIOPSIES, COMPLICATIONS; COMPUTED TOMOGRAPHIC (CT) GUIDANCE; EDITORIALS; PANCREAS, BIOPSY; ULTRASOUND (US) GUIDANCE ID PERCUTANEOUS BIOPSY; ASPIRATION BIOPSY; CANCER RP MUELLER, PR (reprint author), HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEPT RADIOL,FRUIT ST,BOSTON,MA 02114, USA. NR 12 TC 19 Z9 21 U1 0 U2 0 PU RADIOLOGICAL SOC NORTH AMER PI EASTON PA 20TH AND NORTHAMPTON STS, EASTON, PA 18042 SN 0033-8419 J9 RADIOLOGY JI Radiology PD APR PY 1993 VL 187 IS 1 BP 15 EP 16 PG 2 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA KT244 UT WOS:A1993KT24400003 PM 8451402 ER PT J AU BHALLA, M ABBOUD, MR MCLOUD, TC SHEPARD, JAO MUNDEN, MM JACKSON, SM BEATY, JR LAVER, JH AF BHALLA, M ABBOUD, MR MCLOUD, TC SHEPARD, JAO MUNDEN, MM JACKSON, SM BEATY, JR LAVER, JH TI ACUTE CHEST SYNDROME IN SICKLE-CELL DISEASE - CT EVIDENCE OF MICROVASCULAR OCCLUSION SO RADIOLOGY LA English DT Article DE LUNG, PERFUSION; PULMONARY ARTERIES, STENOSIS OR OBSTRUCTION; PULMONARY VEINS, ABNORMALITIES; SICKLE CELL DISEASE (SS, SC) ID PATHOLOGIC CORRELATION; LUNG; INFARCTION; DIAGNOSIS; ANEMIA; EMBOLI AB Patients with sickle cell disease often develop acute chest syndrome (ACS). Signs of ACS include chest pain, fever, prostration, and pulmonary opacities. Pneumonia and infarction have been implicated in the pathogenesis of this syndrome. Infarction as a result of microvascular occlusion and pneumonia are not easily differentiated with chest radiography or ventilation-perfusion scintigraphy. The authors evaluated the ability of thin section (3-mm) chest computed tomography (CT) to help diagnose microvascular occlusion in ACS and thus help differentiate two of its most likely causes. CT scans of the chest of 10 patients with moderate to severe ACS were retrospectively reviewed by two observers, who listed the number of bronchopulmonary segments showing consolidation; areas of ground-glass attenuation due to early hemorrhagic edema; and paucity or absence of small vessels, arterioles, and venules. In all patients, the degree of hypoxia was out of proportion to the extent of consolidation evident at chest radiography. The CT scans showed microvascular occlusion and areas of ground-glass attenuation in nine patients. Infection was ruled out in eight patients. High-resolution CT may play an important role in the initial evaluation and timely selection of an appropriate treatment regimen aimed at improving tissue perfusion, thus forestalling irreversible organ damage and chronic pulmonary arterial hypertension in patients with sickle cell disease. C1 MED UNIV S CAROLINA,DEPT PEDIAT HEMATOL ONCOL,CHARLESTON,SC 29425. MED UNIV S CAROLINA,DEPT RADIOL,CHARLESTON,SC 29425. RP BHALLA, M (reprint author), MASSACHUSETTS GEN HOSP,DEPT RADIOL,32 FRUIT ST,BOSTON,MA 02114, USA. NR 27 TC 52 Z9 53 U1 0 U2 2 PU RADIOLOGICAL SOC NORTH AMER PI EASTON PA 20TH AND NORTHAMPTON STS, EASTON, PA 18042 SN 0033-8419 J9 RADIOLOGY JI Radiology PD APR PY 1993 VL 187 IS 1 BP 45 EP 49 PG 5 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA KT244 UT WOS:A1993KT24400013 PM 8451435 ER PT J AU JARAMILLO, D LAOR, T ZALESKE, DJ AF JARAMILLO, D LAOR, T ZALESKE, DJ TI INDIRECT TRAUMA TO THE GROWTH PLATE - RESULTS OF MR IMAGING AFTER EPIPHYSEAL AND METAPHYSEAL INJURY IN RABBITS SO RADIOLOGY LA English DT Article DE BONES, EPIPHYSES; BONES, GROWTH AND DEVELOPMENT; BONES, INJURIES; BONES, METAPHYSES; CHILDREN, INJURIES; CHILDREN, SKELETAL SYSTEM ID ARREST LINES; CARTILAGE; SLOWDOWN AB Abnormalities of the growth plate secondary to epiphyseal and metaphyseal injury were studied with magnetic resonance (MR) imaging, radiography, and histologic examination in 20 rabbits. Epiphyseal injury resulted in either the formation of a bony bridge across the growth plate or focal curving of the growth plate caused by a decrease in longitudinal growth. Metaphyseal injury resulted in interference with endochondral ossification, thickening of the growth plate, and extension of cartilage into the metaphysis. Serial MR images obtained during the first 6 weeks after injury showed persistence of abnormalities of the growth cartilage after epiphyseal injury, but resolution of abnormalities after metaphyseal injury. Abnormalities of the cartilage were best seen on T2-weighted images. Gadolinium enhancement showed reconstitution of metaphyseal vascularity after metaphyseal injury but did not enable detection of transphyseal vascularity after epiphyseal injury until a bony bridge formed. C1 MASSACHUSETTS GEN HOSP,DEPT ORTHOPAED SURG,BOSTON,MA 02114. HARVARD UNIV,SCH MED,BOSTON,MA 02115. RP JARAMILLO, D (reprint author), CHILDRENS HOSP MED CTR,DEPT RADIOL,300 LONGWOOD AVE,BOSTON,MA 02115, USA. NR 17 TC 75 Z9 75 U1 0 U2 0 PU RADIOLOGICAL SOC NORTH AMER PI EASTON PA 20TH AND NORTHAMPTON STS, EASTON, PA 18042 SN 0033-8419 J9 RADIOLOGY JI Radiology PD APR PY 1993 VL 187 IS 1 BP 171 EP 178 PG 8 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA KT244 UT WOS:A1993KT24400036 PM 8451408 ER PT J AU GAZELLE, GS HAAGA, JR HALPERN, EF AF GAZELLE, GS HAAGA, JR HALPERN, EF TI HEMOSTATIC PROTEIN POLYMER SHEATH - IMPROVEMENT IN HEMOSTASIS AT PERCUTANEOUS BIOPSY IN THE SETTING OF PLATELET DYSFUNCTION SO RADIOLOGY LA English DT Article DE BIOPSIES, COMPLICATIONS; BIOPSIES, TECHNOLOGY; INTERVENTIONAL PROCEDURES, COMPLICATIONS; LIVER, HEMORRHAGE; LIVER, INTERVENTIONAL PROCEDURE ID LIVER-BIOPSY; IMPAIRED COAGULATION; NEEDLE AB To study the effectiveness of the protein polymer sheath (PPS), a device intended to limit hemorrhage caused by percutaneous biopsy, in the setting of platelet dysfunction (which may be an important cause of such hemorrhage), percutaneous biopsies were performed in eight anesthetized pigs: four control pigs and four pigs treated with the experimental aspirinlike drug venopirin. These biopsies were performed with (a) a cutting needle only, (b) the cutting needle equipped with the PPS, and (c) the cutting needle equipped with a thrombin-coated PPS. Needle configuration and biopsy site were randomized. Blood loss associated with each needle configuration was measured and compared with that associated with the other configurations. Venopirin caused a statistically significant increase in blood loss with all needle configurations. The PPS significantly reduced blood loss in both the control pigs and those treated with venopirin (P < .05); thrombin coating was a statistically significant factor only in the venopirin-treated pigs. C1 CASE WESTERN RESERVE UNIV HOSP,DEPT RADIOL,CLEVELAND,OH 44106. RP GAZELLE, GS (reprint author), MASSACHUSETTS GEN HOSP,DEPT RADIOL,FRUIT ST,BOSTON,MA 02114, USA. NR 13 TC 3 Z9 3 U1 0 U2 1 PU RADIOLOGICAL SOC NORTH AMER PI EASTON PA 20TH AND NORTHAMPTON STS, EASTON, PA 18042 SN 0033-8419 J9 RADIOLOGY JI Radiology PD APR PY 1993 VL 187 IS 1 BP 269 EP 272 PG 4 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA KT244 UT WOS:A1993KT24400051 PM 8451426 ER PT J AU SIMON, PM GRIFFIN, DM LANDRY, DM SKATRUD, JB AF SIMON, PM GRIFFIN, DM LANDRY, DM SKATRUD, JB TI INHIBITION OF RESPIRATORY ACTIVITY DURING PASSIVE VENTILATION - A ROLE FOR INTERCOSTAL AFFERENTS SO RESPIRATION PHYSIOLOGY LA English DT Article DE MAMMALS, HUMANS; RECEPTORS, INTERCOSTAL, FEEDBACK INSPIRATORY MUSCLES; RESPIRATORY MUSCLES, INSPIRATORY, FEEDBACK INHIBITION ID TENDON ORGANS; MECHANICAL VENTILATION; INSPIRATORY ACTIVITY; AIR HUNGER; HUMANS; BREATHLESSNESS; QUADRIPLEGICS; FREQUENCY; BLOCKADE; NEURONS AB The purpose of this study was to determine whether receptors from the rib cage are primarily responsible for inhibitory feedback of inspiratory muscle activity during mechanical ventilation. Seven quadriplegics with C5-C6 lesions were compared to 6 normals during mechanical ventilation. All subjects were mechanically hyperventilated with a nasal mask to suppress intrinsic inspiratory muscle activity. End-tidal partial pressure of carbon dioxide (PET(CO2)) was increased by either adding CO2 (FI(CO2)) or decreasing tidal volume (V(T)) until reoccurrence of inspiratory activity, defined as the recruitment threshold (P(CO2)Rt). The difference between P(CO2)RT and eupneic PET(CO2) indicated the presence and magnitude of volume-related inhibition of inspiratory muscle activity during mechanical ventilation. Substantial inhibition of inspiratory activity was observed in both quadriplegics and normals. We conclude that afferent information from the rib cage is not obligatory for the mediation of volume-related inhibition of inspiratory muscle activity during mechanical ventilation. C1 WILLIAM S MIDDLETON MEM VET ADM MED CTR,MED RES SERV,MADISON,WI 53705. UNIV WISCONSIN,DEPT MED,JOHN RANKIN LAB PULM MED,MADISON,WI 53706. UNIV WISCONSIN,DEPT PREVENT MED,MADISON,WI 53706. NR 25 TC 19 Z9 19 U1 0 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0034-5687 J9 RESP PHYSIOL JI Respir. Physiol. PD APR PY 1993 VL 92 IS 1 BP 53 EP 64 DI 10.1016/0034-5687(93)90119-U PG 12 WC Physiology; Respiratory System SC Physiology; Respiratory System GA KY187 UT WOS:A1993KY18700005 PM 8511408 ER PT J AU PETERS, LL LUX, SE AF PETERS, LL LUX, SE TI ANKYRINS - STRUCTURE AND FUNCTION IN NORMAL-CELLS AND HEREDITARY SPHEROCYTES SO SEMINARS IN HEMATOLOGY LA English DT Review ID HUMAN-ERYTHROCYTE-MEMBRANE; NF-KAPPA-B; SPECTRIN-BINDING-PROTEINS; INHERITED HEMOLYTIC-ANEMIAS; KIDNEY EPITHELIAL-CELLS; ANION-EXCHANGE PROTEIN; ACTIN-BUNDLING PROTEIN; CYCLE CONTROL PROTEINS; ALPHA-SPECTRIN; PLASMA-MEMBRANE C1 HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115. RP PETERS, LL (reprint author), CHILDRENS HOSP MED CTR,DIV HEMATOL ONCOL,300 LONGWOOD AVE,BOSTON,MA 02115, USA. FU NHLBI NIH HHS [HL32262, HL15157]; NIDDK NIH HHS [DK34083] NR 329 TC 84 Z9 85 U1 0 U2 1 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 SN 0037-1963 J9 SEMIN HEMATOL JI Semin. Hematol. PD APR PY 1993 VL 30 IS 2 BP 85 EP 118 PG 34 WC Hematology SC Hematology GA KY208 UT WOS:A1993KY20800001 PM 8480190 ER PT J AU FRY, CL CARTER, JE KANTER, MC TEGELER, CH TULEY, MR AF FRY, CL CARTER, JE KANTER, MC TEGELER, CH TULEY, MR TI ANTERIOR ISCHEMIC OPTIC NEUROPATHY IS NOT ASSOCIATED WITH CAROTID-ARTERY ATHEROSCLEROSIS SO STROKE LA English DT Article DE CAROTID ARTERY DISEASES; CEREBROVASCULAR DISORDERS; ULTRASONICS ID AMAUROSIS FUGAX; CLINICAL PROFILE; NATURAL-HISTORY; STROKE; ATTACKS; RISK; ENDARTERECTOMY; DISEASE AB Background and Purpose: The relation between anterior ischemic optic neuropathy and carotid artery atherosclerotic disease is unclear. We studied patients with anterior ischemic optic neuropathy to determine if they had an increased occurrence of carotid artery stenosis. Methods: Fifteen consecutive patients with anterior ischemic optic neuropathy were evaluated prospectively for cervical carotid artery stenosis and compared with 30 age- and sex-matched asymptomatic patients and also with 11 age- and sex-matched patients experiencing transient monocular blindness. Results: There was no difference in the mean stenosis of the internal carotid artery between patients with anterior ischemic optic neuropathy (mean carotid stenosis, 19%) and asymptomatic patients (mean carotid stenosis, 9%; p>0.05), whereas patients with transient monocular blindness had significantly more stenosis (mean, 77%) in the cervical carotid arteries than both control subjects (p<0.0001) and patients with anterior ischemic optic neuropathy (p<0.0001). There was also no difference in the percentage of patients with stenosis greater-than-or-equal-to 30% in anterior ischemic optic neuropathy (two of 15) and asymptomatic patients (five of 30), whereas 10 of 11 patients with transient monocular blindness had stenoses greater-than-or-equal-to 30%, significantly more than patients with anterior ischemic optic neuropathy (p<0.0001) and asymptomatic patients (p<0.0001). Conclusions: Anterior ischemic optic neuropathy is not a marker for atherosclerotic carotid artery stenosis. The pathogenesis of nonarteritic anterior ischemic optic neuropathy does not involve carotid artery stenosis in most patients. C1 AUDIE L MURPHY MEM VET ADM MED CTR,GERIATR RES EDUC & CLIN CTR,DIV STAT,SAN ANTONIO,TX 78284. UNIV TEXAS,HLTH SCI CTR,DEPT OPHTHALMOL,SAN ANTONIO,TX 78284. UNIV TEXAS,HLTH SCI CTR,DEPT NEUROL,SAN ANTONIO,TX 78284. WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT NEUROL,WINSTON SALEM,NC 27103. NR 28 TC 27 Z9 29 U1 0 U2 0 PU AMER HEART ASSOC PI DALLAS PA 7272 GREENVILLE AVENUE, DALLAS, TX 75231-4596 SN 0039-2499 J9 STROKE JI Stroke PD APR PY 1993 VL 24 IS 4 BP 539 EP 542 PG 4 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA KV419 UT WOS:A1993KV41900005 PM 8465359 ER PT J AU LUKACOVA, D REED, GL AF LUKACOVA, D REED, GL TI SINGLE STEP PURIFICATION OF PLATELET FACTOR-XIII USING AN IMMOBILIZED FACTOR-XIII A-SUBUNIT MONOCLONAL-ANTIBODY SO THROMBOSIS AND HAEMOSTASIS LA English DT Article ID FIBRIN-STABILIZING FACTOR; COAGULATION-FACTOR-XIII; CROSS-LINKING; HUMAN-PLASMA; ALPHA-2-PLASMIN INHIBITOR; TRANSGLUTAMINASES; FIBRONECTIN; ACTIVATION; COLLAGEN; PEPTIDE AB To facilitate the analysis of the catalytic subunit of factor XIII we have developed a method for the immunoaffinity purification of this protein from platelets. This method employs a monoclonal antibody that binds to the a-subunit of factor XIII. The anti-factor XIII antibody was immobilized on agarose and then incubated with platelet lysate. Subsequently factor XIII was isolated from the platelet lysate in a single step with a 41% yield as measured by enzyme assay. The purified platelet factor XIII appeared nearly homogeneous when analyzed by polyacrylamide electrophoresis and by immunoblotting with another factor XIII monoclonal antibody. C1 HARVARD UNIV,SCH MED,BOSTON,MA 02115. MASSACHUSETTS GEN HOSP,BOSTON,MA 02114. FU NHLBI NIH HHS [HL02348] NR 36 TC 5 Z9 5 U1 0 U2 1 PU F K SCHATTAUER VERLAG GMBH PI STUTTGART PA P O BOX 10 45 45, LENZHALDE 3, D-70040 STUTTGART, GERMANY SN 0340-6245 J9 THROMB HAEMOSTASIS JI Thromb. Haemost. PD APR 1 PY 1993 VL 69 IS 4 BP 397 EP 400 PG 4 WC Hematology; Peripheral Vascular Disease SC Hematology; Cardiovascular System & Cardiology GA KX551 UT WOS:A1993KX55100020 PM 8497854 ER PT J AU ANDERSON, KC AF ANDERSON, KC TI BACTERIAL-CONTAMINATION OF PLATELETS SO TRANSFUSION SCIENCE LA English DT Article RP ANDERSON, KC (reprint author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV MED ONCOL,BLOOD COMPONENT LAB,44 BINNEY ST,BOSTON,MA 02115, USA. NR 0 TC 12 Z9 12 U1 0 U2 0 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB SN 0955-3886 J9 TRANSFUS SCI JI Transfus. Sci. PD APR PY 1993 VL 14 IS 2 BP 159 EP 162 DI 10.1016/0955-3886(93)90023-N PG 4 WC Hematology SC Hematology GA LC128 UT WOS:A1993LC12800005 ER PT J AU DELMONICO, FL COSIMI, AB KAWAI, T CAVENDER, D LEE, WH JOLLIFFE, LK KNOWLES, RW SCHROEDER KAHAN AF DELMONICO, FL COSIMI, AB KAWAI, T CAVENDER, D LEE, WH JOLLIFFE, LK KNOWLES, RW SCHROEDER KAHAN TI NONHUMAN PRIMATE RESPONSES TO MURINE AND HUMANIZED OKT4A SO TRANSPLANTATION LA English DT Article; Proceedings Paper CT 18TH ANNUAL MEETING OF THE AMERICAN SOC OF TRANSPLANT SURGEONS CY MAY 27-29, 1992 CL CHICAGO, IL SP AMER SOC TRANSPLANT SURGEONS ID MONOCLONAL-ANTIBODY THERAPY; RENAL-ALLOGRAFT RECIPIENTS; HUMAN IMMUNE-RESPONSE; RETREATMENT; REJECTION; TRIAL AB A nonhuman primate antimurine response (MAMA) has been observed in 17 cynomolgus renal allograft recipients of murine OKT 4A. Neither cyclosporine, nor total-lymphoid irradiation, nor donor bone marrow preparation inhibited this antixenogeneic response. In an attempt to alter the antimurine basis of the response, a humanized chimeric OKT4A (IgG4) containing the entire variable portion of the murine OKT4A and a humanized CDR grafted OKT4A mAb sharing only the Complementarity Determining Region from the murine OKT4A, were administered to 8 cynomolgus allograft recipients. MAMA was detected in each recipient. In contrast to sera from recipients of murine OKT4A, sera from recipients of humanized OKT4A displayed no reactivity to other murine mAbs. MAMA specificity did not assay constant (C) region differences between the murine and humanized mAb; however, C region homology in humans should preclude a human antimouse antibody (HAMA) to the Fe portion of a humanized mAb. Furthermore, cynomolgus recipient serum levels of the humanized OKT4A mAb were maintained (>1 mug/ml) for a longer period than following treatment with murine OKT4A (murine <12 days versus between 12 and 24 days for the humanized). If the HAMA response to humanized mAb in future clinical trials, were to be predictably anti-idiotypic, then the opportunity for treatment with sequential mAbs of differing idiotypes would be retained. Moreover, these current studies also suggest that humanized construction may influence the duration of therapeutic mAb levels. Thus, anti-idiotypic reactivity may not be as consequential to the clinical administration of humanized mAb to allograft recipients. C1 HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,TRANSPLANTAT UNIT,BOSTON,MA 02114. R W JOHNSON PHARMACEUT RES INST,RARITAN,NJ 08869. RP DELMONICO, FL (reprint author), HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEPT SURG,BOSTON,MA 02114, USA. NR 28 TC 26 Z9 26 U1 0 U2 0 PU WILLIAMS & WILKINS PI BALTIMORE PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 SN 0041-1337 J9 TRANSPLANTATION JI Transplantation PD APR PY 1993 VL 55 IS 4 BP 722 EP 728 DI 10.1097/00007890-199304000-00007 PG 7 WC Immunology; Surgery; Transplantation SC Immunology; Surgery; Transplantation GA KY800 UT WOS:A1993KY80000007 PM 8475542 ER PT J AU HAUG, CE COLVIN, RB DELMONICO, FL AUCHINCLOSS, H TOLKOFFRUBIN, N PREFFER, FI ROTHLEIN, R NORRIS, S SCHARSCHMIDT, L COSIMI, AB BARKER HARDY TESI KAHAN AF HAUG, CE COLVIN, RB DELMONICO, FL AUCHINCLOSS, H TOLKOFFRUBIN, N PREFFER, FI ROTHLEIN, R NORRIS, S SCHARSCHMIDT, L COSIMI, AB BARKER HARDY TESI KAHAN TI A PHASE-I TRIAL OF IMMUNOSUPPRESSION WITH ANTI-ICAM-1 (CD54) MAB IN RENAL-ALLOGRAFT RECIPIENTS SO TRANSPLANTATION LA English DT Article; Proceedings Paper CT 18TH ANNUAL MEETING OF THE AMERICAN SOC OF TRANSPLANT SURGEONS CY MAY 27-29, 1992 CL CHICAGO, IL SP AMER SOC TRANSPLANT SURGEONS ID BONE-MARROW TRANSPLANTATION; MONOCLONAL-ANTIBODY; REJECTION; GLOBULIN; LFA-1; SURVIVAL; INFUSION AB Several adhesion molecules contribute to the interaction between T cells and antigen presenting cells or target cells. Leukocyte function-associated molecule-1 (LFA-1[CD11a/CD18]) and intercellular adhesion molecule-1 (ICAM-1 [CD54]) are one such critical adhesive receptor-counter-receptor combination. The importance of ICAM-1 dependent adhesion in the rejection response was initially demonstrated in cynomolgus renal allograft recipients treated with the anti-ICAM-1 murine monoclonal antibody BIRR1. BIRR1 also appeared to limit ischemic damage in these animals. A Phase I clinical trial has subsequently been completed in 18 patients who received cadaver donor renal allografts at high risk for delayed graft function (prolonged preservation time, highly-sensitized recipient). An adequate BIRR1 serum level was associated with significantly less delayed graft function (P<.01) and rejection (P<.01). In 1-hr biopsies, mouse IgG was detected along the endothelium of the vessels and glomeruli in the graft. There were no instances of primary nonfunction (PNF), and current allograft survival (follow-up: 16-30 months) in these ''high-risk'' mAb-treated patients is 78%. There were 3 instances of PNF and a graft survival rate of 56% in the recipients of the contralateral kidney allografts treated with conventional immunosuppression. No significant ''first-dose'' effect was associated with BIRR1 administration. These results establish a dosing schedule and the clinical safety of BIRR1. They also suggest that inhibition of leukocyte adhesion by mAb therapy may be useful in controlling allograft rejection and possibly in limiting reperfusion injury. Thus, these observations support the clinical importance of accessory molecules in T cell function. We hypothesize that anti-CD54 mAb acts by blocking leukocyte adhesion to the endothelium, thereby interfering with sensitization or target cell interaction. C1 MASSACHUSETTS GEN HOSP,DEPT MED,BOSTON,MA 02114. MASSACHUSETTS GEN HOSP,DEPT PATHOL,BOSTON,MA 02114. BOEHRINGER INGELHEIM CORP,RIDGEFIELD,CT. RP HAUG, CE (reprint author), MASSACHUSETTS GEN HOSP,DEPT SURG,BOSTON,MA 02114, USA. FU NHLBI NIH HHS [HL-18646] NR 23 TC 237 Z9 241 U1 0 U2 1 PU WILLIAMS & WILKINS PI BALTIMORE PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 SN 0041-1337 J9 TRANSPLANTATION JI Transplantation PD APR PY 1993 VL 55 IS 4 BP 766 EP 773 DI 10.1097/00007890-199304000-00016 PG 8 WC Immunology; Surgery; Transplantation SC Immunology; Surgery; Transplantation GA KY800 UT WOS:A1993KY80000016 PM 8097341 ER PT J AU POWELSON, JA COSIMI, AB LEWIS, WD ROHRER, RJ FREEMAN, RB VACANTI, JP JONAS, M LORBER, MI MARKS, WH BRADLEY, J JENKINS, RL MAKOWA KATZ STARZL AF POWELSON, JA COSIMI, AB LEWIS, WD ROHRER, RJ FREEMAN, RB VACANTI, JP JONAS, M LORBER, MI MARKS, WH BRADLEY, J JENKINS, RL MAKOWA KATZ STARZL TI HEPATIC RETRANSPLANTATION IN NEW-ENGLAND - A REGIONAL EXPERIENCE AND SURVIVAL MODEL SO TRANSPLANTATION LA English DT Article; Proceedings Paper CT 18TH ANNUAL MEETING OF THE AMERICAN SOC OF TRANSPLANT SURGEONS CY MAY 27-29, 1992 CL CHICAGO, IL SP AMER SOC TRANSPLANT SURGEONS ID LIVER RETRANSPLANTATION; TRANSPLANTATION; GRAFT; NONFUNCTION AB Hepatic retransplantation (reTx) offers the only alternative to death for patients who have failed primary hepatic transplantation (PTx). Assuming a finite number of donor organs, reTx also denies the chance of survival for some patients awaiting PTx. The impact of reTx on overall survival (i.e., the survival of all candidates for transplantation) must therefore be clarified. Between 1983 and 1991, 651 patients from the New England Organ Bank underwent liver transplantation, and 73 reTx were performed in 71 patients (11% reTx rate). The 1-year actuarial survival for reTx (48%) was significantly less than for PTx (70%, P<0.05). This survival varied, dependent on the interval of time following PTx in which the reTx was performed (0-3 days, 57% survival; 4-30 days, 24%; 30-365 days, 54%; and >365 days, 83%). Patients on the regional waiting list had an 18% mortality rate while awaiting transplantation. These results were incorporated into a mathematical model describing survival as a function of reTx rate, assuming a limited supply of donor livers. ReTx improves the 1-year survival rate for patients undergoing PTx but decreases overall survival (survival of all candidates) for liver transplantation. In the current era of persistently insufficient donor numbers, strategies based on minimizing the use of reTx, especially in the case of patients in whom chances of success are minimal, will result in the best overall rate of patient survival. C1 NEW ENGLAND ORGAN BANK INC,BROOKLINE,MA. BOSTON CTR LIVER TRANSPLANTAT,BOSTON,MA. NEW ENGLAND DEACONESS HOSP,MASSACHUSETTS GEN HOSP,CHILDRENS HOSP,DEPT SURG,BOSTON,MA 02215. NEW ENGLAND DEACONESS HOSP,MASSACHUSETTS GEN HOSP,CHILDRENS HOSP,TRANSPLANTAT UNIT,BOSTON,MA 02215. TUFTS UNIV,NEW ENGLAND MED CTR,DEPT SURG,BOSTON,MA 02111. TUFTS UNIV,NEW ENGLAND MED CTR,TRANSPLANTAT UNIT,BOSTON,MA 02111. YALE UNIV,NEW HAVEN MED CTR,NEW HAVEN,CT 06520. NR 19 TC 48 Z9 49 U1 0 U2 0 PU WILLIAMS & WILKINS PI BALTIMORE PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 SN 0041-1337 J9 TRANSPLANTATION JI Transplantation PD APR PY 1993 VL 55 IS 4 BP 802 EP 806 DI 10.1097/00007890-199304000-00023 PG 5 WC Immunology; Surgery; Transplantation SC Immunology; Surgery; Transplantation GA KY800 UT WOS:A1993KY80000024 PM 8475555 ER PT J AU LI, XP FAUSTMAN, D AF LI, XP FAUSTMAN, D TI USE OF DONOR BETA-2-MICROGLOBULIN-DEFICIENT TRANSGENIC MOUSE-LIVER CELLS FOR ISOGRAFTS, ALLOGRAFTS, AND XENOGRAFTS SO TRANSPLANTATION LA English DT Note ID MHC; ANTIGENS; SUSCEPTIBILITY; ASSOCIATION; RESTRICTION; EXCHANGE; LYSIS; MICE AB Donor graft major histocompatibility complex class I antigens are targets for both allogeneic and xenogeneic rejection. Mice homozygous for beta2-microglobulin gene disruption express reduced amounts of surface MHC class I antigens. Liver cells from such mutant mice were transplanted into isogeneic, allogeneic, and xenogeneic recipients to evaluate the potential of these animals as transplant donors. The survival of allografts of transgenic 129 mouse liver cells in 15 immunocompetent and histoincompatible mouse recipients (BALB/c, D1.C) was only slightly improved 30 days after transplantation relative to normal 129 mouse allografts. These results could be attributable: (1) to host natural killer cell-mediated lysis of donor MHC class I antigen-deficient cell ; (2) to donor liver cell MHC class I determinants that are reduced but not eliminated serving as rejection targets; (3) to the plentiful host supply of serum beta2-microglobulin reconstituting the graft and restoring donor MHC class I. Culture studies confirmed the ability of exogenous human and bovine beta2-microglobulin to restore rapidly MHC class I antigen expression on transgenic cells. Because cell surface exchange of beta2-microglobulin is less efficient between species with divergent beta2-microglobulin sequences, the survival of transgenic 129 mouse liver cells in guinea pig (60% beta2-microglobulin identity) and Xenopus (34% beta2-microglobulin identity) hosts was investigated. Significant prolongation of MHC class I antigen-deficient liver cell xenografts was apparently only in Xenopus hosts. Furthermore, transplants of transgenic 129 mouse liver cells into isogeneic normal 129 mouse recipients showed evidence of rejection in seven of nine recipients, suggesting that transgenic donor cells also may be susceptible to lysis by host natural killer cells. C1 MASSACHUSETTS GEN HOSP,DIABETES UNIT,IMMUNOBIOL LABS,BLDG 149,13TH ST,BOSTON,MA 02129. NR 32 TC 27 Z9 28 U1 0 U2 0 PU WILLIAMS & WILKINS PI BALTIMORE PA 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 SN 0041-1337 J9 TRANSPLANTATION JI Transplantation PD APR PY 1993 VL 55 IS 4 BP 940 EP 946 DI 10.1097/00007890-199304000-00046 PG 7 WC Immunology; Surgery; Transplantation SC Immunology; Surgery; Transplantation GA KY800 UT WOS:A1993KY80000047 PM 8475570 ER PT J AU DELMONICO, FL COSIMI, AB AF DELMONICO, FL COSIMI, AB TI NONHUMAN PRIMATE RESPONSE TO MURINE AND HUMANIZED MONOCLONAL-ANTIBODIES SO TRANSPLANTATION PROCEEDINGS LA English DT Article; Proceedings Paper CT INTERNATIONAL SYMP ON CLINICAL AND BASIC SCIENCE PERSPECTIVES ON THE USE OF OKT3 CY JUL 23-24, 1992 CL PORTLAND, OR SP OREGON HLTH SCI UNIV, ORTHO BIOTECH ID HUMAN IMMUNE-RESPONSE; THERAPY; OKT3; IMMUNOSUPPRESSION; ALLOGRAFTS; INDUCTION; TOLERANCE; ANTI-CD3 C1 HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,GEN SURG SERV,TRANSPLANTAT UNIT,BOSTON,MA 02114. RP DELMONICO, FL (reprint author), HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEPT SURG,BOSTON,MA 02114, USA. FU NHLBI NIH HHS [HL-18646] NR 22 TC 3 Z9 3 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 SN 0041-1345 J9 TRANSPLANT P JI Transplant. Proc. PD APR PY 1993 VL 25 IS 2 SU 1 BP 65 EP 67 PG 3 WC Immunology; Surgery; Transplantation SC Immunology; Surgery; Transplantation GA KY357 UT WOS:A1993KY35700020 PM 8096663 ER PT J AU BEAL, MF HYMAN, BT KOROSHETZ, W AF BEAL, MF HYMAN, BT KOROSHETZ, W TI DO DEFECTS IN MITOCHONDRIAL ENERGY-METABOLISM UNDERLIE THE PATHOLOGY OF NEURODEGENERATIVE DISEASES SO TRENDS IN NEUROSCIENCES LA English DT Article ID IDIOPATHIC PARKINSONS-DISEASE; COMPLEX-I DEFICIENCY; GLUTAMATE NEUROTOXICITY; ALZHEIMERS-DISEASE; HUNTINGTONS-DISEASE; CYTOCHROME-OXIDASE; SKELETAL-MUSCLE; BRAIN; ACID; LESIONS AB The pathogenesis of nerve cell death in neurodegenerative diseases is unknown. An attractive hypothesis is that an impairment of energy metabolism may underlie slow excitotoxic neuronal death, Several studies have demonstrated mitochondrial or oxidative defects in neurodegenerative diseases impaired energy metabolism results in decreases in high-energy phosphate stores and a deteriorating membrane potential. Under these conditions, the voltage-sensitive Mg2+ block of NMDA receptors is relieved, allowing the receptors to be persistently activated by endogenous concentrations of glutamate. In this way, metabolic defects may lead to neuronal death by a slow 'excitotoxic' mechanism. Recent studies indicate that such a mechanism occurs in vivo, and it may play a role in animal models of Huntington's disease and Parkinson's disease. ff a similar mechanism occurs in neurodegenerative diseases in humans it may be possible to use either excitatory amino acid antagonists or agents to improve neuronal bioenergenetics as therapeutic treatments for these disorders. C1 HARVARD UNIV,SCH MED,BOSTON,MA 02115. RP BEAL, MF (reprint author), MASSACHUSETTS GEN HOSP,NEUROL SERV,BOSTON,MA 02114, USA. FU DS NIH HHS [NINDS 16367]; NIA NIH HHS [AG05134]; NINDS NIH HHS [NS 10828] NR 70 TC 510 Z9 514 U1 0 U2 11 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, OXON, ENGLAND OX5 1GB SN 0166-2236 J9 TRENDS NEUROSCI JI Trends Neurosci. PD APR PY 1993 VL 16 IS 4 BP 125 EP 131 DI 10.1016/0166-2236(93)90117-5 PG 7 WC Neurosciences SC Neurosciences & Neurology GA LJ147 UT WOS:A1993LJ14700001 PM 7682343 ER PT J AU KELLER, PM ARNOLD, BA SHAW, AR TOLMAN, RL VANMIDDLESWORTH, F BONDY, S RUSIECKI, VK KOENIG, S ZOLLAPAZNER, S CONARD, P EMINI, EA CONLEY, AJ AF KELLER, PM ARNOLD, BA SHAW, AR TOLMAN, RL VANMIDDLESWORTH, F BONDY, S RUSIECKI, VK KOENIG, S ZOLLAPAZNER, S CONARD, P EMINI, EA CONLEY, AJ TI IDENTIFICATION OF HIV VACCINE CANDIDATE PEPTIDES BY SCREENING RANDOM PHAGE EPITOPE LIBRARIES SO VIROLOGY LA English DT Article ID HUMAN-IMMUNODEFICIENCY-VIRUS; NEUTRALIZING ANTIBODIES; ADSORPTION PROTEIN; ACID SEQUENCE; GP120; FD; CHIMPANZEES; DETERMINANT; PROTECTION; ENVELOPE C1 MERCK SHARP & DOHME LTD,DEPT VIRUS & CELL BIOL,W POINT,PA 19486. MERCK SHARP & DOHME LTD,DEPT MOLEC & CELLULAR BIOL,W POINT,PA 19486. DEPT SYNTHET CHEM RES,RAHWAY,NJ 07065. MEDIMMUNE INC,GAITHERSBURG,MD 20878. US DEPT VET AFFAIRS,NEW YORK,NY 10010. NYU MED CTR,NEW YORK,NY 10016. FU NIAID NIH HHS [AI 32424] NR 22 TC 84 Z9 89 U1 0 U2 3 PU ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 SN 0042-6822 J9 VIROLOGY JI Virology PD APR PY 1993 VL 193 IS 2 BP 709 EP 716 DI 10.1006/viro.1993.1179 PG 8 WC Virology SC Virology GA KT924 UT WOS:A1993KT92400016 PM 7681612 ER PT J AU MOORE, JP THALI, M JAMESON, BA LEWIS, GK SATTENTAU, QJ SODROSKI, J AF MOORE, JP THALI, M JAMESON, BA LEWIS, GK SATTENTAU, QJ SODROSKI, J TI STRUCTURAL-ANALYSIS OF THE HIV-1 ENVELOPE GLYCOPROTEIN GP120 SO JOURNAL OF CELLULAR BIOCHEMISTRY LA English DT Meeting Abstract C1 AARON DIAMOND AIDS RES CTR,NEW YORK,NY. CTR IMMUNOL,MARSEILLE,FRANCE. HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115. JEFFERSON CANC INST,PHILADELPHIA,PA. UNIV BALTIMORE,BALTIMORE,MD 21201. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012 SN 0730-2312 J9 J CELL BIOCHEM JI J. Cell. Biochem. PD MAR 29 PY 1993 SU 17E BP 4 EP 4 PG 1 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA KX965 UT WOS:A1993KX96500009 ER PT J AU OVCAKDERZIC, S OBRIEN, WA AF OVCAKDERZIC, S OBRIEN, WA TI QUANTITATIVE HIV-1 RNA PCR ANALYSIS FOLLOWING INVIVO IMMUNE ACTIVATION IN PATIENTS WITH ARC SO JOURNAL OF CELLULAR BIOCHEMISTRY LA English DT Meeting Abstract C1 W LOS ANGELES VA MED CTR, DEPT MED, LOS ANGELES, CA USA. UNIV CALIF LOS ANGELES, SCH MED, LOS ANGELES, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0730-2312 J9 J CELL BIOCHEM JI J. Cell. Biochem. PD MAR 29 PY 1993 SU 17E BP 20 EP 20 PG 1 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA KX965 UT WOS:A1993KX96500064 ER PT J AU WYATT, R THALI, M POSNER, M HO, D TILLEY, S PINTER, A ROBINSON, J SODROSKI, J AF WYATT, R THALI, M POSNER, M HO, D TILLEY, S PINTER, A ROBINSON, J SODROSKI, J TI MUTATIONAL ANALYSIS OF HIV-1 EXTERIOR ENVELOPE GLYCOPROTEIN GP120 FUNCTIONAL REGIONS SO JOURNAL OF CELLULAR BIOCHEMISTRY LA English DT Meeting Abstract C1 HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV HUMAN RETROVIROL,BOSTON,MA 02115. HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012 SN 0730-2312 J9 J CELL BIOCHEM JI J. Cell. Biochem. PD MAR 29 PY 1993 SU 17E BP 41 EP 41 PG 1 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA KX965 UT WOS:A1993KX96500147 ER PT J AU OBRIEN, WA OVCAK, S NAMAZIE, A KALHOR, H MAO, SH ZACK, JA AF OBRIEN, WA OVCAK, S NAMAZIE, A KALHOR, H MAO, SH ZACK, JA TI HIV-1 REPLICATION CAN BE INCREASED IN BLOOD FROM SEROPOSITIVE PATIENTS FOLLOWING INFLUENZA IMMUNIZATION SO JOURNAL OF CELLULAR BIOCHEMISTRY LA English DT Meeting Abstract C1 UNIV CALIF LOS ANGELES,SCH MED,LOS ANGELES,CA 90024. W LOS ANGELES VA MED CTR,DEPT MED,LOS ANGELES,CA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012 SN 0730-2312 J9 J CELL BIOCHEM JI J. Cell. Biochem. PD MAR 29 PY 1993 SU 17E BP 68 EP 68 PG 1 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA KX965 UT WOS:A1993KX96500253 ER PT J AU CALIENDO, AM ERON, JJ CHOW, YK DEVORE, KM KAPLAN, J DAQUILA, RT AF CALIENDO, AM ERON, JJ CHOW, YK DEVORE, KM KAPLAN, J DAQUILA, RT TI ENZYMOLOGIC STUDIES OF HIV-1 AZT AND DDI RESISTANCE SO JOURNAL OF CELLULAR BIOCHEMISTRY LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,BOSTON,MA 02129. HARVARD UNIV,SCH MED,BOSTON,MA 02115. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012 SN 0730-2312 J9 J CELL BIOCHEM JI J. Cell. Biochem. PD MAR 29 PY 1993 SU 17E BP 75 EP 75 PG 1 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA KX965 UT WOS:A1993KX96500280 ER PT J AU KALAMS, S JOHNSON, RP TROCHA, A DYNAN, MJ KURNICK, JT WALKER, BD AF KALAMS, S JOHNSON, RP TROCHA, A DYNAN, MJ KURNICK, JT WALKER, BD TI T-CELL RECEPTOR GENE USAGE IN HIV-1 SPECIFIC CYTOTOXIC T-LYMPHOCYTES SO JOURNAL OF CELLULAR BIOCHEMISTRY LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,INFECT DIS UNIT,BOSTON,MA 02129. MASSACHUSETTS GEN HOSP,DEPT PATHOL,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012 SN 0730-2312 J9 J CELL BIOCHEM JI J. Cell. Biochem. PD MAR 29 PY 1993 SU 17E BP 79 EP 79 PG 1 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA KX965 UT WOS:A1993KX96500297 ER PT J AU GROSS, J AF GROSS, J TI AMPHIBIAN REGENERATION AND MAMMALIAN WOUND REPAIR - A MECHANISTIC LINK SO JOURNAL OF CELLULAR BIOCHEMISTRY LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,DEPT DERMATOL,CUTANEOUS BIOL RES CTR,BOSTON,MA 02114. HARVARD UNIV,SCH MED,BOSTON,MA 02115. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012 SN 0730-2312 J9 J CELL BIOCHEM JI J. Cell. Biochem. PD MAR 29 PY 1993 SU 17E BP 102 EP 102 PG 1 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA KX965 UT WOS:A1993KX96500374 ER PT J AU KLAGSBRUN, M POWELL, P JONES, R MARIKOVSKY, M DLUZ, S ERIKSSON, E REIDY, M HIGASHIYAMA, S ABRAHAM, J AF KLAGSBRUN, M POWELL, P JONES, R MARIKOVSKY, M DLUZ, S ERIKSSON, E REIDY, M HIGASHIYAMA, S ABRAHAM, J TI EXPRESSION OF HB-EGF AS A RESPONSE TO INJURY SO JOURNAL OF CELLULAR BIOCHEMISTRY LA English DT Meeting Abstract C1 CHILDRENS HOSP MED CTR,BOSTON,MA 02115. BRIGHAM & WOMENS HOSP,BOSTON,MA 02115. MASSACHUSETTS GEN HOSP,BOSTON,MA 02114. UNIV WASHINGTON,SEATTLE,WA 98195. SCIOS NOVA INC,MT VIEW,CA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012 SN 0730-2312 J9 J CELL BIOCHEM JI J. Cell. Biochem. PD MAR 29 PY 1993 SU 17E BP 104 EP 104 PG 1 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA KX965 UT WOS:A1993KX96500380 ER PT J AU COMPTON, C TROOKMAN, N ROY, D PRESS, W NADIRE, K TONG, Y FALLON, JT REGAUER, S GALLICO, G OCONNOR, N AF COMPTON, C TROOKMAN, N ROY, D PRESS, W NADIRE, K TONG, Y FALLON, JT REGAUER, S GALLICO, G OCONNOR, N TI THE CLINICAL UTILITY AND WOUND-HEALING POTENTIAL OF CULTURED EPITHELIAL-CELLS IN THE TREATMENT OF BURN WOUNDS SO JOURNAL OF CELLULAR BIOCHEMISTRY LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,BOSTON,MA 02114. BRIGHAM & WOMENS HOSP,BOSTON,MA 02115. SHRINERS BURN INST,BOSTON,MA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012 SN 0730-2312 J9 J CELL BIOCHEM JI J. Cell. Biochem. PD MAR 29 PY 1993 SU 17E BP 108 EP 108 PG 1 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA KX965 UT WOS:A1993KX96500392 ER PT J AU ESPAILLAT, A FOSTER, CS LEE, SJ COLVIN, RB AF ESPAILLAT, A FOSTER, CS LEE, SJ COLVIN, RB TI GROWTH-FACTORS AND CYTOKINE EXPRESSION ARE DEMONSTRATED BY POLYMERASE CHAIN-REACTION ANALYSIS OF CORNEAL TISSUE FROM A RAT EPITHELIAL SCRAPE WOUND MODEL SO JOURNAL OF CELLULAR BIOCHEMISTRY LA English DT Meeting Abstract C1 HARVARD UNIV,SCH MED,RHOADS MOLEC IMMUNOL LAB,BOSTON,MA 02114. HARVARD UNIV,SCH MED,HILLES IMMUNOL LAB,BOSTON,MA 02114. HARVARD UNIV,MASSACHUSETTS GEN HOSP,MASSACHUSETTS EYE & EAR INFIRM,SCH MED,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012 SN 0730-2312 J9 J CELL BIOCHEM JI J. Cell. Biochem. PD MAR 29 PY 1993 SU 17E BP 119 EP 119 PG 1 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA KX965 UT WOS:A1993KX96500429 ER PT J AU LEE, SJ KAUFMAN, AH LIN, IM COLVIN, RB FOSTER, CS AF LEE, SJ KAUFMAN, AH LIN, IM COLVIN, RB FOSTER, CS TI POLYMERASE CHAIN-REACTION (PCR) ANALYSIS OF CORNEAL FIBRONECTIN ISOFORM GENE-EXPRESSION IN A RAT ALKALI-BURN MODEL OF WOUND-HEALING SO JOURNAL OF CELLULAR BIOCHEMISTRY LA English DT Meeting Abstract C1 HARVARD UNIV,MASSACHUSETTS EYE & EAR INFIRM,SCH MED,RHOADS MOLEC IMMUNOL LAB,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012 SN 0730-2312 J9 J CELL BIOCHEM JI J. Cell. Biochem. PD MAR 29 PY 1993 SU 17E BP 121 EP 121 PG 1 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA KX965 UT WOS:A1993KX96500436 ER PT J AU YOUNG, HE LUCAS, PA LAURENCIN, CT AF YOUNG, HE LUCAS, PA LAURENCIN, CT TI MUSCLE MORPHOGENETIC PROTEIN INDUCES SKELETAL-MUSCLE REGENERATION SO JOURNAL OF CELLULAR BIOCHEMISTRY LA English DT Meeting Abstract C1 MERCER UNIV,SCH MED,DIV BASIC MED SCI,MACON,GA 31207. MERCER UNIV,SCH MED,DEPT SURG,MACON,GA 31207. MED CTR CENT GEORGIA,DEPT SURG,MACON,GA 31206. MIT,DIV HLTH SCI & TECHNOL,CAMBRIDGE,MA 02139. HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEPT ORTHOPAED SURG,BOSTON,MA 02115. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012 SN 0730-2312 J9 J CELL BIOCHEM JI J. Cell. Biochem. PD MAR 29 PY 1993 SU 17E BP 130 EP 130 PG 1 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA KX965 UT WOS:A1993KX96500473 ER PT J AU GIRARD, MT STRISSEL, KJ RINEHART, WB MAGNER, J FINI, ME AF GIRARD, MT STRISSEL, KJ RINEHART, WB MAGNER, J FINI, ME TI EPITHELIAL REGULATION OF SAA3 EXPRESSION BY CORNEAL STROMAL CELLS (KERATOCYTES) SO JOURNAL OF CELLULAR BIOCHEMISTRY LA English DT Meeting Abstract C1 HARVARD UNIV,SCH MED,DEPT DERMATOL,BOSTON,MA 02129. MASSACHUSETTS GEN HOSP,MASSACHUSSETS GEN HOSP HARVARD CUTANEOUS BIOL RES CTR,BOSTON,MA 02129. NR 1 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012 SN 0730-2312 J9 J CELL BIOCHEM JI J. Cell. Biochem. PD MAR 29 PY 1993 SU 17E BP 132 EP 132 PG 1 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA KX965 UT WOS:A1993KX96500480 ER PT J AU VITALE, AT LIU, JJ CAI, XX LEE, SJ FOSTER, CS COLVIN, RB AF VITALE, AT LIU, JJ CAI, XX LEE, SJ FOSTER, CS COLVIN, RB TI FIBRONECTIN ISOFORM EXPRESSION IN THE WOUNDED CORNEAL EPITHELIUM - POLYMERASE CHAIN-REACTION ANALYSIS IN A RAT EPITHELIAL SCRAPE WOUND MODEL SO JOURNAL OF CELLULAR BIOCHEMISTRY LA English DT Meeting Abstract C1 HARVARD UNIV,SCH MED,MASSACHUSETTS EYE & EAR INFIRM,RHOADS MOLEC IMMUNOL LAB,BOSTON,MA 02115. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012 SN 0730-2312 J9 J CELL BIOCHEM JI J. Cell. Biochem. PD MAR 29 PY 1993 SU 17E BP 134 EP 134 PG 1 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA KX965 UT WOS:A1993KX96500489 ER PT J AU GROSS, J AF GROSS, J TI AMPHIBIAN REGENERATION AND MAMMALIAN WOUND REPAIR - A MECHANISTIC LINK SO JOURNAL OF CELLULAR BIOCHEMISTRY LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,DEPT DERMATOL,CUTANEOUS BIOL RES CTR,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012 SN 0730-2312 J9 J CELL BIOCHEM JI J. Cell. Biochem. PD MAR 29 PY 1993 SU 17E BP 142 EP 142 PG 1 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA KX965 UT WOS:A1993KX96500510 ER PT J AU VERTEL, BM WALTERS, LM GRIER, B MILLS, DK SCHWARTZ, NB KEARNS, AE GOETINCK, PF AF VERTEL, BM WALTERS, LM GRIER, B MILLS, DK SCHWARTZ, NB KEARNS, AE GOETINCK, PF TI THE IMPLICATIONS OF INTRACELLULAR TRAFFICKING AND PROCESSING EVENTS FOR EXTRACELLULAR-MATRIX ASSEMBLY AND FUNCTION IN CARTILAGE SO JOURNAL OF CELLULAR BIOCHEMISTRY LA English DT Meeting Abstract C1 UNIV CHICAGO,DEPT BIOCHEM,CHICAGO,IL 60637. UNIV CHICAGO,DEPT MOLEC BIOL,CHICAGO,IL 60637. UNIV CHICAGO,DEPT PEDIAT,CHICAGO,IL 60637. CHICAGO MED SCH,UHS,DEPT CELL BIOL & ANAT,CHICAGO,IL 60064. HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,CUTANEOUS BIOL RES CTR,BOSTON,MA 02129. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012 SN 0730-2312 J9 J CELL BIOCHEM JI J. Cell. Biochem. PD MAR 29 PY 1993 SU 17E BP 166 EP 166 PG 1 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA KX965 UT WOS:A1993KX96500592 ER PT J AU CULVER, KW LINK, CJ AKDEMIR, N MOORMAN, D STANLEY, D BUTLER, D ACKERMANN, M JACOBSON, C SCHNITZER, J BLAESE, RM AF CULVER, KW LINK, CJ AKDEMIR, N MOORMAN, D STANLEY, D BUTLER, D ACKERMANN, M JACOBSON, C SCHNITZER, J BLAESE, RM TI INVIVO GENE-TRANSFER FOR THE TREATMENT OF SOLID TUMORS SO JOURNAL OF CELLULAR BIOCHEMISTRY LA English DT Meeting Abstract C1 GENET THERAPY INC,GAITHERSBURG,MD 20878. IOWA METHODIST MED CTR,DES MOINES,IA. NCI,BETHESDA,MD 20892. IOWA STATE UNIV SCI & TECHNOL,AMES,IA 50011. MASSACHUSETTS GEN HOSP,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012 SN 0730-2312 J9 J CELL BIOCHEM JI J. Cell. Biochem. PD MAR 29 PY 1993 SU 17E BP 186 EP 186 PG 1 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA KX965 UT WOS:A1993KX96500660 ER PT J AU HUIZENGA, DE SASSANFAR, M SZOSTAK, J AF HUIZENGA, DE SASSANFAR, M SZOSTAK, J TI THE INVITRO SELECTION OF ATP SPECIFIC DNA APTAMERS SO JOURNAL OF CELLULAR BIOCHEMISTRY LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,DEPT MOLEC BIOL,BOSTON,MA 02114. HARVARD UNIV,SCH MED,BOSTON,MA 02115. NR 1 TC 0 Z9 0 U1 1 U2 4 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012 SN 0730-2312 J9 J CELL BIOCHEM JI J. Cell. Biochem. PD MAR 29 PY 1993 SU 17E BP 207 EP 207 PG 1 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA KX965 UT WOS:A1993KX96500733 ER PT J AU AEBISCHER, P HOFFMAN, D BREAKEFIELD, XO SHORT, P AF AEBISCHER, P HOFFMAN, D BREAKEFIELD, XO SHORT, P TI TRANSPLANTATION OF GENETICALLY ENGINEERED POLYMER ENCAPSULATED CELL-LINES IN THE NERVOUS-SYSTEM SO JOURNAL OF CELLULAR BIOCHEMISTRY LA English DT Meeting Abstract C1 BROWN UNIV,ARTIFICIAL ORGANS BIOMAT & CELLULAR TECHNOL SECT,PROVIDENCE,RI 02912. MASSACHUSETTS GEN HOSP,DEPT NEUROGENET,BOSTON,MA 02114. UNIV LAUSANNE,CHU VAUDOIS,DIV SURG RES,CH-1000 LAUSANNE 17,SWITZERLAND. RI Aebischer, Patrick/E-1387-2013 NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012 SN 0730-2312 J9 J CELL BIOCHEM JI J. Cell. Biochem. PD MAR 29 PY 1993 SU 17E BP 219 EP 219 PG 1 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA KX965 UT WOS:A1993KX96500775 ER PT J AU ORY, DS RIVERA, A REAM, B FALLON, JT GOLD, HK MULLIGAN, RC AF ORY, DS RIVERA, A REAM, B FALLON, JT GOLD, HK MULLIGAN, RC TI MICROVASCULAR ENDOTHELIAL-CELL GENE-TRANSFER IN A RABBIT MODEL SO JOURNAL OF CELLULAR BIOCHEMISTRY LA English DT Meeting Abstract C1 WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142. MASSACHUSETTS GEN HOSP,CARDIAC UNIT,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012 SN 0730-2312 J9 J CELL BIOCHEM JI J. Cell. Biochem. PD MAR 29 PY 1993 SU 17E BP 219 EP 219 PG 1 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA KX965 UT WOS:A1993KX96500773 ER PT J AU HU, JS TURKA, LA THOMPSON, CB KINGSTON, RE AF HU, JS TURKA, LA THOMPSON, CB KINGSTON, RE TI POTENTIAL INVOLVEMENT OF HEB, A HELIX-LOOP-HELIX TRANSCRIPTION FACTOR, IN T-CELL DEVELOPMENT SO JOURNAL OF CELLULAR BIOCHEMISTRY LA English DT Meeting Abstract C1 UNIV MICHIGAN,ANN ARBOR,MI 48109. HARVARD UNIV,SCH MED,BOSTON,MA 02115. MASSACHUSETTS GEN HOSP,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012 SN 0730-2312 J9 J CELL BIOCHEM JI J. Cell. Biochem. PD MAR 29 PY 1993 SU 17E BP 263 EP 263 PG 1 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA KX965 UT WOS:A1993KX96500927 ER PT J AU OCONNOR, R GOLDMACHER, VS TEICHER, BA BLATTLER, WA AF OCONNOR, R GOLDMACHER, VS TEICHER, BA BLATTLER, WA TI INTERACTIONS OF ANTI-B4-BR WITH CHEMOTHERAPEUTIC-AGENTS ON B-ALL CELLS-INVITRO SO JOURNAL OF CELLULAR BIOCHEMISTRY LA English DT Meeting Abstract C1 IMMUNOGEN INC,CAMBRIDGE,MA 02139. HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012 SN 0730-2312 J9 J CELL BIOCHEM JI J. Cell. Biochem. PD MAR 29 PY 1993 SU 17E BP 270 EP 270 PG 1 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA KX965 UT WOS:A1993KX96500954 ER PT J AU MICHISHITA, M VIDEM, V ARNAOUT, MA AF MICHISHITA, M VIDEM, V ARNAOUT, MA TI A NOVEL DIVALENT CATION-BINDING SITE IN THE A-DOMAIN OF THE BETA-2-INTEGRIN-CR3 (CD11B/CD18) IS ESSENTIAL FOR LIGAND-BINDING SO CELL LA English DT Article ID COMPLEMENT RECEPTOR TYPE-3; AMINO-ACID-SEQUENCE; COMMON BETA-SUBUNIT; LEUKOCYTE ADHESION GLYCOPROTEIN; LEU-CAM DEFICIENCY; VONWILLEBRAND-FACTOR; ALPHA-SUBUNIT; MONOCLONAL-ANTIBODIES; MOLECULAR-CLONING; POLYMORPHONUCLEAR LEUKOCYTES AB A recombinant peptide encoding the CD11b A domain bound Mn-54(2+), with a high affinity. Other divalent cations, including Mg2+, Zn2+, Ni2+, Co2+, and Cd2+, but not Ca2+ or Ba2+, competed effectively for Mn2+ binding. Amino acid substitutions within two conserved and noncontiguous regions in the recombinant peptide abolished Mn-54(2+) binding. When these substitutions were introduced independently in complement receptor type 3 (CR3), each abolished the metal-dependent binding of the receptor to the major C3 opsonin iC3b, without impairing subunit association or surface expression of the receptor. These findings identify an unsuspected and novel metal-binding site within the A domain of CR3 that is required for metal-dependent ligand binding and also identify a good target for designing drugs aimed at countering the inflammatory potential of this key receptor. C1 HARVARD UNIV,SCH MED,BOSTON,MA 02129. RP MICHISHITA, M (reprint author), MASSACHUSETTS GEN HOSP,DEPT MED,LEUKOCYTE BIOL & INFLAMMAT PROGRAM,BOSTON,MA 02129, USA. FU NIAID NIH HHS [AI-21964, AI-28465] NR 74 TC 331 Z9 332 U1 1 U2 8 PU CELL PRESS PI CAMBRIDGE PA 1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 SN 0092-8674 J9 CELL JI Cell PD MAR 26 PY 1993 VL 72 IS 6 BP 857 EP 867 DI 10.1016/0092-8674(93)90575-B PG 11 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA KU175 UT WOS:A1993KU17500007 PM 8458080 ER PT J AU MACDONALD, ME AMBROSE, CM DUYAO, MP MYERS, RH LIN, C SRINIDHI, L BARNES, G TAYLOR, SA JAMES, M GROOT, N MACFARLANE, H JENKINS, B ANDERSON, MA WEXLER, NS GUSELLA, JF BATES, GP BAXENDALE, S HUMMERICH, H KIRBY, S NORTH, M YOUNGMAN, S MOTT, R ZEHETNER, G SEDLACEK, Z POUSTKA, A FRISCHAUF, AM LEHRACH, H BUCKLER, AJ CHURCH, D DOUCETTESTAMM, L ODONOVAN, MC RIBARAMIREZ, L SHAH, M STANTON, VP STROBEL, SA DRATHS, KM WALES, JL DERVAN, P HOUSMAN, DE ALTHERR, M SHIANG, R THOMPSON, L FIELDER, T WASMUTH, JJ TAGLE, D VALDES, J ELMER, L ALLARD, M CASTILLA, L SWAROOP, M BLANCHARD, K COLLINS, FS SNELL, R HOLLOWAY, T GILLESPIE, K DATSON, N SHAW, D HARPER, PS AF MACDONALD, ME AMBROSE, CM DUYAO, MP MYERS, RH LIN, C SRINIDHI, L BARNES, G TAYLOR, SA JAMES, M GROOT, N MACFARLANE, H JENKINS, B ANDERSON, MA WEXLER, NS GUSELLA, JF BATES, GP BAXENDALE, S HUMMERICH, H KIRBY, S NORTH, M YOUNGMAN, S MOTT, R ZEHETNER, G SEDLACEK, Z POUSTKA, A FRISCHAUF, AM LEHRACH, H BUCKLER, AJ CHURCH, D DOUCETTESTAMM, L ODONOVAN, MC RIBARAMIREZ, L SHAH, M STANTON, VP STROBEL, SA DRATHS, KM WALES, JL DERVAN, P HOUSMAN, DE ALTHERR, M SHIANG, R THOMPSON, L FIELDER, T WASMUTH, JJ TAGLE, D VALDES, J ELMER, L ALLARD, M CASTILLA, L SWAROOP, M BLANCHARD, K COLLINS, FS SNELL, R HOLLOWAY, T GILLESPIE, K DATSON, N SHAW, D HARPER, PS TI A NOVEL GENE CONTAINING A TRINUCLEOTIDE REPEAT THAT IS EXPANDED AND UNSTABLE ON HUNTINGTONS-DISEASE CHROMOSOMES SO CELL LA English DT Article ID POLYMORPHIC DNA MARKER; LINKAGE DISEQUILIBRIUM; FRAGILE-X; REGION; LOCALIZATION; CONSTRUCTION; LOCATION; STRATEGY; COMPLEX; LOCUS AB The Huntington's disease (HD) gene has been mapped in 4p16.3 but has eluded identification. We have used haplotype analysis of linkage disequilibrium to spotlight a small segment of 4p16.3 as the likely location of the defect. A new gene, IT15, isolated using cloned trapped exons from the target area contains a polymorphic trinucleotide repeat that is expanded and unstable on HD chromosomes. A (CAG)n repeat longer than the normal range was observed on HD chromosomes from all 75 disease families examined, comprising a variety of ethnic backgrounds and 4p16.3 haplotypes. The (CAG)n repeat appears to be located within the coding sequence of a predicted approximately 348 kd protein that is widely expressed but unrelated to any known gene. Thus, the HD mutation involves an unstable DNA segment, similar to those described in fragile X syndrome, spino-bulbar muscular atrophy, and myotonic dystrophy, acting in the context of a novel 4p16.3 gene to produce a dominant phenotype. C1 MASSACHUSETTS GEN HOSP, MOLEC NEUROGENET UNIT, BOSTON, MA 02114 USA. HARVARD UNIV, SCH MED, DEPT GENET, BOSTON, MA 02114 USA. BOSTON UNIV, SCH MED, DEPT NEUROL, BOSTON, MA 02118 USA. HEREDITARY DIS FDN, SANTA MONICA, CA 90401 USA. IMPERIAL CANC RES FUND, GENOME ANAL LAB, LONDON WC2A 3PX, ENGLAND. MIT, CTR CANC RES, CAMBRIDGE, MA 02139 USA. CALTECH, DIV CHEM & CHEM ENGN, PASADENA, CA 91125 USA. UNIV CALIF IRVINE, DEPT BIOL CHEM, IRVINE, CA 92717 USA. UNIV MICHIGAN, DEPT INTERNAL MED & GENET, ANN ARBOR, MI 48109 USA. UNIV MICHIGAN, HOWARD HUGHES MED INST, ANN ARBOR, MI 48109 USA. UNIV WALES COLL MED, INST MED GENET, CARDIFF CF4 4XN, S GLAM, WALES. RI turton, miranda/F-4682-2011; Bates, Gillian/E-1146-2012; OI Bates, Gillian/0000-0002-4041-6305; O'Donovan, Michael/0000-0001-7073-2379 NR 64 TC 3496 Z9 3557 U1 31 U2 225 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 0092-8674 EI 1097-4172 J9 CELL JI Cell PD MAR 26 PY 1993 VL 72 IS 6 BP 971 EP 983 DI 10.1016/0092-8674(93)90585-E PG 13 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA KU175 UT WOS:A1993KU17500017 ER PT J AU SHIN, J LEE, S STROMINGER, JL AF SHIN, J LEE, S STROMINGER, JL TI TRANSLOCATION OF TCR-ALPHA CHAINS INTO THE LUMEN OF THE ENDOPLASMIC-RETICULUM AND THEIR DEGRADATION SO SCIENCE LA English DT Article ID CELL RECEPTOR COMPLEX; PROTEINS; RETENTION; MEMBRANE; CD4; ER AB After synthesis, the alpha chain of the T cell antigen receptor (TCRalpha) can form a complex with other TCR chains and move to the cell surface, or TCRalpha can undergo degradation in the endoplasmic reticulum (ER) if it remains unassembled. The mechanism of translocation and degradation in the ER is unclear. It was found that the putative transmembrane region of TCRalpha (alpha(tm)) was incompetent on its own to act as a transmembrane region. Molecules that contained alpha(tm) were translocated into the ER lumen and then underwent either rapid degradation or secretion, depending on the sequence of the cytoplasmic domain. A specific signal for ER degradation within alpha(tm) does not appear to be present. RP SHIN, J (reprint author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV TUMOR VIROL,BOSTON,MA 02115, USA. FU NCI NIH HHS [CA47554]; NIAID NIH HHS [AI20182]; NIGMS NIH HHS [GM48961] NR 23 TC 67 Z9 67 U1 0 U2 2 PU AMER ASSOC ADVANCEMENT SCIENCE PI WASHINGTON PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 SN 0036-8075 J9 SCIENCE JI Science PD MAR 26 PY 1993 VL 259 IS 5103 BP 1901 EP 1904 DI 10.1126/science.8456316 PG 4 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA KU172 UT WOS:A1993KU17200033 PM 8456316 ER PT J AU LEE, TH KLAMPFER, L SHOWS, TB VILCEK, J AF LEE, TH KLAMPFER, L SHOWS, TB VILCEK, J TI TRANSCRIPTIONAL REGULATION OF TSG6, A TUMOR NECROSIS FACTOR-1-INDUCIBLE AND INTERLEUKIN-1-INDUCIBLE PRIMARY RESPONSE GENE CODING FOR A SECRETED HYALURONAN-BINDING PROTEIN SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID FACTOR-KAPPA-B; NUCLEAR FACTOR; HUMAN-FIBROBLASTS; FACTOR-ALPHA; EUKARYOTIC PROMOTERS; LINK PROTEINS; EXPRESSION; ACTIVATION; INDUCTION; CYTOKINES AB TSG6 was originally identified as a tumor necrosis factor (TNF)-inducible gene in human fibroblasts. Earlier we showed that the secretory TSG6 protein is a member of a family of hyaluronan-binding proteins that includes cartilage link protein, proteoglycan core protein, and the adhesion receptor CD44. In the present study we have used Southern blot analysis to demonstrate that TSG6 is a single-copy gene in the human and murine species. With the aid of a somatic cell hybrid mapping panel, TSG6 was assigned to human chromosome 2. Nuclear run-on analysis revealed that TNF produced a rapid, primary transcriptional activation of the TSG6 gene in normal human FS-4 fibroblasts. In order to learn more about the regulation of TSG6 gene expression, we cloned the TSG6 gene from a genomic library of human white blood cells. Sequencing of a 1.3-kilobase fragment of the 5'-flanking region of the TSG6 gene identified TATA-like and CAAT sequences near the transcription start site. In addition, potential binding sites for NF-IL-6, AP-1, interferon regulatory factors (IRF)-l and -2, and glucocorticoid response elements were identified in the 5'-flanking region. A single transcription start site was identified by primer extension. Deletion analysis of the 5'-flanking region of the TSG6 DNA linked to the chloramphenicol acetyltransferase reporter gene revealed that a construct containing TSG6 DNA from positions-165 to +78 could be transcriptionally activated by interleukin(IL)-1, and to a lesser extent by TNF, upon transfection into FS-4 fibroblasts. The region that imparts inducibility by IL-1 or TNF (positions -165 to -58) contains potential binding sites for IRF- 1 and -2, AP-1, and NF-IL-6. A region mediating transcriptional silencing was localized further upstream (between positions -332 and -165). The results suggest that TSG6 gene expression is regulated by an interplay of positively and negatively acting transactivating factors. C1 ROSWELL PK CANC INST,DEPT HUMAN GENET,BUFFALO,NY 14263. NYU MED CTR,DEPT MICROBIOL,NEW YORK,NY 10016. NYU MED CTR,KAPLAN CANC CTR,NEW YORK,NY 10016. RP LEE, TH (reprint author), MASSACHUSETTS GEN HOSP,DEPT MOLEC BIOL,BOSTON,MA 02114, USA. FU NCI NIH HHS [R35CA49731]; NHGRI NIH HHS [HG00333] NR 35 TC 50 Z9 50 U1 0 U2 2 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD MAR 25 PY 1993 VL 268 IS 9 BP 6154 EP 6160 PG 7 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA KT368 UT WOS:A1993KT36800015 PM 8454591 ER PT J AU PODOLSKY, DK LYNCHDEVANEY, K STOW, JL OATES, P MURGUE, B DEBEAUMONT, M SANDS, BE MAHIDA, YR AF PODOLSKY, DK LYNCHDEVANEY, K STOW, JL OATES, P MURGUE, B DEBEAUMONT, M SANDS, BE MAHIDA, YR TI IDENTIFICATION OF HUMAN INTESTINAL TREFOIL FACTOR - GOBLET CELL-SPECIFIC EXPRESSION OF A PEPTIDE TARGETED FOR APICAL SECRETION SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID PANCREATIC SPASMOLYTIC POLYPEPTIDE; EPIDERMAL GROWTH-FACTOR; STOMACH MUCOSA; PSP; DIFFERENTIATION; LINE; RAT; PROTEIN; PS2-PROTEIN; CARCINOMA AB Trefoil peptides are a recently recognized group of small peptides abundantly produced at mucosal surfaces that offer the opportunity to define mechanisms of mucosal cell-specific differentiation and to illuminate new mechanisms for the preservation of mucosal integrity. We report the cDNA cloning of a 75-amino acid human trefoil factor expressed in small and large intestinal mucosas that is highly homologous to the intestinal trefoil factor, with 70% identity at the amino acid level of the predicted mature protein. This human intestinal trefoil factor is also homologous, although to a lesser extent, to trefoil peptides expressed at other sites in the gastrointestinal tract in man, exhibiting absolute conservation of the P domain motif (CX9CX9CX4CCX9WCF) that defines this family of peptides. These findings indicate a high degree of evolutionary conservation of organ/region-specific members of this peptide family. In situ hybridization of intestinal trefoil factor demonstrates a high degree of expression in mature small intestine villus and colonic epithelial goblet cells. Immunogold staining demonstrates high concentrations of intestinal trefoil factor in the rough endoplasmic reticulum and theca of goblet cells as well as throughout the mucosal surface, consistent with vectorial secretion of this factor by goblet cells onto the intestinal luminal surface. In addition, intestinal trefoil factor was also localized within columnar epithelial cells by immunogold labeling despite the absence of mRNA. These observations suggest that peptide secreted by goblet cells might be taken up from the luminal surface and transcytosed by enterocytes. Human intestinal trefoil factor expression was also detected in the HT-29N2 and HT-29H2 subclones in conjunction with the emergence of the goblet cell phenotype, but not in the CaCO2 cell line that exhibits enterocytic phenotype. In summary, these findings confirm the existence of a highly conserved family of peptides that are abundantly expressed in distinctive regions throughout the gastrointestinal tract in a highly cell-specific pattern reflecting a goblet cell differentiation pathway. They form one of the more abundant constituents of the interface between the mucosa and ''outside' environment and may provide a new paradigm of regulation of the integrity of epithelial surfaces as well as a previously unrecognized dimension of goblet cell function. C1 MASSACHUSETTS GEN HOSP,RENAL UNIT,BOSTON,MA 02114. MASSACHUSETTS GEN HOSP,NEW ENGLAND REG PRIMATE RES CTR STUDY INFLAMMATORY BOWEL DIS,BOSTON,MA 02114. RP PODOLSKY, DK (reprint author), MASSACHUSETTS GEN HOSP,GASTROINTESTINAL UNIT,BOSTON,MA 02114, USA. OI Stow, Jennifer/0000-0002-5409-9101 FU NIDDK NIH HHS [DK07191, DK34422, DK43351] NR 36 TC 237 Z9 244 U1 1 U2 6 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD MAR 25 PY 1993 VL 268 IS 9 BP 6694 EP 6702 PG 9 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA KT368 UT WOS:A1993KT36800088 PM 8454642 ER PT J AU CARLSON, KJ NICHOLS, DH SCHIFF, I AF CARLSON, KJ NICHOLS, DH SCHIFF, I TI CURRENT CONCEPTS - INDICATIONS FOR HYSTERECTOMY SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Review ID CHRONIC PELVIC PAIN; PROSTAGLANDIN-SYNTHETASE INHIBITORS; TOTAL ABDOMINAL HYSTERECTOMY; LONG-TERM; BILATERAL OOPHORECTOMY; PSYCHOLOGICAL-ASPECTS; LEIOMYOMATA UTERI; REPRODUCTIVE AGE; UNITED-STATES; DOUBLE-BLIND C1 MASSACHUSETTS GEN HOSP, VINCENT MEM GYNECOL SERV, BOSTON, MA 02114 USA. MASSACHUSETTS GEN HOSP, MED SERV, BOSTON, MA 02114 USA. HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA. FU AHRQ HHS [R01 HS06121] NR 57 TC 217 Z9 222 U1 3 U2 3 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 EI 1533-4406 J9 NEW ENGL J MED JI N. Engl. J. Med. PD MAR 25 PY 1993 VL 328 IS 12 BP 856 EP 860 PG 5 WC Medicine, General & Internal SC General & Internal Medicine GA KT814 UT WOS:A1993KT81400007 PM 8357364 ER PT J AU RUBIN, RH LIVNI, E BABICH, J ALPERT, NM LIU, YY THAM, E PROSSER, B CLEELAND, R CALLAHAN, RJ CORREIA, JA STRAUSS, HW FISCHMAN, AJ AF RUBIN, RH LIVNI, E BABICH, J ALPERT, NM LIU, YY THAM, E PROSSER, B CLEELAND, R CALLAHAN, RJ CORREIA, JA STRAUSS, HW FISCHMAN, AJ TI PHARMACOKINETICS OF FLEROXACIN AS STUDIED BY POSITRON EMISSION TOMOGRAPHY AND [F-18] FLEROXACIN SO AMERICAN JOURNAL OF MEDICINE LA English DT Article ID INVITRO ACTIVITY; RO-23-6240; QUINOLONE; ANIMALS; AM-833 AB A new method of tracing the disposition of fleroxacin was tested in infected and noninfected animals in an effort to develop a technique that might be applicable in humans. [F-18]fleroxacin was synthesized and shown to be identical physically, chemically, and in its antimicrobial activity to the commercially produced product. Tracer amounts of [F-18]fleroxacin were coinjected with a pharmacologic dose of unlabeled drug (10 mg/kg) into normal mice, rats with focal thigh infection due to Escherichia coli, and normal and infected rabbits. The rats and mice were killed at fixed time intervals after injection, and the concentration of drug was determined by radioactive counting in a well-type counter; the rabbits were studied both by this method and by positron emission tomographic (PET) imaging. These studies validated the reliability of the new approach and suggested that it could be applied safely to humans. In all three animal species studied, delivery of [F-18]fleroxacin to most tissues was rapid, with the notable exception of the brain. Accumulation of drug in infected thigh muscle was similar to that in normal muscle. The concentrations of drug reached in various tissues suggest that fleroxacin will be particularly useful in the treatment of gastrointestinal, urinary tract, hepatobiliary, and skeletal infections and that it shows promise for the treatment of lung and soft tissue infection. The minimal concentrations of drug delivered to the brain should decrease the occurrence of central nervous system toxicity with this particular fluoroquinolone. C1 MASSACHUSETTS GEN HOSP,MED SERV,CLIN INVEST PROGRAM,BOSTON,MA 02114. MASSACHUSETTS GEN HOSP,DEPT RADIOL,DIV NUCL MED,BOSTON,MA 02114. HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115. HARVARD UNIV,SCH MED,DEPT RADIOL,BOSTON,MA 02115. HOFFMANN LA ROCHE INC,NUTLEY,NJ 07110. NR 17 TC 1 Z9 1 U1 0 U2 1 PU EXCERPTA MEDICA INC PI NEW YORK PA 245 WEST 17TH STREET, NEW YORK, NY 10011 SN 0002-9343 J9 AM J MED JI Am. J. Med. PD MAR 22 PY 1993 VL 94 SU 3A BP 31 EP 37 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA KV069 UT WOS:A1993KV06900006 ER PT J AU RAY, WA TAYLOR, JA MEADOR, KG LICHTENSTEIN, MJ GRIFFIN, MR FOUGHT, R ADAMS, ML BLAZER, DG AF RAY, WA TAYLOR, JA MEADOR, KG LICHTENSTEIN, MJ GRIFFIN, MR FOUGHT, R ADAMS, ML BLAZER, DG TI REDUCING ANTIPSYCHOTIC DRUG-USE IN NURSING-HOMES - A CONTROLLED TRIAL OF PROVIDER EDUCATION SO ARCHIVES OF INTERNAL MEDICINE LA English DT Article ID CARE FACILITY; DEMENTIA; RISK; RESIDENTS; BEHAVIORS AB Objective: In the United States, 20% or more of nursing home residents receive antipsychotic drugs, primarily for the behavioral manifestations of dementia. This high level of use of drugs with substantial toxicity has engendered a strong and persistent controversy and recently has led to explicit regulatory measures to curtail use (Omnibus Budget Reconciliation Act of 1987). We developed and tested a comprehensive program to reduce antipsychotic use through education of physicians, nurses, and other nursing home staff. The primary elements of the program were instruction in use of behavioral techniques to manage behavior problems and encouragement of a trial of gradual antipsychotic withdrawal. Design: In a nonrandomized controlled trial, the program was implemented (beginning in August 1990) in two rural Tennessee community nursing homes with elevated antipsychotic use; two other comparable homes were selected as concurrent controls. Patients: Throughout the study 194 residents were in the education homes and 184 were in the control homes. Residents in both groups of homes had comparable demographic characteristics and functional status, and each group had a baseline rate of 29 days of antipsychotic use per 100 days of nursing home residence. Main Outcome Measures: The primary end points were postintervention changes in administration of antipsychotics and other psychotropic drugs, use of physical restraints, and frequency of behavior problems. Results: Days of antipsychotic use decreased by 72% in the education homes vs 13% in the control homes (P<.001). No significant changes were noted in the use of other psychotropic drugs in either group. Days of physical restraint use decreased 36% in the education homes vs 5% in the control homes (P<.001). Behavior problem frequency did not increase in either group, even among the 48% of baseline antipsychotic users in the education homes who had antipsychotic drug regimens discontinued for 3 or more months. Conclusions: The educational program led to a substantial reduction in antipsychotic use with no increase in the frequency of behavior problems. This suggests that for many antipsychotic drug users benefits may be marginal and that programs to reduce such drug use among the 250 000 US nursing home residents receiving these drugs should have high priority. C1 VANDERBILT UNIV,MED CTR,SCH MED,DEPT PSYCHIAT,NASHVILLE,TN 37232. UNIV TEXAS,HLTH SCI CTR,SAN ANTONIO,TX 78284. AUDIE L MURPHY MEM VET ADM MED CTR,CTR GERIATR RES EDUC & CLIN,SAN ANTONIO,TX 78284. DUKE UNIV,MED CTR,DEPT PSYCHIAT,DURHAM,NC 27710. RP RAY, WA (reprint author), VANDERBILT UNIV,MED CTR,SCH MED,DEPT PREVENT MED,NASHVILLE,TN 37232, USA. NR 46 TC 118 Z9 118 U1 0 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610 SN 0003-9926 J9 ARCH INTERN MED JI Arch. Intern. Med. PD MAR 22 PY 1993 VL 153 IS 6 BP 713 EP 721 DI 10.1001/archinte.153.6.713 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA KR996 UT WOS:A1993KR99600005 PM 8447709 ER PT J AU EPSTEIN, RJ AF EPSTEIN, RJ TI 6 AUTHORS IN SEARCH OF A CITATION - VILLAINS OR VICTIMS OF THE VANCOUVER CONVENTION SO BRITISH MEDICAL JOURNAL LA English DT Article AB Objectives-To analyse trends in the number of authors per article over the past 10 years. Design-Analysis of articles from random volumes of eight biomedical journals. Subjects-Cell, Nature, Proceedings of the National Academy of Sciences USA (PNAS), Journal of Clinical Investigation (JCI), Biochemical and Biophysical Research Communications (BBRC), Journal of Clinical Oncology (JCO), New England Journal of Medicine (NEJM), Lancet. Main outcome measures-Median and modal numbers of authors. Results-All journals except Cell and Nature showed a trend towards increasing authorship numbers over the study period. The trend was most noticeable in journals such as JCO which feature clinical research. General medical journals (Lancet, NEJM) with a median of six to seven authors per article published far fewer seven author than six author studies, which suggests that author number may be influenced by the Vancouver convention which precludes citation of more than six authors. Conclusions-The phenomenon of expanding authorship in biomedical journal articles is not explained by the hypothesis that newer research technologies have necessitated more extensive collaboration. Rather, the data suggest that conferral of authorship may sometimes have a volitional component which contributes to rising author numbers. It is proposed that replacement of the Vancouver convention with a ''first author, last author'' citation system may help stem this rise in author numbers. RP EPSTEIN, RJ (reprint author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DEPT MED,DIV CELL & MOLEC BIOL,BOSTON,MA 02115, USA. NR 5 TC 60 Z9 63 U1 0 U2 3 PU BRITISH MED JOURNAL PUBL GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR SN 0959-8138 J9 BRIT MED J JI Br. Med. J. PD MAR 20 PY 1993 VL 306 IS 6880 BP 765 EP 767 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA KU173 UT WOS:A1993KU17300028 PM 8369041 ER PT J AU HUA, QX JIA, WH FRANK, BH WEISS, MA AF HUA, QX JIA, WH FRANK, BH WEISS, MA TI COMPARISON OF THE DYNAMICS OF AN ENGINEERED INSULIN MONOMER AND DIMER BY ACID-QUENCHED AMIDE PROTON-EXCHANGE - NONLOCAL STABILIZATION OF INTERCHAIN HYDROGEN-BONDS BY DIMERIZATION SO JOURNAL OF MOLECULAR BIOLOGY LA English DT Article DE NMR SPECTROSCOPY; INSULIN; PROTEIN DYNAMICS; PROTEIN PROTEIN INTERACTIONS ID DES-PENTAPEPTIDE-INSULIN; ALPHA-LACTALBUMIN; SECONDARY STRUCTURE; 2-DIMENSIONAL NMR; COMPACT STATE; CYTOCHROME-C; B-CHAIN; RECEPTOR; BINDING; ASSIGNMENT C1 HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115. ELI LILLY & CO,LILLY RES LAB,DEPT PARENTERAL RES & DEV,INDIANAPOLIS,IN 46285. HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEPT MED,BOSTON,MA 02114. CHINESE ACAD SCI,INST BIOPHYS,BEIJING,PEOPLES R CHINA. FU NIDDK NIH HHS [DK40949] NR 55 TC 23 Z9 24 U1 0 U2 0 PU ACADEMIC PRESS LTD PI LONDON PA 24-28 OVAL RD, LONDON, ENGLAND NW1 7DX SN 0022-2836 J9 J MOL BIOL JI J. Mol. Biol. PD MAR 20 PY 1993 VL 230 IS 2 BP 387 EP 394 DI 10.1006/jmbi.1993.1156 PG 8 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA KW260 UT WOS:A1993KW26000006 PM 8464054 ER PT J AU SHIVDASANI, RA HALUSKA, FG DOCK, NL DOVER, JS KINEKE, EJ ANDERSON, KC AF SHIVDASANI, RA HALUSKA, FG DOCK, NL DOVER, JS KINEKE, EJ ANDERSON, KC TI GRAFT-VERSUS-HOST DISEASE ASSOCIATED WITH TRANSFUSION OF BLOOD FROM UNRELATED HLA-HOMOZYGOUS DONORS SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Note ID AUTOLOGOUS BONE-MARROW; IMMUNOCOMPETENT PATIENT; NEURO-BLASTOMA; FATAL GRAFT; PRODUCTS; IRRADIATION; PREVENTION; SURGERY; CHILD C1 HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV TUMOR IMMUNOL,44 BINNEY ST,BOSTON,MA 02115. HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV MED ONCOL,BOSTON,MA 02115. HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV IMMUNOGENET,BOSTON,MA 02115. NEW ENGLAND DEACONESS HOSP,DIV DERMATOL,BOSTON,MA 02215. HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115. AMER RED CROSS,BLOOD SERV,SYRACUSE,NY. NR 33 TC 53 Z9 54 U1 0 U2 0 PU MASS MEDICAL SOC PI BOSTON PA 10 SHATTUCK, BOSTON, MA 02115 SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD MAR 18 PY 1993 VL 328 IS 11 BP 766 EP 770 DI 10.1056/NEJM199303183281105 PG 5 WC Medicine, General & Internal SC General & Internal Medicine GA KR848 UT WOS:A1993KR84800005 PM 8437597 ER PT J AU GROWDON, JH AF GROWDON, JH TI TACRINE IN ALZHEIMERS-DISEASE SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Letter RP GROWDON, JH (reprint author), MASSACHUSETTS GEN HOSP,BOSTON,MA 02114, USA. NR 5 TC 2 Z9 2 U1 0 U2 0 PU MASS MEDICAL SOC PI BOSTON PA 10 SHATTUCK, BOSTON, MA 02115 SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD MAR 18 PY 1993 VL 328 IS 11 BP 810 EP 810 PG 1 WC Medicine, General & Internal SC General & Internal Medicine GA KR848 UT WOS:A1993KR84800020 ER PT J AU KOPANS, DB AF KOPANS, DB TI EVALUATION OF A BREAST MASS SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Letter ID MAMMOGRAPHY RP KOPANS, DB (reprint author), MASSACHUSETTS GEN HOSP, BOSTON, MA 02114 USA. NR 6 TC 1 Z9 1 U1 0 U2 0 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 EI 1533-4406 J9 NEW ENGL J MED JI N. Engl. J. Med. PD MAR 18 PY 1993 VL 328 IS 11 BP 810 EP 811 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA KR848 UT WOS:A1993KR84800021 PM 8437607 ER PT J AU BIEDERMAN, J FARAONE, SV LAPEY, K MICK, E AF BIEDERMAN, J FARAONE, SV LAPEY, K MICK, E TI CONTINUITY OF ADHD INTO ADULTHOOD SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,PEDIAT PSYCHOPHAMACOL,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD MAR 15 PY 1993 VL 33 IS 6A SU S BP A102 EP A103 PG 2 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA LA417 UT WOS:A1993LA41700240 ER PT J AU BIEDERMAN, J ROSENBAUM, JF KAGAN, J AF BIEDERMAN, J ROSENBAUM, JF KAGAN, J TI BEHAVIORAL-INHIBITION AS A TEMPERAMENTAL RISK FACTOR FOR ANXIETY DISORDERS SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract C1 HARVARD UNIV,SCH MED,MASSACHUSETTS GEN HOSP,DEPT PSYCHIAT,BOSTON,MA 02115. NR 0 TC 3 Z9 3 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD MAR 15 PY 1993 VL 33 IS 6A SU S BP A39 EP A39 PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA LA417 UT WOS:A1993LA41700009 ER PT J AU COHEN, LS SICHEL, DA DIMMOCK, J ROSENBAUM, JF AF COHEN, LS SICHEL, DA DIMMOCK, J ROSENBAUM, JF TI BEHAVIORAL OUTCOME IN INFANTS OF MOTHERS PRESENTING TO A PERINATAL PSYCHIATRIC CLINIC SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract C1 HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEPT PSYCHIAT,CLIN PSYCHOPHARMACOL CLIN,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD MAR 15 PY 1993 VL 33 IS 6A SU S BP A56 EP A56 PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA LA417 UT WOS:A1993LA41700070 ER PT J AU FAVA, M ALPERT, JE ROSENBAUM, JF AF FAVA, M ALPERT, JE ROSENBAUM, JF TI PSYCHOPATHOLOGY DURING CHILDHOOD AND ADOLESCENCE OF UNIPOLAR DEPRESSIVE ADULTS SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,CLIN PSYCHOPHARMACOL UNIT,DEPRESS RES PROGRAM,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD MAR 15 PY 1993 VL 33 IS 6A SU S BP A65 EP A65 PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA LA417 UT WOS:A1993LA41700103 ER PT J AU INTRATOR, J KEILP, J DORFMAN, D BERNSTEIN, D SCHAEFER, C WAKEMAN, J HARPUR, T HARE, R HANDELSMAN, L STRITZKE, P AF INTRATOR, J KEILP, J DORFMAN, D BERNSTEIN, D SCHAEFER, C WAKEMAN, J HARPUR, T HARE, R HANDELSMAN, L STRITZKE, P TI PATTERNS OF CEREBRAL ACTIVATION IN PSYCHOPATHS DURING PROCESSING AFFECTIVE AND NEUTRAL WORDS AS MEASURED BY SINGLE-PHOTON EMISSION TOMOGRAPHY (SPECT) SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract C1 BRONX VET ADM MED CTR,BRONX,NY. UNIV ILLINOIS,CHICAGO,IL 60680. UNIV BRITISH COLUMBIA,VANCOUVER V6T 1W5,BC,CANADA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD MAR 15 PY 1993 VL 33 IS 6A SU S BP A160 EP A160 PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA LA417 UT WOS:A1993LA41700446 ER PT J AU POLLACK, MH OTTO, MW HAMMERNESS, PG ROSENBAUM, JF AF POLLACK, MH OTTO, MW HAMMERNESS, PG ROSENBAUM, JF TI CHILDHOOD ANXIETY IN ADULT PANIC PATIENTS AND THEIR CHILDREN SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,CLIN PSYCHOPHARMACOL & BEHAV THERAPY UNIT,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD MAR 15 PY 1993 VL 33 IS 6A SU S BP A42 EP A42 PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA LA417 UT WOS:A1993LA41700020 ER PT J AU RENSHAW, PF BIEDERMAN, J WILENS, TE SPENCER, T COHEN, BM AF RENSHAW, PF BIEDERMAN, J WILENS, TE SPENCER, T COHEN, BM TI MRI ABNORMALITIES IN CHILDREN WITH ADHD SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,BOSTON,MA 02114. MCLEAN BRAIN IMAGING CTR,BELMONT,MA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD MAR 15 PY 1993 VL 33 IS 6A SU S BP A110 EP A110 PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA LA417 UT WOS:A1993LA41700266 ER PT J AU RENSHAW, PF STOLL, AL ROTHSCHILD, A FAVA, M COHEN, BM AF RENSHAW, PF STOLL, AL ROTHSCHILD, A FAVA, M COHEN, BM TI MULTIPLE BRAIN LH MRS ABNORMALITIES IN DEPRESSED-PATIENTS SUGGEST IMPAIRED 2ND MESSENGER CYCLING SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract C1 MCLEAN HOSP,CTR BRAIN IMAGINE,BELMONT,MA 02178. MASSACHUSETTS GEN HOSP,CLIN PSYCHOPHARMACOL UNIT,BOSTON,MA 02114. NR 0 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD MAR 15 PY 1993 VL 33 IS 6A SU S BP A44 EP A45 PG 2 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA LA417 UT WOS:A1993LA41700030 ER PT J AU ROSENBAUM, JF BIEDERMAN, J KAGAN, J AF ROSENBAUM, JF BIEDERMAN, J KAGAN, J TI CHILDHOOD BEHAVIORAL-INHIBITION - MARKER OF RISK FOR ANXIETY DISORDER SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,CLIN PSYCHOPHARMACOL UNIT,BOSTON,MA 02114. MASSACHUSETTS GEN HOSP,PEDIAT PSYCHOPHARMACOL UNIT,BOSTON,MA 02114. HARVARD UNIV,DEPT PSYCHOL,CAMBRIDGE,MA 02138. NR 0 TC 1 Z9 1 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD MAR 15 PY 1993 VL 33 IS 6A SU S BP A104 EP A104 PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA LA417 UT WOS:A1993LA41700245 ER PT J AU SACHS, GS CONKLIN, A THIBAULT, A MCCORMICK, M BIEDERMAN, J AF SACHS, GS CONKLIN, A THIBAULT, A MCCORMICK, M BIEDERMAN, J TI CHILDREN OF BIPOLAR PARENTS SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,HARVARD BIPOLAR RES PROGRAM,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD MAR 15 PY 1993 VL 33 IS 6A SU S BP A56 EP A56 PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA LA417 UT WOS:A1993LA41700071 ER PT J AU SPERANZA, A MOHS, R MILLER, A AF SPERANZA, A MOHS, R MILLER, A TI CLINICAL AND NEUROENDOCRINE PREDICTORS OF MORTALITY IN ALZHEIMERS-DISEASE SO BIOLOGICAL PSYCHIATRY LA English DT Meeting Abstract C1 BRONX VET AFFAIRS MED CTR,NEW YORK,NY 10029. MT SINAI MED CTR,NEW YORK,NY 10029. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 SN 0006-3223 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD MAR 15 PY 1993 VL 33 IS 6A SU S BP A140 EP A140 PG 1 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA LA417 UT WOS:A1993LA41700379 ER PT J AU CHAUHAN, D KHARBANDA, SM RUBIN, E BARUT, BA MOHRBACHER, A KUFE, DW ANDERSON, KC AF CHAUHAN, D KHARBANDA, SM RUBIN, E BARUT, BA MOHRBACHER, A KUFE, DW ANDERSON, KC TI REGULATION OF C-JUN GENE-EXPRESSION IN HUMAN T-LYMPHOCYTES SO BLOOD LA English DT Article ID STIMULATORY FACTOR-II; TRANSCRIPTION FACTOR AP-1; MYELOID-LEUKEMIA CELLS; TUMOR-NECROSIS-FACTOR; PROTO-ONCOGENE; GROWTH-FACTOR; INTERLEUKIN-6 GENE; IL-6 PRODUCTION; FOS GENE; B-CELLS C1 HARVARD UNIV, SCH MED,DANA FARBER CANC INST,DIV TUMOR IMMUNOL, 44 BINNEY ST, BOSTON, MA 02115 USA. HARVARD UNIV, SCH MED, DANA FARBER CANC INST, CLIN PHARMACOL LAB, BOSTON, MA 02115 USA. HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02115 USA. FU NCI NIH HHS [CA50947] NR 75 TC 21 Z9 21 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 SN 0006-4971 J9 BLOOD JI Blood PD MAR 15 PY 1993 VL 81 IS 6 BP 1540 EP 1548 PG 9 WC Hematology SC Hematology GA KT363 UT WOS:A1993KT36300018 PM 8453101 ER PT J AU BILLETT, AL KORNMEHL, E TARBELL, NJ WEINSTEIN, HJ GELBER, RD RITZ, J SALLAN, SE AF BILLETT, AL KORNMEHL, E TARBELL, NJ WEINSTEIN, HJ GELBER, RD RITZ, J SALLAN, SE TI AUTOLOGOUS BONE-MARROW TRANSPLANTATION AFTER A LONG 1ST REMISSION FOR CHILDREN WITH RECURRENT ACUTE LYMPHOBLASTIC-LEUKEMIA SO BLOOD LA English DT Article ID TOTAL-BODY IRRADIATION; 2ND REMISSION; RELAPSE; CHILDHOOD; LYMPHOMA; THERAPY; DONORS; CELLS C1 HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV BIOSTAT,BOSTON,MA 02115. HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV TUMOR IMMUNOL,BOSTON,MA 02115. CHILDRENS HOSP MED CTR,DIV HEMATOL ONCOL,BOSTON,MA 02115. CHILDRENS HOSP MED CTR,DEPT RADIAT THERAPY,BOSTON,MA 02115. HARVARD UNIV,SCH MED,JOINT CTR RADIAT THERAPY,BOSTON,MA 02115. HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02115. HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115. HARVARD UNIV,SCH PUBL HLTH,DEPT BIOSTAT,BOSTON,MA 02115. RP BILLETT, AL (reprint author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DEPT PEDIAT ONCOL,44 BINNEY ST,BOSTON,MA 02115, USA. RI Ritz, Jerome/C-7929-2009 OI Ritz, Jerome/0000-0001-5526-4669 FU NCI NIH HHS [CA06516-29, CA34183-08] NR 35 TC 53 Z9 53 U1 0 U2 0 PU W B SAUNDERS CO PI PHILADELPHIA PA INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 SN 0006-4971 J9 BLOOD JI Blood PD MAR 15 PY 1993 VL 81 IS 6 BP 1651 EP 1657 PG 7 WC Hematology SC Hematology GA KT363 UT WOS:A1993KT36300034 PM 8453110 ER PT J AU MAUCH, PM KALISH, LA KADIN, M COLEMAN, CN OSTEEN, R HELLMAN, S AF MAUCH, PM KALISH, LA KADIN, M COLEMAN, CN OSTEEN, R HELLMAN, S TI PATTERNS OF PRESENTATION OF HODGKIN DISEASE - IMPLICATIONS FOR ETIOLOGY AND PATHOGENESIS SO CANCER LA English DT Article DE HODGKIN DISEASE; STAGING LAPAROTOMY; EPIDEMIOLOGY; CONTIGUOUS INVOLVEMENT ID REED-STERNBERG CELLS; STAGING LAPAROTOMY; EXPERIENCE; EXPRESSION AB Background. The etiology of Hodgkin disease remains uncertain. Patterns of presentation of Hodgkin disease are analyzed by histologic subtype with implications for etiology and pathogenesis. Methods. The authors performed a detailed analysis of anatomic sites of involvement, histopathologic findings, and clinical features in 719 patients with Hodgkin disease who underwent staging laparotomy with splenectomy between April 1969 and December 1986. The presence of disease in each of 17 sites of potential nodal involvement was determined for each patient from a combination of clinical and surgical staging. Association among nodal sites was assessed in 2 X 2 tables by estimating the odds ratio and testing the significance with the chi-square test. A strict significance level (P = 0.01) was used. Log-linear models were used for assessing association in 2 X 2 tables while adjusting for other factors. Results. The mediastinum, left side of neck, and right side of neck were the most common sites involved for patients with nodular sclerosing (NS) or mixed cellularity (MC) histologic subtypes. Each of these sites was involved 60% of the time. These sites were four or more times as common as other nodal sites above or below the diaphragm. In contrast, the mediastinum was involved in only 8% of patients with lymphocyte predominance (LP) histologic subtype. Significant associations were found between mediastinal disease and low cervical/supraclavicular lymph node disease, mediastinal disease and NS histologic subtypes, peripheral nodal disease and LP histologic subtypes, and between splenic disease and mixed cellularity/lymphocyte depletion (MC/LD) Hodgkin disease. The age at onset and sex of patients with Hodgkin disease and the patterns of nodal distribution were somewhat different for NS and MC/LD histologic subtypes. Even greater differences were seen between LP and other histologic subtypes. Conclusions. This study supports the conclusion that NS and MC Hodgkin disease spread by continguity, most often originating in the neck or mediastinum, and is consistent with evidence suggesting an infectious agent in the pathogenesis of these subtypes of Hodgkin disease. In contrast, LP Hodgkin disease is characterized by different sites of presentation and patterns of spread. This suggests that two or perhaps three clinicopathologic subtypes of Hodgkin disease exist. Implications for etiology and pathogenesis are discussed. C1 BRIGHAM & WOMENS HOSP,DEPT SURG,BOSTON,MA 02115. BETH ISRAEL HOSP,DEPT PATHOL,BOSTON,MA 02215. HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV BIOSTAT & EPIDEMIOL,BOSTON,MA 02115. HARVARD UNIV,SCH PUBL HLTH,DEPT BIOSTAT,BOSTON,MA 02115. HARVARD UNIV,SCH MED,DEPT SURG,BOSTON,MA 02115. HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115. HARVARD UNIV,SCH MED,DEPT RADIAT THERAPY,BOSTON,MA 02115. RP MAUCH, PM (reprint author), JOINT CTR RADIAT THERAPY,50 BINNEY ST,BOSTON,MA 02115, USA. FU NCI NIH HHS [CA-06516] NR 35 TC 67 Z9 67 U1 1 U2 2 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012 SN 0008-543X J9 CANCER JI Cancer PD MAR 15 PY 1993 VL 71 IS 6 BP 2062 EP 2071 DI 10.1002/1097-0142(19930315)71:6<2062::AID-CNCR2820710622>3.0.CO;2-0 PG 10 WC Oncology SC Oncology GA KQ381 UT WOS:A1993KQ38100021 PM 8443755 ER PT J AU CARROLL, RS GLOWACKA, D DASHNER, K BLACK, PM AF CARROLL, RS GLOWACKA, D DASHNER, K BLACK, PM TI PROGESTERONE-RECEPTOR EXPRESSION IN MENINGIOMAS SO CANCER RESEARCH LA English DT Article ID STEROID-RECEPTORS; BREAST-CANCER; MONOCLONAL-ANTIBODIES; ESTROGEN; BINDING; LOCALIZATION; MANIPULATION; DEPENDENCY; FRAGMENTS; INVITRO AB The possibility that the female sex steroid progesterone plays a role in meningioma proliferation has been suggested by a number of investigators; and it had been shown that many meningiomas have high affinity progesterone binding sites. The aim of this study was to examine the expression of progesterone receptor mRNA and correlate it with the nuclear localization of progesterone receptor by immunocytochemistry in a large number of meningiomas. Thirty-three meningiomas were examined for the presence of measurable amounts of progesterone receptor mRNA by Northern blot analysis and 11 of these were analyzed for receptor protein by immunohistochemistry. These were compared with normal arachnoid and an arachnoid cell line. Sixty-four % of the meningiomas expressed progesterone receptor mRNA. This occurred in a similar pattern to what has previously been shown for T-47 D cells, a breast carcinoma cell line with 11.4-, 6.1-, 5.2-, 4.5-, 3.2-, and 2.5-kilobase mRNA species. This suggests that progesterone receptor expression is not tumor specific. There was a marked predominance of women among those patients whose tumors expressed progesterone receptor; 81% were female and 19% were male. The immunohistochemistry data correlate well with the Northern blot analysis. The staining was clearly nuclear, suggesting that the receptor is in a location to be activated. These data suggest that progesterone receptor mRNA and protein is expressed in meningiomas and support the concept that progesterone may play an important role in meningioma growth. C1 BRIGHAM & WOMENS HOSP,CTR BRAIN TUMOR,BOSTON,MA 02115. CHILDRENS HOSP MED CTR,BOSTON,MA 02115. HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115. HARVARD UNIV,SCH MED,DEPT SURG,BOSTON,MA 02115. RP CARROLL, RS (reprint author), BRIGHAM & WOMENS HOSP,NEUROSURG LABS,BOSTON,MA 02115, USA. NR 37 TC 98 Z9 99 U1 0 U2 0 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA PUBLIC LEDGER BLDG, SUITE 816, 150 S. INDEPENDENCE MALL W., PHILADELPHIA, PA 19106 SN 0008-5472 J9 CANCER RES JI Cancer Res. PD MAR 15 PY 1993 VL 53 IS 6 BP 1312 EP 1316 PG 5 WC Oncology SC Oncology GA KR297 UT WOS:A1993KR29700020 PM 8443810 ER PT J AU LAVIN, CW MCKEOWN, CA CHATURVEDI, N FINKELSTEIN, M JAKOBIEC, FA AF LAVIN, CW MCKEOWN, CA CHATURVEDI, N FINKELSTEIN, M JAKOBIEC, FA TI PRESERVATION OF THE ANTERIOR CILIARY VESSELS DURING STRABISMUS SURGERY IN A PRIMATE MODEL OF ANTERIOR SEGMENT ISCHEMIA SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract C1 MASSACHUSETTS EYE & EAR INFIRM,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD MAR 15 PY 1993 VL 34 IS 4 BP 709 EP 709 PG 1 WC Ophthalmology SC Ophthalmology GA KT893 UT WOS:A1993KT89300029 ER PT J AU AIELLO, LP AIELLO, LM KING, GL AF AIELLO, LP AIELLO, LM KING, GL TI IDENTIFICATION AND PARTIAL SEQUENCE-ANALYSIS OF GLUCOSE REGULATED GENES IN RETINAL PERICYTES SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract C1 JOSLIN DIABET CTR,JOSLIN RES LABS,BOSTON,MA. JOSLIN DIABET CTR,BEETHAM EYE INST,BOSTON,MA. NR 0 TC 2 Z9 2 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD MAR 15 PY 1993 VL 34 IS 4 BP 712 EP 712 PG 1 WC Ophthalmology SC Ophthalmology GA KT893 UT WOS:A1993KT89300043 ER PT J AU FONG, DS WARRAM, JM AIELLO, LM LAFELL, L RAND, LI KROLEWSKI, A AF FONG, DS WARRAM, JM AIELLO, LM LAFELL, L RAND, LI KROLEWSKI, A TI PROSPECTIVE EVALUATION OF CARDIAC AUTONOMIC NEUROPATHY AND PROLIFERATIVE DIABETIC-RETINOPATHY SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract C1 HARVARD UNIV,SCH MED,JOSLIN DIABET CTR,BOSTON,MA 02115. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD MAR 15 PY 1993 VL 34 IS 4 BP 714 EP 714 PG 1 WC Ophthalmology SC Ophthalmology GA KT893 UT WOS:A1993KT89300054 ER PT J AU PU, X KERN, T INOGUCHI, T KING, GL AF PU, X KERN, T INOGUCHI, T KING, GL TI ACTIVATION OF DIACYLGLYCEROL AND PROTEIN-KINASE-C BY BOTH DIABETES AND HYPERGALACTOSEMIA - A POSSIBLE MECHANISM FOR THE DEVELOPMENT OF DIABETIC-RETINOPATHY SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract C1 JOSLIN DIABET CTR,BOSTON,MA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD MAR 15 PY 1993 VL 34 IS 4 BP 715 EP 715 PG 1 WC Ophthalmology SC Ophthalmology GA KT893 UT WOS:A1993KT89300056 ER PT J AU SAMY, CN DREYER, EB AF SAMY, CN DREYER, EB TI THE EFFICACY OF MITOMYCIN-C ADJUNCTIVE THERAPY IN THE MANAGEMENT OF NEOVASCULAR GLAUCOMA SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract C1 HARVARD UNIV,MASSACHUSETTS EYE & EAR INFIRM,SCH MED,GLAUCOMA CONSULTAT SERV,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD MAR 15 PY 1993 VL 34 IS 4 BP 729 EP 729 PG 1 WC Ophthalmology SC Ophthalmology GA KT893 UT WOS:A1993KT89300125 ER PT J AU ANGLADE, E DREYER, E AF ANGLADE, E DREYER, E TI THE EFFECT OF MITOMYCIN-C AND 5-FLUOROURACIL ON CORNEAL ENDOTHELIUM IN TRABECULECTOMY SURGERY SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract C1 HARVARD UNIV,MASSACHUSETTS EYE & EAR INFIRM,SCH MED,BOSTON,MA 02114. NR 0 TC 2 Z9 2 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD MAR 15 PY 1993 VL 34 IS 4 BP 730 EP 730 PG 1 WC Ophthalmology SC Ophthalmology GA KT893 UT WOS:A1993KT89300129 ER PT J AU DOBROGOWSKI, MJ PARK, RI PARK, CH LATINA, MA AF DOBROGOWSKI, MJ PARK, RI PARK, CH LATINA, MA TI ELECTROCYLOABLATION - A NEW CYCLODESTRUCTIVE TREATMENT FOR GLAUCOMA SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract C1 UNIV BRITISH COLUMBIA,VANCOUVER V6T 1W5,BC,CANADA. MASSACHUSETTS GEN HOSP,SCHEPENS EYE RES INST,BOSTON,MA 02114. MASSACHUSETTS GEN HOSP,WELLMAN LABS,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD MAR 15 PY 1993 VL 34 IS 4 BP 739 EP 739 PG 1 WC Ophthalmology SC Ophthalmology GA KT893 UT WOS:A1993KT89300188 ER PT J AU TAKAMOTO, T SCHWARTZ, B NANGIA, V AF TAKAMOTO, T SCHWARTZ, B NANGIA, V TI CORRELATION OF AMOUNT OF THE RETINAL NERVE-FIBERS WITH OPTIC DISC AREA IN NORMAL EYES SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract C1 TUFTS UNIV,SCH MED,BOSTON,MA 02111. SIMMONS EYE ASSOCIATES,BOSTON,MA. MASSACHUSETTS EYE & EAR INFIRM,BOSTON,MA 02114. NR 1 TC 1 Z9 1 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD MAR 15 PY 1993 VL 34 IS 4 BP 762 EP 762 PG 1 WC Ophthalmology SC Ophthalmology GA KT893 UT WOS:A1993KT89300302 ER PT J AU TANG, M PAWLYK, BS SIDMAN, RL AF TANG, M PAWLYK, BS SIDMAN, RL TI ERG CORRELATIONS WITH RETINAL HISTOLOGY IN HOMOZYGOUS AND HETEROZYGOUS VITILIGO MUTANT MICE SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract C1 MASSACHUSETTS EYE & EAR INFIRM,BERMAN GUND LAB,BOSTON,MA 02114. NE REG PRIMATE RES CTR,SOUTHBOROUGH,MA. HARVARD UNIV,SCH MED,BOSTON,MA 02115. NR 0 TC 3 Z9 3 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD MAR 15 PY 1993 VL 34 IS 4 BP 767 EP 767 PG 1 WC Ophthalmology SC Ophthalmology GA KT893 UT WOS:A1993KT89300326 ER PT J AU TURCO, PD EAGAN, SM CHRISTEN, WG AF TURCO, PD EAGAN, SM CHRISTEN, WG TI CORRELATES OF REFRACTIVE IMPROVEMENT IN A LOW VISION POPULATION SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract C1 MASSACHUSETTS EYE & EAR INFIRM,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD MAR 15 PY 1993 VL 34 IS 4 BP 787 EP 787 PG 1 WC Ophthalmology SC Ophthalmology GA KT893 UT WOS:A1993KT89300427 ER PT J AU FINKELSTEIN, M POLLACK, A BILYK, JR LEVIN, L SHORE, JW RUBIN, PAD AF FINKELSTEIN, M POLLACK, A BILYK, JR LEVIN, L SHORE, JW RUBIN, PAD TI SOFT-TISSUE REACTION TO BB PELLETS OF VARYING METAL COMPOSITION SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract C1 HARVARD UNIV,MASSACHUSETTS EYE & EAR INFIRM,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD MAR 15 PY 1993 VL 34 IS 4 BP 829 EP 829 PG 1 WC Ophthalmology SC Ophthalmology GA KT893 UT WOS:A1993KT89300630 ER PT J AU THEODOSIADIS, P MOULTON, RS WALSH, AW GRAGOUDAS, ES DAMICO, DJ AF THEODOSIADIS, P MOULTON, RS WALSH, AW GRAGOUDAS, ES DAMICO, DJ TI EXPERIMENTAL RETINAL-DETACHMENT AFTER YELLOW LASER BRANCH RETINAL VEIN OCCLUSION IN THE RAT SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract C1 MASSACHUSETTS EYE & EAR INFIRM,RETINA SERV,BOSTON,MA 02114. HARVARD UNIV,SCH MED,DEPT OPHTHALMOL,BOSTON,MA 02115. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD MAR 15 PY 1993 VL 34 IS 4 BP 841 EP 841 PG 1 WC Ophthalmology SC Ophthalmology GA KT893 UT WOS:A1993KT89300684 ER PT J AU CIULLA, TA VOLPE, NJ AF CIULLA, TA VOLPE, NJ TI EMBOLIC FREQUENCY AND COEXISTING DISEASE IN CENTRAL RETINAL ARTERY-OCCLUSION SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract C1 MASSACHUSETTS EYE & EAR INFIRM,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD MAR 15 PY 1993 VL 34 IS 4 BP 842 EP 842 PG 1 WC Ophthalmology SC Ophthalmology GA KT893 UT WOS:A1993KT89300690 ER PT J AU PORTER, DP TROCME, SD FOSTER, CS DOHLMAN, CH AF PORTER, DP TROCME, SD FOSTER, CS DOHLMAN, CH TI CONJUNCTIVAL DEPOSITION OF EOSINOPHIL MAJOR BASIC-PROTEIN, NEUTROPHIL ELASTASE, AND MAST-CELL TRYPTASE IN ATOPIC KERATOCONJUNCTIVITIS SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract C1 UNIV TEXAS,MED BRANCH,GALVESTON,TX 77550. HARVARD UNIV,MASSACHUSETTS EYE & EAR INFIRM,HILLES IMMUNOL LAB,BOSTON,MA 02114. NR 0 TC 7 Z9 7 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD MAR 15 PY 1993 VL 34 IS 4 BP 855 EP 855 PG 1 WC Ophthalmology SC Ophthalmology GA KT893 UT WOS:A1993KT89300760 ER PT J AU AHMED, AR MOHIMEN, A NEUMAN, R FOSTER, CS AF AHMED, AR MOHIMEN, A NEUMAN, R FOSTER, CS TI A 205-KD AUTOANTIGEN CHARACTERIZES OCULAR CICATRICIAL PEMPHIGOID SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract C1 CTR BLOOD RES,BOSTON,MA. MASSACHUSETTS EYE & EAR INFIRM,BOSTON,MA 02114. HARVARD UNIV,SCH MED,BOSTON,MA 02115. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD MAR 15 PY 1993 VL 34 IS 4 BP 857 EP 857 PG 1 WC Ophthalmology SC Ophthalmology GA KT893 UT WOS:A1993KT89300775 ER PT J AU KURTZ, MJ HETH, CA AF KURTZ, MJ HETH, CA TI INGESTION OF ROS AND HORMONAL RESPONSE IN HUMAN RETINAL-PIGMENT EPITHELIUM GROWN IN MEDIUM CONTAINING HIGH BICARBONATE SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract C1 BOSTON UNIV,COLL GEN STUDIES,BOSTON,MA 02215. HARVARD UNIV,MASSACHUSETTS EYE & EAR INFIRM,SCH MED,BERMAN GUND LAB,BOSTON,MA 02114. NR 0 TC 1 Z9 1 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD MAR 15 PY 1993 VL 34 IS 4 BP 866 EP 866 PG 1 WC Ophthalmology SC Ophthalmology GA KT893 UT WOS:A1993KT89300817 ER PT J AU REGAN, S EGAN, KM WALSH, SM SEDDON, JM GRAGOUDAS, ES AF REGAN, S EGAN, KM WALSH, SM SEDDON, JM GRAGOUDAS, ES TI GEOGRAPHIC-DISTRIBUTION OF CASES OF UVEAL MELANOMA IN MASSACHUSETTS SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract C1 MASSACHUSETTS EYE & EAR INFIRM,RETINA SERV,BOSTON,MA 02114. MASSACHUSETTS EYE & EAR INFIRM,EPIDEMIOL UNIT,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD MAR 15 PY 1993 VL 34 IS 4 BP 889 EP 889 PG 1 WC Ophthalmology SC Ophthalmology GA KT893 UT WOS:A1993KT89300935 ER PT J AU GONZALEZ, VH HU, LK GRAGOUDAS, ES YOUNG, LHY AF GONZALEZ, VH HU, LK GRAGOUDAS, ES YOUNG, LHY TI PHOTODYNAMIC THERAPY OF PIGMENTED CHOROIDAL MELANOMAS SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract C1 HARVARD UNIV,MASSACHUSETTS EYE & EAR INFIRM,SCH MED,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD MAR 15 PY 1993 VL 34 IS 4 BP 891 EP 891 PG 1 WC Ophthalmology SC Ophthalmology GA KT893 UT WOS:A1993KT89300947 ER PT J AU WALSH, SM REGAN, S EGAN, KM GRAGOUDAS, ES AF WALSH, SM REGAN, S EGAN, KM GRAGOUDAS, ES TI DEVELOPMENT OF POSTERIOR SUBCAPSULAR CATARACT AFTER PROTON-BEAM IRRADIATION FOR UVEAL MELANOMA SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract C1 MASSACHUSETTS EYE & EAR INFIRM,RETINA SERV,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD MAR 15 PY 1993 VL 34 IS 4 BP 891 EP 891 PG 1 WC Ophthalmology SC Ophthalmology GA KT893 UT WOS:A1993KT89300945 ER PT J AU SHIMA, D ADAMIS, AP YEO, KT YEO, TK BERSE, B BROWN, L AF SHIMA, D ADAMIS, AP YEO, KT YEO, TK BERSE, B BROWN, L TI HYPOXIC REGULATION OF VASCULAR-PERMEABILITY FACTOR (VASCULAR ENDOTHELIAL GROWTH-FACTOR) MESSENGER-RNA AND PROTEIN SECRETION BY HUMAN RETINAL-PIGMENT EPITHELIAL-CELLS SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract C1 HARVARD UNIV,CHILDRENS HOSP,SCH MED,BOSTON,MA 02115. HARVARD UNIV,MASSACHUSETTS EYE & EAR INFIRM,SCH MED,BOSTON,MA 02114. HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,BOSTON,MA 02215. NR 1 TC 5 Z9 5 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD MAR 15 PY 1993 VL 34 IS 4 BP 900 EP 900 PG 1 WC Ophthalmology SC Ophthalmology GA KT893 UT WOS:A1993KT89300988 ER PT J AU GRANSTEIN, RD KNISELY, TL HOSOI, J AF GRANSTEIN, RD KNISELY, TL HOSOI, J TI HYDROCORTISONE IS A PROBABLE MEDIATOR OF THE INHIBITORY ACTIVITY OF AQUEOUS-HUMOR ON LANGERHANS CELL ANTIGEN PRESENTING FUNCTION SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,HARVARD CUTANEOUS BIOL RES CTR,BOSTON,MA 02114. REPLIGEN CORP,CAMBRIDGE,MA. NR 1 TC 1 Z9 1 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD MAR 15 PY 1993 VL 34 IS 4 BP 903 EP 903 PG 1 WC Ophthalmology SC Ophthalmology GA KT893 UT WOS:A1993KT89301002 ER PT J AU KOLODNY, NH LAWRENCE, BA BARTELS, SP AF KOLODNY, NH LAWRENCE, BA BARTELS, SP TI CONFIRMATION BY MAGNETIC-RESONANCE-IMAGING OF THE DIFFUSIONAL PATHWAY BETWEEN THE CILIARY PROCESSES AND THE ANTERIOR-CHAMBER IN THE OWL MONKEY SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract C1 EYE RES INST,BOSTON,MA. HARVARD UNIV,SCH MED,BOSTON,MA 02115. WELLESLEY COLL,WELLESLEY,MA 02181. MASSACHUSETTS EYE & EAR INFIRM,BOSTON,MA 02114. BRIGHAM & WOMENS HOSP,BOSTON,MA 02115. NR 0 TC 1 Z9 1 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD MAR 15 PY 1993 VL 34 IS 4 BP 921 EP 921 PG 1 WC Ophthalmology SC Ophthalmology GA KT893 UT WOS:A1993KT89301084 ER PT J AU SCHROEDER, A ERICKSON, KA AF SCHROEDER, A ERICKSON, KA TI VERAPAMIL INCREASES FACILITY OF OUTFLOW IN THE HUMAN EYE INVITRO SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract C1 HARVARD UNIV,MASSACHUSETTS EYE & EAR INFIRM,SCH MED,BOSTON,MA 02114. NR 0 TC 5 Z9 5 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD MAR 15 PY 1993 VL 34 IS 4 BP 924 EP 924 PG 1 WC Ophthalmology SC Ophthalmology GA KT893 UT WOS:A1993KT89301104 ER PT J AU STROH, EM HIROSE, T WARMAN, M SANG, D AF STROH, EM HIROSE, T WARMAN, M SANG, D TI OCULAR MANIFESTATIONS OF OSTEOPOROSIS-PSEUDOGLIOMA SYNDROME SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract C1 RETINA ASSOCIATES,BOSTON,MA. SCHEPENS EYE RES INST,BOSTON,MA. MASSACHUSETTS EYE & EAR INFIRM,BOSTON,MA 02114. CHILDRENS HOSP MED CTR,BOSTON,MA 02115. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD MAR 15 PY 1993 VL 34 IS 4 BP 955 EP 955 PG 1 WC Ophthalmology SC Ophthalmology GA KT893 UT WOS:A1993KT89301246 ER PT J AU AJANI, UA SEDDON, JM AF AJANI, UA SEDDON, JM TI SMOKING AND RISK OF UVEAL MELANOMA SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract C1 HARVARD UNIV,MASSACHUSETTS EYE & EAR INFIRM,SCH MED,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD MAR 15 PY 1993 VL 34 IS 4 BP 964 EP 964 PG 1 WC Ophthalmology SC Ophthalmology GA KT893 UT WOS:A1993KT89301288 ER PT J AU HART, L GONZALEZ, VH GRAGOUDAS, ES YOUNG, LHY AF HART, L GONZALEZ, VH GRAGOUDAS, ES YOUNG, LHY TI COLOR DOPPLER IMAGING OF CHOROIDAL MELANOMAS FOLLOWING PHOTODYNAMIC THERAPY SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract C1 HARVARD UNIV,MASSACHUSETTS EYE & EAR INFIRM,SCH MED,BOSTON,MA 02114. NR 0 TC 1 Z9 1 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD MAR 15 PY 1993 VL 34 IS 4 BP 967 EP 967 PG 1 WC Ophthalmology SC Ophthalmology GA KT893 UT WOS:A1993KT89301306 ER PT J AU HU, LK HASAN, T GRAGOUDAS, ES YOUNG, LHY AF HU, LK HASAN, T GRAGOUDAS, ES YOUNG, LHY TI PHOTOIMMUNOTHERAPY OF HUMAN UVEAL MELANOMA SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract C1 HARVARD UNIV,MASSACHUSETTS EYE & EAR INFIRM,SCH MED,BOSTON,MA 02114. HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD MAR 15 PY 1993 VL 34 IS 4 BP 967 EP 967 PG 1 WC Ophthalmology SC Ophthalmology GA KT893 UT WOS:A1993KT89301305 ER PT J AU KNISELY, TL HOSOI, J NAZARENO, R GRANSTEIN, RD AF KNISELY, TL HOSOI, J NAZARENO, R GRANSTEIN, RD TI IDENTIFICATION OF HYDROCORTISONE AS AN INHIBITORY FACTOR AND THE ABSENCE OF CORTISOL BINDING GLOBULIN IN AQUEOUS-HUMOR - ANALYSIS OF ACTIVITY IN COMBINATION WITH TGF-BETA SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract C1 REPLIGEN CORP,CAMBRIDGE,MA. MASSACHUSETTS GEN HOSP,HARVARD CUTANEOUS BIOL RES CTR,BOSTON,MA 02114. NR 0 TC 1 Z9 1 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD MAR 15 PY 1993 VL 34 IS 4 BP 973 EP 973 PG 1 WC Ophthalmology SC Ophthalmology GA KT893 UT WOS:A1993KT89301331 ER PT J AU HETH, CA MARESCALCHI, PA AF HETH, CA MARESCALCHI, PA TI GENERATION OF INOSITOL TRIPHOSPHATE AND CAMP IN CULTURED RETINAL-PIGMENT EPITHELIUM DURING EARLY PHAGOCYTIC CHALLENGE SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract C1 HARVARD UNIV,MASSACHUSETTS EYE & EAR INFIRM,SCH MED,BERMAN GUND LAB,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD MAR 15 PY 1993 VL 34 IS 4 BP 982 EP 982 PG 1 WC Ophthalmology SC Ophthalmology GA KT893 UT WOS:A1993KT89301376 ER PT J AU SARFARAZI, FM CREAN, EV RICHARDSON, TM AF SARFARAZI, FM CREAN, EV RICHARDSON, TM TI 5-FLUOROURACL STIMULATES RESURFACING IN PARTIALLY DENUDED TRABECULAR CELL-CULTURES SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract C1 HARVARD UNIV,SCH MED,MASSACHUSETTS EYE & EAR INFIRM,HOWE LAB,BOSTON,MA 02115. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD MAR 15 PY 1993 VL 34 IS 4 BP 993 EP 993 PG 1 WC Ophthalmology SC Ophthalmology GA KT893 UT WOS:A1993KT89301427 ER PT J AU LANE, L ZHAO, TZ FOSTER, CS AF LANE, L ZHAO, TZ FOSTER, CS TI HISTOPATHOLOGIC EVALUATION OF MEDICATION IN A NEW MURINE OCULAR ALLERGY MODEL MIMICKING HUMAN HAY-FEVER CONJUNCTIVITIS SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract C1 HARVARD UNIV,MASSACHUSETTS EYE & EAR INFIRM,SCH MED,HILLES IMMUNOL LAB,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD MAR 15 PY 1993 VL 34 IS 4 BP 999 EP 999 PG 1 WC Ophthalmology SC Ophthalmology GA KT893 UT WOS:A1993KT89301452 ER PT J AU MESSMER, EM DELAMAZA, S FOSTER, CS AF MESSMER, EM DELAMAZA, S FOSTER, CS TI CONJUNCTIVAL AND SCLERAL BIOPSY IN RHEUMATOID-ARTHRITIS ASSOCIATED PERIPHERAL ULCERATIVE KERATITIS AND NECROTIZING SCLERITIS SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract C1 HARVARD UNIV,MASSACHUSETTS EYE & EAR INFIRM,SCH MED,OCULAR IMMUNOL SERV,BOSTON,MA 02114. UNIV WURZBURG,HOSP EYE,W-8700 WURZBURG,GERMANY. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD MAR 15 PY 1993 VL 34 IS 4 BP 999 EP 999 PG 1 WC Ophthalmology SC Ophthalmology GA KT893 UT WOS:A1993KT89301454 ER PT J AU LI, Z LEE, S FOSTER, C AF LI, Z LEE, S FOSTER, C TI INTERLEUKIN-1-BETA, INTERLEUKIN-6 AND TUMOR-NECROSIS-FACTOR-ALPHA GENE-EXPRESSION IN A MURINE MODEL OF HERPES RETINITIS SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract C1 HARVARD UNIV,MASSACHUSETTS EYE & EAR INFIRM,SCH MED,RHOADS MOLEC IMMUNOL LAB,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD MAR 15 PY 1993 VL 34 IS 4 BP 1025 EP 1025 PG 1 WC Ophthalmology SC Ophthalmology GA KT893 UT WOS:A1993KT89301583 ER PT J AU MATSUBARA, M MODY, MK BARTLETT, JD GIRARD, MT MAGNER, JW FINI, ME AF MATSUBARA, M MODY, MK BARTLETT, JD GIRARD, MT MAGNER, JW FINI, ME TI THE RABBIT GENE FOR 92 KILODALTON MATRIX METALLOPROTEINASE - REGULATION BY TGF-BETA SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,CUTANEOUS BIOL RES CTR,BOSTON,MA 02114. HARVARD UNIV,SCH MED,DEPT DERMATOL,BOSTON,MA 02115. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD MAR 15 PY 1993 VL 34 IS 4 BP 1058 EP 1058 PG 1 WC Ophthalmology SC Ophthalmology GA KT893 UT WOS:A1993KT89301745 ER PT J AU BROWN, M LI, WW DUTT, S SANCHEZ, F MORAN, M RAIZMAN, M AF BROWN, M LI, WW DUTT, S SANCHEZ, F MORAN, M RAIZMAN, M TI A SYNTHETIC METALLOPROTEINASE INHIBITOR POTENTIATES THE ANTIANGIOGENIC EFFECT OF PREDNISOLONE IN THE CORNEA SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract C1 NEW ENGLAND EYE CTR,BOSTON,MA. TUFTS UNIV,SCH MED,DEPT OPHTHALMOL,BOSTON,MA 02111. MASSACHUSETTS GEN HOSP,DEPT MED,BOSTON,MA 02114. GLYCOMED INC,ALAMEDA,CA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD MAR 15 PY 1993 VL 34 IS 4 BP 1059 EP 1059 PG 1 WC Ophthalmology SC Ophthalmology GA KT893 UT WOS:A1993KT89301750 ER PT J AU SHIELDS, SR NETLAND, PA KALINA, PH COTRAN, PR AF SHIELDS, SR NETLAND, PA KALINA, PH COTRAN, PR TI ERBIUM LASER SCLEROSTOMY VIA TRANSCORNEAL APPROACH IN RABBITS SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract C1 MASSACHUSETTS EYE & EAR INFIRM,BOSTON,MA 02114. NR 0 TC 1 Z9 1 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD MAR 15 PY 1993 VL 34 IS 4 BP 1071 EP 1071 PG 1 WC Ophthalmology SC Ophthalmology GA KT893 UT WOS:A1993KT89301803 ER PT J AU ROSENFELD, PJ MILLER, S DRVIA, TP BERSON, EL SANDBERG, MA AF ROSENFELD, PJ MILLER, S DRVIA, TP BERSON, EL SANDBERG, MA TI THE CONVENTIONAL FULL-FIELD ERG CAN HELP IDENTIFY CARRIERS OF RHODOPSIN NULL MUTATIONS SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract C1 HARVARD UNIV,MASSACHUSETTS EYE & EAR INFIRM,SCH MED,BERMAN GUND LAB,BOSTON,MA 02114. HARVARD UNIV,MASSACHUSETTS EYE & EAR INFIRM,SCH MED,HOWE LAB,BOSTON,MA 02114. NR 1 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD MAR 15 PY 1993 VL 34 IS 4 BP 1078 EP 1078 PG 1 WC Ophthalmology SC Ophthalmology GA KT893 UT WOS:A1993KT89301838 ER PT J AU SANDBERG, MA PAWLYK, BS FRANSON, WK DRYIA, TP BERSON, EL AF SANDBERG, MA PAWLYK, BS FRANSON, WK DRYIA, TP BERSON, EL TI EFFECT OF LIGHT ON THE RATE OF ERG DECLINE IN TRANSGENIC MICE WITH THE HUMAN RHODOPSIN MUTATION PRO23HIS SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract C1 HARVARD UNIV,MASSACHUSETTS EYE & EAR INFIRM,SCH MED,BERMAN GUND LAB,BOSTON,MA 02114. HARVARD UNIV,MASSACHUSETTS EYE & EAR INFIRM,SCH MED,HOWE LAB,BOSTON,MA 02114. NR 0 TC 4 Z9 4 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD MAR 15 PY 1993 VL 34 IS 4 BP 1078 EP 1078 PG 1 WC Ophthalmology SC Ophthalmology GA KT893 UT WOS:A1993KT89301837 ER PT J AU KORNMEHL, EW BREDVIK, BK KELMAN, CD RAIZMAN, MB DEVORE, DP AF KORNMEHL, EW BREDVIK, BK KELMAN, CD RAIZMAN, MB DEVORE, DP TI BIOCOMPATIBILITY OF A COLLAGEN CORNEAL ALLOGRAFT DERIVED FROM RABBIT DERMIS SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract C1 NEW YORK MED COLL,VALHALLA,NY 10595. AUTOGENESIS TECHNOL,ACTON,MA. TUFTS UNIV,SCH MED,NEW ENGLAND EYE CTR,BOSTON,MA 02111. HARVARD UNIV,MASSACHUSETTS EYE & EAR INFIRM,SCH MED,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD MAR 15 PY 1993 VL 34 IS 4 BP 1088 EP 1088 PG 1 WC Ophthalmology SC Ophthalmology GA KT893 UT WOS:A1993KT89301891 ER PT J AU TUTKUN, I AKOVA, YA FOSTER, CS AF TUTKUN, I AKOVA, YA FOSTER, CS TI PENETRATING KERATOPLASTY IN CICATRIZING CONJUNCTIVAL DISEASES SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract C1 HARVARD UNIV,MASSACHUSETTS EYE & EAR INFIRM,SCH MED,OCULAR IMMUNOL SERV,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD MAR 15 PY 1993 VL 34 IS 4 BP 1105 EP 1105 PG 1 WC Ophthalmology SC Ophthalmology GA KT893 UT WOS:A1993KT89301977 ER PT J AU CLERMONT, A BURSELL, SE WOLPERT, H WALD, H OREN, B SIMONSON, D KING, G AIELLO, L AF CLERMONT, A BURSELL, SE WOLPERT, H WALD, H OREN, B SIMONSON, D KING, G AIELLO, L TI THE RESPONSE OF THE RETINAL CIRCULATION TO ACUTE CHANGES IN BLOOD-GLUCOSE SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract C1 JOSLIN DIABET CTR,BOSTON,MA. NR 0 TC 4 Z9 4 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD MAR 15 PY 1993 VL 34 IS 4 BP 1127 EP 1127 PG 1 WC Ophthalmology SC Ophthalmology GA KT893 UT WOS:A1993KT89302090 ER PT J AU OREN, B BURSELL, SE CLERMONT, A KING, G AF OREN, B BURSELL, SE CLERMONT, A KING, G TI THE EFFECT OF ENDOTHELIN ON RETINAL CIRCULATION IN NONDIABETIC AND DIABETIC RATS SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract C1 JOSLIN DIABET CTR,BOSTON,MA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD MAR 15 PY 1993 VL 34 IS 4 BP 1127 EP 1127 PG 1 WC Ophthalmology SC Ophthalmology GA KT893 UT WOS:A1993KT89302089 ER PT J AU BURSELL, SE WILKISON, W HALVORSEN, YD CLERMONT, A MCGOVERN, T SPIEGELMAN, B AF BURSELL, SE WILKISON, W HALVORSEN, YD CLERMONT, A MCGOVERN, T SPIEGELMAN, B TI THE EFFECT OF MONOBUTYRIN, AN ANGIOGENIC FACTOR, ON RETINAL BLOOD-FLOW SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract C1 JOSLIN DIABET FDN INC,BOSTON,MA 02215. HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD MAR 15 PY 1993 VL 34 IS 4 BP 1128 EP 1128 PG 1 WC Ophthalmology SC Ophthalmology GA KT893 UT WOS:A1993KT89302092 ER PT J AU CHRISTEN, WG GLYNN, RJ MANSON, JE SEDDON, JM HENNEKENS, CH AF CHRISTEN, WG GLYNN, RJ MANSON, JE SEDDON, JM HENNEKENS, CH TI ASPIRIN AND AGE-RELATED MACULOPATHY SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract C1 BRIGHAM & WOMENS HOSP,BOSTON,MA 02115. MASSACHUSETTS EYE & EAR INFIRM,BOSTON,MA 02114. HARVARD UNIV,SCH MED,BOSTON,MA 02115. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD MAR 15 PY 1993 VL 34 IS 4 BP 1133 EP 1133 PG 1 WC Ophthalmology SC Ophthalmology GA KT893 UT WOS:A1993KT89302118 ER PT J AU GLYNN, RJ CHRISTEN, WG MANSON, JE SEDDON, JM HENNEKENS, CH AF GLYNN, RJ CHRISTEN, WG MANSON, JE SEDDON, JM HENNEKENS, CH TI CARDIOVASCULAR RISK-FACTORS AND AGE-RELATED MACULOPATHY SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract C1 BRIGHAM & WOMENS HOSP,BOSTON,MA 02115. MASSACHUSETTS EYE & EAR INFIRM,BOSTON,MA 02114. HARVARD UNIV,SCH MED,BOSTON,MA 02115. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD MAR 15 PY 1993 VL 34 IS 4 BP 1133 EP 1133 PG 1 WC Ophthalmology SC Ophthalmology GA KT893 UT WOS:A1993KT89302117 ER PT J AU LIN, IM KAUFMAN, AH COLVIN, RB FOSTER, CS LEE, SJ AF LIN, IM KAUFMAN, AH COLVIN, RB FOSTER, CS LEE, SJ TI THE EXPRESSION OF ALTERNATIVELY-SPLICED FORMS OF FIBRONECTIN MESSENGER-RNA ANALYZED BY POLYMERASE CHAIN-REACTION IN A RAT SUPERFICIAL KERATECTOMY MODEL SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract C1 MASSACHUSETTS EYE & EAR INFIRM,BOSTON,MA 02114. NR 0 TC 1 Z9 1 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD MAR 15 PY 1993 VL 34 IS 4 BP 1147 EP 1147 PG 1 WC Ophthalmology SC Ophthalmology GA KT893 UT WOS:A1993KT89302185 ER PT J AU MCLAUGHLIN, ME BERSON, EL DRYJA, TP AF MCLAUGHLIN, ME BERSON, EL DRYJA, TP TI MUTATIONS IN THE BETA-SUBUNIT OF PHOSPHODIESTERASE IN PATIENTS WITH AUTOSOMAL RECESSIVE RETINITIS-PIGMENTOSA SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract C1 HARVARD UNIV,SCH MED,HOWE LAB,BOSTON,MA 02115. HARVARD UNIV,SCH MED,BERMAN GUND LAB,BOSTON,MA 02115. MASSACHUSETTS EYE & EAR INFIRM,BOSTON,MA 02114. NR 2 TC 1 Z9 1 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD MAR 15 PY 1993 VL 34 IS 4 BP 1148 EP 1148 PG 1 WC Ophthalmology SC Ophthalmology GA KT893 UT WOS:A1993KT89302186 ER PT J AU KAJIWARA, K BERSON, EL DRYJA, TP AF KAJIWARA, K BERSON, EL DRYJA, TP TI SCREEN FOR MUTATIONS IN THE ENTIRE CODING SEQUENCE OF THE HUMAN RDS PERIPHERIN GENE IN PATIENTS WITH HEREDITARY RETINAL DEGENERATIONS SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract C1 HARVARD UNIV,SCH MED,HOWE LAB,BOSTON,MA 02115. HARVARD UNIV,SCH MED,BERMAN GUND LAB,BOSTON,MA 02115. MASSACHUSETTS EYE & EAR INFIRM,BOSTON,MA 02114. NR 0 TC 3 Z9 3 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD MAR 15 PY 1993 VL 34 IS 4 BP 1149 EP 1149 PG 1 WC Ophthalmology SC Ophthalmology GA KT893 UT WOS:A1993KT89302193 ER PT J AU DRYJA, TP BERSON, EL RAO, V OPRIAN, DD AF DRYJA, TP BERSON, EL RAO, V OPRIAN, DD TI HETEROZYGOUS MISSENSE MUTATION IN THE RHODOPSIN GENE AS A CAUSE OF CONGENITAL STATIONARY NIGHT BLINDNESS SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract C1 HARVARD UNIV,SCH MED,BERMAN GUND LAB,BOSTON,MA 02115. HARVARD UNIV,SCH MED,HOWE LAB,BOSTON,MA 02115. MASSACHUSETTS EYE & EAR INFIRM,BOSTON,MA 02114. BRANDEIS UNIV,DEPT BIOCHEM,WALTHAM,MA 02254. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD MAR 15 PY 1993 VL 34 IS 4 BP 1150 EP 1150 PG 1 WC Ophthalmology SC Ophthalmology GA KT893 UT WOS:A1993KT89302196 ER PT J AU LANE, AM DEROSA, JT EGAN, KM ADAMIS, AP GUYER, DR MILLER, JW SLAKTER, JS YANNUZZI, LA GRAGOUDAS, ES AF LANE, AM DEROSA, JT EGAN, KM ADAMIS, AP GUYER, DR MILLER, JW SLAKTER, JS YANNUZZI, LA GRAGOUDAS, ES TI SAFETY AND TOLERANCE OF INTERFERON-ALFA-2A THERAPY FOR CHOROIDAL NEOVASCULARIZATION SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract C1 MASSACHUSETTS EYE & EAR INFIRM,BOSTON,MA 02114. MANHATTAN EYE EAR & THROAT HOSP,NEW YORK,NY 10021. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD MAR 15 PY 1993 VL 34 IS 4 BP 1159 EP 1159 PG 1 WC Ophthalmology SC Ophthalmology GA KT893 UT WOS:A1993KT89302242 ER PT J AU MILLER, S SANDBERG, MA GAUDIO, AR AF MILLER, S SANDBERG, MA GAUDIO, AR TI FOVEAL CONE ERGS IN FELLOW EYES OF PATIENTS WITH UNILATERAL NEOVASCULAR AGE-RELATED MACULAR DEGENERATION SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract C1 HARVARD UNIV,MASSACHUSETTS EYE & EAR INFIRM,SCH MED,BERMAN GUND LAB,BOSTON,MA 02114. NR 0 TC 1 Z9 1 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD MAR 15 PY 1993 VL 34 IS 4 BP 1160 EP 1160 PG 1 WC Ophthalmology SC Ophthalmology GA KT893 UT WOS:A1993KT89302249 ER PT J AU TOLENTINO, MJ MILLER, S GAUDIO, AR SANDBERG, MA AF TOLENTINO, MJ MILLER, S GAUDIO, AR SANDBERG, MA TI VISUAL-FIELD DEFICITS IN EARLY AGE-RELATED MACULAR DEGENERATION SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract C1 HARVARD UNIV,MASSACHUSETTS EYE & EAR INFIRM,SCH MED,BERMAN GUND LAB,BOSTON,MA 02114. NR 1 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD MAR 15 PY 1993 VL 34 IS 4 BP 1160 EP 1160 PG 1 WC Ophthalmology SC Ophthalmology GA KT893 UT WOS:A1993KT89302246 ER PT J AU KRUPSKY, S OAK, SS FRIEDMAN, E AF KRUPSKY, S OAK, SS FRIEDMAN, E TI COLOR DOPPLER CHANGES IN THE VASCULAR-RESISTANCE IN THE AGING EYE SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract C1 HARVARD UNIV,MASSACHUSETTS EYE & EAR INFIRM,SCH MED,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 1 U2 2 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD MAR 15 PY 1993 VL 34 IS 4 BP 1161 EP 1161 PG 1 WC Ophthalmology SC Ophthalmology GA KT893 UT WOS:A1993KT89302255 ER PT J AU MOULTON, RS WALSH, AW MILLER, JW HAIMOVICI, R HASAN, T MICHAUD, N GRAGOUDAS, ES AF MOULTON, RS WALSH, AW MILLER, JW HAIMOVICI, R HASAN, T MICHAUD, N GRAGOUDAS, ES TI RESPONSE OF RETINAL AND CHOROIDAL VESSELS TO PHOTODYNAMIC THERAPY USING BENZOPORPHYRIN DERIVATIVE MONOACID SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract C1 HARVARD UNIV,MASSACHUSETTS EYE & EAR INFIRM,LASER RES CTR,BOSTON,MA 02114. HARVARD UNIV,MASSACHUSETTS GEN HOSP,WELLMAN LABS,BOSTON,MA 02114. NR 0 TC 2 Z9 4 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD MAR 15 PY 1993 VL 34 IS 4 BP 1169 EP 1169 PG 1 WC Ophthalmology SC Ophthalmology GA KT893 UT WOS:A1993KT89302292 ER PT J AU JAIN, VK CHRISTEN, WG NETLAND, PA WIGGS, JL AF JAIN, VK CHRISTEN, WG NETLAND, PA WIGGS, JL TI RELIABILITY OF DIGITAL OCULAR PALPATION IN THE ESTIMATION OF INTRAOCULAR-PRESSURE SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract C1 MASSACHUSETTS EYE & EAR INFIRM,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD MAR 15 PY 1993 VL 34 IS 4 BP 1192 EP 1192 PG 1 WC Ophthalmology SC Ophthalmology GA KT893 UT WOS:A1993KT89302405 ER PT J AU DAMICO, DJ MOULTON, RS HANNINEN, LA AF DAMICO, DJ MOULTON, RS HANNINEN, LA TI ERBIUM YAG LASER INTERACTION WITH THE RETINA SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract C1 MASSACHUSETTS EYE & EAR INFIRM,RETINA SERV,BOSTON,MA 02114. MASSACHUSETTS EYE & EAR INFIRM,MORSE LASER LAB,BOSTON,MA 02114. HARVARD UNIV,SCH MED,SCHEPENS EYE RES INST,BOSTON,MA 02115. HARVARD UNIV,SCH MED,DEPT OPHTHALMOL,BOSTON,MA 02115. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD MAR 15 PY 1993 VL 34 IS 4 BP 1212 EP 1212 PG 1 WC Ophthalmology SC Ophthalmology GA KT893 UT WOS:A1993KT89302498 ER PT J AU LEVIN, LA ACKERMAN, RH CHAO, LC BURBANK, K AF LEVIN, LA ACKERMAN, RH CHAO, LC BURBANK, K TI USE OF NEURAL NETWORK TO MODEL THE ERYTHROCYTE SEDIMENTATION-RATE SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract C1 MASSACHUSETTS EYE & EAR INFIRM,BOSTON,MA 02114. MASSACHUSETTS GEN HOSP,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD MAR 15 PY 1993 VL 34 IS 4 BP 1215 EP 1215 PG 1 WC Ophthalmology SC Ophthalmology GA KT893 UT WOS:A1993KT89302510 ER PT J AU RIZZO, JF AF RIZZO, JF TI PRESERVATION OF CENTRAL ACUITY WITH MACULAR INFARCTION - HYPOTHESES ON THE RESILIENCE OF FOVEAL OUTFLOW CHANNELS TO RETINAL ISCHEMIA SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract C1 HARVARD UNIV,MASSACHUSETTS EYE & EAR INFIRM,SCH MED,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD MAR 15 PY 1993 VL 34 IS 4 BP 1215 EP 1215 PG 1 WC Ophthalmology SC Ophthalmology GA KT893 UT WOS:A1993KT89302511 ER PT J AU LAWRENCE, MG MANGIONE, CM ORAV, EJ SEDDON, JM AF LAWRENCE, MG MANGIONE, CM ORAV, EJ SEDDON, JM TI INFLUENCE OF SURGICAL APPROACH AND INTRAOCULAR-LENS DESIGN ON INCIDENCE OF YAG CAPSULOTOMY IN PATIENTS UNDERGOING CATARACT-EXTRACTION SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract C1 HARVARD UNIV,SCH MED,BOSTON,MA 02115. HARVARD UNIV,SCH PUBL HLTH,BOSTON,MA 02115. MASSACHUSETTS EYE & EAR INFIRM,BOSTON,MA 02114. BRIGHAM & WOMENS HOSP,BOSTON,MA 02115. NR 0 TC 1 Z9 1 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD MAR 15 PY 1993 VL 34 IS 4 BP 1225 EP 1225 PG 1 WC Ophthalmology SC Ophthalmology GA KT893 UT WOS:A1993KT89302560 ER PT J AU MANGIONE, CM PHILLIPS, RS LAWRENCE, MG SEDDON, JM ORAV, EJ GOLDMAN, L AF MANGIONE, CM PHILLIPS, RS LAWRENCE, MG SEDDON, JM ORAV, EJ GOLDMAN, L TI ATTENUATION OF FUNCTIONAL DECLINE IN ELDERLY ADULTS FOLLOWING CATARACT-EXTRACTION AND INTRAOCULAR-LENS IMPLANTATION SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract C1 BRIGHAM & WOMENS HOSP,BOSTON,MA 02115. HARVARD UNIV,SCH MED,BOSTON,MA 02115. HARVARD UNIV,SCH PUBL HLTH,BOSTON,MA 02115. BETH ISRAEL HOSP,BOSTON,MA 02215. MASSACHUSETTS EYE & EAR INFIRM,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD MAR 15 PY 1993 VL 34 IS 4 BP 1225 EP 1225 PG 1 WC Ophthalmology SC Ophthalmology GA KT893 UT WOS:A1993KT89302558 ER PT J AU ALBERT, DM SHOKRAVI, M MARCUS, DM EGAN, K SAORNIL, MA AF ALBERT, DM SHOKRAVI, M MARCUS, DM EGAN, K SAORNIL, MA TI INHIBITION OF ANGIOGENESIS BY VITAMIN-D SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract C1 UNIV WISCONSIN,MADISON,WI 53706. MASSACHUSETTS EYE & EAR INFIRM,BOSTON,MA 02114. UNIV VALLADOLID,VALLADOLID,SPAIN. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD MAR 15 PY 1993 VL 34 IS 4 BP 1226 EP 1226 PG 1 WC Ophthalmology SC Ophthalmology GA KT893 UT WOS:A1993KT89302563 ER PT J AU KIM, SK HELIN, K HARLOW, E DRYJA, TP AF KIM, SK HELIN, K HARLOW, E DRYJA, TP TI THE DEVELOPMENT OF A NOVEL ELISA TO QUANTITATIVELY MEASURE RB PROTEIN - EVALUATION OF ITS USEFULNESS AS A TOOL IN THE DIAGNOSIS OF HEREDITARY RETINOBLASTOMA SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract C1 MASSACHUSETTS EYE & EAR INFIRM,BOSTON,MA 02114. MASSACHUSETTS GEN HOSP,CANC RES CTR,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD MAR 15 PY 1993 VL 34 IS 4 BP 1226 EP 1226 PG 1 WC Ophthalmology SC Ophthalmology GA KT893 UT WOS:A1993KT89302564 ER PT J AU MARCUS, DM KIM, S BREM, H BRAUNER, E CHAPPELL, R FOLKMAN, J ALBERT, DM AF MARCUS, DM KIM, S BREM, H BRAUNER, E CHAPPELL, R FOLKMAN, J ALBERT, DM TI THE EFFECT OF AN ANTIANGIOGENIC COMPOUND (AGM-1470) ON TRANSGENIC MURINE RETINOBLASTOMA SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract C1 UNIV WISCONSIN,DEPT OPHTHALMOL,MADISON,WI 53706. MASSACHUSETTS EYE & EAR INFIRM,DAVID G COGAN EYE PATHOL LAB,BOSTON,MA 02114. CHILDRENS HOSP MED CTR,BOSTON,MA 02115. NR 0 TC 1 Z9 1 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD MAR 15 PY 1993 VL 34 IS 4 BP 1226 EP 1226 PG 1 WC Ophthalmology SC Ophthalmology GA KT893 UT WOS:A1993KT89302562 ER PT J AU MORROW, J RAPAPORT, J MCGEE, TL NORK, TM SCHWARTZ, T DRYIA, TP AF MORROW, J RAPAPORT, J MCGEE, TL NORK, TM SCHWARTZ, T DRYIA, TP TI LOW-PENETRANCE RETINOBLASTOMA IN 2 FAMILIES SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract C1 HARVARD UNIV,MASSACHUSETTS EYE & EAR INFIRM,SCH MED,DEPT OPHTHALMOL,BOSTON,MA 02114. W VIRGINIA UNIV,HLTH SCI CTR,CTR EYE,DEPT OPHTHALMOL,MORGANTOWN,WV 26506. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD MAR 15 PY 1993 VL 34 IS 4 BP 1227 EP 1227 PG 1 WC Ophthalmology SC Ophthalmology GA KT893 UT WOS:A1993KT89302570 ER PT J AU MUKAI, S HUANG, O LUDEKE, BI HERRERA, GH DRYIA, TP YANDELL, DW AF MUKAI, S HUANG, O LUDEKE, BI HERRERA, GH DRYIA, TP YANDELL, DW TI LOW PENETRANCE HEREDITARY RETINOBLASTOMA IN 4 FAMILIES DUE TO THE MISSENSE MUTATION ARG661TRP IN RB1 SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract C1 MASSACHUSETTS EYE & EAR INFIRM,BOSTON,MA 02114. HARVARD UNIV,SCH MED,BOSTON,MA 02115. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD MAR 15 PY 1993 VL 34 IS 4 BP 1227 EP 1227 PG 1 WC Ophthalmology SC Ophthalmology GA KT893 UT WOS:A1993KT89302571 ER PT J AU SMITH, EM TALAMO, JH PETASHNICK, DE TROKEL, SL AF SMITH, EM TALAMO, JH PETASHNICK, DE TROKEL, SL TI COMPARISON OF THE AXIS OF ASTIGMATISM OF SUBJECTS IN THE SEATED AND SUPINE POSITIONS SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract C1 RHODE ISL HOSP,PROVIDENCE,RI 02902. MASSACHUSETTS EYE & EAR INFIRM,BOSTON,MA 02114. HARKNESS EYE INST,NEW YORK,NY. NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD MAR 15 PY 1993 VL 34 IS 4 BP 1250 EP 1250 PG 1 WC Ophthalmology SC Ophthalmology GA KT893 UT WOS:A1993KT89302690 ER PT J AU PARK, SS DAMICO, DJ PATON, B BAKER, AS AF PARK, SS DAMICO, DJ PATON, B BAKER, AS TI TREATMENT OF EXOGENOUS CANDIDA ENDOPHTHALMITIS IN RABBITS WITH ORAL FLUCONAZOLE OR COMBINATION FLUCONAZOLE AND FLUCYTOSINE SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract C1 HARVARD UNIV,SCH MED,DEPT OPHTHALMOL,BOSTON,MA 02115. MASSACHUSETTS EYE & EAR INFIRM,RETINA SERV,BOSTON,MA 02114. MASSACHUSETTS EYE & EAR INFIRM,INFECT DIS SERV,BOSTON,MA 02114. MASSACHUSETTS EYE & EAR INFIRM,PORTER MICROBIOL LAB,BOSTON,MA 02114. HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD MAR 15 PY 1993 VL 34 IS 4 BP 1258 EP 1258 PG 1 WC Ophthalmology SC Ophthalmology GA KT893 UT WOS:A1993KT89302733 ER PT J AU NANGIA, V SCHWARTZ, B AF NANGIA, V SCHWARTZ, B TI SCATTER OF VISUAL-FIELD THRESHOLDS ON LONG-TERM FOLLOW-UP OF OCULAR HYPERTENSIVES COMPARED TO NORMALS SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract C1 TUFTS UNIV,SCH MED,SIMONS EYE ASSOCIATES,BOSTON,MA 02111. MASSACHUSETTS EYE & EAR INFIRM,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD MAR 15 PY 1993 VL 34 IS 4 BP 1263 EP 1263 PG 1 WC Ophthalmology SC Ophthalmology GA KT893 UT WOS:A1993KT89302754 ER PT J AU CHUN, LLY KRUPNIK, VE CHANG, Y AF CHUN, LLY KRUPNIK, VE CHANG, Y TI A HEPARIN-BINDING PROTEIN PROMOTES NEURITE OUTGROWTH FROM PURIFIED RAT RETINAL GANGLION-CELLS SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,NEUROSURG SERV,BOSTON,MA 02114. HARVARD UNIV,SCH MED,PROGRAM NEUROSCI,BOSTON,MA 02115. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD MAR 15 PY 1993 VL 34 IS 4 BP 1284 EP 1284 PG 1 WC Ophthalmology SC Ophthalmology GA KT893 UT WOS:A1993KT89302866 ER PT J AU NETLAND, PA CHATURVEDI, N DREYER, EB AF NETLAND, PA CHATURVEDI, N DREYER, EB TI CALCIUM-CHANNEL BLOCKERS IN THE MANAGEMENT OF LOW-TENSION AND OPEN-ANGLE GLAUCOMA SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract C1 MASSACHUSETTS EYE & EAR INFIRM,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD MAR 15 PY 1993 VL 34 IS 4 BP 1287 EP 1287 PG 1 WC Ophthalmology SC Ophthalmology GA KT893 UT WOS:A1993KT89302878 ER PT J AU HAIMOVICI, R KRAMER, M FLOTTE, T MILLER, JW HASAN, T GRAGOUDAS, ES AF HAIMOVICI, R KRAMER, M FLOTTE, T MILLER, JW HASAN, T GRAGOUDAS, ES TI LOCALIZATION OF BENZOPORPHYRIN DERIVATIVE MONOACID IN THE RABBIT EYE SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract C1 MASSACHUSETTS EYE & EAR INFIRM,LASER RES CTR,BOSTON,MA 02114. MASSACHUSETTS GEN HOSP,WELLMAN LABS,BOSTON,MA 02114. HARVARD UNIV,SCH MED,BOSTON,MA 02115. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD MAR 15 PY 1993 VL 34 IS 4 BP 1303 EP 1303 PG 1 WC Ophthalmology SC Ophthalmology GA KT893 UT WOS:A1993KT89302953 ER PT J AU WALSH, AW MILLER, JW MICHAUD, N HASAN, T GRAGOUDAS, ES AF WALSH, AW MILLER, JW MICHAUD, N HASAN, T GRAGOUDAS, ES TI PHOTODYNAMIC THERAPY OF EXPERIMENTAL CHOROIDAL NEOVASCULARIZATION USING BENZOPORPHYRIN DERIVATIVE MONOACID SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract C1 MASSACHUSETTS EYE & EAR INFIRM,LASER RES CTR,BOSTON,MA 02114. MASSACHUSETTS GEN HOSP,WELLMAN LABS,BOSTON,MA 02114. HARVARD UNIV,SCH MED,BOSTON,MA 02115. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD MAR 15 PY 1993 VL 34 IS 4 BP 1303 EP 1303 PG 1 WC Ophthalmology SC Ophthalmology GA KT893 UT WOS:A1993KT89302952 ER PT J AU PEDROZASERES, M VITALE, AT ESPAILLAT, A LEE, SJ FOSTER, CS AF PEDROZASERES, M VITALE, AT ESPAILLAT, A LEE, SJ FOSTER, CS TI DISTRIBUTION AND EXPRESSION OF COLLAGEN TYPE-I AND TYPE-III IN NORMAL RAT CORNEA AND IN WOUNDED RAT CORNEAL EPITHELIUM - ANALYSIS BY POLYMERASE CHAIN-REACTION SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract C1 HARVARD UNIV,MASSACHUSETTS EYE & EAR INFIRM,SCH MED,RHOADS MOLEC IMMUNOL LAB,BOSTON,MA 02114. NR 0 TC 1 Z9 1 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD MAR 15 PY 1993 VL 34 IS 4 BP 1318 EP 1318 PG 1 WC Ophthalmology SC Ophthalmology GA KT893 UT WOS:A1993KT89303032 ER PT J AU ESPAILLAT, A FOSTER, CS VITALE, A LEE, SJ AF ESPAILLAT, A FOSTER, CS VITALE, A LEE, SJ TI ANALYSIS OF THE EIIIB REGION OF FIBRONECTIN BY POLYMERASE CHAIN-REACTION OF THE RAT CORNEAL TISSUE SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract C1 HARVARD UNIV,MASSACHUSETTS EYE & EAR INFIRM,SCH MED,RHOADS MOLEC IMMUNOL LAB,BOSTON,MA 02114. HARVARD UNIV,MASSACHUSETTS EYE & EAR INFIRM,SCH MED,HILLES IMMUNOL LAB,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD MAR 15 PY 1993 VL 34 IS 4 BP 1319 EP 1319 PG 1 WC Ophthalmology SC Ophthalmology GA KT893 UT WOS:A1993KT89303034 ER PT J AU MOLINAMURPHY, IL BILYK, JR PRINCE, MR SHORE, JW RUBIN, PAD AF MOLINAMURPHY, IL BILYK, JR PRINCE, MR SHORE, JW RUBIN, PAD TI NONINVASIVE TECHNIQUES FOR ASSESSING FIBROVASCULAR INGROWTH INTO HYDROXYAPATITE AND POROUS POLYETHYLENE IMPLANTS SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract C1 HARVARD UNIV,MASSACHUSETTS EYE & EAR INFIRM,BOSTON,MA 02114. HARVARD UNIV,MASSACHUSETTS GEN HOSP,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD MAR 15 PY 1993 VL 34 IS 4 BP 1344 EP 1344 PG 1 WC Ophthalmology SC Ophthalmology GA KT893 UT WOS:A1993KT89303170 ER PT J AU HEILIGENHAUS, A BERRA, A FOSTER, CS AF HEILIGENHAUS, A BERRA, A FOSTER, CS TI IMMUNIZATION WITH A SYNTHETIC GLYCOPROTEIN-D PEPTIDE PROTECTS AGAINST HERPES STROMAL KERATITIS BY INFLUENCING T-CELLS SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract C1 MASSACHUSETTS EYE & EAR INFIRM,HILLES IMMUNOL LAB,BOSTON,MA 02114. HARVARD UNIV,SCH MED,BOSTON,MA 02115. UNIV ESSEN GESAMTHSCH,DEPT OPHTHALMOL,W-4300 ESSEN 1,GERMANY. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD MAR 15 PY 1993 VL 34 IS 4 BP 1345 EP 1345 PG 1 WC Ophthalmology SC Ophthalmology GA KT893 UT WOS:A1993KT89303174 ER PT J AU DUTT, JE RIBLET, R FOSTER, CS AF DUTT, JE RIBLET, R FOSTER, CS TI THE INFLUENCE OF IGH-C LINKED LOCI ON MURINE HERPES KERATITIS SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract C1 MED BIOL INST,LA JOLLA,CA. MASSACHUSETTS EYE & EAR INFIRM,HILLES IMMUNOL LAB,BOSTON,MA 02114. HARVARD UNIV,SCH MED,BOSTON,MA 02115. NR 0 TC 3 Z9 3 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD MAR 15 PY 1993 VL 34 IS 4 BP 1347 EP 1347 PG 1 WC Ophthalmology SC Ophthalmology GA KT893 UT WOS:A1993KT89303181 ER PT J AU ZHAO, T BERRA, A FOSTER, CS AF ZHAO, T BERRA, A FOSTER, CS TI DETECTION OF HERPES-SIMPLEX VIRUS TYPE-I USING INSITU PCR SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract C1 MASSACHUSETTS EYE & EAR INFIRM,HILLES IMMUNOL LAB,BOSTON,MA 02114. HARVARD UNIV,SCH MED,BOSTON,MA 02115. NR 0 TC 0 Z9 1 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD MAR 15 PY 1993 VL 34 IS 4 BP 1347 EP 1347 PG 1 WC Ophthalmology SC Ophthalmology GA KT893 UT WOS:A1993KT89303183 ER PT J AU CRUMP, A RODRIGUEZ, A LEE, SJ FOSTER, CS CANTOR, H AF CRUMP, A RODRIGUEZ, A LEE, SJ FOSTER, CS CANTOR, H TI INDUCTION OF IMMUNE TOLERANCE TO HSV-1 KERATITIS (HSK) IN C.AL-20 (IGH-1D) SUSCEPTIBLE MICE SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract C1 MASSACHUSETTS EYE & EAR INFIRM,HILLES IMMUNOL LAB,BOSTON,MA 02114. HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115. HARVARD UNIV,SCH MED,BOSTON,MA 02115. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD MAR 15 PY 1993 VL 34 IS 4 BP 1349 EP 1349 PG 1 WC Ophthalmology SC Ophthalmology GA KT893 UT WOS:A1993KT89303197 ER PT J AU ABRAMS, KL DREYER, EB AF ABRAMS, KL DREYER, EB TI EXCITOTOXICITY IN CANINE SUDDEN ACQUIRED RETINAL DEGENERATION SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract C1 VET OPHTHALMOL SERV,WARWICK,RI. HARVARD UNIV,MASSACHUSETTS EYE & EAR INFIRM,SCH MED,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD MAR 15 PY 1993 VL 34 IS 4 BP 1370 EP 1370 PG 1 WC Ophthalmology SC Ophthalmology GA KT893 UT WOS:A1993KT89303295 ER PT J AU LI, T BREAKEFIELD, XO GARBER, D KNIPE, D ROOF, D MUKAI, S BERSON, EL AF LI, T BREAKEFIELD, XO GARBER, D KNIPE, D ROOF, D MUKAI, S BERSON, EL TI EVALUATION OF DERIVATIVES OF HERPES-SIMPLEX VIRUS TYPE-1 (HSV-1) AS POTENTIAL VECTORS FOR GENE-THERAPY OF THE NEURAL RETINA AND THE RETINAL-PIGMENT EPITHELIUM SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract C1 HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,BERMAN GUND LAB,BOSTON,MA 02114. HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,HOWE LAB,BOSTON,MA 02114. NR 0 TC 3 Z9 3 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD MAR 15 PY 1993 VL 34 IS 4 BP 1370 EP 1370 PG 1 WC Ophthalmology SC Ophthalmology GA KT893 UT WOS:A1993KT89303293 ER PT J AU AYLIFFE, W ESPAILLAT, A FOSTER, CS LEE, SJ AF AYLIFFE, W ESPAILLAT, A FOSTER, CS LEE, SJ TI POLYMERASE CHAIN-REACTION ANALYSIS OF TNF-ALPHA GENE-EXPRESSION IN RAT CORNEAL WOUND-HEALING SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract C1 MASSACHUSETTS EYE & EAR INFIRM,RHOADS MOLEC IMMUNOL LAB,BOSTON,MA 02114. NR 0 TC 2 Z9 2 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD MAR 15 PY 1993 VL 34 IS 4 BP 1376 EP 1376 PG 1 WC Ophthalmology SC Ophthalmology GA KT893 UT WOS:A1993KT89303323 ER PT J AU FOSTER, CS PEDROZASERES, M BERRA, A HEILIGENHAUS, A JAYARAMAN, S AF FOSTER, CS PEDROZASERES, M BERRA, A HEILIGENHAUS, A JAYARAMAN, S TI CD4+ V-BETA-8.1,2 TH2 T-CELLS PARTICIPATE IN MURINE HERPES STROMAL KERATITIS (HSK) SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract C1 JAMES N GAMBLE INST MED RES,DIV CLIN VIROL,CINCINNATI,OH. HARVARD UNIV,MASSACHUSETTS EYE & EAR INFIRM,SCH MED,HILLES IMMUNOL LAB,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD MAR 15 PY 1993 VL 34 IS 4 BP 1379 EP 1379 PG 1 WC Ophthalmology SC Ophthalmology GA KT893 UT WOS:A1993KT89303335 ER PT J AU WIGGS, JL PAGLINAUAN, CM BELLOWS, AR HUTCHINSON, BT WALTON, DS AF WIGGS, JL PAGLINAUAN, CM BELLOWS, AR HUTCHINSON, BT WALTON, DS TI AUTOSOMAL DOMINANT GLAUCOMA - CLINICAL-FEATURES OF 20 PEDIGREES SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract C1 MASSACHUSETTS EYE & EAR INFIRM,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD MAR 15 PY 1993 VL 34 IS 4 BP 1387 EP 1387 PG 1 WC Ophthalmology SC Ophthalmology GA KT893 UT WOS:A1993KT89303379 ER PT J AU KAUFMAN, AH LIN, LM COLVIN, RB FOSTER, CS LEE, SJ AF KAUFMAN, AH LIN, LM COLVIN, RB FOSTER, CS LEE, SJ TI POLYMERASE CHAIN-REACTION ANALYSIS OF FIBRONECTIN ISOFORM MESSENGER-RNA EXPRESSION IN A RAT CORNEAL ALKALI BURN MODEL SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract C1 MASSACHUSETTS EYE & EAR INFIRM,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD MAR 15 PY 1993 VL 34 IS 4 BP 1408 EP 1408 PG 1 WC Ophthalmology SC Ophthalmology GA KT893 UT WOS:A1993KT89303482 ER PT J AU RODRIGUEZ, A BERRA, A PAZOS, B HEILIGENHAUS, A BERRA, I FOSTER, CS AF RODRIGUEZ, A BERRA, A PAZOS, B HEILIGENHAUS, A BERRA, I FOSTER, CS TI PREVENTION OF MURINE HSV-1 CHORIORETINITIS WITH INTRAVITREAL ANTI-CD11B ANTIBODY SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract C1 HARVARD UNIV,MASSACHUSETTS EYE & EAR INFIRM,SCH MED,HILLES IMMUNOL LAB,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD MAR 15 PY 1993 VL 34 IS 4 BP 1409 EP 1409 PG 1 WC Ophthalmology SC Ophthalmology GA KT893 UT WOS:A1993KT89303489 ER PT J AU ARRUNATEGUICORREA, VR LEE, SJ BRODEUR, PH FOSTER, CS AF ARRUNATEGUICORREA, VR LEE, SJ BRODEUR, PH FOSTER, CS TI V(H) FAMILY EXPRESSION IN B-CELL DEFICIENT MICE AFTER ANTERIOR-CHAMBER HSV INOCULATION SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract C1 HARVARD UNIV,MASSACHUSETTS EYE & EAR INFIRM,SCH MED,HILLES IMMUNOL LAB,BOSTON,MA 02114. HARVARD UNIV,MASSACHUSETTS EYE & EAR INFIRM,SCH MED,RHOADS MOLEC IMMUNOL LABS,BOSTON,MA 02114. TUFTS UNIV,DEPT PATHOL,MEDFORD,MA 02155. NR 1 TC 1 Z9 1 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD MAR 15 PY 1993 VL 34 IS 4 BP 1410 EP 1410 PG 1 WC Ophthalmology SC Ophthalmology GA KT893 UT WOS:A1993KT89303494 ER PT J AU BERRA, A HEILIGENHAUS, A BERRA, I LEE, SJ FOSTER, CS AF BERRA, A HEILIGENHAUS, A BERRA, I LEE, SJ FOSTER, CS TI DYNAMICS OF SPLENIC-V-BETA TCR IN A MURINE HSV-1 MODEL OF CHORIORETINITIS SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract C1 HARVARD UNIV,MASSACHUSETTS EYE & EAR INFIRM,SCH MED,HILLES IMMUNOL LAB,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD MAR 15 PY 1993 VL 34 IS 4 BP 1410 EP 1410 PG 1 WC Ophthalmology SC Ophthalmology GA KT893 UT WOS:A1993KT89303490 ER PT J AU LEE, SJ LI, Z FOSTER, CS AF LEE, SJ LI, Z FOSTER, CS TI TRANSFORMING GROWTH-FACTOR-BETA AND INTERFERON-GAMMA GENE-EXPRESSION IN A MURINE MODEL OF HERPES RETINITIS SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract C1 HARVARD UNIV,MASSACHUSETTS EYE & EAR INFIRM,SCH MED,RHOADS MOLEC IMMUNOL LAB,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD MAR 15 PY 1993 VL 34 IS 4 BP 1412 EP 1412 PG 1 WC Ophthalmology SC Ophthalmology GA KT893 UT WOS:A1993KT89303505 ER PT J AU BERRA, I BERRA, A LEE, SJ FOSTER, CS AF BERRA, I BERRA, A LEE, SJ FOSTER, CS TI PROINFLAMMATORY CYTOKINES IN A MURINE MODEL OF HERPETIC STROMAL KERATITIS SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract C1 HARVARD UNIV,MASSACHUSETTS EYE & EAR INFIRM,SCH MED,RHOADS IMMUNOL LAB,BOSTON,MA 02114. HARVARD UNIV,MASSACHUSETTS EYE & EAR INFIRM,SCH MED,HILLES IMMUNOL LAB,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD MAR 15 PY 1993 VL 34 IS 4 BP 1413 EP 1413 PG 1 WC Ophthalmology SC Ophthalmology GA KT893 UT WOS:A1993KT89303510 ER PT J AU KURYLO, DD CORKIN, S GROWDON, JH AF KURYLO, DD CORKIN, S GROWDON, JH TI PERCEPTUAL ORGANIZATION IN ALZHEIMERS-DISEASE SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract C1 MIT,CAMBRIDGE,MA 02139. MASSACHUSETTS GEN HOSP,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD MAR 15 PY 1993 VL 34 IS 4 BP 1415 EP 1415 PG 1 WC Ophthalmology SC Ophthalmology GA KT893 UT WOS:A1993KT89303519 ER PT J AU ADAMIS, AP MILLER, JW OREILLY, M BROWN, L BERSE, B YEO, TK YEO, KT AF ADAMIS, AP MILLER, JW OREILLY, M BROWN, L BERSE, B YEO, TK YEO, KT TI VASCULAR-PERMEABILITY FACTOR (VASCULAR ENDOTHELIAL GROWTH-FACTOR) IS PRODUCED IN THE RETINA AND ELEVATED LEVELS ARE PRESENT IN THE AQUEOUS-HUMOR OF EYES WITH IRIS NEOVASCULARIZATION SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract C1 HARVARD UNIV,MASSACHUSETTS EYE & EAR INFIRM,SCH MED,BOSTON,MA 02114. HARVARD UNIV,CHILDRENS HOSP,SCH MED,BOSTON,MA 02115. HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,BOSTON,MA 02215. NR 0 TC 9 Z9 9 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD MAR 15 PY 1993 VL 34 IS 4 BP 1440 EP 1440 PG 1 WC Ophthalmology SC Ophthalmology GA KT893 UT WOS:A1993KT89303647 ER PT J AU MILLER, JW OREILLY, MS MOULTON, RS FOLKMAN, L AF MILLER, JW OREILLY, MS MOULTON, RS FOLKMAN, L TI TREATMENT OF EXPERIMENTAL INTRAOCULAR NEOVASCULARIZATION USING AGM1470 SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract C1 HARVARD UNIV,CHILDRENS HOSP,SCH MED,BOSTON,MA 02115. HARVARD UNIV,MASSACHUSETTS EYE & EAR INFIRM,SCH MED,LASER RES CTR,BOSTON,MA 02114. NR 0 TC 1 Z9 1 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD MAR 15 PY 1993 VL 34 IS 4 BP 1441 EP 1441 PG 1 WC Ophthalmology SC Ophthalmology GA KT893 UT WOS:A1993KT89303652 ER PT J AU BERESTKA, JS LAWRENCE, MG ORAV, EJ MANGIONE, CM AF BERESTKA, JS LAWRENCE, MG ORAV, EJ MANGIONE, CM TI POSTOPERATIVE REFRACTIVE ERROR AND VISUAL OUTCOME AFTER CATARACT-EXTRACTION SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract C1 HARVARD UNIV,SCH MED,BOSTON,MA 02115. HARVARD UNIV,SCH PUBL HLTH,BOSTON,MA 02115. MASSACHUSETTS EYE & EAR INFIRM,BOSTON,MA 02114. BRIGHAM & WOMENS HOSP,BOSTON,MA 02115. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD MAR 15 PY 1993 VL 34 IS 4 BP 1454 EP 1454 PG 1 WC Ophthalmology SC Ophthalmology GA KT893 UT WOS:A1993KT89303713 ER PT J AU VAITHINATHAN, R BERSON, EL DRYJA, TP AF VAITHINATHAN, R BERSON, EL DRYJA, TP TI FURTHER SCREENING OF THE RHODOPSIN GENE IN PATIENTS WITH AUTOSOMAL DOMINANT RETINITIS-PIGMENTOSA SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract C1 HARVARD UNIV,SCH MED,HOWE LAB,BOSTON,MA 02115. HARVARD UNIV,SCH MED,BERMAN GUND LAB,BOSTON,MA 02115. MASSACHUSETTS EYE & EAR INFIRM,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD MAR 15 PY 1993 VL 34 IS 4 BP 1459 EP 1459 PG 1 WC Ophthalmology SC Ophthalmology GA KT893 UT WOS:A1993KT89303737 ER PT J AU MCGEE, TL DESTEFANO, JD BERSON, EL DRYJA, TP AF MCGEE, TL DESTEFANO, JD BERSON, EL DRYJA, TP TI A COMPLETE SCREEN OF THE ENTIRE CODING SEQUENCE OF THE IRBP GENE FOR MUTATIONS IN PATIENTS WITH HEREDITARY RETINAL DEGENERATIONS SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract C1 HARVARD UNIV,SCH MED,HOWE LAB OPHTHALMOL,BOSTON,MA 02115. HARVARD UNIV,SCH MED,BERMAN GUND LAB,BOSTON,MA 02115. MASSACHUSETTS EYE & EAR INFIRM,BOSTON,MA 02114. NR 0 TC 2 Z9 2 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD MAR 15 PY 1993 VL 34 IS 4 BP 1460 EP 1460 PG 1 WC Ophthalmology SC Ophthalmology GA KT893 UT WOS:A1993KT89303742 ER PT J AU CICILA, GT LEE, SJ ARRUNATEGUICORREA, V FOSTER, CS AF CICILA, GT LEE, SJ ARRUNATEGUICORREA, V FOSTER, CS TI T-CELL RECEPTOR (TCR) GENE-EXPRESSION IN B-CELL-DEFICIENT MICE - POLYMERASE CHAIN-REACTION (PCR) ANALYSIS IN A MURINE HERPES RETINITIS MODEL SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract C1 HARVARD UNIV,MASSACHUSETTS EYE & EAR INFIRM,SCH MED,RHOADS MOLEC IMMUNOL LAB,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD MAR 15 PY 1993 VL 34 IS 4 BP 1486 EP 1486 PG 1 WC Ophthalmology SC Ophthalmology GA KT893 UT WOS:A1993KT89303884 ER PT J AU HARRIS, LR LATHAN, CE WALL, C AF HARRIS, LR LATHAN, CE WALL, C TI THE EFFECT OF Z-AXIS LINEAR ACCELERATION OF THE HEAD ON VERTICAL OPTOKINETIC NYSTAGMUS DEPENDS ON VISUAL VELOCITY SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract C1 YORK UNIV,N YORK M3J 1P3,ONTARIO,CANADA. MIT,MAN VEHICLE LAB,CAMBRIDGE,MA 02139. MASSACHUSETTS EYE & EAR INFIRM,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD MAR 15 PY 1993 VL 34 IS 4 BP 1501 EP 1501 PG 1 WC Ophthalmology SC Ophthalmology GA KT893 UT WOS:A1993KT89303962 ER PT J AU DREYER, EB LIPTON, SA AF DREYER, EB LIPTON, SA TI A PROPOSED ROLE FOR EXCITATORY AMINO-ACIDS IN GLAUCOMA VISUAL-LOSS SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract C1 HARVARD UNIV,MASSACHUSETTS EYE & EAR INFIRM,SCH MED,BOSTON,MA 02114. HARVARD UNIV,CHILDRENS HOSP,SCH MED,BOSTON,MA 02115. NR 0 TC 4 Z9 4 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD MAR 15 PY 1993 VL 34 IS 4 BP 1504 EP 1504 PG 1 WC Ophthalmology SC Ophthalmology GA KT893 UT WOS:A1993KT89303973 ER PT J AU KALINA, PH DREYER, EB AF KALINA, PH DREYER, EB TI PERSONAL-COMPUTER BASED OPTIC-NERVE ANALYSIS - A RELATIVELY INEXPENSIVE APPROACH SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract C1 HARVARD UNIV,MASSACHUSETTS EYE & EAR INFIRM,SCH MED,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT-RAVEN PUBL PI PHILADELPHIA PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 SN 0146-0404 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD MAR 15 PY 1993 VL 34 IS 4 BP 1505 EP 1505 PG 1 WC Ophthalmology SC Ophthalmology GA KT893 UT WOS:A1993KT89303976 ER PT J AU WILLIAMS, KP SHOELSON, SE AF WILLIAMS, KP SHOELSON, SE TI A PHOTOAFFINITY SCAN MAPS REGIONS OF THE P85 SH2 DOMAIN INVOLVED IN PHOSPHOPROTEIN BINDING SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Note ID GROWTH-FACTOR RECEPTORS; SIGNAL TRANSDUCTION; KINASE-ACTIVITY; PHOSPHOTYROSINE; PROTEINS AB Src homology 2 (SH2) domains are modular phosphotyrosine binding pockets found within a wide variety of cytoplasmic signaling molecules. Here we develop a new approach to analyzing protein-protein interfaces termed photoaffinity scanning, and apply the method to map regions of the phosphatidylinositol 3-kinase p85 SH2 domain that participate in phosphoprotein binding. Each residue except phosphotyrosine (pY) within a tightly binding, IRS-1-derived phosphopeptide (GNGDpYMPMSPKS) was substituted with the photoactive amino acid, benzoylphenylalanine (Bpa). Whereas most substitutions had little effect on binding affinity, Bpa substitution of either Met (+1 and +3 with respect to pY) reduced affinity 50-100-fold to confirm their importance in the pYMXM recognition motif. In three cases photolysis of SH2 domain/Bpa phosphopeptide complexes led to cross-linking of >50% of the SH2 domain; cross-link positions were identified by microsequence, amino acid composition, and electrospray mass spectrometric analyses. Bpa-1 cross-links within alpha-helix I, whereas Bpa+1 and Bpa+4 cross-link the SH2 domain within the flexible loop C-terminal to alpha-helix II. Moreover, cross-linking at any position prevents SH2 domain cleavage at a trypsin-sensitive site within the flexible loop between beta-strands 1 and 2. Therefore, at least three distinct SH2 regions in addition to the beta-sheet participate in phosphoprotein binding; the loop cross-linked by phosphopeptide residues C-terminal to pY appears to confer specificity to the phosphoprotein/SH2 domain interaction. C1 HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,JOSLIN DIABET CTR,DEPT MED,DIV RES,BOSTON,MA 02215. FU NIDDK NIH HHS [DK36836] NR 22 TC 44 Z9 44 U1 0 U2 0 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 SN 0021-9258 J9 J BIOL CHEM JI J. Biol. Chem. PD MAR 15 PY 1993 VL 268 IS 8 BP 5361 EP 5364 PG 4 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA KR822 UT WOS:A1993KR82200006 PM 7680644 ER PT J AU WELLER, PF RAND, TH BARRETT, T ELOVIC, A WONG, DTW FINBERG, RW AF WELLER, PF RAND, TH BARRETT, T ELOVIC, A WONG, DTW FINBERG, RW TI ACCESSORY CELL-FUNCTION OF HUMAN EOSINOPHILS - HLA-DR-DEPENDENT, MHC-RESTRICTED ANTIGEN-PRESENTATION AND IL-1-ALPHA EXPRESSION SO JOURNAL OF IMMUNOLOGY LA English DT Article ID COLONY-STIMULATING FACTOR; PRESENTING CELLS; MESSENGER-RNA; INTERLEUKIN-3; NEUTROPHILS; ACTIVATION; MONOCYTES; COMPLEXES; RELEASE; ALPHA AB Although peripheral blood eosinophils express little of the class II MHC protein, HLA-DR, eosinophils could be induced to express HLA-DR by exposures to cytokines, including granulocyte-macrophage-CSF, IL-4, and IFN-gamma, with granulocyte-macrophage-CSF eliciting the greatest level of HLA-DR expression as assessed by flow cytometry. The capacity of HLA-DR+ eosinophils to function as APC was evaluated with blood eosinophils isolated free of mononuclear cells, cultured with granulocyte-macrophage-CSF to induce HLA-DR expression and then exposed to the Ag tetanus toxoid. HLA-DR+ eosinophils fixed with paraformaldehyde after Ag exposure stimulated T cell proliferation, whereas HLA-DR+ eosinophils fixed with paraformaldehyde before Ag exposure failed to stimulate lymphocyte proliferation. The lymphocyte proliferative responses elicited by Ag-pulsed HLA-DR+ eosinophils were inhibited by anti-HLA-DR mAb and were restricted to HLA-DR compatible lymphocytes. Moreover, eosinophils from a hypereosinophilic donor, both before and more prominently after stimulation with PMA, contained transcripts for IL-1-alpha mRNA detectable by Northern blot hybridization and in situ hybridization and expressed IL-1-alpha protein detectable by immunohistochemistry. These findings indicate that human eosinophils can process Ag, express the costimulatory cytokine IL-1-alpha, and after cytokine-elicited induction of HLA-DR expression can function as HLA-DR-dependent, MHC-restricted APC in stimulating T lymphocyte responses. C1 HARVARD UNIV,SCH DENT MED,DEPT ORAL PATHOL,BOSTON,MA 02215. HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115. HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,CHARLES A DANA RES INST,HARVARD THORNDIKE LABS,BOSTON,MA 02215. RP WELLER, PF (reprint author), HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,CHARLES A DANA RES INST,DEPT MED,DA-617,330 BROOKLINE AVE,BOSTON,MA 02215, USA. RI Finberg, Robert/E-3323-2010 FU NHLBI NIH HHS [HL46563]; NIAID NIH HHS [AI20241, AI31982] NR 33 TC 148 Z9 148 U1 0 U2 1 PU AMER ASSOC IMMUNOLOGISTS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 SN 0022-1767 J9 J IMMUNOL JI J. Immunol. PD MAR 15 PY 1993 VL 150 IS 6 BP 2554 EP 2562 PG 9 WC Immunology SC Immunology GA KR934 UT WOS:A1993KR93400049 PM 8450230 ER PT J AU LEVINE, RA CAPE, EG YOGANATHAN, AP AF LEVINE, RA CAPE, EG YOGANATHAN, AP TI PRESSURE RECOVERY DISTAL TO STENOSES - EXPANDING CLINICAL-APPLICATIONS OF ENGINEERING PRINCIPLES SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Editorial Material ID WAVE DOPPLER VELOCITIES; AORTIC-STENOSIS; BLOOD-FLOW; CORONARY VASODILATION; PROSTHETIC VALVES; PULSATILE FLOW; ULTRASOUND; GRADIENTS; ECHOCARDIOGRAPHY; INVITRO C1 GEORGIA INST TECHNOL,SCH CHEM ENGN,CARDIOVASC FLUID MECH,778 ATLANTIC DR,ATLANTA,GA 30332. HARVARD UNIV,SCH MED,MASSACHUSETTS GEN HOSP,CARDIAC ULTRASOUND LAB,BOSTON,MA 02115. GEORGIA INST TECHNOL,SCH CHEM ENGN,CARDIOVASC FLUID MECH LAB,ATLANTA,GA 30332. UNIV PITTSBURGH,CHILDRENS HOSP PITTSBURGH,DIV PEDIAT CARDIOL,PITTSBURGH,PA 15260. FU NHLBI NIH HHS [HL45485, HL38176] NR 37 TC 12 Z9 12 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD MAR 15 PY 1993 VL 21 IS 4 BP 1026 EP 1028 PG 3 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA KT865 UT WOS:A1993KT86500025 PM 8450151 ER PT J AU CAPE, EG YOGANATHAN, AP LEVINE, RA AF CAPE, EG YOGANATHAN, AP LEVINE, RA TI INCREASED HEART-RATE CAN CAUSE UNDERESTIMATION OF REGURGITANT JET SIZE BY DOPPLER COLOR FLOW MAPPING SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Article ID VENTRICULAR SEPTAL-DEFECT; MITRAL REGURGITATION; VALVULAR REGURGITATION; VALVE REPAIR; FRAME RATE; REAL-TIME; INVITRO; QUANTIFICATION; VARIABILITY; ORIFICE AB Objectives. This study addressed the hypothesis that at a constant peak flow rate, an increasing heart rate could decrease the maximal apparent jet size by Doppler color flow mapping. Background. Recent studies have attempted to predict the severity of regurgitation from maximal jet area by Doppler color flow mapping, which correlates with flow rate for free jets at constant driving pressure and steady flow. In patients, however, maximal jet area exists for only a limited time per beat and the likelihood of visualizing it by Doppler color flow mapping depends on its duration relative to the color frame sampling rate. Increased heart rate could potentially diminish apparent jet size, particularly at slow frame rates that may not permit visualization of the maximal jet area in all beats. Methods. This interaction was examined in pulsatile flow, holding orifice size and peak flow rate constant and varying pump pulse rate (70 to 180 beats/min) and frame rate (three rates) for jets of low and high momentum. Maximal jet area was measured in 10 consecutive beats at each pulse rate and frame rate and averaged. Results. For the low momentum jet, the 10-beat average of peak jet area decreased progressively with increasing pulse rate. As pulse rate increased from 70 to 180 beats/min, maximal jet area decreased 23% at the fastest frame rate and 42% at the slowest frame rate, with prominent beat to beat variability. Jet area decreased 13% to 20% at pulse rates as low as 90 beats/min. In contrast, for the high momentum jet, maximal jet area decreased by less-than-or-equal-to 9% from low to high pulse rate at any frame rate. Conclusions. Increased heart rate can cause underestimation of apparent jet size by Doppler color flow mapping for a given peak flow rate, particularly for jets with low momentum and delayed penetration into the receiving chamber. This observation may be relevant to acute severe regurgitation with increased heart rate in which such underestimation has been reported, as well as to right-sided lesions and children with rapid heart rates. It will also affect new techniques proposed to quantify regurgitation on the basis of velocities derived from Doppler color flow images. In practice, this effect can be reduced by increasing frame rate and selecting maximal apparent jet size at rapid heart rates and should be considered in relating jet size to the severity of regurgitation. C1 HARVARD UNIV,SCH MED,MASSACHUSETTS GEN HOSP,CARDIAC ULTRASOUND LAB,BOSTON,MA 02115. GEORGIA INST TECHNOL,SCH CHEM ENGN,CARDIOVASC FLUID MECH LAB,ATLANTA,GA 30332. RP CAPE, EG (reprint author), UNIV PITTSBURGH,CHILDRENS HOSP PITTSBURGH,DIV PEDIAT CARDIOL,3705 5TH AVE,PITTSBURGH,PA 15213, USA. FU NHLBI NIH HHS [HL45485, HL38176] NR 34 TC 25 Z9 25 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD MAR 15 PY 1993 VL 21 IS 4 BP 1029 EP 1037 PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA KT865 UT WOS:A1993KT86500026 PM 8450152 ER PT J AU DATTA, R TANEJA, N SUKHATME, VP QURESHI, SA WEICHSELBAUM, R KUFE, DW AF DATTA, R TANEJA, N SUKHATME, VP QURESHI, SA WEICHSELBAUM, R KUFE, DW TI REACTIVE OXYGEN INTERMEDIATES TARGET CC(A/T)6GG SEQUENCES TO MEDIATE ACTIVATION OF THE EARLY GROWTH RESPONSE-1 TRANSCRIPTION FACTOR GENE BY IONIZING-RADIATION SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article ID HUMAN-IMMUNODEFICIENCY-VIRUS; FINGER-ENCODING GENE; DNA-BINDING ACTIVITY; PROTEIN-KINASE-C; FACTOR-KAPPA-B; LEUKEMIA-CELLS; N-ACETYLCYSTEINE; CULTURED-CELLS; EGR-1 GENE; EXPRESSION AB The cellular response to ionizing radiation includes induction of the early growth response 1 gene (EGR1). The present work has examined the involvement of reactive oxygen intermediates (ROIs) in this response. Exposure of human HL-525 cells, an HL-60 subclone deficient in protein kinase C-mediated signaling, to both ionizing radiation and H2O2 was associated with increases in EGR-1 transcripts. These increases in EGR-1 expression were inhibited by the antioxidant N-acetyl-L-cysteine (NAC). Nuclear run-on assays demonstrate that NAC inhibits the activation of EGR1 transcription by these agents. Previous studies have shown that induction of EGR1 by x-rays is conferred by serum response or CC(A/T)6GG (CArG) elements. The present studies demonstrate similar findings with H2O2 and the finding that activation of the EGR1 promoter region containing CArG elements is abrogated by NAC. Moreover, we show that NAC inhibits the ability of a single CArG box to confer x-ray and H2O2 inducibility when linked to a heterologous promoter. Taken together, these findings indicate that ROIs induce EGR1 transcription by activation of CArG elements. C1 UNIV CHICAGO,HOWARD HUGHES MED INST,DEPT MED & MOLEC GENET & CELL BIOL,CHICAGO,IL 60637. CUNY HUNTER COLL,NEW YORK,NY 10021. UNIV CHICAGO,DEPT RADIAT & CELLULAR ONCOL,CHICAGO,IL 60637. UNIV CHICAGO,PRITZKER SCH MED,CHICAGO,IL 60637. RP DATTA, R (reprint author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,CLIN PHARMACOL LAB,BOSTON,MA 02115, USA. FU NCI NIH HHS [CA41068, CA42596, CA55241] NR 46 TC 173 Z9 186 U1 0 U2 2 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD MAR 15 PY 1993 VL 90 IS 6 BP 2419 EP 2422 DI 10.1073/pnas.90.6.2419 PG 4 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA KT370 UT WOS:A1993KT37000069 PM 8384722 ER PT J AU BRADY, JN PIRAS, G RADONOVICH, MF DUVALL, JF FATTAEY, A KASHANCHI, F AF BRADY, JN PIRAS, G RADONOVICH, MF DUVALL, JF FATTAEY, A KASHANCHI, F TI DIRECT INTERACTION OF HUMAN TFIID WITH THE HIV-1 TRANSACTIVATOR TAT SO JOURNAL OF CELLULAR BIOCHEMISTRY LA English DT Meeting Abstract C1 NCI,MOLEC VIROL LAB,BETHESDA,MD 20892. MASSACHUSETTS GEN HOSP,CTR CANC,BOSTON,MA 02129. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012 SN 0730-2312 J9 J CELL BIOCHEM JI J. Cell. Biochem. PD MAR 13 PY 1993 SU 17D BP 22 EP 22 PG 1 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA KV880 UT WOS:A1993KV88000074 ER PT J AU BENNINK, JR BACIK, I LAPHAM, C ARNOLD, D SPIES, T COX, J DENG, YP DAY, P ANDERSON, R RESTIFO, N EISENLOHR, L ESQUIVEL, F YEWDELL, JW AF BENNINK, JR BACIK, I LAPHAM, C ARNOLD, D SPIES, T COX, J DENG, YP DAY, P ANDERSON, R RESTIFO, N EISENLOHR, L ESQUIVEL, F YEWDELL, JW TI PRESENTATION OF VIRAL-ANTIGENS TO CYTOTOXIC T-LYMPHOCYTES SO JOURNAL OF CELLULAR BIOCHEMISTRY LA English DT Meeting Abstract C1 NIAID,BETHESDA,MD 20892. HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115. NCI,BETHESDA,MD 20892. THOMAS JEFFERSON CANC INST,PHILADELPHIA,PA. RI Restifo, Nicholas/A-5713-2008; yewdell, jyewdell@nih.gov/A-1702-2012 NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012 SN 0730-2312 J9 J CELL BIOCHEM JI J. Cell. Biochem. PD MAR 13 PY 1993 SU 17D BP 32 EP 32 PG 1 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA KV880 UT WOS:A1993KV88000100 ER PT J AU KALAMS, S JOHNSON, RP TROCHA, A DYNAN, MJ KURNICK, JT WALKER, BD AF KALAMS, S JOHNSON, RP TROCHA, A DYNAN, MJ KURNICK, JT WALKER, BD TI T-CELL RECEPTOR GENE USAGE IN HIV-1 SPECIFIC CYTOTOXIC T-LYMPHOCYTES SO JOURNAL OF CELLULAR BIOCHEMISTRY LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,INFECT DIS UNIT,BOSTON,MA 02129. MASSACHUSETTS GEN HOSP,DEPT PATHOL,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012 SN 0730-2312 J9 J CELL BIOCHEM JI J. Cell. Biochem. PD MAR 13 PY 1993 SU 17D BP 51 EP 51 PG 1 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA KV880 UT WOS:A1993KV88000162 ER PT J AU LEE, SJ LI, ZZ ARRUNATEGUICORREA, V FOSTER, CS AF LEE, SJ LI, ZZ ARRUNATEGUICORREA, V FOSTER, CS TI ANALYSIS OF T-CELL RECEPTOR (TCR) V-BETA REPERTOIRE RESPONDING TO ANTERIOR-CHAMBER (AC) INOCULATION OF HERPES-SIMPLEX VIRUS (HSV) IN A MURINE MODEL OF HERPES RETINITIS (HR) SO JOURNAL OF CELLULAR BIOCHEMISTRY LA English DT Meeting Abstract C1 HARVARD UNIV,MASSACHUSETTS EYE & EAR INFIRM,SCH MED,BOSTON,MA 02114. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012 SN 0730-2312 J9 J CELL BIOCHEM JI J. Cell. Biochem. PD MAR 13 PY 1993 SU 17D BP 51 EP 51 PG 1 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA KV880 UT WOS:A1993KV88000163 ER PT J AU JOHNSON, RP TROCHA, A DYNAN, M BERGMANN, CC GAMMON, MC ZWEERINK, HJ BLATTNER, W WALKER, BD AF JOHNSON, RP TROCHA, A DYNAN, M BERGMANN, CC GAMMON, MC ZWEERINK, HJ BLATTNER, W WALKER, BD TI SEQUENCE VARIATION IN THE HUMAN-IMMUNODEFICIENCY-VIRUS AS A MECHANISM OF ESCAPE FROM CYTOTOXIC T-LYMPHOCYTES SO JOURNAL OF CELLULAR BIOCHEMISTRY LA English DT Meeting Abstract C1 MASSACHUSETTS GEN HOSP,INFECT DIS UNIT,BOSTON,MA 02114. UNIV SO CALIF,DEPT NEUROL,LOS ANGELES,CA 90089. MERCK SHARP & DOHME LTD,RAHWAY,NJ 07065. NCI,BETHESDA,MD 20892. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012 SN 0730-2312 J9 J CELL BIOCHEM JI J. Cell. Biochem. PD MAR 13 PY 1993 SU 17D BP 74 EP 74 PG 1 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA KV880 UT WOS:A1993KV88000251 ER PT J AU BENNINK, JR BACIK, I LAPHAM, C ARNOLD, D SPIES, T COX, J DENG, YP DAY, P ANDERSON, R RESTIFO, N EISENLOHR, L ESQUIVEL, F YEWDELL, JW AF BENNINK, JR BACIK, I LAPHAM, C ARNOLD, D SPIES, T COX, J DENG, YP DAY, P ANDERSON, R RESTIFO, N EISENLOHR, L ESQUIVEL, F YEWDELL, JW TI PRESENTATION OF VIRAL-ANTIGENS TO CYTOTOXIC T-LYMPHOCYTES SO JOURNAL OF CELLULAR BIOCHEMISTRY LA English DT Meeting Abstract C1 NIAID,BETHESDA,MD 20892. HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115. NCI,BETHESDA,MD 20892. THOMAS JEFFERSON CANC INST,PHILADELPHIA,PA. RI Restifo, Nicholas/A-5713-2008 NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012 SN 0730-2312 J9 J CELL BIOCHEM JI J. Cell. Biochem. PD MAR 13 PY 1993 SU 17D BP 90 EP 90 PG 1 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA KV880 UT WOS:A1993KV88000310 ER PT J AU FERRARA, JLM AF FERRARA, JLM TI THE ROLE OF INTERLEUKIN-1 (IL-1) AND IL-1 RECEPTOR ANTAGONIST IN GRAFT-VERSUS-HOST DISEASE SO JOURNAL OF CELLULAR BIOCHEMISTRY LA English DT Meeting Abstract C1 HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115. HARVARD UNIV,SCH MED,BOSTON,MA 02115. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012 SN 0730-2312 J9 J CELL BIOCHEM JI J. Cell. Biochem. PD MAR 13 PY 1993 SU 17D BP 96 EP 96 PG 1 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA KV880 UT WOS:A1993KV88000325 ER PT J AU CHATTERJEE, B JUNG, MH HER, S SLOMCZYNSKA, M SONG, CS AF CHATTERJEE, B JUNG, MH HER, S SLOMCZYNSKA, M SONG, CS TI MULTICOMPONENT REGULATION OF ANDROGEN SENSITIVITY DURING MATURATION AND AGING SO JOURNAL OF CELLULAR BIOCHEMISTRY LA English DT Meeting Abstract C1 UNIV TEXAS,HLTH SCI CTR,DEPT CELLULAR & STRUCT BIOL,SAN ANTONIO,TX 78284. AUDIE L MURPHY MEM VET ADM MED CTR,SAN ANTONIO,TX 78284. NR 0 TC 0 Z9 0 U1 0 U2 1 PU WILEY-LISS PI NEW YORK PA DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012 SN 0730-2312 J9 J CELL BIOCHEM JI J. Cell. Biochem. PD MAR 13 PY 1993 SU 17D BP 158 EP 158 PG 1 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA KV880 UT WOS:A1993KV88000549 ER EF